
ecNumber	1.1.1.1	commentary	class III isoenzyme	
ecNumber	1.1.1.1	commentary	class I isoenzymes: alpha,gamma2, gamma2gamma2, alpha,gamma1, alpha,beta1, beta1,gamma2, gamma1,gamma1, beta1,gamma1, beta1,beta1	
ecNumber	1.1.1.1	commentary	class II isoenzyme: pi-ADH	
ecNumber	1.1.1.1	commentary	isoenzymes: beta2beta2, beta2beta1, alphabeta2 and beta2gamma1	
ecNumber	1.1.1.1	commentary	class III isoenzyme; isoenzyme chi-ADH	
ecNumber	1.1.1.1	commentary	isoenzyme alpha,alpha, beta1,beta1, gamma1,gamma1 and gamma2,gamma2	
ecNumber	1.1.1.1	commentary	anodic enzyme form	
ecNumber	1.1.1.1	commentary	isoenzymes beta1,beta1, beta2,beta2 and beta3,beta3	
ecNumber	1.1.1.1	commentary	anodic enzyme form; chi-ADH	
ecNumber	1.1.1.1	commentary	ADHIndianapolis form 1 and 2 and 3	
ecNumber	1.1.1.1	commentary	isoenzyme pi	
ecNumber	1.1.1.1	commentary	class IV enzyme, sigma-ADH	
ecNumber	1.1.1.1	commentary	mue-alcolhol dehydrogenase	
ecNumber	1.1.1.1	commentary	class I enzyme, several isozymes	
ecNumber	1.1.1.1	commentary	alcohol dehydrogenase 2, 2 allelic forms	
ecNumber	1.1.1.1	commentary	isozyme 1C	2 (gamma2gamma2)	
ecNumber	1.1.1.1	commentary	isozymes ADH1B1, ADH1B2, and ADH4	
ecNumber	1.1.1.1	commentary	class IV alcohol dehydrogenase	
ecNumber	1.1.1.1	commentary		
ecNumber	1.1.1.1	commentary		
ecNumber	1.1.1.1	commentary		
ecNumber	1.1.1.2	commentary	human	
ecNumber	1.1.1.2	commentary	human	
ecNumber	1.1.1.8	commentary		
ecNumber	1.1.1.8	commentary		
ecNumber	1.1.1.10	commentary		
ecNumber	1.1.1.10	commentary		
ecNumber	1.1.1.14	commentary		
ecNumber	1.1.1.14	commentary		
ecNumber	1.1.1.19	commentary		
ecNumber	1.1.1.21	commentary	expressed in transgenic mice	
ecNumber	1.1.1.21	commentary	recombinant enzyme	
ecNumber	1.1.1.21	commentary	female and male	
ecNumber	1.1.1.21	commentary	isoform hALR2	
ecNumber	1.1.1.21	commentary	recombinant protein	
ecNumber	1.1.1.21	commentary		
ecNumber	1.1.1.21	commentary		
ecNumber	1.1.1.21	commentary	isoform ALR2	
ecNumber	1.1.1.21	commentary	ALR2	
ecNumber	1.1.1.21	commentary	ALR2 and AKR1B10	
ecNumber	1.1.1.21	commentary		
ecNumber	1.1.1.21	commentary		
ecNumber	1.1.1.22	commentary		
ecNumber	1.1.1.22	commentary	recombinant His-tagged enzyme	
ecNumber	1.1.1.22	commentary	chemically synthesized gene expressed in Escherichia coli	
ecNumber	1.1.1.22	commentary		
ecNumber	1.1.1.26	commentary		
ecNumber	1.1.1.26	commentary	patients with primary hyperoxaluria type 2	
ecNumber	1.1.1.26	commentary		
ecNumber	1.1.1.27	commentary		
ecNumber	1.1.1.27	commentary	several isozymes, overview	
ecNumber	1.1.1.27	commentary		
ecNumber	1.1.1.27	commentary		
ecNumber	1.1.1.27	commentary		
ecNumber	1.1.1.29	commentary		
ecNumber	1.1.1.30	commentary		
ecNumber	1.1.1.31	commentary		
ecNumber	1.1.1.34	commentary		
ecNumber	1.1.1.34	commentary		
ecNumber	1.1.1.35	commentary	gene HADHSC	
ecNumber	1.1.1.35	commentary		
ecNumber	1.1.1.35	commentary		
ecNumber	1.1.1.35	commentary		
ecNumber	1.1.1.36	commentary		
ecNumber	1.1.1.36	commentary	alignment of the amino acid sequence of the hydratase 2 domain from human MFE-2 with those of other known hydratase 2 domains from eukaryotes shown	
ecNumber	1.1.1.36	commentary	alignment of nucleotide-binding site from human MFE-2 with Saccharomyces cerevisiae and Candida tropicalis MFE-2 shown	
ecNumber	1.1.1.37	commentary	human	
ecNumber	1.1.1.37	commentary		
ecNumber	1.1.1.37	commentary		
ecNumber	1.1.1.37	commentary		
ecNumber	1.1.1.38	commentary		
ecNumber	1.1.1.39	commentary		
ecNumber	1.1.1.40	commentary		
ecNumber	1.1.1.40	commentary		
ecNumber	1.1.1.B40	commentary	isoenzymes type 1 and type 2	
ecNumber	1.1.1.B40	commentary	isozyme 11beta-HSD2	
ecNumber	1.1.1.B40	commentary	isozymes HSD1 and HSD2	
ecNumber	1.1.1.B40	commentary	isozymes 11beta-HSD1 and 11beta-HSD2	
ecNumber	1.1.1.B40	commentary	female and male, isozymes 11beta-HSD1 and 11beta-HSD2	
ecNumber	1.1.1.B40	commentary	normotensive persons and patients with low renin hypertension, LREH	
ecNumber	1.1.1.B40	commentary	seven different women with ovarian cancer of different types, overview	
ecNumber	1.1.1.B40	commentary	isoform HSD2	
ecNumber	1.1.1.B40	commentary		
ecNumber	1.1.1.B40	commentary	isozyme 11beta-HSD2; isozyme 11beta-HSD2	
ecNumber	1.1.1.B40	commentary		
ecNumber	1.1.1.B40	commentary	isozymes 11beta-HSD1 and 11beta-HSD2	
ecNumber	1.1.1.B40	commentary	isozyme 11beta-HSD1; isozyme 11beta-HSD1	
ecNumber	1.1.1.B40	commentary	isoform 11beta-HSD2	
ecNumber	1.1.1.B40	commentary		
ecNumber	1.1.1.41	commentary		
ecNumber	1.1.1.41	commentary		
ecNumber	1.1.1.41	commentary		
ecNumber	1.1.1.42	commentary		
ecNumber	1.1.1.42	commentary	IDH1	
ecNumber	1.1.1.42	commentary		
ecNumber	1.1.1.42	commentary	IDH2	
ecNumber	1.1.1.42	commentary		
ecNumber	1.1.1.43	commentary	pregnant and nonpregnant women	
ecNumber	1.1.1.43	commentary		
ecNumber	1.1.1.44	commentary	human; Krebs ascites cells	
ecNumber	1.1.1.44	commentary	human	
ecNumber	1.1.1.44	commentary		
ecNumber	1.1.1.44	commentary		
ecNumber	1.1.1.47	commentary		
ecNumber	1.1.1.49	commentary	2 isoforms: A(+) and A(-), where A(-) is a mutant derivative of A(+) with V68M exchange	
ecNumber	1.1.1.49	commentary	2 isoenzymes	
ecNumber	1.1.1.49	commentary	wild-type and deficient mutant	
ecNumber	1.1.1.49	commentary	wild-type and 3 enzyme-deficient children, i.e. mutants 1,2, and 3	
ecNumber	1.1.1.49	commentary	X-linked house-keeping enzyme	
ecNumber	1.1.1.49	commentary	asymptomatic patient with high in vitro glucose-6-phosphate dehydrogenase deficiency, carrying a inherited mutation at A55T	
ecNumber	1.1.1.49	commentary		
ecNumber	1.1.1.49	commentary		
ecNumber	1.1.1.50	commentary	1-4 different enzyme isoforms	
ecNumber	1.1.1.50	commentary	type 2 isoform	
ecNumber	1.1.1.50	commentary	type III enzyme	
ecNumber	1.1.1.50	commentary	isozymes AKR1C1, AKR1C2, and AKR1C4	
ecNumber	1.1.1.50	commentary	4 isozymes AKR1C1-4	
ecNumber	1.1.1.50	commentary	type 3 isozyme AKR1C2	
ecNumber	1.1.1.50	commentary	type 2 isozyme AKR1C3	
ecNumber	1.1.1.50	commentary	4 isozyme AKR1C1-AKR1C4	
ecNumber	1.1.1.50	commentary	4 isozymes AKR1C1-AKR1C4	
ecNumber	1.1.1.50	commentary		
ecNumber	1.1.1.50	commentary		
ecNumber	1.1.1.50	commentary	4 isozymes AKR1C1-AKR1C4	
ecNumber	1.1.1.50	commentary		
ecNumber	1.1.1.51	commentary	isozymes 17beta-HSD3 and 17beta-HSD5	
ecNumber	1.1.1.51	commentary		
ecNumber	1.1.1.51	commentary		
ecNumber	1.1.1.51	commentary		
ecNumber	1.1.1.53	commentary		
ecNumber	1.1.1.62	commentary		
ecNumber	1.1.1.62	commentary	17beta,20alpha-hydroxysteroid dehydrogenase	
ecNumber	1.1.1.62	commentary	type 1 enzyme	
ecNumber	1.1.1.62	commentary	17beta-HSD1	
ecNumber	1.1.1.62	commentary	isoform 1, 17HSD1	
ecNumber	1.1.1.62	commentary	isoforms 1-4, 17beta-HSD 1-4	
ecNumber	1.1.1.62	commentary	isoforms 1, 2 and 5, 17beta-HSD1, 2 and 5	
ecNumber	1.1.1.62	commentary	isoforms 4, 5, 7, 8, 10, and 11, 17beta-HSD 4, 5, 7, 8, 10, and 11	
ecNumber	1.1.1.62	commentary	isozymes 17beta-HSD4 and 17beta-HSD1	
ecNumber	1.1.1.62	commentary	several isozymes, encoded by different genes	
ecNumber	1.1.1.62	commentary		
ecNumber	1.1.1.62	commentary	isoform 17betaHSD6	
ecNumber	1.1.1.62	commentary		
ecNumber	1.1.1.62	commentary	type 1 enzyme	
ecNumber	1.1.1.62	commentary	isotype 1, 17beta-HSD type 1	
ecNumber	1.1.1.62	commentary	isoform HSD17B1	
ecNumber	1.1.1.62	commentary		
ecNumber	1.1.1.62	commentary	isoform HSD17B2	
ecNumber	1.1.1.62	commentary		
ecNumber	1.1.1.62	commentary		
ecNumber	1.1.1.62	commentary		
ecNumber	1.1.1.62	commentary		
ecNumber	1.1.1.64	commentary	isozymes 17beta-HSD4 and 17beta-HSD1	
ecNumber	1.1.1.64	commentary		
ecNumber	1.1.1.64	commentary		
ecNumber	1.1.1.64	commentary		
ecNumber	1.1.1.71	commentary		
ecNumber	1.1.1.71	commentary		
ecNumber	1.1.1.79	commentary	; recombinant	
ecNumber	1.1.1.79	commentary		
ecNumber	1.1.1.79	commentary		
ecNumber	1.1.1.81	commentary		
ecNumber	1.1.1.81	commentary		
ecNumber	1.1.1.88	commentary		
ecNumber	1.1.1.95	commentary	gene PHGDH	
ecNumber	1.1.1.95	commentary		
ecNumber	1.1.1.95	commentary	gene PHGDH	
ecNumber	1.1.1.95	commentary		
ecNumber	1.1.1.96	commentary		
ecNumber	1.1.1.98	commentary	three different forms: HAOX1, HAOX2, HAOX3	
ecNumber	1.1.1.99	commentary	three different forms: HAOX1, HAOX2, HAOX3	
ecNumber	1.1.1.100	commentary		
ecNumber	1.1.1.100	commentary	cf EC 1.1.1.62	
ecNumber	1.1.1.101	commentary		
ecNumber	1.1.1.102	commentary		
ecNumber	1.1.1.102	commentary		
ecNumber	1.1.1.103	commentary		
ecNumber	1.1.1.105	commentary	recombinant enzyme expressed in Sf9 cells	
ecNumber	1.1.1.105	commentary		
ecNumber	1.1.1.105	commentary		
ecNumber	1.1.1.105	commentary		
ecNumber	1.1.1.105	commentary		
ecNumber	1.1.1.105	commentary		
ecNumber	1.1.1.105	commentary		
ecNumber	1.1.1.112	commentary		
ecNumber	1.1.1.135	commentary	enzyme is identical to 3-hydroxyacyl-CoA dehydrogenase type II	
ecNumber	1.1.1.141	commentary	; enzyme expression is induced in human eryrthroleukemia cells by dexamethasone	
ecNumber	1.1.1.141	commentary	gene 15-Pgdh	
ecNumber	1.1.1.141	commentary	; patients with primary hypertrophic osteoarthropathy	
ecNumber	1.1.1.141	commentary		
ecNumber	1.1.1.141	commentary		
ecNumber	1.1.1.145	commentary	3beta-HSD I; 3beta-HSD II	
ecNumber	1.1.1.145	commentary	3beta-HSD I	
ecNumber	1.1.1.145	commentary	type 2 isozyme, gene HSD3B2	
ecNumber	1.1.1.145	commentary	isoform DHRS4	
ecNumber	1.1.1.145	commentary	type 1 enzyme	
ecNumber	1.1.1.145	commentary	isoforms Hsd3B1, Hsd3B2	
ecNumber	1.1.1.145	commentary		
ecNumber	1.1.1.145	commentary	3beta-HSD1	
ecNumber	1.1.1.145	commentary	3beta-HSD1; isozyme 3beta-HSD1, bifunctional enzyme	
ecNumber	1.1.1.145	commentary	3beta-HSD1; type 1 isozyme	
ecNumber	1.1.1.145	commentary	isoform 3betaHSD1	
ecNumber	1.1.1.145	commentary		
ecNumber	1.1.1.145	commentary	3beta-HSD2	
ecNumber	1.1.1.145	commentary	3beta-HSD2; isozyme 3beta-HSD2, bifunctional enzyme	
ecNumber	1.1.1.145	commentary	isoform 3betaHSD2	
ecNumber	1.1.1.145	commentary		
ecNumber	1.1.1.146	commentary	isoenzyme type 1	
ecNumber	1.1.1.146	commentary	isoenzymes type 1 and type 2	
ecNumber	1.1.1.146	commentary	; isozyme 11beta-HSD1	
ecNumber	1.1.1.146	commentary	isozymes HSD1 and HSD2	
ecNumber	1.1.1.146	commentary	isozymes 11beta-HSD1 and 11beta-HSD2	
ecNumber	1.1.1.146	commentary	male	
ecNumber	1.1.1.146	commentary	female and male, isozymes 11beta-HSD1 and 11beta-HSD2	
ecNumber	1.1.1.146	commentary	isozyme 11betaHSD1	
ecNumber	1.1.1.146	commentary	11beta-HSD1	
ecNumber	1.1.1.146	commentary	obese women	
ecNumber	1.1.1.146	commentary	isozyme 11beta-HSD1	
ecNumber	1.1.1.146	commentary	; type I isoform	
ecNumber	1.1.1.146	commentary	; type I and type II isoforms	
ecNumber	1.1.1.146	commentary	11 beta-hydroxysteroid dehydrogenase type 1	
ecNumber	1.1.1.146	commentary	patients with alcoholic liver disease	
ecNumber	1.1.1.146	commentary	patients with glycogen storage disease type 1a or type 1b	
ecNumber	1.1.1.146	commentary	type I isoform	
ecNumber	1.1.1.146	commentary	morbidly obese patients	
ecNumber	1.1.1.146	commentary		
ecNumber	1.1.1.146	commentary	isozyme 11beta-HSD1	
ecNumber	1.1.1.146	commentary	type I isoform	
ecNumber	1.1.1.146	commentary	isoform 11beta-HSD1	
ecNumber	1.1.1.146	commentary		
ecNumber	1.1.1.146	commentary		
ecNumber	1.1.1.147	commentary		
ecNumber	1.1.1.149	commentary	women about 47 years old and with body mass index of about 27	
ecNumber	1.1.1.149	commentary	isoform AKR1C1	
ecNumber	1.1.1.149	commentary		
ecNumber	1.1.1.149	commentary		
ecNumber	1.1.1.150	commentary	retinol dehydrogenase isoforms RDH12 and RDH13	
ecNumber	1.1.1.153	commentary	gene SPR	
ecNumber	1.1.1.153	commentary		
ecNumber	1.1.1.153	commentary		
ecNumber	1.1.1.160	commentary		
ecNumber	1.1.1.170	commentary		
ecNumber	1.1.1.170	commentary		
ecNumber	1.1.1.172	commentary		
ecNumber	1.1.1.178	commentary		
ecNumber	1.1.1.178	commentary	bifunctional 17beta-hydroxysteroid dehydrogenase type 10/2-methyl-3-hydroxybutyryl-CoA dehydrogenase	
ecNumber	1.1.1.178	commentary		
ecNumber	1.1.1.179	commentary		
ecNumber	1.1.1.181	commentary		
ecNumber	1.1.1.184	commentary	isozyme CBR3	
ecNumber	1.1.1.184	commentary	isoform CBR1	
ecNumber	1.1.1.184	commentary	carbonyl reductase 1	
ecNumber	1.1.1.184	commentary		
ecNumber	1.1.1.184	commentary	isoform Cbr3, comparison with prostaglandin 9-ketoreductase Cbr1	
ecNumber	1.1.1.184	commentary		
ecNumber	1.1.1.184	commentary	isoform CBR 3	
ecNumber	1.1.1.184	commentary	isoform CBR1	
ecNumber	1.1.1.184	commentary	isoform CBR 1	
ecNumber	1.1.1.184	commentary		
ecNumber	1.1.1.188	commentary	2 isozymes PGFS-I and PGFS-II, soluble and membrane-associated isozymes	
ecNumber	1.1.1.188	commentary		
ecNumber	1.1.1.188	commentary		
ecNumber	1.1.1.188	commentary	AKR1C3	
ecNumber	1.1.1.188	commentary	isoform AKR1C3	
ecNumber	1.1.1.188	commentary		
ecNumber	1.1.1.189	commentary		
ecNumber	1.1.1.196	commentary	human	
ecNumber	1.1.1.197	commentary	human	
ecNumber	1.1.1.205	commentary	type I and type II	
ecNumber	1.1.1.205	commentary	mutants of type II; type II	
ecNumber	1.1.1.205	commentary	type II	
ecNumber	1.1.1.205	commentary	isozyme IMPDH II	
ecNumber	1.1.1.205	commentary	IMPDH II	
ecNumber	1.1.1.205	commentary	type II isozyme	
ecNumber	1.1.1.205	commentary	type I and type II isozymes	
ecNumber	1.1.1.205	commentary	type II IMPDH isozyme	
ecNumber	1.1.1.205	commentary	isozyme IMPDH2	
ecNumber	1.1.1.205	commentary	type 1 enzyme, retinal-specific isoforms IMPDH1(546) and IMPDH1(595) and canonical isoform IMPDH1(514)	
ecNumber	1.1.1.205	commentary	thiopurine-treated patients with inflammatory bowel disease	
ecNumber	1.1.1.205	commentary	isoforms IMPDH1 and IMPDH2	
ecNumber	1.1.1.205	commentary	patients with kidney transplantation	
ecNumber	1.1.1.205	commentary	IMPDH type II	
ecNumber	1.1.1.205	commentary	stable kidney transplant recipients	
ecNumber	1.1.1.205	commentary	renal transplant patients	
ecNumber	1.1.1.205	commentary		
ecNumber	1.1.1.205	commentary	type II	
ecNumber	1.1.1.205	commentary	IMPDH 2	
ecNumber	1.1.1.205	commentary	isoform IMPDH 2	
ecNumber	1.1.1.205	commentary	isoform IMPDH2	
ecNumber	1.1.1.205	commentary		
ecNumber	1.1.1.205	commentary	IMPDH2	
ecNumber	1.1.1.205	commentary	type I isozyme	
ecNumber	1.1.1.205	commentary		
ecNumber	1.1.1.205	commentary	IMPDH 1	
ecNumber	1.1.1.205	commentary	isoform IMPDH 1	
ecNumber	1.1.1.205	commentary	isoform IMPDH1	
ecNumber	1.1.1.205	commentary	IMPDH1	
ecNumber	1.1.1.209	commentary		
ecNumber	1.1.1.211	commentary		
ecNumber	1.1.1.211	commentary		
ecNumber	1.1.1.213	commentary		
ecNumber	1.1.1.213	commentary		
ecNumber	1.1.1.213	commentary	gene AKR1C2 or DDH2	
ecNumber	1.1.1.213	commentary		
ecNumber	1.1.1.218	commentary		
ecNumber	1.1.1.220	commentary	enzyme is identical to aldose reductase	
ecNumber	1.1.1.225	commentary		
ecNumber	1.1.1.231	commentary		
ecNumber	1.1.1.239	commentary		
ecNumber	1.1.1.239	commentary		
ecNumber	1.1.1.270	commentary	3-ketosteroid reductase activity of the human 3(alpha-beta)-hydroxysteroid epimerase; human	
ecNumber	1.1.1.270	commentary	isozymes AKR1C1 and AKR1C2	
ecNumber	1.1.1.270	commentary		
ecNumber	1.1.1.270	commentary		
ecNumber	1.1.1.270	commentary		
ecNumber	1.1.1.271	commentary		
ecNumber	1.1.1.271	commentary	gene fx	
ecNumber	1.1.1.278	commentary		
ecNumber	1.1.1.284	commentary	class II alcohol dehydrogenase	
ecNumber	1.1.1.284	commentary		
ecNumber	1.1.1.300	commentary	recombinant enzyme	
ecNumber	1.1.1.300	commentary	Austrian kindreds with individuals affected by autosomal recessive childhood-onset severe retinal dystrophy	
ecNumber	1.1.1.300	commentary	isoform RDH12	
ecNumber	1.1.1.300	commentary	isoforms RDH12 and RDH13	
ecNumber	1.1.1.300	commentary		
ecNumber	1.1.1.300	commentary		
ecNumber	1.1.1.300	commentary		
ecNumber	1.1.1.300	commentary		
ecNumber	1.1.1.300	commentary		
ecNumber	1.1.1.300	commentary	; recombinant enzyme	
ecNumber	1.1.1.300	commentary		
ecNumber	1.1.1.300	commentary	; isoform 4, from full length cDNA, isoform of NRDR without residues 85-118; alternatively spliced variant NRDRB1 with a complete deletion of exon 3, activity of NRDRB1 much lower than activity of NRDR in forward and reverse reaction; isoform 5, from full length cDNA, isoform of NRDR without residues 85-118 and 160-204; alternatively spliced variant NRDRB2 with a complete deletion of exons 3 and 6; isoform 6, from full length cDNA, isoform of NRDR without residues 1-203; alternatively spliced variant NRDRA1 with a complete deletion of exons 3-6	
ecNumber	1.1.1.300	commentary	recombinant enzyme	
ecNumber	1.1.1.300	commentary		
ecNumber	1.1.1.300	commentary		
ecNumber	1.1.1.305	commentary		
ecNumber	1.1.1.315	commentary	isoform Rdh10	
ecNumber	1.1.1.315	commentary		
ecNumber	1.1.1.315	commentary		
ecNumber	1.1.1.315	commentary		
ecNumber	1.1.1.345	commentary		
ecNumber	1.1.1.357	commentary		
ecNumber	1.1.1.357	commentary		
ecNumber	1.1.1.357	commentary		
ecNumber	1.1.1.357	commentary		
ecNumber	1.1.1.357	commentary		
ecNumber	1.1.1.391	commentary		
ecNumber	1.1.2.4	commentary		
ecNumber	1.1.3.15	commentary		
ecNumber	1.1.3.15	commentary		
ecNumber	1.1.3.27	commentary		
ecNumber	1.1.5.3	commentary		
ecNumber	1.1.5.3	commentary		
ecNumber	1.1.99.1	commentary	gene Chdh	
ecNumber	1.1.99.1	commentary		
ecNumber	1.1.99.2	commentary		
ecNumber	1.1.99.2	commentary	families affected from L-2-hydroxyglutaric aciduria	
ecNumber	1.1.99.2	commentary		
ecNumber	1.1.99.6	commentary		
ecNumber	1.1.99.24	commentary		
ecNumber	1.1.99.24	commentary		
ecNumber	1.1.99.28	commentary		
ecNumber	1.1.99.39	commentary		
ecNumber	1.1.99.39	commentary		
ecNumber	1.2.1.3	commentary	isoenzyme E1, E2, and E3	
ecNumber	1.2.1.3	commentary	isoenzyme E3	
ecNumber	1.2.1.3	commentary	usual livers contains cytosolic ALDH1 and ALDH2, the atypical phenotype contains only the ALDH1 isoenzyme and immunologically cross-reactive material resulting from a mutation of the ALDH2 locus. 50% of orientals are atypical in respect to ALDH isoenzymes	
ecNumber	1.2.1.3	commentary		
ecNumber	1.2.1.3	commentary		
ecNumber	1.2.1.3	commentary		
ecNumber	1.2.1.3	commentary		
ecNumber	1.2.1.3	commentary		
ecNumber	1.2.1.4	commentary		
ecNumber	1.2.1.5	commentary	isoenzyme E1 and E2	
ecNumber	1.2.1.5	commentary	ALDH3	
ecNumber	1.2.1.5	commentary		
ecNumber	1.2.1.5	commentary		
ecNumber	1.2.1.5	commentary		
ecNumber	1.2.1.5	commentary		
ecNumber	1.2.1.8	commentary		
ecNumber	1.2.1.8	commentary	aldehyde dehydrogenase E3 isoenzyme is a betaine aldehyde dehydrogenase	
ecNumber	1.2.1.12	commentary		
ecNumber	1.2.1.12	commentary		
ecNumber	1.2.1.12	commentary		
ecNumber	1.2.1.13	commentary		
ecNumber	1.2.1.18	commentary		
ecNumber	1.2.1.19	commentary		
ecNumber	1.2.1.23	commentary		
ecNumber	1.2.1.24	commentary	single nucleotide polymorphism in the coding sequence as well as in the exons and the 5'-regulatory region of the succinic semialdehyde dehydrogenase gene can not be related to idiopathic generalized epilepsy or abnormal photoparoxysomal response	
ecNumber	1.2.1.24	commentary		
ecNumber	1.2.1.24	commentary		
ecNumber	1.2.1.24	commentary	complete sequence of cDNA clone H46643 with C538/transition; naturally occuring missense variants, which may significantly contribute to inter-individual variation of SSADH activity, possibly influencing endogenous level of 4-aminobutyric acid and 4-hydroxybutyric acid	
ecNumber	1.2.1.27	commentary		
ecNumber	1.2.1.27	commentary		
ecNumber	1.2.1.31	commentary		
ecNumber	1.2.1.31	commentary		
ecNumber	1.2.1.31	commentary		
ecNumber	1.2.1.36	commentary		
ecNumber	1.2.1.36	commentary		
ecNumber	1.2.1.36	commentary		
ecNumber	1.2.1.41	commentary		
ecNumber	1.2.1.46	commentary		
ecNumber	1.2.1.47	commentary		
ecNumber	1.2.1.48	commentary	Sjoegren-Larsson syndrome is caused by mutations in the ALDH3A2 gene. Diversity of mutations and polymorphisms in the fatty aldehyde dehydrogenase gene ALDH3A2	
ecNumber	1.2.1.48	commentary	Sj&ouml;gren-Larsson syndrome is caused by mutations in the ALDH3A2 gene that codes for FALDH	
ecNumber	1.2.1.48	commentary		
ecNumber	1.2.1.48	commentary		
ecNumber	1.2.1.49	commentary		
ecNumber	1.2.1.84	commentary	FAR1	
ecNumber	1.2.1.84	commentary		
ecNumber	1.2.1.88	commentary		
ecNumber	1.2.1.88	commentary		
ecNumber	1.2.2.4	commentary		
ecNumber	1.2.3.1	commentary	Japanese children	
ecNumber	1.2.3.1	commentary		
ecNumber	1.2.3.1	commentary		
ecNumber	1.2.4.1	commentary	hyperdiploid strain of Ehrlich-Lettre ascites carcinoma cells	
ecNumber	1.2.4.1	commentary	comparison of recombinant somatic cell-specific isoform PDH1 and testis-specific isoform PDH2	
ecNumber	1.2.4.1	commentary		
ecNumber	1.2.4.1	commentary		
ecNumber	1.2.4.2	commentary	enzyme is part of the alpha-ketoglutarate dehydrogenase complex KGDHC	
ecNumber	1.2.4.2	commentary	enzyme E2 is a component of the 2-oxoglutarate dehydrogenase multienzyme complex	
ecNumber	1.2.4.2	commentary		
ecNumber	1.2.4.2	commentary		
ecNumber	1.2.4.2	commentary		
ecNumber	1.2.4.4	commentary	the lipoic acid-bearing domain is part of the E2 transacylase subunit of the branched-chain alpha-keto acid dehydrogenase complex	
ecNumber	1.2.4.4	commentary		
ecNumber	1.2.98.1	commentary	liver alcoholdehydrogenase class II, class I isoenzymes beta1,beta1 and gamma2,gamma2	
ecNumber	1.3.1.1	commentary	colorectal cancer patients treated with 5-fluorouracil	
ecNumber	1.3.1.1	commentary		
ecNumber	1.3.1.2	commentary	healthy Japanese volunteers	
ecNumber	1.3.1.2	commentary	patients who underwent curative resection for lung cancer	
ecNumber	1.3.1.2	commentary		
ecNumber	1.3.1.2	commentary		
ecNumber	1.3.1.3	commentary	gene AKR1D1	
ecNumber	1.3.1.3	commentary		
ecNumber	1.3.1.3	commentary	gene SRD5B1	
ecNumber	1.3.1.3	commentary		
ecNumber	1.3.1.6	commentary		
ecNumber	1.3.1.B13	commentary		
ecNumber	1.3.1.16	commentary		
ecNumber	1.3.1.20	commentary	DD2	
ecNumber	1.3.1.20	commentary	DD4	
ecNumber	1.3.1.20	commentary	DD1, DD4	
ecNumber	1.3.1.20	commentary	DD1, DD2	
ecNumber	1.3.1.20	commentary	Cell lines constitutively overexpressing enzyme isoform 1 or 2	
ecNumber	1.3.1.20	commentary	patients with esophageal squamous cell carcinoma	
ecNumber	1.3.1.20	commentary	role of enzyme in formation of benzo[a]pyrene adducts	
ecNumber	1.3.1.20	commentary	patients with ovarian cancer	
ecNumber	1.3.1.20	commentary		
ecNumber	1.3.1.20	commentary	DD1, DD2, DD4, type 2 3alpha-hydroxysteroid/dihydrodiol dehydrogenase	
ecNumber	1.3.1.20	commentary	aldo-keto reductase family 1 member C2, AKR1C2	
ecNumber	1.3.1.20	commentary	DD1, DD2	
ecNumber	1.3.1.20	commentary	aldo-keto reductase family 1 member C1, AKR1C1	
ecNumber	1.3.1.21	commentary	gene dhcr7, enzyme DHCR7	
ecNumber	1.3.1.21	commentary	expression in Caenorhabditis elegans	
ecNumber	1.3.1.21	commentary	patients with Smith-Lemli-Opitz syndrome	
ecNumber	1.3.1.21	commentary	gene DHCR7	
ecNumber	1.3.1.21	commentary		
ecNumber	1.3.1.21	commentary	enzyme Dhcr7, gene dhcr7	
ecNumber	1.3.1.21	commentary	enzyme Dhcr7, no additional isoforms, no alternative splicing	
ecNumber	1.3.1.21	commentary	patient with Smith-Lemli-Opitz syndrome	
ecNumber	1.3.1.22	commentary	2 isozymes 5alpha-R1 and 5alpha-R2	
ecNumber	1.3.1.22	commentary	isoform I and II	
ecNumber	1.3.1.22	commentary	recombinant isoforms 1 and 2, expressed in baculoviral system	
ecNumber	1.3.1.22	commentary	; male and female, 2 isozymes 5alphaR-1 and 5alphaR-2	
ecNumber	1.3.1.22	commentary	patients, median age 70, range 55-86 years	
ecNumber	1.3.1.22	commentary		
ecNumber	1.3.1.22	commentary	isoform steroid 5-alpha-reductase 1	
ecNumber	1.3.1.22	commentary	isoform 5alpha-SR2	
ecNumber	1.3.1.22	commentary	isoform steroid 5-alpha-reductase 2	
ecNumber	1.3.1.22	commentary	isoform SRDA2	
ecNumber	1.3.1.22	commentary	isoform SRDA3	
ecNumber	1.3.1.24	commentary	expression in 293A cell, increase in level of heme oxigenase 1 mRNA and protein	
ecNumber	1.3.1.24	commentary		
ecNumber	1.3.1.24	commentary		
ecNumber	1.3.1.24	commentary		
ecNumber	1.3.1.27	commentary		
ecNumber	1.3.1.34	commentary	female, in the neonatal period	
ecNumber	1.3.1.34	commentary		
ecNumber	1.3.1.34	commentary		
ecNumber	1.3.1.38	commentary	expression in Escherichia coli fused to maltose-binding protein	
ecNumber	1.3.1.38	commentary		
ecNumber	1.3.1.38	commentary		
ecNumber	1.3.1.48	commentary		
ecNumber	1.3.1.70	commentary	human	
ecNumber	1.3.1.70	commentary	gene TM7SF2, enzyme SR-1	
ecNumber	1.3.1.70	commentary		
ecNumber	1.3.1.70	commentary	patient, mutant TM7SF2	
ecNumber	1.3.1.70	commentary	gene TM7SF2	
ecNumber	1.3.1.70	commentary	patient, mutant LBR	
ecNumber	1.3.1.72	commentary	human	
ecNumber	1.3.1.72	commentary	gene DHCR24	
ecNumber	1.3.1.72	commentary		
ecNumber	1.3.1.72	commentary		
ecNumber	1.3.1.74	commentary		
ecNumber	1.3.1.91	commentary		
ecNumber	1.3.1.94	commentary		
ecNumber	1.3.3.3	commentary	swedish patients suffering hereditary coproporphyria HCP	
ecNumber	1.3.3.3	commentary	male dentists and female dental assistents	
ecNumber	1.3.3.3	commentary	dentists and dental assistents	
ecNumber	1.3.3.3	commentary	; patients with hereditary coproporphyria	
ecNumber	1.3.3.3	commentary		
ecNumber	1.3.3.3	commentary	male patient with a typical attack of hepatic porphyria	
ecNumber	1.3.3.3	commentary	precursor	
ecNumber	1.3.3.4	commentary		
ecNumber	1.3.3.4	commentary	healthy persons and finnish variegate porphyria patients	
ecNumber	1.3.3.4	commentary		
ecNumber	1.3.3.6	commentary		
ecNumber	1.3.3.6	commentary	ACOX1a and ACOX1b isoforms are encoded by a single gene	
ecNumber	1.3.3.6	commentary		
ecNumber	1.3.5.1	commentary	succinate dehydrogenase	
ecNumber	1.3.5.1	commentary	; genes SDHC, SDHD, and SDHB	
ecNumber	1.3.5.1	commentary	genes SDHD and SDHB	
ecNumber	1.3.5.1	commentary	genes SDHB and SDHD	
ecNumber	1.3.5.1	commentary	subunit encoding genes SDHA, and SDHD	
ecNumber	1.3.5.1	commentary	patients with pheochromocytomas or paragangliomas	
ecNumber	1.3.5.1	commentary		
ecNumber	1.3.5.1	commentary	gene SDHB; subunit B encoding gene SDHB	
ecNumber	1.3.5.1	commentary	gene SDHC; subunit C encoding gene SDHC	
ecNumber	1.3.5.2	commentary	; truncated recombinant protein	
ecNumber	1.3.5.2	commentary	; U937 membranes	
ecNumber	1.3.5.2	commentary	; recombinant protein	
ecNumber	1.3.5.2	commentary	truncated recombinant protein	
ecNumber	1.3.5.2	commentary	recombinant protein	
ecNumber	1.3.5.2	commentary	recombinant truncated enzyme	
ecNumber	1.3.5.2	commentary		
ecNumber	1.3.5.2	commentary		
ecNumber	1.3.5.2	commentary		
ecNumber	1.3.8.1	commentary		
ecNumber	1.3.8.1	commentary		
ecNumber	1.3.8.1	commentary	gene ACADS	
ecNumber	1.3.8.4	commentary	expressed in Escherichia coli	
ecNumber	1.3.8.4	commentary	genetic mutation profile of isovaleric acidemia patients in Taiwan	
ecNumber	1.3.8.4	commentary		
ecNumber	1.3.8.4	commentary		
ecNumber	1.3.8.6	commentary	recombinant enzyme	
ecNumber	1.3.8.6	commentary	patient suffering glutaric aciduria type I	
ecNumber	1.3.8.6	commentary	patient suffering glutaric aciduria type I, an autosomal recessive inborn error	
ecNumber	1.3.8.6	commentary	black South African population	
ecNumber	1.3.8.6	commentary		
ecNumber	1.3.8.6	commentary	mature mitochondrial enzyme without targeting sequence	
ecNumber	1.3.8.6	commentary		
ecNumber	1.3.8.7	commentary	skin fibroblast cell lines from healthy subjects and from patients with medium-chain, long-chain and with multiple-chain acyl-CoA dehydrogenase deficiency	
ecNumber	1.3.8.7	commentary	K304E point mutation leading to a higher susceptibility of the mutant enzyme for degradation is one of several mutations, which are responsible for medium chain acyl-CoA dehydrogenase deficiency	
ecNumber	1.3.8.7	commentary	T168A mutation found in patients with medium-chain acyl-CoA deficiency	
ecNumber	1.3.8.7	commentary	Japanese patients with medium-chain acyl-CoA dehydrogenase deficiency	
ecNumber	1.3.8.7	commentary	gene ACADM	
ecNumber	1.3.8.7	commentary		
ecNumber	1.3.8.7	commentary		
ecNumber	1.3.8.8	commentary	8-year-old male autistic patient	
ecNumber	1.3.8.8	commentary		
ecNumber	1.3.8.8	commentary		
ecNumber	1.3.8.9	commentary		
ecNumber	1.3.8.9	commentary		
ecNumber	1.3.98.1	commentary	patients with rheumatoid arthritis	
ecNumber	1.3.98.3	commentary		
ecNumber	1.3.98.3	commentary	gene cig5	
ecNumber	1.3.99.5	commentary	recombinant isoforms I and II, expression in HEK293 cells	
ecNumber	1.3.99.5	commentary	patients with recurrent prostate cancer, isoforms I and II	
ecNumber	1.3.99.5	commentary	patients with hirsutism	
ecNumber	1.3.99.5	commentary	Korean sisters with male pseudohermaphroditism	
ecNumber	1.3.99.5	commentary	patients with homocystic ovary syndrome, isoforms SRD5A1 and SRD5A2	
ecNumber	1.3.99.5	commentary	isoforms 1 and 2	
ecNumber	1.3.99.5	commentary	patients with clinically localized prostate cancer	
ecNumber	1.3.99.5	commentary		
ecNumber	1.3.99.5	commentary		
ecNumber	1.3.99.5	commentary	gene SRD5A1	
ecNumber	1.3.99.5	commentary	gene SRD5A1; gene SRD5A1	
ecNumber	1.3.99.5	commentary		
ecNumber	1.3.99.5	commentary	gene SRD5A2; Ecuadorian population, gene SRD5A2	
ecNumber	1.3.99.5	commentary	gene SRD5A2; isozymes SRD5alpha1, SRD5alpha2, and SRD5alpha3	
ecNumber	1.3.99.5	commentary	gene SRD5A2; gene SRD5A2	
ecNumber	1.3.99.5	commentary	gene SRD5A2	
ecNumber	1.3.99.6	commentary	gene SRD5B1, enzyme AKR1D1, healthy persons and 3 different patients with neonatal onset cholestatic liver disease and normal gamma-glutamyl transpeptidase activity	
ecNumber	1.3.99.6	commentary		
ecNumber	1.3.99.12	commentary		
ecNumber	1.3.99.23	commentary		
ecNumber	1.4.1.2	commentary		
ecNumber	1.4.1.3	commentary		
ecNumber	1.4.1.3	commentary	two human isozymes hGDH1 and hGDH2, genes GLUD1 and GLUD2	
ecNumber	1.4.1.3	commentary		
ecNumber	1.4.1.3	commentary	gene GLUD2 encoding isozyme GDH2	
ecNumber	1.4.1.3	commentary		
ecNumber	1.4.1.4	commentary		
ecNumber	1.4.1.10	commentary		
ecNumber	1.4.1.15	commentary		
ecNumber	1.4.3.1	commentary		
ecNumber	1.4.3.1	commentary		
ecNumber	1.4.3.2	commentary	lymphoid and non lymphoid malignancies, lymphoma cell lines L428, KM-H2, and SU-DHL-4	
ecNumber	1.4.3.2	commentary		
ecNumber	1.4.3.3	commentary	recombinant	
ecNumber	1.4.3.3	commentary	Norwegian schizophrenia patients	
ecNumber	1.4.3.3	commentary		
ecNumber	1.4.3.3	commentary		
ecNumber	1.4.3.4	commentary	isozyme MAO A	
ecNumber	1.4.3.4	commentary	Korean individuals	
ecNumber	1.4.3.4	commentary	male children	
ecNumber	1.4.3.4	commentary	MAO-A and MAO-B are encoded by separate genes	
ecNumber	1.4.3.4	commentary	isozyme MAO-B	
ecNumber	1.4.3.4	commentary		
ecNumber	1.4.3.4	commentary	expressed in Saccharomyces cerevisiae	
ecNumber	1.4.3.4	commentary	expressed in Pichia pastoris strain KM71	
ecNumber	1.4.3.4	commentary	recombinant	
ecNumber	1.4.3.4	commentary	MAOA	
ecNumber	1.4.3.4	commentary		
ecNumber	1.4.3.4	commentary	recombinant	
ecNumber	1.4.3.4	commentary	transgenic C57Bl6 mice inducibly expressing human MAO-B selectively within astrocytes	
ecNumber	1.4.3.4	commentary	MAOB	
ecNumber	1.4.3.4	commentary	MAO-B; isozyme MAO B	
ecNumber	1.4.3.4	commentary		
ecNumber	1.4.3.5	commentary	overview	
ecNumber	1.4.3.5	commentary		
ecNumber	1.4.3.5	commentary		
ecNumber	1.4.3.13	commentary	structurally and functionally diverse enzyme forms: lysyl oxidase and 4 LOX-like proteins LOXL, LOXL2, LOXL3, and LOXL4, probably existing splicing variants of LOXL3	
ecNumber	1.4.3.13	commentary	lysyl oxidase LO and several lysyloxidase-like proteins LOXL1-4	
ecNumber	1.4.3.13	commentary	enzyme forms: lysyl oxidase and 4 LOX-like proteins LOXL1, LOXL2, LOXL3, and LOXL4	
ecNumber	1.4.3.13	commentary	isoenzymes LOXL, LOXL2, LOXL3, and LOXL4	
ecNumber	1.4.3.13	commentary		
ecNumber	1.4.3.13	commentary		
ecNumber	1.4.3.13	commentary		
ecNumber	1.4.3.13	commentary		
ecNumber	1.4.3.21	commentary	recombinant	
ecNumber	1.4.3.21	commentary		
ecNumber	1.4.3.21	commentary	AOC2	
ecNumber	1.4.3.21	commentary	AOC3	
ecNumber	1.4.3.21	commentary		
ecNumber	1.4.3.22	commentary	recombinant	
ecNumber	1.4.3.22	commentary		
ecNumber	1.4.3.22	commentary	in human three functioning genes exist that encode copper-containing amine oxidases	
ecNumber	1.4.3.22	commentary	gene AOC1	
ecNumber	1.4.3.22	commentary		
ecNumber	1.4.4.2	commentary	; adult patients with mild hyperglycinemia, infantile hypotonia, mental retardation, behavioral hyperirritability, and aggressive outbursts	
ecNumber	1.4.4.2	commentary		
ecNumber	1.4.4.2	commentary		
ecNumber	1.4.4.2	commentary		
ecNumber	1.5.1.2	commentary		
ecNumber	1.5.1.2	commentary	patients with cutis laxia type 2	
ecNumber	1.5.1.2	commentary		
ecNumber	1.5.1.3	commentary	cultured mammalian cells, overview	
ecNumber	1.5.1.3	commentary	methotrexate-resistant WIL-2 lymphoblastoid cells; methotrexate-sensitive cell line HeLa BU-25, methotrexate-insensitive cell line VA2-B	
ecNumber	1.5.1.3	commentary	methotrexate-resistant WIL-2 lymphoblastoid cells	
ecNumber	1.5.1.3	commentary	cancer patients with and without thrombosis	
ecNumber	1.5.1.3	commentary	patients with osteosarcoma	
ecNumber	1.5.1.3	commentary	children with acute lymphoblastic leukemia	
ecNumber	1.5.1.3	commentary	c.86 + 60_78 insertion/deletion polymorphism is associated with serum and red blood cell folate concentrations in women	
ecNumber	1.5.1.3	commentary	mothers of a spina bifida affected child, spina biWda patients, and controls	
ecNumber	1.5.1.3	commentary		
ecNumber	1.5.1.3	commentary		
ecNumber	1.5.1.3	commentary		
ecNumber	1.5.1.5	commentary	MCF-7, M4, LS-180, CCRF-CEM, MG-63	
ecNumber	1.5.1.5	commentary	; enzyme is unique in mammals	
ecNumber	1.5.1.5	commentary		
ecNumber	1.5.1.5	commentary		
ecNumber	1.5.1.6	commentary		
ecNumber	1.5.1.6	commentary		
ecNumber	1.5.1.6	commentary		
ecNumber	1.5.1.8	commentary		
ecNumber	1.5.1.9	commentary	not separable from L-lysine-alpha-ketoglutarate reductase	
ecNumber	1.5.1.9	commentary		
ecNumber	1.5.1.15	commentary	human; normal human fibroblasts MCH-39, EBV-transformed normal human lymphoblast lines TL3 and TL4, human tumor lines MNNG/HOS(TE85 clone F-5), MCF-7, CCRF-CEM, osteosarcoma MG-63(ATCC CRL 1427), human chronic myeolitic leukemia line K562, Burkitt lymphoma line Raji, human choriocarcinoma BeWo, human intestinal carcinoma HCT	
ecNumber	1.5.1.15	commentary		
ecNumber	1.5.1.15	commentary	human	
ecNumber	1.5.1.15	commentary	patients with alcoholic cirrhosis	
ecNumber	1.5.1.15	commentary		
ecNumber	1.5.1.20	commentary	patients with enzyme deficiency	
ecNumber	1.5.1.20	commentary	healthy men and women aged 19-63 years	
ecNumber	1.5.1.20	commentary	recombinant enzyme, expression in Escherichia coli, Baculovirus system, or HEK293 cells	
ecNumber	1.5.1.20	commentary	patients with colorectal cancer	
ecNumber	1.5.1.20	commentary	patients with systemic sclerosis	
ecNumber	1.5.1.20	commentary	patients with Parkinson's disease	
ecNumber	1.5.1.20	commentary	patients with rheumatoid arthritis	
ecNumber	1.5.1.20	commentary	pediatric patients with acute lymphoblastic leukemia	
ecNumber	1.5.1.20	commentary	patients with bipolar disorder	
ecNumber	1.5.1.20	commentary		
ecNumber	1.5.1.20	commentary	patients with spina bifida	
ecNumber	1.5.1.20	commentary		
ecNumber	1.5.1.21	commentary		
ecNumber	1.5.1.25	commentary		
ecNumber	1.5.1.25	commentary		
ecNumber	1.5.1.30	commentary		
ecNumber	1.5.1.30	commentary		
ecNumber	1.5.1.30	commentary	bifunctional enzymebiliverdin reductase/flavin reductase (NADPH)	
ecNumber	1.5.1.30	commentary	gene fre-1	
ecNumber	1.5.1.34	commentary	enzyme from liver, fibroblast cultures and continous lymphoid cells shows identical antigenic properties	
ecNumber	1.5.1.34	commentary	activity is reduced in patients with haematological malignancies	
ecNumber	1.5.1.34	commentary		
ecNumber	1.5.1.34	commentary	patients from Calabria, Italy, one patient with traces of activity, two patients without activity	
ecNumber	1.5.1.34	commentary	patients with vitiligo	
ecNumber	1.5.1.34	commentary		
ecNumber	1.5.3.7	commentary		
ecNumber	1.5.3.7	commentary		
ecNumber	1.5.3.13	commentary		
ecNumber	1.5.3.13	commentary		
ecNumber	1.5.3.16	commentary	splice variant isozymes SMO1 and SMO5	
ecNumber	1.5.3.16	commentary	gene hSMO	
ecNumber	1.5.3.16	commentary		
ecNumber	1.5.3.16	commentary	gene SMOX, splice variant isozymes SMO1 and SMO5	
ecNumber	1.5.3.16	commentary		
ecNumber	1.5.5.1	commentary	gene is located to chromosome 4q33, deficiency of the enzyme causes glutaric acidemia type II	
ecNumber	1.5.5.1	commentary		
ecNumber	1.5.5.1	commentary	ETF-QO; patients suffering glutaric acidemia type II due to a mutational defect in the ETF:QO gene	
ecNumber	1.5.5.1	commentary		
ecNumber	1.5.5.2	commentary		
ecNumber	1.5.5.3	commentary		
ecNumber	1.5.5.3	commentary		
ecNumber	1.5.8.3	commentary		
ecNumber	1.5.8.4	commentary		
ecNumber	1.5.8.4	commentary		
ecNumber	1.5.99.B2	commentary		
ecNumber	1.5.99.B2	commentary	precursor	
ecNumber	1.5.99.B2	commentary	located on chromosome22 (22q11.2), region deleted in velo-cardio-facial syndrome	
ecNumber	1.6.1.1	commentary		
ecNumber	1.6.1.2	commentary		
ecNumber	1.6.1.2	commentary		
ecNumber	1.6.1.5	commentary		
ecNumber	1.6.1.5	commentary		
ecNumber	1.6.2.2	commentary	deficiency leads to 2 different types of recessive congenital methemoglobinemia, in type 1 the soluble enzyme in erythrocytes is affected, in type 2 both soluble and membrane-bound isoforms are affected	
ecNumber	1.6.2.2	commentary	different cancer cell lines	
ecNumber	1.6.2.2	commentary	patients with type I recessive congenital methaemoglobinaemia	
ecNumber	1.6.2.2	commentary	native and recombinant enzyme	
ecNumber	1.6.2.2	commentary		
ecNumber	1.6.2.2	commentary	sequence of natural mutant gene from a patient with recessive congenital methemoglobinemia; patients with recessive congenital methemoglobinemia	
ecNumber	1.6.2.2	commentary	patients with recessive hereditary methemoglobinemia due to cytochrome b5 reductase deficiency	
ecNumber	1.6.2.2	commentary		
ecNumber	1.6.2.2	commentary		
ecNumber	1.6.2.2	commentary		
ecNumber	1.6.2.4	commentary	Saccharomyces cerevisiae /Homo sapiens chimeric protein	
ecNumber	1.6.2.4	commentary		
ecNumber	1.6.2.4	commentary		
ecNumber	1.6.2.5	commentary	human, Morris hepatoma 7800 C1 cells	
ecNumber	1.6.3.1	commentary	multienzyme complex	
ecNumber	1.6.3.1	commentary	multicomponent NADPH-oxidase consisting of a heterodimeric flavocytochrome b558, localized in the membrane and at least two cytosolic components p47-phox and p67-phox, enzyme plays a role in chronic granulomatous diseases, enzyme system is activated upon exposure to the appropriate stimuli leading to assembly in the plasma membrane of membrane-bound and cytosolic components	
ecNumber	1.6.3.1	commentary	female	
ecNumber	1.6.3.1	commentary	isoform Nox1	
ecNumber	1.6.3.1	commentary	isoform THOX2, patients with congenital thyroidism	
ecNumber	1.6.3.1	commentary	isoform Nox3	
ecNumber	1.6.3.1	commentary	dual NADPH oxidases/peroxidases, Duox1 and Duox2. Regulation of expression by immunomodulatory Th1 and Th2 cytokines	
ecNumber	1.6.3.1	commentary	isoform Nox2, reconmbinant enzyme	
ecNumber	1.6.3.1	commentary	isoforms Duox1, Duox2, stable transfection in HEK293 and Chinese hamster ovary cells. Enzymes demonstrate a functional NADPH/Ca2+-dependent H2O2-generating activity. Human Duox2 is more active than human Duox1, but only half as active as its porcine counterpart	
ecNumber	1.6.3.1	commentary	isoform Duox2	
ecNumber	1.6.3.1	commentary	patients with sickle cell disease	
ecNumber	1.6.3.1	commentary	children with acute asthma	
ecNumber	1.6.3.1	commentary	patients with idiopathic pulmonary arterial hypertension	
ecNumber	1.6.3.1	commentary	patients with bronchial asthma	
ecNumber	1.6.3.1	commentary	isoform Nox4, expression in patients with neuroepithelial tumors	
ecNumber	1.6.3.1	commentary	isoform Nox5-S	
ecNumber	1.6.3.1	commentary	patients with atherosclerosis	
ecNumber	1.6.3.1	commentary	isoform dual oxidase 2	
ecNumber	1.6.3.1	commentary	high-risk cardiac patients with aspirin resistance	
ecNumber	1.6.3.1	commentary		
ecNumber	1.6.3.1	commentary		
ecNumber	1.6.3.1	commentary		
ecNumber	1.6.3.5	commentary		
ecNumber	1.6.3.5	commentary		
ecNumber	1.6.5.2	commentary	NAD(P)H:quinone acceptor oxidoreductase 2	
ecNumber	1.6.5.2	commentary	breast cancer cell lines	
ecNumber	1.6.5.2	commentary	recombinant enzyme	
ecNumber	1.6.5.2	commentary	recombinant enzyme expressed in Chinese hamster ovary cells	
ecNumber	1.6.5.2	commentary	patients with multiple sclerosis	
ecNumber	1.6.5.2	commentary	isoform NQO2	
ecNumber	1.6.5.2	commentary	recombinant enzyme, stably transfected to breast cancer cell line MDA468	
ecNumber	1.6.5.2	commentary	patients with sporadic colorectal cancer	
ecNumber	1.6.5.2	commentary	recombiant isoform NQO1	
ecNumber	1.6.5.2	commentary	patients with liver damage due to acetaminophen overdose or primary biliary cirrhosis	
ecNumber	1.6.5.2	commentary	; prostatic adenocarcinoma patients	
ecNumber	1.6.5.2	commentary	; patients with congestive heart failure after anthracycline treatment during childhood	
ecNumber	1.6.5.2	commentary	; patients with urothelial cancer in Taiwan	
ecNumber	1.6.5.2	commentary	; recombinant protein	
ecNumber	1.6.5.2	commentary	breast cancer patients	
ecNumber	1.6.5.2	commentary	simoidoscopy patients	
ecNumber	1.6.5.2	commentary		
ecNumber	1.6.5.2	commentary	comparison with quinone reductase 2	
ecNumber	1.6.5.2	commentary	; recombinant protein and in human colon adenocarcinoma cells	
ecNumber	1.6.5.2	commentary		
ecNumber	1.6.5.3	commentary	patients with Parkinson's disease from an Indian population	
ecNumber	1.6.5.3	commentary		
ecNumber	1.6.5.3	commentary		
ecNumber	1.6.5.3	commentary		
ecNumber	1.6.5.4	commentary		
ecNumber	1.6.5.5	commentary		
ecNumber	1.6.5.5	commentary		
ecNumber	1.6.5.8	commentary		
ecNumber	1.6.5.10	commentary	urothelial carcinoma patients	
ecNumber	1.6.5.10	commentary		
ecNumber	1.6.99.1	commentary		
ecNumber	1.6.99.3	commentary		
ecNumber	1.7.1.1	commentary		
ecNumber	1.7.1.7	commentary		
ecNumber	1.7.1.7	commentary		
ecNumber	1.7.1.7	commentary		
ecNumber	1.7.1.10	commentary		
ecNumber	1.7.1.10	commentary	HepG2 cells	
ecNumber	1.7.1.10	commentary	2 enzyme forms are present, one may be identical to the multienzyme complex from pig	
ecNumber	1.7.2.1	commentary		
ecNumber	1.7.2.1	commentary		
ecNumber	1.7.2.1	commentary		
ecNumber	1.7.3.3	commentary		
ecNumber	1.8.1.B1	commentary		
ecNumber	1.8.1.4	commentary		
ecNumber	1.8.1.4	commentary		
ecNumber	1.8.1.6	commentary		
ecNumber	1.8.1.7	commentary		
ecNumber	1.8.1.7	commentary		
ecNumber	1.8.1.8	commentary		
ecNumber	1.8.1.9	commentary	3 different isoforms TR1, TR2, TR3; cell line JPX9	
ecNumber	1.8.1.9	commentary	HeLa cells	
ecNumber	1.8.1.9	commentary	recombinant	
ecNumber	1.8.1.9	commentary		
ecNumber	1.8.1.9	commentary	patients with rheumatoid arthritis	
ecNumber	1.8.1.9	commentary	isoform TR1	
ecNumber	1.8.1.9	commentary		
ecNumber	1.8.1.9	commentary		
ecNumber	1.8.1.9	commentary		
ecNumber	1.8.1.12	commentary		
ecNumber	1.8.2.1	commentary		
ecNumber	1.8.3.1	commentary	expression in Escherichia coli	
ecNumber	1.8.3.1	commentary		
ecNumber	1.8.3.1	commentary	three patients with isolated sulfite oxidase deficiency, who manifested intractable seizures and severe hypotonia in the immediate postnatal period with an unknown diagnosis, despite extensive workup	
ecNumber	1.8.3.1	commentary		
ecNumber	1.8.3.2	commentary	Alrp protein	
ecNumber	1.8.3.2	commentary		
ecNumber	1.8.3.2	commentary	gene QSOX1	
ecNumber	1.8.3.2	commentary		
ecNumber	1.8.3.2	commentary		
ecNumber	1.8.3.2	commentary		
ecNumber	1.8.3.B2	commentary		
ecNumber	1.8.3.3	commentary		
ecNumber	1.8.3.5	commentary		
ecNumber	1.8.3.5	commentary		
ecNumber	1.8.3.7	commentary		
ecNumber	1.8.3.7	commentary		
ecNumber	1.8.3.7	commentary		
ecNumber	1.8.3.7	commentary		
ecNumber	1.8.4.2	commentary	macrophage migration inhibitory factor is a cytokine and pituitary hormone	
ecNumber	1.8.4.2	commentary		
ecNumber	1.8.4.B3	commentary		
ecNumber	1.8.4.B3	commentary		
ecNumber	1.8.4.11	commentary		
ecNumber	1.8.4.11	commentary	alternative splicing variants, overview	
ecNumber	1.8.4.11	commentary	female caucasian individuals	
ecNumber	1.8.4.11	commentary		
ecNumber	1.8.4.11	commentary	isozyme MsrA3; alternative splicing variants, overview	
ecNumber	1.8.4.11	commentary		
ecNumber	1.8.4.12	commentary	MsrB variants one of which is also called Sel-X, encoded by distinct genes, MsrB is a selenoprotein	
ecNumber	1.8.4.12	commentary	MsrB, one isozyme of which is termed CBS-1	
ecNumber	1.8.4.12	commentary	several splicing variants resulting in three isozymes MsrB1-3	
ecNumber	1.8.4.12	commentary	isozymes MsrB1-3	
ecNumber	1.8.4.12	commentary	isozymes MsrB1 or selenoprotein R, MsrB2 or CBS-1, and MsrB3	
ecNumber	1.8.4.12	commentary	isozymes MsrB1, MsrB2, and MsrB3	
ecNumber	1.8.4.12	commentary	isozyme MsrB2	
ecNumber	1.8.4.12	commentary		
ecNumber	1.8.4.12	commentary	; overexpressed in Escherichia coli BL21	
ecNumber	1.8.4.12	commentary		
ecNumber	1.8.4.12	commentary		
ecNumber	1.8.4.12	commentary		
ecNumber	1.8.5.1	commentary		
ecNumber	1.8.5.1	commentary		
ecNumber	1.8.5.1	commentary	isoform GSTO-1	
ecNumber	1.8.5.1	commentary		
ecNumber	1.8.5.4	commentary		
ecNumber	1.8.5.4	commentary		
ecNumber	1.8.98.2	commentary		
ecNumber	1.8.98.2	commentary		
ecNumber	1.9.3.1	commentary	recombinant enzyme expressed in Escherichia coli, comparison with Arabidopsis thaliana and horse enzyme	
ecNumber	1.9.3.1	commentary	patients with mutations in genes SCO2 or SURF1 affecting enzyme assembly	
ecNumber	1.9.3.1	commentary	isoform cytochrome oxidase III	
ecNumber	1.9.3.1	commentary		
ecNumber	1.9.3.1	commentary		
ecNumber	1.10.2.2	commentary	human	
ecNumber	1.10.2.2	commentary		
ecNumber	1.10.2.2	commentary		
ecNumber	1.10.3.1	commentary		
ecNumber	1.10.3.3	commentary		
ecNumber	1.10.3.5	commentary	human	
ecNumber	1.10.5.1	commentary	stably expressed in CHO cells	
ecNumber	1.10.5.1	commentary	expressed in CHO cells	
ecNumber	1.10.5.1	commentary	recombinant	
ecNumber	1.10.5.1	commentary		
ecNumber	1.10.5.1	commentary	comparison with quinone reductase 1	
ecNumber	1.10.5.1	commentary	recombinant	
ecNumber	1.10.5.1	commentary		
ecNumber	1.11.1.2	commentary		
ecNumber	1.11.1.6	commentary	patients with acne vulgaris	
ecNumber	1.11.1.6	commentary		
ecNumber	1.11.1.6	commentary		
ecNumber	1.11.1.7	commentary		
ecNumber	1.11.1.7	commentary	thioredoxin peroxidase	
ecNumber	1.11.1.7	commentary		
ecNumber	1.11.1.7	commentary		
ecNumber	1.11.1.8	commentary	two isoforms found	
ecNumber	1.11.1.8	commentary	recombinant	
ecNumber	1.11.1.8	commentary	patients with hypothyroidism who have features suggestive of an iodotyrosine deiodinase defect for mutations in DEHAL1	
ecNumber	1.11.1.8	commentary		
ecNumber	1.11.1.8	commentary		
ecNumber	1.11.1.9	commentary	Saos-2 cell line; U2-OS cell line	
ecNumber	1.11.1.9	commentary	Hep-G2 cells	
ecNumber	1.11.1.9	commentary	; transgenic mice with 200 copies of the human GPx-1 gene	
ecNumber	1.11.1.9	commentary		
ecNumber	1.11.1.9	commentary		
ecNumber	1.11.1.9	commentary		
ecNumber	1.11.1.9	commentary		
ecNumber	1.11.1.9	commentary		
ecNumber	1.11.1.9	commentary		
ecNumber	1.11.1.9	commentary		
ecNumber	1.11.1.9	commentary		
ecNumber	1.11.1.9	commentary		
ecNumber	1.11.1.12	commentary		
ecNumber	1.11.1.12	commentary		
ecNumber	1.11.1.12	commentary		
ecNumber	1.11.1.15	commentary		
ecNumber	1.11.1.15	commentary		
ecNumber	1.11.1.15	commentary		
ecNumber	1.11.1.15	commentary		
ecNumber	1.11.1.15	commentary		
ecNumber	1.11.1.15	commentary		
ecNumber	1.11.2.2	commentary	myeloperoxidase and eosinophil peroxidase	
ecNumber	1.11.2.2	commentary	myeloperoxidase has six isozymes	
ecNumber	1.11.2.2	commentary	myeloperoxidase	
ecNumber	1.11.2.2	commentary		
ecNumber	1.11.2.2	commentary		
ecNumber	1.13.11.5	commentary		
ecNumber	1.13.11.5	commentary		
ecNumber	1.13.11.6	commentary		
ecNumber	1.13.11.6	commentary		
ecNumber	1.13.11.11	commentary		
ecNumber	1.13.11.11	commentary		
ecNumber	1.13.11.11	commentary		
ecNumber	1.13.11.11	commentary		
ecNumber	1.13.11.12	commentary		
ecNumber	1.13.11.17	commentary		
ecNumber	1.13.11.18	commentary		
ecNumber	1.13.11.19	commentary		
ecNumber	1.13.11.20	commentary		
ecNumber	1.13.11.20	commentary		
ecNumber	1.13.11.24	commentary		
ecNumber	1.13.11.27	commentary	enzyme form 1, 2, and 3	
ecNumber	1.13.11.27	commentary	enzyme form 3	
ecNumber	1.13.11.27	commentary		
ecNumber	1.13.11.27	commentary		
ecNumber	1.13.11.31	commentary	gene ALOX15	
ecNumber	1.13.11.31	commentary	platelet-type 12S-lipoxygenase isozyme	
ecNumber	1.13.11.31	commentary	isozyme 12-hLO	
ecNumber	1.13.11.31	commentary	isozymes P-12-LO and L-12-LO	
ecNumber	1.13.11.31	commentary		
ecNumber	1.13.11.31	commentary		
ecNumber	1.13.11.31	commentary		
ecNumber	1.13.11.31	commentary	isozyme platelet 12-hLO	
ecNumber	1.13.11.31	commentary		
ecNumber	1.13.11.33	commentary	two human isozymes: platelet 12-hLO, reticulocyte 15-hLO-1, and epithelial 15-hLO-2	
ecNumber	1.13.11.33	commentary	isozymes 15-hLO-1 and 15-hLO-2	
ecNumber	1.13.11.33	commentary	isozymes 15-HLOa and 15-HLOb	
ecNumber	1.13.11.33	commentary	isozyme 15-LO-1	
ecNumber	1.13.11.33	commentary		
ecNumber	1.13.11.33	commentary		
ecNumber	1.13.11.33	commentary	gene ALOX15	
ecNumber	1.13.11.33	commentary		
ecNumber	1.13.11.34	commentary		
ecNumber	1.13.11.34	commentary		
ecNumber	1.13.11.52	commentary	IDO2	
ecNumber	1.13.11.52	commentary	with lung cancer	
ecNumber	1.13.11.52	commentary	recombinant	
ecNumber	1.13.11.52	commentary		
ecNumber	1.13.11.52	commentary	definite classification as EC 1.13.11.52 based on protein sequence	
ecNumber	1.13.11.52	commentary	IDO1	
ecNumber	1.13.11.52	commentary		
ecNumber	1.13.11.52	commentary	definite classification as EC 1.13.11.11 based on protein sequence	
ecNumber	1.13.11.52	commentary		
ecNumber	1.13.11.52	commentary		
ecNumber	1.13.11.53	commentary		
ecNumber	1.13.11.53	commentary		
ecNumber	1.13.11.54	commentary		
ecNumber	1.13.11.54	commentary		
ecNumber	1.13.11.58	commentary		
ecNumber	1.13.11.63	commentary		
ecNumber	1.13.11.63	commentary	gene Bcmo1	
ecNumber	1.13.11.63	commentary	gene cmo1	
ecNumber	1.13.11.63	commentary	gene BCMO1; gene Bcmo1	
ecNumber	1.13.11.63	commentary		
ecNumber	1.13.11.71	commentary		
ecNumber	1.13.11.71	commentary		
ecNumber	1.13.99.1	commentary		
ecNumber	1.13.99.1	commentary		
ecNumber	1.13.99.3	commentary		
ecNumber	1.14.11.1	commentary	three isoforms	
ecNumber	1.14.11.1	commentary		
ecNumber	1.14.11.1	commentary		
ecNumber	1.14.11.B1	commentary	KDM4E	
ecNumber	1.14.11.B1	commentary	hypoxia can stimulate enzyme mRNA and protein expression, involving binding of hypoxia-induced factor 1 to a specific hypoxia responsive element in the enzyme's promoter	
ecNumber	1.14.11.B1	commentary	LSD1, i.e. KDM1	
ecNumber	1.14.11.B1	commentary		
ecNumber	1.14.11.B1	commentary		
ecNumber	1.14.11.B1	commentary	isoform JMJD2A	
ecNumber	1.14.11.B1	commentary		
ecNumber	1.14.11.B1	commentary	KDM4A; KDM4A	
ecNumber	1.14.11.B1	commentary	KDM4B	
ecNumber	1.14.11.B1	commentary	KDM4D	
ecNumber	1.14.11.B1	commentary	KDM4C	
ecNumber	1.14.11.2	commentary	Chinese patients with hereditary gingival fibromatosis	
ecNumber	1.14.11.2	commentary	isoform P4H	
ecNumber	1.14.11.2	commentary	prolyl-4-hydroxylase alpha 1	
ecNumber	1.14.11.2	commentary	isozymes P4H-I, P4H-II and P4H-III, or P4H-1, P4H-2 and P4H-3	
ecNumber	1.14.11.2	commentary	three isoforms I, II, III of the alpha-subunit	
ecNumber	1.14.11.2	commentary	sveral isozymes	
ecNumber	1.14.11.2	commentary		
ecNumber	1.14.11.2	commentary		
ecNumber	1.14.11.2	commentary	alpha-subunit	
ecNumber	1.14.11.2	commentary	alpha-subunit	
ecNumber	1.14.11.2	commentary		
ecNumber	1.14.11.2	commentary		
ecNumber	1.14.11.2	commentary	isoform EGLN2	
ecNumber	1.14.11.2	commentary		
ecNumber	1.14.11.2	commentary	isoform EGLN1	
ecNumber	1.14.11.2	commentary		
ecNumber	1.14.11.2	commentary	isoform EGLN3	
ecNumber	1.14.11.B2	commentary	isozymes JMJD2A, JMJD2B, and JMJD2C	
ecNumber	1.14.11.B2	commentary	gene AOF1	
ecNumber	1.14.11.B2	commentary	X-linked gene KDM5C	
ecNumber	1.14.11.B2	commentary		
ecNumber	1.14.11.B2	commentary	isoform LSD1	
ecNumber	1.14.11.B2	commentary		
ecNumber	1.14.11.B2	commentary		
ecNumber	1.14.11.4	commentary	HT 1080 sarcoma cells	
ecNumber	1.14.11.4	commentary	three isoenzymes	
ecNumber	1.14.11.4	commentary	3 isozyme LH1-3	
ecNumber	1.14.11.4	commentary	3 isozymes LH1-3, isozyme LH2 exists in 2 splicing variants LH2a and LH2b	
ecNumber	1.14.11.4	commentary	isozyme lysyl hydroxylase 1, i.e. LH1, Ehlers-Danlos syndrome type VIA patients	
ecNumber	1.14.11.4	commentary	isozyme LH3	
ecNumber	1.14.11.4	commentary	isozyme LH2	
ecNumber	1.14.11.4	commentary	gene PLOD2, encoding for splice variants LH2a and LH2b	
ecNumber	1.14.11.4	commentary		
ecNumber	1.14.11.4	commentary	genes PLOD1 and PLOD2	
ecNumber	1.14.11.4	commentary		
ecNumber	1.14.11.4	commentary	isozyme LH2, gene PLOD2; gene PLOD2 encoding isozyme LH2	
ecNumber	1.14.11.4	commentary	2 splicing variants of isozyme LH2, termed LH2long and LH2short	
ecNumber	1.14.11.4	commentary		
ecNumber	1.14.11.4	commentary	isozyme LH3, gene PLOD3	
ecNumber	1.14.11.4	commentary	; isoform LH3, possessing lysyl hydroxylase, collagengalactosyltransferase and glucosyltransferase activities	
ecNumber	1.14.11.4	commentary	gene Plod3	
ecNumber	1.14.11.4	commentary		
ecNumber	1.14.11.7	commentary		
ecNumber	1.14.11.7	commentary	isoforms P3H1	
ecNumber	1.14.11.7	commentary	gene LEPRE1	
ecNumber	1.14.11.7	commentary	isoform P3H2	
ecNumber	1.14.11.7	commentary	P3H2	
ecNumber	1.14.11.7	commentary	P3H3	
ecNumber	1.14.11.8	commentary		
ecNumber	1.14.11.8	commentary		
ecNumber	1.14.11.16	commentary	human osteosarcoma	
ecNumber	1.14.11.16	commentary		
ecNumber	1.14.11.16	commentary		
ecNumber	1.14.11.16	commentary		
ecNumber	1.14.11.16	commentary	cf. EC 1.14.11.30	
ecNumber	1.14.11.17	commentary		
ecNumber	1.14.11.18	commentary	human	
ecNumber	1.14.11.18	commentary		
ecNumber	1.14.11.18	commentary		
ecNumber	1.14.11.27	commentary	KDM4B	
ecNumber	1.14.11.27	commentary		
ecNumber	1.14.11.27	commentary	isoform JMJD2A	
ecNumber	1.14.11.27	commentary	histone demethylase Jmjd2A	
ecNumber	1.14.11.27	commentary		
ecNumber	1.14.11.27	commentary	KDM4A; KDM4A	
ecNumber	1.14.11.27	commentary		
ecNumber	1.14.11.27	commentary	KDM4C; KDM4C	
ecNumber	1.14.11.28	commentary		
ecNumber	1.14.11.28	commentary	P3H2	
ecNumber	1.14.11.28	commentary	P3H3	
ecNumber	1.14.11.29	commentary	isozyme PHD2	
ecNumber	1.14.11.29	commentary		
ecNumber	1.14.11.29	commentary	HPH-3	
ecNumber	1.14.11.29	commentary	isozyme PHD1	
ecNumber	1.14.11.29	commentary		
ecNumber	1.14.11.29	commentary	HIF-P4H-2	
ecNumber	1.14.11.29	commentary	HPH-2	
ecNumber	1.14.11.29	commentary	isozyme PHD2	
ecNumber	1.14.11.29	commentary		
ecNumber	1.14.11.29	commentary	HIF-P4H-3	
ecNumber	1.14.11.29	commentary	isozyme PHD3	
ecNumber	1.14.11.29	commentary		
ecNumber	1.14.11.30	commentary	gene fih	
ecNumber	1.14.11.30	commentary		
ecNumber	1.14.11.30	commentary		
ecNumber	1.14.11.33	commentary		
ecNumber	1.14.11.33	commentary	isoform ABH2	
ecNumber	1.14.11.33	commentary		
ecNumber	1.14.11.33	commentary	isoform ABH3	
ecNumber	1.14.11.42	commentary		
ecNumber	1.14.11.51	commentary		
ecNumber	1.14.11.51	commentary		
ecNumber	1.14.11.53	commentary		
ecNumber	1.14.11.53	commentary	fragment	
ecNumber	1.14.11.53	commentary		
ecNumber	1.14.11.53	commentary		
ecNumber	1.14.11.54	commentary		
ecNumber	1.14.11.54	commentary		
ecNumber	1.14.12.17	commentary		
ecNumber	1.14.13.B3	commentary		
ecNumber	1.14.13.8	commentary	diet of Brussels sprouts	
ecNumber	1.14.13.8	commentary	isozymes FMO1-FMO5	
ecNumber	1.14.13.8	commentary	isozyme FMO1-FMO5	
ecNumber	1.14.13.8	commentary	isozymes FMO1 and FMO3	
ecNumber	1.14.13.8	commentary	isozymes FMO1-FMO5, FMOs exist as a multi-gene family consisting of individual members that are expressed in a tissue-, developmental-, and sex-specific fashion	
ecNumber	1.14.13.8	commentary	isozyme FMO3	
ecNumber	1.14.13.8	commentary	isozymes FMO1FMO6	
ecNumber	1.14.13.8	commentary	genes FMO1-FMO6, FMO6 is a pseudogene	
ecNumber	1.14.13.8	commentary	FMO multigene family	
ecNumber	1.14.13.8	commentary		
ecNumber	1.14.13.8	commentary	FMO4	
ecNumber	1.14.13.8	commentary		
ecNumber	1.14.13.8	commentary	FMO3; gene FMO3	
ecNumber	1.14.13.8	commentary	FMO3	
ecNumber	1.14.13.8	commentary	Europian-, Latin-, African-, and Asian-American schizophrenia patients	
ecNumber	1.14.13.8	commentary		
ecNumber	1.14.13.8	commentary	FMO5	
ecNumber	1.14.13.8	commentary		
ecNumber	1.14.13.8	commentary	FMO1; gene FMO1	
ecNumber	1.14.13.8	commentary	FMO1	
ecNumber	1.14.13.8	commentary		
ecNumber	1.14.13.8	commentary	isozyme FMO1	
ecNumber	1.14.13.8	commentary	FMO2	
ecNumber	1.14.13.8	commentary		
ecNumber	1.14.13.8	commentary	isozyme FMO5	
ecNumber	1.14.13.9	commentary		
ecNumber	1.14.13.9	commentary		
ecNumber	1.14.13.29	commentary	human	
ecNumber	1.14.13.30	commentary		
ecNumber	1.14.13.30	commentary	isozyme CYP4F2	
ecNumber	1.14.13.30	commentary		
ecNumber	1.14.13.30	commentary		
ecNumber	1.14.13.39	commentary	inducible	
ecNumber	1.14.13.39	commentary	neuronal enzyme, full-length enzyme, FAD-FMN-domain, FAD-NADPH-domain	
ecNumber	1.14.13.39	commentary	expression in Pichia pastoris	
ecNumber	1.14.13.39	commentary	isozymes NOS1 and NOS3	
ecNumber	1.14.13.39	commentary		
ecNumber	1.14.13.39	commentary	isozyme eNOS	
ecNumber	1.14.13.39	commentary		
ecNumber	1.14.13.39	commentary		
ecNumber	1.14.13.39	commentary		
ecNumber	1.14.13.39	commentary	isoform Nos2, inducible nitric oxide synthase	
ecNumber	1.14.13.70	commentary	human	
ecNumber	1.14.13.70	commentary	gene CYP51	
ecNumber	1.14.13.70	commentary		
ecNumber	1.14.13.70	commentary		
ecNumber	1.14.13.96	commentary		
ecNumber	1.14.13.148	commentary		
ecNumber	1.14.13.148	commentary		
ecNumber	1.14.13.148	commentary	isozyme FMO3	
ecNumber	1.14.13.178	commentary		
ecNumber	1.14.13.194	commentary		
ecNumber	1.14.13.199	commentary		
ecNumber	1.14.13.199	commentary		
ecNumber	1.14.13.205	commentary		
ecNumber	1.14.13.225	commentary		
ecNumber	1.14.14.1	commentary	expression in Oryza sativa	
ecNumber	1.14.14.1	commentary	several isozymes, e.g. CYP4F and CYP4A	
ecNumber	1.14.14.1	commentary	CYP4A11	
ecNumber	1.14.14.1	commentary		
ecNumber	1.14.14.1	commentary		
ecNumber	1.14.14.1	commentary		
ecNumber	1.14.14.1	commentary		
ecNumber	1.14.14.1	commentary		
ecNumber	1.14.14.1	commentary		
ecNumber	1.14.14.1	commentary		
ecNumber	1.14.14.1	commentary		
ecNumber	1.14.14.B9	commentary		
ecNumber	1.14.14.B9	commentary		
ecNumber	1.14.14.14	commentary		
ecNumber	1.14.14.14	commentary		
ecNumber	1.14.14.16	commentary	man	
ecNumber	1.14.14.16	commentary	expression in COS-1 cells	
ecNumber	1.14.14.16	commentary	Middle European patients with congenital adrenal hyperplasia	
ecNumber	1.14.14.16	commentary	Italian patients with congenital adrenal hyperplasia	
ecNumber	1.14.14.16	commentary	; gene CYP21A2	
ecNumber	1.14.14.16	commentary		
ecNumber	1.14.14.16	commentary	gene CYP21A2	
ecNumber	1.14.14.16	commentary		
ecNumber	1.14.14.17	commentary	HepG2 cells	
ecNumber	1.14.14.17	commentary		
ecNumber	1.14.14.18	commentary	isozyme HO-1	
ecNumber	1.14.14.18	commentary	gene ho-1	
ecNumber	1.14.14.18	commentary	two isoforms, an inducible HO-1 and a constitutive HO-2	
ecNumber	1.14.14.18	commentary	isoforms HO-1 and HO-2	
ecNumber	1.14.14.18	commentary		
ecNumber	1.14.14.18	commentary	isozyme HO-1	
ecNumber	1.14.14.18	commentary	isozyme HO-1, an inducible heat-shock protein	
ecNumber	1.14.14.18	commentary	gene HMOX1	
ecNumber	1.14.14.18	commentary	inducible isozyme HO-1	
ecNumber	1.14.14.18	commentary		
ecNumber	1.14.14.18	commentary		
ecNumber	1.14.14.18	commentary	constitutive isozyme HO-2	
ecNumber	1.14.14.19	commentary	recombinant enzyme, expression in Saccharomyces cerevisiae, enzyme catalyzes both 17alpha-hydroxylation and 17,20-lyase reaction which eliminates at C20,21 acetate to yield a C19 steroid	
ecNumber	1.14.14.19	commentary	bifunctional 17alpha-hydroxylase and 17,20-lyase in steroid biosynthesis	
ecNumber	1.14.14.19	commentary	recombinant enzyme	
ecNumber	1.14.14.19	commentary	female patient with a malignant mixed germ cell tumor	
ecNumber	1.14.14.19	commentary	female patient with enzyme deficiency	
ecNumber	1.14.14.19	commentary	; gene CYP17	
ecNumber	1.14.14.19	commentary	gene CYP17A1	
ecNumber	1.14.14.19	commentary	gene CYP17	
ecNumber	1.14.14.19	commentary		
ecNumber	1.14.14.19	commentary	gene CYP17A1	
ecNumber	1.14.14.19	commentary		
ecNumber	1.14.14.23	commentary	gene CYP7AI	
ecNumber	1.14.14.23	commentary	gene CYP7A1	
ecNumber	1.14.14.23	commentary		
ecNumber	1.14.14.23	commentary		
ecNumber	1.14.14.23	commentary	gene CYP7A1	
ecNumber	1.14.14.24	commentary		
ecNumber	1.14.14.24	commentary		
ecNumber	1.14.14.24	commentary		
ecNumber	1.14.14.24	commentary		
ecNumber	1.14.14.24	commentary	gene CYP2R1	
ecNumber	1.14.14.25	commentary	gene CYP46A1	
ecNumber	1.14.14.25	commentary		
ecNumber	1.14.14.25	commentary		
ecNumber	1.14.14.25	commentary	gene CYP46A1	
ecNumber	1.14.14.26	commentary		
ecNumber	1.14.14.29	commentary		
ecNumber	1.14.14.29	commentary	gene Cyp7B1	
ecNumber	1.14.14.29	commentary		
ecNumber	1.14.14.32	commentary	recombinant enzyme, expression in Saccharomyces cerevisiae, enzyme catalyzes both 17alpha-hydroxylation of steroids, EC 1.14.99.9, and 17,20-lyase reaction	
ecNumber	1.14.14.32	commentary		
ecNumber	1.14.14.32	commentary	; CYP17A1; CYP17A1	
ecNumber	1.14.14.32	commentary		
ecNumber	1.14.14.32	commentary	cf. EC 1.14.14.19	
ecNumber	1.14.14.51	commentary		
ecNumber	1.14.14.55	commentary	human	
ecNumber	1.14.14.55	commentary		
ecNumber	1.14.14.55	commentary		
ecNumber	1.14.14.56	commentary		
ecNumber	1.14.14.57	commentary		
ecNumber	1.14.15.3	commentary		
ecNumber	1.14.15.4	commentary	adult Danish Caucasian Type 1 diabetic patients with diabetic nephropathy	
ecNumber	1.14.15.4	commentary	British hypertensive patients	
ecNumber	1.14.15.4	commentary	Moroccan Jews	
ecNumber	1.14.15.4	commentary	573 members of 105 British Caucasian families, genes CYP11B1 and CYP11B2	
ecNumber	1.14.15.4	commentary	gene CYP11B1, a consanguineous Turkish family	
ecNumber	1.14.15.4	commentary	gene CYP11B1	
ecNumber	1.14.15.4	commentary		
ecNumber	1.14.15.4	commentary	cytochrome P450 11B1, mitochondrial precursor	
ecNumber	1.14.15.4	commentary		
ecNumber	1.14.15.4	commentary		
ecNumber	1.14.15.5	commentary		
ecNumber	1.14.15.6	commentary	fusion protein with adrenodoxin and/or adrenodoxin reductase	
ecNumber	1.14.15.6	commentary	gene CYP11A1	
ecNumber	1.14.15.6	commentary		
ecNumber	1.14.15.6	commentary	gene CYP11A1	
ecNumber	1.14.15.15	commentary	both alcohol:NAD+ oxidoreductase activity, EC 1.1.1.1, and 5beta-cholestane-3alpha,7alpha,12alpha,26-tetraol:NAD+ 26-oxidoreductase activity, EC 1.1.1.161, are catalyzed by the same active side of the same enzyme protein	
ecNumber	1.14.15.15	commentary	gene CYP27A1	
ecNumber	1.14.15.15	commentary		
ecNumber	1.14.15.15	commentary	gene CYP27A1	
ecNumber	1.14.15.16	commentary		
ecNumber	1.14.15.16	commentary	gene CYP24A1	
ecNumber	1.14.15.18	commentary	several splicing variants	
ecNumber	1.14.15.18	commentary	female patients with papillary thyroid carcinoma	
ecNumber	1.14.15.18	commentary	women with and without breast cancer	
ecNumber	1.14.15.18	commentary		
ecNumber	1.14.15.18	commentary		
ecNumber	1.14.16.1	commentary	recombinant enzyme	
ecNumber	1.14.16.1	commentary	gene pah	
ecNumber	1.14.16.1	commentary		
ecNumber	1.14.16.1	commentary		
ecNumber	1.14.16.1	commentary	gene pah	
ecNumber	1.14.16.2	commentary		
ecNumber	1.14.16.2	commentary	4 isoforms hTH1, hTH2, hTH3, hTH4	
ecNumber	1.14.16.2	commentary	isoform 1 hTH1	
ecNumber	1.14.16.2	commentary	isozyme TH-1 to TH-4	
ecNumber	1.14.16.2	commentary	isozymes TH1 and TH4	
ecNumber	1.14.16.2	commentary	isozyme TH 1	
ecNumber	1.14.16.2	commentary		
ecNumber	1.14.16.2	commentary		
ecNumber	1.14.16.4	commentary	enzyme from a carcinoid tumor	
ecNumber	1.14.16.4	commentary	borderline patients	
ecNumber	1.14.16.4	commentary	isozymes TPH1 and TPH2	
ecNumber	1.14.16.4	commentary	isozyme TPH1; isozyme TPH2	
ecNumber	1.14.16.4	commentary	isozymes TPH1 and TPPH2	
ecNumber	1.14.16.4	commentary	Japanese individuals	
ecNumber	1.14.16.4	commentary		
ecNumber	1.14.16.4	commentary	Han Chinese subjects, gene TPH1 encodes isozyme TPH1	
ecNumber	1.14.16.4	commentary	TPH1; North European Caucasians, healthy persons and major depression patients, isozyme TPH1	
ecNumber	1.14.16.4	commentary	patients with major depression, gene TPH1	
ecNumber	1.14.16.4	commentary	isozyme TPH1; isozyme TPH1	
ecNumber	1.14.16.4	commentary	Korean subjects with major depressive disorder	
ecNumber	1.14.16.4	commentary		
ecNumber	1.14.16.4	commentary	genes tph1 and tph2	
ecNumber	1.14.16.4	commentary	Han Chinese subjects, gene TPH2 encoding isozyme TPH2	
ecNumber	1.14.16.4	commentary	Caucasian subjects	
ecNumber	1.14.16.4	commentary	healthy persons and affective disorder patients from Germany and Russia	
ecNumber	1.14.16.4	commentary	North European Caucasians, healthy persons and major depression patients, isozyme TPH2	
ecNumber	1.14.16.4	commentary	gene TPH2	
ecNumber	1.14.16.4	commentary	isozyme TPH2; isozyme TPH2	
ecNumber	1.14.16.4	commentary	isozyme TPH2	
ecNumber	1.14.16.4	commentary	Caucasian individuals	
ecNumber	1.14.16.4	commentary	alcohol-dependent patients of Caucasian origin from southern Germany	
ecNumber	1.14.16.4	commentary	depressive patients, gene TPH2	
ecNumber	1.14.16.4	commentary		
ecNumber	1.14.16.5	commentary		
ecNumber	1.14.17.1	commentary	African Americans, gene DBH	
ecNumber	1.14.17.1	commentary	gene DBH	
ecNumber	1.14.17.1	commentary		
ecNumber	1.14.17.1	commentary		
ecNumber	1.14.17.3	commentary	bifunctional enzyme	
ecNumber	1.14.17.3	commentary		
ecNumber	1.14.17.3	commentary	bifunctional enzyme showing peptidylglycine alpha-hydroxylating monooxygenase, PHM, EC 1.14.17.3, and peptidylamidoglycolate lyase, PAL, EC 4.3.2.5, activities	
ecNumber	1.14.17.3	commentary		
ecNumber	1.14.18.1	commentary		
ecNumber	1.14.18.1	commentary		
ecNumber	1.14.18.2	commentary		
ecNumber	1.14.18.2	commentary	deletion in the gene	
ecNumber	1.14.18.5	commentary		
ecNumber	1.14.18.6	commentary		
ecNumber	1.14.18.6	commentary		
ecNumber	1.14.18.9	commentary		
ecNumber	1.14.18.9	commentary		
ecNumber	1.14.19.1	commentary	hSCD1 cloned from a human liver cDNA library	
ecNumber	1.14.19.1	commentary	male humans	
ecNumber	1.14.19.1	commentary		
ecNumber	1.14.19.1	commentary		
ecNumber	1.14.19.1	commentary	hSCD5 cloned from a human brain cDNA library	
ecNumber	1.14.19.3	commentary	human	
ecNumber	1.14.19.3	commentary	gene FADS1	
ecNumber	1.14.19.3	commentary		
ecNumber	1.14.19.17	commentary		
ecNumber	1.14.19.20	commentary		
ecNumber	1.14.19.20	commentary		
ecNumber	1.14.19.30	commentary		
ecNumber	1.14.19.30	commentary		
ecNumber	1.14.19.44	commentary	Han Chinese	
ecNumber	1.14.19.44	commentary		
ecNumber	1.14.19.47	commentary		
ecNumber	1.14.21.4	commentary	very low activity	
ecNumber	1.14.99.1	commentary	overview	
ecNumber	1.14.99.1	commentary	recombinant enzyme, product of COX-2	
ecNumber	1.14.99.1	commentary	recombinant isozymes 1 and 2	
ecNumber	1.14.99.1	commentary	a homology modeling structure of human PGHS-1 is constructed using the Swiss-Model server and the ovine crystal structure 1Q4G as template	
ecNumber	1.14.99.1	commentary		
ecNumber	1.14.99.1	commentary	PGHS-1	
ecNumber	1.14.99.1	commentary	isozyme PGHS-1	
ecNumber	1.14.99.1	commentary		
ecNumber	1.14.99.1	commentary	PGHS-2	
ecNumber	1.14.99.1	commentary	isozyme PGHS-2	
ecNumber	1.14.99.1	commentary		
ecNumber	1.14.99.19	commentary		
ecNumber	1.14.99.20	commentary	fetus, neonate, 1-18 years	
ecNumber	1.14.99.29	commentary		
ecNumber	1.14.99.29	commentary	gene dohh, substrain PEXT-1	
ecNumber	1.14.99.38	commentary	patients with Alzheimers disease	
ecNumber	1.14.99.38	commentary		
ecNumber	1.14.99.38	commentary		
ecNumber	1.14.99.38	commentary	gene Ch25h	
ecNumber	1.14.99.38	commentary	gene Ch25h	
ecNumber	1.14.99.38	commentary	gene Ch25h	
ecNumber	1.14.99.38	commentary	gene Ch25h	
ecNumber	1.14.99.38	commentary	activity of EC 1.14.99.15 and 1.14.99.38	
ecNumber	1.15.1.1	commentary	Mn-SOD	
ecNumber	1.15.1.1	commentary	Cu,Zn-SOD; Mn-SOD	
ecNumber	1.15.1.1	commentary	EC-SOD with Cu,Zn-SOD activity	
ecNumber	1.15.1.1	commentary	Cu,Zn-SOD	
ecNumber	1.15.1.1	commentary	CuZn-type enzyme, expression in Escherichia coli	
ecNumber	1.15.1.1	commentary	isoform SOD1	
ecNumber	1.15.1.1	commentary	isoform MnSOD	
ecNumber	1.15.1.1	commentary	patients with idiopathic pulmonary fibrosis/usual interstitial pneumonia	
ecNumber	1.15.1.1	commentary	isoform hSOD3, expression in Pichia pastoris	
ecNumber	1.15.1.1	commentary	patients with familial amyotrophic lateral scerosis FALS	
ecNumber	1.15.1.1	commentary	manganese superoxide dismutase	
ecNumber	1.15.1.1	commentary	patients undergoing bypass graft surgery	
ecNumber	1.15.1.1	commentary	healthy Japanese and Caucasian individuals	
ecNumber	1.15.1.1	commentary	gene sod-1	
ecNumber	1.15.1.1	commentary		
ecNumber	1.15.1.1	commentary		
ecNumber	1.15.1.1	commentary	MnSOD	
ecNumber	1.15.1.1	commentary		
ecNumber	1.16.1.2	commentary		
ecNumber	1.16.1.3	commentary		
ecNumber	1.16.1.3	commentary	in addition to reductive activation of methionine synthase, methionine synthase reductase is able to reduce aquacobalamin to cob(II)alamin in the presence of NADPH. This reduction leads to stimulation of the conversion of apomethionine synthase and aquacobalamin to the methionine synthase holoenzyme	
ecNumber	1.16.1.5	commentary		
ecNumber	1.16.1.5	commentary	methionine synthase reductase shows additionally aquacobalamin reductase activity	
ecNumber	1.16.1.8	commentary	variant I22/L175; variant M22/S175	
ecNumber	1.16.1.8	commentary	variant I22M	
ecNumber	1.16.1.8	commentary	postmenopausal women, certain genetic polymorphisms of enzyme leading to a reduced activity may cause hyperhomocysteinemia and affect bone metabolism	
ecNumber	1.16.1.8	commentary	expression by baculovirus-infected insect cells	
ecNumber	1.16.1.8	commentary		
ecNumber	1.16.1.8	commentary	patients with homocystinuria	
ecNumber	1.16.1.8	commentary	variant I22/S175; variant M22/S175	
ecNumber	1.16.1.8	commentary		
ecNumber	1.16.3.1	commentary	Cohn's fraction F-IV-1 of normal human pooled plasma; human	
ecNumber	1.16.3.1	commentary	human; human hepatoblastoma cell line HepG2	
ecNumber	1.16.3.1	commentary	human	
ecNumber	1.16.3.1	commentary	multicopper oxidase hephaestin, with additional ferroxidase activity. Expression in baby hamster kidney cells	
ecNumber	1.16.3.1	commentary	commercial product ceruloplasmin	
ecNumber	1.16.3.1	commentary	patients with Wilson disease and ATP7B genotypes	
ecNumber	1.16.3.1	commentary	patients with Parkinson's disease, Alzheimer's disease, Huntington's disease and lateral amyotrophic sclerosis	
ecNumber	1.16.3.1	commentary	children with Henoch-Schoenlein purpura	
ecNumber	1.16.3.1	commentary	patients with chronic lymphocytic leukemia	
ecNumber	1.16.3.1	commentary		
ecNumber	1.16.3.1	commentary	human	
ecNumber	1.16.3.1	commentary		
ecNumber	1.16.3.1	commentary		
ecNumber	1.16.3.1	commentary	ferritin heavy chain	
ecNumber	1.16.5.1	commentary		
ecNumber	1.17.1.4	commentary	dehydrogenase activity predominant form	
ecNumber	1.17.1.4	commentary		
ecNumber	1.17.1.4	commentary		
ecNumber	1.17.3.2	commentary	gastric mucosa of Helicobacter pylori positive and negative pediatric patients	
ecNumber	1.17.3.2	commentary	Greek population	
ecNumber	1.17.3.2	commentary	female and male	
ecNumber	1.17.3.2	commentary	gene XO	
ecNumber	1.17.3.2	commentary		
ecNumber	1.17.4.1	commentary	HeLa cells	
ecNumber	1.17.4.1	commentary	Molt 4F cells	
ecNumber	1.17.4.1	commentary	patients with advanced myeloid leukemia	
ecNumber	1.17.4.1	commentary	adults with refractory acute leukemias and aggressive myeloproliferative disorders, MPD	
ecNumber	1.17.4.1	commentary		
ecNumber	1.17.4.1	commentary		
ecNumber	1.17.4.1	commentary	small subunit RIR2	
ecNumber	1.17.4.1	commentary	ribonucleoside-diphosphate reductase subunit M2 B	
ecNumber	1.17.4.1	commentary	isoform p53R2	
ecNumber	1.17.4.2	commentary	human	
ecNumber	1.17.4.2	commentary	patients with advanced myeloid leukemia	
ecNumber	1.17.4.2	commentary	adults with refractory acute leukemias and aggressive myeloproliferative disorders, MPD	
ecNumber	1.17.4.2	commentary		
ecNumber	1.17.4.2	commentary	isozymes R2 and p53R2	
ecNumber	1.17.4.4	commentary	mutant V66M	
ecNumber	1.17.4.4	commentary	subjects with calcification of the aortic far wall	
ecNumber	1.17.4.4	commentary	patient with warfarin resistance	
ecNumber	1.17.4.4	commentary	gene VKORC1	
ecNumber	1.17.4.4	commentary		
ecNumber	1.17.4.4	commentary	gene rs9923231 or VKORC1	
ecNumber	1.17.4.4	commentary	wild-type enzyme	
ecNumber	1.17.4.4	commentary	VKORC1 subunit 1; Chinese and Causasian men, gene VKORC1	
ecNumber	1.17.4.4	commentary		
ecNumber	1.17.4.4	commentary	; mutants V29L, V45A, and L128R, oveview	
ecNumber	1.17.4.4	commentary	gene rs9923231	
ecNumber	1.17.4.5	commentary		
ecNumber	1.17.4.5	commentary		
ecNumber	1.17.99.3	commentary		
ecNumber	1.18.1.6	commentary		
ecNumber	1.20.4.1	commentary	glyceraldehyde-3-phosphate dehydrogenase working as arsenate reductase	
ecNumber	1.20.4.2	commentary		
ecNumber	1.20.4.2	commentary		
ecNumber	1.20.4.2	commentary	isoforms GSTO1, GSTO2 and their natural polymorphisms. Enzyme has additionally thioltransferase, dehydroascorbate reductase and dimethylarsonate reductase activities	
ecNumber	1.20.99.1	commentary		
ecNumber	1.21.1.1	commentary		
ecNumber	1.21.1.1	commentary		
ecNumber	1.21.1.1	commentary	gene DEHAL1	
ecNumber	1.21.99.3	commentary	5-deiodinase activity	
ecNumber	1.21.99.3	commentary	isozyme type III	
ecNumber	1.21.99.3	commentary		
ecNumber	1.21.99.3	commentary	; congential hypothyroidism	
ecNumber	1.21.99.3	commentary	three deiodinase isozymes Dio1, Dio2, and Dio3	
ecNumber	1.21.99.3	commentary	; isozyme type III	
ecNumber	1.21.99.3	commentary	gene DIO3	
ecNumber	1.21.99.4	commentary	type I and type II enzyme isoforms	
ecNumber	1.21.99.4	commentary	patients with thyroglobulin transport defect	
ecNumber	1.21.99.4	commentary		
ecNumber	1.21.99.4	commentary	three deiodinase isozymes Dio1, Dio2, and Dio3	
ecNumber	1.21.99.4	commentary	; tye I enzyme DIO1	
ecNumber	1.21.99.4	commentary		
ecNumber	1.21.99.4	commentary	; tye II enzyme DIO2	
ecNumber	1.21.99.4	commentary		
ecNumber	1.21.99.4	commentary		
ecNumber	2.1.1.1	commentary	radioresistant bladder carcinoma cell line MGH-UI	
ecNumber	2.1.1.1	commentary	patients with idiopathic Parkinson's disease	
ecNumber	2.1.1.1	commentary		
ecNumber	2.1.1.1	commentary	gene NNMT	
ecNumber	2.1.1.1	commentary		
ecNumber	2.1.1.2	commentary	13 years old, female, L197P transition on exon 6 of the guanidinoacetate N-methyltransferase gene	
ecNumber	2.1.1.2	commentary		
ecNumber	2.1.1.2	commentary	fibroblast cell line	
ecNumber	2.1.1.2	commentary		
ecNumber	2.1.1.4	commentary	tissues and Y79 retinoblastoma cells	
ecNumber	2.1.1.4	commentary	Y79 retinoblastoma cells	
ecNumber	2.1.1.4	commentary		
ecNumber	2.1.1.4	commentary	the ASMT gene is spliced in an alternative way to form at least three possible isoforms	
ecNumber	2.1.1.4	commentary		
ecNumber	2.1.1.5	commentary	recombinant	
ecNumber	2.1.1.5	commentary		
ecNumber	2.1.1.5	commentary	; fragment	
ecNumber	2.1.1.5	commentary	recombinant enzyme	
ecNumber	2.1.1.5	commentary		
ecNumber	2.1.1.6	commentary	thalamus COMT isoform	
ecNumber	2.1.1.6	commentary	2 forms	
ecNumber	2.1.1.6	commentary	hepatoma cell line G2	
ecNumber	2.1.1.6	commentary	2 forms which differ in nature of intramolecular disulfide bonds	
ecNumber	2.1.1.6	commentary	both S-COMT and MB-COMT	
ecNumber	2.1.1.6	commentary	wild type and variant isoform	
ecNumber	2.1.1.6	commentary	a common single-nucleotide polymorphism within COMT, Val158Met, significantly affects protein abundance and enzyme activity but not mRNA expression levels. Val is a predominant factor that determines higher COMT activity in the prefrontal cortex, which presumably leads to lower synaptic dopamine levels and relatively deleterious prefrontal function	
ecNumber	2.1.1.6	commentary	variants 108M and 108V	
ecNumber	2.1.1.6	commentary	recombinant	
ecNumber	2.1.1.6	commentary		
ecNumber	2.1.1.6	commentary		
ecNumber	2.1.1.8	commentary	two polymorphic forms of enzyme	
ecNumber	2.1.1.8	commentary	patients with food allergy	
ecNumber	2.1.1.8	commentary		
ecNumber	2.1.1.8	commentary	two polymorphic forms of enzyme	
ecNumber	2.1.1.8	commentary		
ecNumber	2.1.1.9	commentary	high-affinity form and low-affinity form	
ecNumber	2.1.1.9	commentary		
ecNumber	2.1.1.10	commentary		
ecNumber	2.1.1.13	commentary	HeLa cells, HepG2 cells and transformed kidney cells	
ecNumber	2.1.1.13	commentary		
ecNumber	2.1.1.17	commentary		
ecNumber	2.1.1.17	commentary		
ecNumber	2.1.1.20	commentary	recombinant enzyme	
ecNumber	2.1.1.20	commentary	; prostate cancer patients and normal control individuals	
ecNumber	2.1.1.20	commentary	women	
ecNumber	2.1.1.20	commentary	three cases of GNMT mutations known, all suffering from mild liver disease and display elevated methionine levels	
ecNumber	2.1.1.20	commentary	cholangiocarcinoma patients	
ecNumber	2.1.1.20	commentary		
ecNumber	2.1.1.20	commentary	normal enzyme and naturally occurring H176N mutation which is found in humans with hypermethioninaemia	
ecNumber	2.1.1.22	commentary		
ecNumber	2.1.1.25	commentary		
ecNumber	2.1.1.28	commentary	recombinant enzyme; recombinant enzyme with C-terminal His6 tag	
ecNumber	2.1.1.28	commentary	the phenylethanolamine N-methyltransferase inhibitory potency of 3-trifluoromethyl-1,2,3,4-tetrahydroisoquinoline is lower than the of other 1,2,3,4-tetrahydroisoquinolines, some of them show good selectivity due to their extremely low alpha2-adrenoceptor affinity	
ecNumber	2.1.1.28	commentary	immunohistochemical analysis in normal human medulla shows a expression of phenylethanolamine N-methyltransferase localized to the cytoplasm. All tyrosine hydroxylase-positive cells contain phenylethanolamine N-methyltransferase. All normal human chromaffin cells also strongly express noradrenaline transporter, which is always colocalized with phenylethanolamine N-methyltransferase. Double-labeling experiments on phaeochromocytoma tissue reveals, that the expression of phenylethanolamine N-methyltransferase is variable, ranging from strong to weak to absent. The immunohistochemical detection of phenylethanolamine N-methyltransferase correlates with the presence of adrenaline in all but one sample (but the intensitiy levels do not correlate). In human phaeochromocytomas the expression of the noradrenaline transporter is not consistently co-localized with phenylethanolamine N-methyltransferase.	
ecNumber	2.1.1.28	commentary	21 male and 1 female patient at 0-12 years after heart transplantation, mean age 45.7 years: During the first years after heart transplantation, phenylethanolamine N-methyltransferase mRNA levels are relatively high compared with later years. There is a correlation of phenylethanolamine N-methyltransferase mRNA with years elapsed form heart transplantation (r = -0.56). There is a negative linear correlation between phenylethanolamine N-methyltransferase mRNA and the low frequency band of the power spectrum (r = - 0.47).	
ecNumber	2.1.1.28	commentary	female Japanese woman, gene PNMT	
ecNumber	2.1.1.28	commentary		
ecNumber	2.1.1.28	commentary	expression plasmid pET17PNMT-his	
ecNumber	2.1.1.28	commentary		
ecNumber	2.1.1.33	commentary		
ecNumber	2.1.1.37	commentary	recombinant	
ecNumber	2.1.1.37	commentary	isozyme Dnmt1; isozyme Dnmt3b	
ecNumber	2.1.1.37	commentary	isozymes DNMT1 and DNMT3a	
ecNumber	2.1.1.37	commentary		
ecNumber	2.1.1.37	commentary		
ecNumber	2.1.1.37	commentary		
ecNumber	2.1.1.37	commentary		
ecNumber	2.1.1.43	commentary	SET9, also called SET7	
ecNumber	2.1.1.43	commentary		
ecNumber	2.1.1.43	commentary		
ecNumber	2.1.1.43	commentary		
ecNumber	2.1.1.43	commentary	NSD2	
ecNumber	2.1.1.43	commentary		
ecNumber	2.1.1.43	commentary	SET7	
ecNumber	2.1.1.43	commentary		
ecNumber	2.1.1.43	commentary	SETD2	
ecNumber	2.1.1.43	commentary		
ecNumber	2.1.1.43	commentary	HeLa cells; SET8 sequence	
ecNumber	2.1.1.43	commentary		
ecNumber	2.1.1.43	commentary		
ecNumber	2.1.1.45	commentary	human; neoplastic leukemic CCRF-CEM cells	
ecNumber	2.1.1.45	commentary	HeLa cells	
ecNumber	2.1.1.45	commentary	neoplastic leukemic CCRF-CEM cells	
ecNumber	2.1.1.45	commentary	AML cells; human; MCF-7 breast cancer cells	
ecNumber	2.1.1.45	commentary	HeLa cells; MCF-7 breast cancer cells	
ecNumber	2.1.1.45	commentary	MCF-7 breast cancer cells	
ecNumber	2.1.1.45	commentary	human sarcome HT1080 cells	
ecNumber	2.1.1.45	commentary	human colon tumor cell line HCT116/200-10	
ecNumber	2.1.1.45	commentary	human colorectal tumor cell line C	
ecNumber	2.1.1.45	commentary	human	
ecNumber	2.1.1.45	commentary	; patients with advanced colorectal carcinoma	
ecNumber	2.1.1.45	commentary	; patients with advanced non-small cell lung cancer	
ecNumber	2.1.1.45	commentary		
ecNumber	2.1.1.45	commentary	human	
ecNumber	2.1.1.45	commentary		
ecNumber	2.1.1.56	commentary	HeLa cells	
ecNumber	2.1.1.56	commentary		
ecNumber	2.1.1.56	commentary		
ecNumber	2.1.1.57	commentary	HeLa S-3 cells infected with vaccinia virus, no activity in uninfected cells	
ecNumber	2.1.1.57	commentary		
ecNumber	2.1.1.60	commentary		
ecNumber	2.1.1.60	commentary		
ecNumber	2.1.1.61	commentary		
ecNumber	2.1.1.61	commentary		
ecNumber	2.1.1.62	commentary	human, HeLa S3 cells	
ecNumber	2.1.1.63	commentary	three allelic variants: V1, V2, and V3	
ecNumber	2.1.1.63	commentary		
ecNumber	2.1.1.63	commentary		
ecNumber	2.1.1.64	commentary		
ecNumber	2.1.1.67	commentary	293T cells; HeLa cells; human	
ecNumber	2.1.1.67	commentary	human	
ecNumber	2.1.1.67	commentary	natural variant Glu28Val, TPMT	13; natural variant Gly144Arg, variant TPMT	10; natural variant His227Gln, variant TPMT	7; natural variant Ser125Leu, variant TPMT	12; wild-type variant	
ecNumber	2.1.1.67	commentary		
ecNumber	2.1.1.67	commentary	variant Arg163His, i.e. variant TPMT	16, loss-of function allele of TPMT, patients heterozygous for the Arg163His mutation are intermediate methylators; variant Lys122Thr, i.e. variant TPMT	19, missense mutation in patients with Crohn's disease, patients heterozygous for the Lys122Thr mutation have normal TPMT activity; wild-type variant TPMT	1	
ecNumber	2.1.1.67	commentary		
ecNumber	2.1.1.71	commentary	human	
ecNumber	2.1.1.71	commentary		
ecNumber	2.1.1.72	commentary		
ecNumber	2.1.1.72	commentary		
ecNumber	2.1.1.77	commentary	HeLa cells; human	
ecNumber	2.1.1.77	commentary	human	
ecNumber	2.1.1.77	commentary		
ecNumber	2.1.1.77	commentary		
ecNumber	2.1.1.80	commentary		
ecNumber	2.1.1.100	commentary		
ecNumber	2.1.1.B109	commentary	gene TRM140	
ecNumber	2.1.1.114	commentary		
ecNumber	2.1.1.114	commentary		
ecNumber	2.1.1.137	commentary		
ecNumber	2.1.1.137	commentary	; gene arsM	
ecNumber	2.1.1.137	commentary		
ecNumber	2.1.1.166	commentary		
ecNumber	2.1.1.201	commentary		
ecNumber	2.1.1.202	commentary		
ecNumber	2.1.1.203	commentary		
ecNumber	2.1.1.203	commentary		
ecNumber	2.1.1.204	commentary		
ecNumber	2.1.1.204	commentary		
ecNumber	2.1.1.218	commentary		
ecNumber	2.1.1.220	commentary	gene TRM61 encoding subunit TrmI-61	
ecNumber	2.1.1.220	commentary	subunits TRM6 or TRM61	
ecNumber	2.1.1.220	commentary	Q96FX7: subunit Trm61p (catalytic subunit), Q9UJA5: subunit Trm6p (non-catalytic subunit)	
ecNumber	2.1.1.220	commentary		
ecNumber	2.1.1.221	commentary	gene TRMT10A or RG9MTD2	
ecNumber	2.1.1.221	commentary		
ecNumber	2.1.1.222	commentary		
ecNumber	2.1.1.228	commentary	gene TRMT5	
ecNumber	2.1.1.228	commentary		
ecNumber	2.1.1.228	commentary	from the KIAA 1393 plasmid; gene TRM5	
ecNumber	2.1.1.229	commentary		
ecNumber	2.1.1.233	commentary		
ecNumber	2.1.1.244	commentary	gene METTL11a/C9orf32/Ad-003	
ecNumber	2.1.1.244	commentary		
ecNumber	2.1.1.244	commentary	gene METTL11A	
ecNumber	2.1.1.257	commentary		
ecNumber	2.1.1.260	commentary		
ecNumber	2.1.1.260	commentary	gene NEP1	
ecNumber	2.1.1.268	commentary		
ecNumber	2.1.1.296	commentary	gene FTSJD1 or HMTR2	
ecNumber	2.1.1.296	commentary	gene CMTR2	
ecNumber	2.1.1.299	commentary		
ecNumber	2.1.1.309	commentary	WBS22; gene WBSCR22	
ecNumber	2.1.1.310	commentary		
ecNumber	2.1.1.319	commentary	isoform PRMT3	
ecNumber	2.1.1.319	commentary	isoform PRMT4	
ecNumber	2.1.1.319	commentary	isoform PRMT6	
ecNumber	2.1.1.319	commentary		
ecNumber	2.1.1.319	commentary	isoform PRMT1	
ecNumber	2.1.1.319	commentary	isoform PRMT8	
ecNumber	2.1.1.320	commentary		
ecNumber	2.1.1.320	commentary	isoform PRMT5	
ecNumber	2.1.1.320	commentary		
ecNumber	2.1.1.320	commentary	isoform PRMT9	
ecNumber	2.1.1.321	commentary		
ecNumber	2.1.1.321	commentary	isoform PRMT7	
ecNumber	2.1.1.321	commentary		
ecNumber	2.1.2.1	commentary		
ecNumber	2.1.2.1	commentary		
ecNumber	2.1.2.1	commentary		
ecNumber	2.1.2.2	commentary	human	
ecNumber	2.1.2.2	commentary	recombinant	
ecNumber	2.1.2.2	commentary		
ecNumber	2.1.2.2	commentary		
ecNumber	2.1.2.3	commentary	human	
ecNumber	2.1.2.3	commentary		
ecNumber	2.1.2.3	commentary	human	
ecNumber	2.1.2.3	commentary	bifunctional 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase	
ecNumber	2.1.2.3	commentary		
ecNumber	2.1.2.5	commentary		
ecNumber	2.1.2.5	commentary		
ecNumber	2.1.2.5	commentary		
ecNumber	2.1.2.9	commentary		
ecNumber	2.1.2.9	commentary		
ecNumber	2.1.2.10	commentary		
ecNumber	2.1.2.10	commentary		
ecNumber	2.1.3.2	commentary		
ecNumber	2.1.3.3	commentary	normal liver enzyme and enzyme from a liver of a patient with Reye's syndrome	
ecNumber	2.1.3.3	commentary	ornithine transcarbamoyltransferase deficiency is the most common cause of inherited urea cycle disorders	
ecNumber	2.1.3.3	commentary	patients with ornithine transcarbamylase deficiency	
ecNumber	2.1.3.3	commentary	patients with non-alcoholic steatohepatitis	
ecNumber	2.1.3.3	commentary	patients with Alzheimer's disease	
ecNumber	2.1.3.3	commentary		
ecNumber	2.1.3.3	commentary		
ecNumber	2.1.3.3	commentary	mRNA isoforms OTC-t1, OTC-t2, and OTC-t3 are transcribed from the OTC gene	
ecNumber	2.1.4.1	commentary	human	
ecNumber	2.1.4.1	commentary		
ecNumber	2.1.4.1	commentary	cytosolic enzyme, DDBJ/EMBL/GenBank database, cDNA sequence; mitochondrial enzyme, DDBJ/EMBL/GenBank database, cDNA sequence	
ecNumber	2.1.4.1	commentary	gene AGAT	
ecNumber	2.2.1.1	commentary		
ecNumber	2.2.1.1	commentary		
ecNumber	2.2.1.1	commentary		
ecNumber	2.2.1.1	commentary		
ecNumber	2.2.1.2	commentary	; pregnant and nonpregnant women	
ecNumber	2.2.1.2	commentary		
ecNumber	2.3.1.1	commentary	; 3 families of patients with naturally occurring mutations leading to enzyme deficiency	
ecNumber	2.3.1.1	commentary	bifunctional N-acetylglutamate synthase/kinase	
ecNumber	2.3.1.1	commentary		
ecNumber	2.3.1.1	commentary	recombinant	
ecNumber	2.3.1.1	commentary		
ecNumber	2.3.1.4	commentary	3 isoenzymes	
ecNumber	2.3.1.4	commentary		
ecNumber	2.3.1.4	commentary		
ecNumber	2.3.1.5	commentary	genetic polymorphism	
ecNumber	2.3.1.5	commentary	two isozymes NAT1, NAT2	
ecNumber	2.3.1.5	commentary	recombinant NAT2, several genetic variants	
ecNumber	2.3.1.5	commentary	NAT1	
ecNumber	2.3.1.5	commentary	NAT1 and NAT2	
ecNumber	2.3.1.5	commentary	human	
ecNumber	2.3.1.5	commentary	isozyme NAT1	
ecNumber	2.3.1.5	commentary	isozyme NAT2	
ecNumber	2.3.1.5	commentary		
ecNumber	2.3.1.5	commentary	isoform NAT 2	
ecNumber	2.3.1.5	commentary	NAT2; isozyme NAT2	
ecNumber	2.3.1.5	commentary	isozyme NAT2; isozyme NAT2	
ecNumber	2.3.1.5	commentary	isoform NAT2	
ecNumber	2.3.1.5	commentary		
ecNumber	2.3.1.5	commentary	isoform NAT 1	
ecNumber	2.3.1.5	commentary	isozyme NAT1; gene NAT1	
ecNumber	2.3.1.5	commentary	isozyme NAT1; isozyme NAT1	
ecNumber	2.3.1.5	commentary		
ecNumber	2.3.1.6	commentary		
ecNumber	2.3.1.6	commentary		
ecNumber	2.3.1.7	commentary	human	
ecNumber	2.3.1.7	commentary		
ecNumber	2.3.1.7	commentary		
ecNumber	2.3.1.9	commentary	patient with enzyme deficiency	
ecNumber	2.3.1.9	commentary		
ecNumber	2.3.1.9	commentary		
ecNumber	2.3.1.12	commentary	enzyme forms the core of the pyruvate dehydrogenase multienzyme complex	
ecNumber	2.3.1.12	commentary		
ecNumber	2.3.1.12	commentary		
ecNumber	2.3.1.13	commentary		
ecNumber	2.3.1.13	commentary	isoform Glyat	
ecNumber	2.3.1.13	commentary		
ecNumber	2.3.1.13	commentary	isoform Glyatl2	
ecNumber	2.3.1.13	commentary		
ecNumber	2.3.1.14	commentary		
ecNumber	2.3.1.15	commentary		
ecNumber	2.3.1.15	commentary		
ecNumber	2.3.1.15	commentary		
ecNumber	2.3.1.16	commentary	isoform Elovl6	
ecNumber	2.3.1.16	commentary		
ecNumber	2.3.1.16	commentary	gene ACAA2; gene ACAA2	
ecNumber	2.3.1.16	commentary	isoform Elovl6	
ecNumber	2.3.1.17	commentary	normal patients and patients with Canavan disease	
ecNumber	2.3.1.17	commentary		
ecNumber	2.3.1.20	commentary	isoform DGAT1	
ecNumber	2.3.1.20	commentary		
ecNumber	2.3.1.20	commentary		
ecNumber	2.3.1.20	commentary	isoform DGAT1	
ecNumber	2.3.1.20	commentary	gene DC3; X-linked gene DC3	
ecNumber	2.3.1.20	commentary	gene DGAT2; gene DGAT2	
ecNumber	2.3.1.20	commentary		
ecNumber	2.3.1.20	commentary	isoform DGAT2	
ecNumber	2.3.1.21	commentary	M-CPT I	
ecNumber	2.3.1.21	commentary	2 isoforms M-CPT I and L-CPT I	
ecNumber	2.3.1.21	commentary	CPT I; CPT II	
ecNumber	2.3.1.21	commentary	CPT II deficient mutant	
ecNumber	2.3.1.21	commentary	CPT1-B; CPT1-C	
ecNumber	2.3.1.21	commentary	gene CPT IB	
ecNumber	2.3.1.21	commentary	tissue-specific isozymes L-CPT1 and M-CPT1	
ecNumber	2.3.1.21	commentary	Japanese population, isozymes CPT1 and CPT2	
ecNumber	2.3.1.21	commentary	isozymes L-CPT1 and M-CPT1	
ecNumber	2.3.1.21	commentary	isozyme M-CPT I	
ecNumber	2.3.1.21	commentary	isozyme CPT1A	
ecNumber	2.3.1.21	commentary	obese NIDDM patients	
ecNumber	2.3.1.21	commentary		
ecNumber	2.3.1.21	commentary	CPT2	
ecNumber	2.3.1.21	commentary	isoform CPT2	
ecNumber	2.3.1.21	commentary		
ecNumber	2.3.1.21	commentary	CPT1A; CPT1-A	
ecNumber	2.3.1.21	commentary		
ecNumber	2.3.1.21	commentary	isoform CPT1C	
ecNumber	2.3.1.21	commentary		
ecNumber	2.3.1.22	commentary		
ecNumber	2.3.1.22	commentary	isozyme DGAT1	
ecNumber	2.3.1.22	commentary	isoform MGAT2	
ecNumber	2.3.1.22	commentary		
ecNumber	2.3.1.22	commentary	gene MOGAT	
ecNumber	2.3.1.22	commentary	isoform MGAT3	
ecNumber	2.3.1.22	commentary		
ecNumber	2.3.1.22	commentary		
ecNumber	2.3.1.23	commentary		
ecNumber	2.3.1.23	commentary		
ecNumber	2.3.1.23	commentary		
ecNumber	2.3.1.23	commentary	gene LPCAT3; gene LPCAT3	
ecNumber	2.3.1.23	commentary	LPCAT3, one of four isozymes, gene LPCAT3	
ecNumber	2.3.1.23	commentary		
ecNumber	2.3.1.23	commentary		
ecNumber	2.3.1.23	commentary	isoform PCAT2	
ecNumber	2.3.1.23	commentary		
ecNumber	2.3.1.23	commentary	isoform PCAT1	
ecNumber	2.3.1.24	commentary		
ecNumber	2.3.1.24	commentary		
ecNumber	2.3.1.24	commentary	isozyme CERS1	
ecNumber	2.3.1.24	commentary		
ecNumber	2.3.1.24	commentary		
ecNumber	2.3.1.24	commentary		
ecNumber	2.3.1.24	commentary	isozyme CERS2	
ecNumber	2.3.1.25	commentary		
ecNumber	2.3.1.26	commentary	transforming growth factor-beta1 increases enzyme expression 2fold with an increase in activity of 1.8fold during differentiation of monocytes to macrophages. Addition of transforming growth factor-beta1 after differentiation does not alter enzyme expression	
ecNumber	2.3.1.26	commentary	recombinant isoforms ACAT1 and ACAT2 with His-tag each	
ecNumber	2.3.1.26	commentary	isoform ACAT1	
ecNumber	2.3.1.26	commentary	isoforms ACTA1 and ACAT2, overexpression in rat hepatoma McA-RH7777 cells	
ecNumber	2.3.1.26	commentary	expression in chinese hamster ovary cells, isoform ACAT2	
ecNumber	2.3.1.26	commentary		
ecNumber	2.3.1.26	commentary	ACAT2	
ecNumber	2.3.1.26	commentary		
ecNumber	2.3.1.26	commentary	SOAT2 or ACAT2	
ecNumber	2.3.1.26	commentary	ACAT1	
ecNumber	2.3.1.26	commentary		
ecNumber	2.3.1.26	commentary	SOAT1 or ACAT1	
ecNumber	2.3.1.29	commentary		
ecNumber	2.3.1.32	commentary		
ecNumber	2.3.1.32	commentary		
ecNumber	2.3.1.33	commentary	gene Nat16	
ecNumber	2.3.1.37	commentary	2 isoforms ALAS-1 and ALAS-2, a houskeeping form and an erythroid-specific form	
ecNumber	2.3.1.37	commentary	major splice variant of enzyme isoform ALAS2, expression in Escherichia coli	
ecNumber	2.3.1.37	commentary		
ecNumber	2.3.1.37	commentary	isoform ALAS1	
ecNumber	2.3.1.37	commentary		
ecNumber	2.3.1.37	commentary	erythroid-specific gene ALAS2; erythroid-specific gene hALAS2	
ecNumber	2.3.1.37	commentary	gene alas2	
ecNumber	2.3.1.39	commentary		
ecNumber	2.3.1.41	commentary	expression in Escherichia coli, without N-terminal targeting sequence	
ecNumber	2.3.1.41	commentary	the human beta-ketoacyl [ACP] synthase from the mitochondrial type II fatty acid synthase	
ecNumber	2.3.1.42	commentary		
ecNumber	2.3.1.42	commentary		
ecNumber	2.3.1.43	commentary	nondiabetic men without cardiovascular disease	
ecNumber	2.3.1.43	commentary	gene lcat	
ecNumber	2.3.1.43	commentary		
ecNumber	2.3.1.43	commentary		
ecNumber	2.3.1.43	commentary	gene lcat	
ecNumber	2.3.1.45	commentary		
ecNumber	2.3.1.45	commentary		
ecNumber	2.3.1.45	commentary		
ecNumber	2.3.1.48	commentary	GCN5; recombinant enzyme hPCAF, i.e. human p300/CBP associated factor	
ecNumber	2.3.1.48	commentary	MORF protein, i.e. monocytic leukemia zinc finger protein-related factor	
ecNumber	2.3.1.48	commentary	PCAF protein	
ecNumber	2.3.1.48	commentary	GCN5	
ecNumber	2.3.1.48	commentary	GCN5; PCAF protein	
ecNumber	2.3.1.48	commentary	gene taf1	
ecNumber	2.3.1.48	commentary	gene Hbo1	
ecNumber	2.3.1.48	commentary	Tip60, p/CAF, and p300	
ecNumber	2.3.1.48	commentary	MOF	
ecNumber	2.3.1.48	commentary		
ecNumber	2.3.1.48	commentary		
ecNumber	2.3.1.48	commentary		
ecNumber	2.3.1.48	commentary	p300	
ecNumber	2.3.1.48	commentary	fragment EST clone of MORF protein, i.e. monocytic leukemia zinc finger protein-related factor	
ecNumber	2.3.1.48	commentary		
ecNumber	2.3.1.48	commentary	CBP	
ecNumber	2.3.1.48	commentary		
ecNumber	2.3.1.48	commentary	gene Gcn5	
ecNumber	2.3.1.48	commentary		
ecNumber	2.3.1.48	commentary	catalytic subunit of the male-specific lethal hiostone acetyltransferase complex	
ecNumber	2.3.1.48	commentary		
ecNumber	2.3.1.48	commentary	ATAC2	
ecNumber	2.3.1.50	commentary	; gene hLCB1 and hLCB2	
ecNumber	2.3.1.50	commentary	patiens with hereditary sensory neuropathy type I	
ecNumber	2.3.1.50	commentary	isozymes SPT1 and SPT2	
ecNumber	2.3.1.50	commentary	SPT contains subunits SPTLC1-SPTLC3	
ecNumber	2.3.1.50	commentary	4 distinct SPT isozymes	
ecNumber	2.3.1.50	commentary		
ecNumber	2.3.1.50	commentary	subunits hLCB1 (O15269) and hLCB2a/b (O15270)	
ecNumber	2.3.1.50	commentary	subunits SPTLC1 (O15269) and SPTLC2(O15270); subunits SPTLC1 and SPTLC2	
ecNumber	2.3.1.50	commentary	gene hLCB1	
ecNumber	2.3.1.50	commentary	human SPT1	
ecNumber	2.3.1.50	commentary	subunits SPT1 and SPT2	
ecNumber	2.3.1.50	commentary		
ecNumber	2.3.1.50	commentary	subunit hLCB1	
ecNumber	2.3.1.50	commentary	subunit 2 and 3	
ecNumber	2.3.1.50	commentary	gene hLCB2	
ecNumber	2.3.1.50	commentary	human SPT2	
ecNumber	2.3.1.50	commentary	subunit SPTLC2; British families	
ecNumber	2.3.1.50	commentary		
ecNumber	2.3.1.51	commentary	gene AGPAT8	
ecNumber	2.3.1.51	commentary		
ecNumber	2.3.1.51	commentary	AGPAT2; gene AGPAT2	
ecNumber	2.3.1.51	commentary		
ecNumber	2.3.1.51	commentary	gene AGPAT7; gene AGPAT7	
ecNumber	2.3.1.51	commentary		
ecNumber	2.3.1.51	commentary		
ecNumber	2.3.1.51	commentary		
ecNumber	2.3.1.51	commentary		
ecNumber	2.3.1.51	commentary		
ecNumber	2.3.1.56	commentary	isoforms NAT1 and NAT2	
ecNumber	2.3.1.56	commentary		
ecNumber	2.3.1.57	commentary	recombinant enzyme, expressed in Escherichia coli DH5alpha	
ecNumber	2.3.1.57	commentary	recombinant enzyme, expressed in Escherichia coli CAG2242	
ecNumber	2.3.1.57	commentary	human cDNA expressed in MCF-7 human breast carcinoma cells	
ecNumber	2.3.1.57	commentary	cloned from human breast cancer cDNA library	
ecNumber	2.3.1.57	commentary	French-Canadian population	
ecNumber	2.3.1.57	commentary	gene SAT1	
ecNumber	2.3.1.57	commentary		
ecNumber	2.3.1.57	commentary	2 isozymes SSAT-1 and SSAT-2; isozyme SSAT-1; 2 isozymes SSAT-1 and SSAT-2	
ecNumber	2.3.1.57	commentary	hSSAT gene	
ecNumber	2.3.1.57	commentary	encodes SSAT1 protein	
ecNumber	2.3.1.57	commentary	Ssat1	
ecNumber	2.3.1.57	commentary		
ecNumber	2.3.1.57	commentary	isozyme SSAT-2; 2 isozymes SSAT-1 and SSAT-2	
ecNumber	2.3.1.61	commentary		
ecNumber	2.3.1.61	commentary	male transgenic Tg19959 mice (model of amyloid deposition, 2 mutations in the human amyloid precursor protein) are crossed with dihydrolipoyl succinyltransferase deficient female mice (DLST+/-)	
ecNumber	2.3.1.63	commentary		
ecNumber	2.3.1.65	commentary	recombinant enzyme	
ecNumber	2.3.1.65	commentary	Japanese individuals	
ecNumber	2.3.1.65	commentary		
ecNumber	2.3.1.65	commentary		
ecNumber	2.3.1.67	commentary		
ecNumber	2.3.1.67	commentary		
ecNumber	2.3.1.67	commentary	; gene Lpcat2	
ecNumber	2.3.1.68	commentary		
ecNumber	2.3.1.71	commentary		
ecNumber	2.3.1.71	commentary	isoform Glyat	
ecNumber	2.3.1.71	commentary		
ecNumber	2.3.1.75	commentary		
ecNumber	2.3.1.75	commentary	AWAT1, i.e. DGA2; X-linked gene AWAT1/DGA2; gene DGAT2L3; isozyme DGA2 or AWAT1	
ecNumber	2.3.1.75	commentary	isozyme AWAT1	
ecNumber	2.3.1.75	commentary		
ecNumber	2.3.1.75	commentary	MFAT	
ecNumber	2.3.1.75	commentary	AWAT2, i.e. DC4; X-linked genes AWAT1/DGA2 and AWAT2/DC4; gene DGAT2L4; isozyme DC4 or AWAT2	
ecNumber	2.3.1.75	commentary	isozyme AWAT2	
ecNumber	2.3.1.75	commentary	gene DGAT2L6; isozyme DC3	
ecNumber	2.3.1.76	commentary	cell cultures	
ecNumber	2.3.1.76	commentary		
ecNumber	2.3.1.78	commentary		
ecNumber	2.3.1.78	commentary	isoform 2	
ecNumber	2.3.1.78	commentary		
ecNumber	2.3.1.80	commentary		
ecNumber	2.3.1.80	commentary		
ecNumber	2.3.1.81	commentary		
ecNumber	2.3.1.85	commentary	modulation of enzyme expression by siRNA	
ecNumber	2.3.1.85	commentary		
ecNumber	2.3.1.85	commentary	thioesterase domain of enzyme	
ecNumber	2.3.1.85	commentary		
ecNumber	2.3.1.86	commentary	type II fatty acid synthase complex, expression in Sf9 cells	
ecNumber	2.3.1.87	commentary	recombinant enzyme	
ecNumber	2.3.1.87	commentary	Caucasian population	
ecNumber	2.3.1.87	commentary		
ecNumber	2.3.1.87	commentary		
ecNumber	2.3.1.88	commentary	human	
ecNumber	2.3.1.88	commentary		
ecNumber	2.3.1.88	commentary	human	
ecNumber	2.3.1.88	commentary	variant hARD1235	
ecNumber	2.3.1.88	commentary	isoform Naa10	
ecNumber	2.3.1.88	commentary		
ecNumber	2.3.1.88	commentary		
ecNumber	2.3.1.88	commentary		
ecNumber	2.3.1.97	commentary	2 different splice variants	
ecNumber	2.3.1.97	commentary	isozyme NMT1	
ecNumber	2.3.1.97	commentary	isozymes NMT1 and NMT2	
ecNumber	2.3.1.97	commentary	isozyme NMT-1	
ecNumber	2.3.1.97	commentary		
ecNumber	2.3.1.97	commentary	isoform NMT-2	
ecNumber	2.3.1.97	commentary		
ecNumber	2.3.1.97	commentary	isozyme NMT2; isozyme NMT2	
ecNumber	2.3.1.97	commentary	NMT isoform HsNMT2; NMT isoform HsNMT2	
ecNumber	2.3.1.97	commentary	isoform NMT-1	
ecNumber	2.3.1.97	commentary	isozyme NMT1; isozyme NMT1	
ecNumber	2.3.1.97	commentary	NMT isoform HsNMT1; NMT isoform HsNMT1	
ecNumber	2.3.1.97	commentary		
ecNumber	2.3.1.105	commentary		
ecNumber	2.3.1.108	commentary		
ecNumber	2.3.1.108	commentary		
ecNumber	2.3.1.118	commentary		
ecNumber	2.3.1.118	commentary	expression of isiforms NAT1	3 and NAT2	4 in Escherichia coli	
ecNumber	2.3.1.118	commentary	isoform NAT2	
ecNumber	2.3.1.125	commentary		
ecNumber	2.3.1.135	commentary	gene Lrat	
ecNumber	2.3.1.135	commentary		
ecNumber	2.3.1.135	commentary		
ecNumber	2.3.1.137	commentary	human	
ecNumber	2.3.1.137	commentary	HeLa cells	
ecNumber	2.3.1.137	commentary	GenBank accession number AF168793	
ecNumber	2.3.1.137	commentary		
ecNumber	2.3.1.142	commentary		
ecNumber	2.3.1.147	commentary	individuals with and without asthma	
ecNumber	2.3.1.147	commentary		
ecNumber	2.3.1.148	commentary		
ecNumber	2.3.1.149	commentary		
ecNumber	2.3.1.155	commentary	human	
ecNumber	2.3.1.168	commentary		
ecNumber	2.3.1.168	commentary		
ecNumber	2.3.1.168	commentary	gene E2; pseudogene E2	
ecNumber	2.3.1.168	commentary	gene E2, complete sequence	
ecNumber	2.3.1.176	commentary		
ecNumber	2.3.1.176	commentary		
ecNumber	2.3.1.192	commentary		
ecNumber	2.3.1.199	commentary		
ecNumber	2.3.1.199	commentary		
ecNumber	2.3.1.225	commentary		
ecNumber	2.3.1.225	commentary	DHHC17 or HIP14	
ecNumber	2.3.1.225	commentary	ZDHC16, gene ZDHHC116; gene ZDHHC2	
ecNumber	2.3.1.225	commentary	ZDHC4, gene ZDHHC4; gene ZDHHC4	
ecNumber	2.3.1.225	commentary	ZDHC2, gene ZDHHC2; gene ZDHHC2	
ecNumber	2.3.1.225	commentary	DHHC9	
ecNumber	2.3.1.250	commentary	gene porc	
ecNumber	2.3.1.250	commentary		
ecNumber	2.3.1.250	commentary	gene PORCN	
ecNumber	2.3.1.254	commentary		
ecNumber	2.3.1.255	commentary		
ecNumber	2.3.1.255	commentary		
ecNumber	2.3.1.255	commentary		
ecNumber	2.3.1.256	commentary		
ecNumber	2.3.1.257	commentary		
ecNumber	2.3.1.257	commentary	; NatD	
ecNumber	2.3.1.257	commentary		
ecNumber	2.3.1.258	commentary		
ecNumber	2.3.1.258	commentary		
ecNumber	2.3.1.259	commentary		
ecNumber	2.3.1.259	commentary		
ecNumber	2.3.2.1	commentary		
ecNumber	2.3.2.2	commentary	6 isoforms in hepatic cellular carcinoma	
ecNumber	2.3.2.2	commentary	patients with coronary artery disease	
ecNumber	2.3.2.2	commentary	cohort study on construction workers	
ecNumber	2.3.2.2	commentary		
ecNumber	2.3.2.2	commentary	precursor	
ecNumber	2.3.2.2	commentary	isoform GGT1	
ecNumber	2.3.2.2	commentary		
ecNumber	2.3.2.2	commentary	precursor	
ecNumber	2.3.2.5	commentary		
ecNumber	2.3.2.5	commentary		
ecNumber	2.3.2.5	commentary		
ecNumber	2.3.2.8	commentary		
ecNumber	2.3.2.8	commentary		
ecNumber	2.3.2.B8	commentary		
ecNumber	2.3.2.B8	commentary	isoform UbcH5	
ecNumber	2.3.2.B8	commentary		
ecNumber	2.3.2.B8	commentary		
ecNumber	2.3.2.B12	commentary		
ecNumber	2.3.2.B12	commentary	isoform CYC4	
ecNumber	2.3.2.B12	commentary		
ecNumber	2.3.2.B12	commentary	isoform Prp19	
ecNumber	2.3.2.13	commentary	coagulation factor XIIIa	
ecNumber	2.3.2.13	commentary	coagulation factor XIIIa; zymogen factor XIII i.e. proenzyme of XIIIa	
ecNumber	2.3.2.13	commentary	expression in baculovirus system	
ecNumber	2.3.2.13	commentary	expression in Nicotiana tabacum cultured cells	
ecNumber	2.3.2.13	commentary	enzyme activity is elevated after oxidative stress or UV irradiation. Intrinsic activity or activation of enzyme is cell-type specific and does not correlate with enzyme expression level	
ecNumber	2.3.2.13	commentary	expression in SK-n-BE(2) neuroblastoma cell	
ecNumber	2.3.2.13	commentary	commentary	
ecNumber	2.3.2.13	commentary	patients with deficiencies in enzyme activity	
ecNumber	2.3.2.13	commentary	recombinant factor XIIIa	
ecNumber	2.3.2.13	commentary	coeliac patients and healthy indivuduals	
ecNumber	2.3.2.13	commentary	factor XIIIa	
ecNumber	2.3.2.13	commentary	recombinant endothelial enzyme	
ecNumber	2.3.2.13	commentary	isoform tTG	
ecNumber	2.3.2.13	commentary	recombinantly expressed in Escherichia coli	
ecNumber	2.3.2.13	commentary	isoform TG2	
ecNumber	2.3.2.13	commentary		
ecNumber	2.3.2.13	commentary	isoform TG2	
ecNumber	2.3.2.13	commentary		
ecNumber	2.3.2.13	commentary		
ecNumber	2.3.2.13	commentary	expression in baculovirus sytem	
ecNumber	2.3.2.B13	commentary		
ecNumber	2.3.2.B13	commentary		
ecNumber	2.3.2.23	commentary	35 active E2 enzymes have been identified	
ecNumber	2.3.2.23	commentary		
ecNumber	2.3.2.23	commentary		
ecNumber	2.3.2.23	commentary		
ecNumber	2.3.2.23	commentary		
ecNumber	2.3.2.23	commentary		
ecNumber	2.3.2.23	commentary	isoform Ubc4	
ecNumber	2.3.2.23	commentary		
ecNumber	2.3.2.23	commentary	isoform Uba3	
ecNumber	2.3.2.23	commentary		
ecNumber	2.3.2.23	commentary		
ecNumber	2.3.2.24	commentary		
ecNumber	2.3.2.24	commentary		
ecNumber	2.3.2.24	commentary		
ecNumber	2.3.2.24	commentary		
ecNumber	2.3.2.24	commentary		
ecNumber	2.3.2.24	commentary		
ecNumber	2.3.2.24	commentary		
ecNumber	2.3.2.24	commentary		
ecNumber	2.3.2.24	commentary		
ecNumber	2.3.2.24	commentary		
ecNumber	2.3.2.24	commentary		
ecNumber	2.3.2.24	commentary		
ecNumber	2.3.2.24	commentary		
ecNumber	2.3.2.24	commentary		
ecNumber	2.3.2.24	commentary		
ecNumber	2.3.2.24	commentary		
ecNumber	2.3.2.24	commentary		
ecNumber	2.3.2.24	commentary		
ecNumber	2.3.2.24	commentary		
ecNumber	2.3.2.24	commentary		
ecNumber	2.3.2.24	commentary		
ecNumber	2.3.2.24	commentary		
ecNumber	2.3.2.24	commentary		
ecNumber	2.3.2.24	commentary		
ecNumber	2.3.2.24	commentary		
ecNumber	2.3.2.25	commentary		
ecNumber	2.3.2.25	commentary		
ecNumber	2.3.2.25	commentary	isoform Ube2W	
ecNumber	2.3.2.25	commentary		
ecNumber	2.3.2.26	commentary		
ecNumber	2.3.2.26	commentary		
ecNumber	2.3.2.26	commentary		
ecNumber	2.3.2.26	commentary	isoform E6-AP	
ecNumber	2.3.2.26	commentary	isoform E6AP	
ecNumber	2.3.2.26	commentary		
ecNumber	2.3.2.26	commentary		
ecNumber	2.3.2.26	commentary		
ecNumber	2.3.2.26	commentary		
ecNumber	2.3.2.26	commentary	isoform 2	
ecNumber	2.3.2.26	commentary		
ecNumber	2.3.2.26	commentary	isoform Smurf1	
ecNumber	2.3.2.26	commentary		
ecNumber	2.3.2.27	commentary		
ecNumber	2.3.2.27	commentary	isoform parkin	
ecNumber	2.3.2.27	commentary		
ecNumber	2.3.2.27	commentary	isoform TEB4	
ecNumber	2.3.2.27	commentary	isoform MGRN1	
ecNumber	2.3.2.27	commentary		
ecNumber	2.3.2.27	commentary	isoform c-Cbl	
ecNumber	2.3.2.27	commentary		
ecNumber	2.3.2.27	commentary	isoform TRIM25	
ecNumber	2.3.2.27	commentary	isoform RNF43	
ecNumber	2.3.2.27	commentary		
ecNumber	2.3.2.27	commentary	isoform TRIM22	
ecNumber	2.3.2.27	commentary		
ecNumber	2.3.2.27	commentary	isoform PirH2	
ecNumber	2.3.2.27	commentary		
ecNumber	2.3.2.27	commentary		
ecNumber	2.3.2.27	commentary	isoform TRIM5	
ecNumber	2.3.2.27	commentary		
ecNumber	2.3.2.27	commentary	isoform RN181	
ecNumber	2.3.2.27	commentary	isoform gp78	
ecNumber	2.3.2.27	commentary		
ecNumber	2.3.2.27	commentary	isoform CHIP	
ecNumber	2.3.2.27	commentary	isoform HHARI	
ecNumber	2.3.2.27	commentary		
ecNumber	2.3.3.1	commentary		
ecNumber	2.3.3.1	commentary		
ecNumber	2.3.3.8	commentary	male renal stone patients, supplementary diet with potassium-magnesium citrate	
ecNumber	2.3.3.8	commentary	patients suffering diabetes	
ecNumber	2.3.3.8	commentary	recombinant enzyme	
ecNumber	2.3.3.8	commentary		
ecNumber	2.3.3.8	commentary		
ecNumber	2.3.3.10	commentary		
ecNumber	2.3.3.10	commentary	HeLa cells	
ecNumber	2.3.3.10	commentary	HepG2 cells	
ecNumber	2.3.3.10	commentary	human	
ecNumber	2.3.3.10	commentary	isoform HMGCS2	
ecNumber	2.3.3.10	commentary		
ecNumber	2.3.3.10	commentary	human, mitochondrial isoform	
ecNumber	2.3.3.10	commentary	isoform HMGCS2	
ecNumber	2.3.3.10	commentary	human, cytosolic isoform	
ecNumber	2.3.3.10	commentary	isoform HMGCS1	
ecNumber	2.3.3.16	commentary		
ecNumber	2.4.1.1	commentary	recombinant phosphorylase a	
ecNumber	2.4.1.1	commentary	recombinant enzyme	
ecNumber	2.4.1.1	commentary	isoform BB	
ecNumber	2.4.1.1	commentary	phosphorylase a	
ecNumber	2.4.1.1	commentary		
ecNumber	2.4.1.1	commentary	phosphorylase a	
ecNumber	2.4.1.1	commentary		
ecNumber	2.4.1.B7	commentary		
ecNumber	2.4.1.11	commentary	patients with type 2 diabetes	
ecNumber	2.4.1.11	commentary	patient with glycogen storage disease type 0	
ecNumber	2.4.1.11	commentary	patients with polycystic ovary syndrome	
ecNumber	2.4.1.11	commentary	patients with obesity and type 2 diabetes mellitus	
ecNumber	2.4.1.11	commentary		
ecNumber	2.4.1.11	commentary	muscle-specific glycogen synthase GYS1	
ecNumber	2.4.1.17	commentary	overview	
ecNumber	2.4.1.17	commentary	several enzyme isoforms	
ecNumber	2.4.1.17	commentary	several isozymes	
ecNumber	2.4.1.17	commentary	isozymes UGT1A1, UGT1A6, UGT1A9, UGT2B7, and UGT2B15	
ecNumber	2.4.1.17	commentary	isozyme UGT1A6; isozyme UGT2B17	
ecNumber	2.4.1.17	commentary	isozymes UGT1A9 and UGT2B7, renal transplant patients under mycopenolate mofetil therapy	
ecNumber	2.4.1.17	commentary	isozyme UGT1A6; isozyme UGT2B4	
ecNumber	2.4.1.17	commentary	isozymes UGT1A1, UGT1A3, UGT1A8, UGT1A9, UGT1A10, and UGT2B7	
ecNumber	2.4.1.17	commentary	isozymes UGT1A1, 1A3, 1A4, 1A6, 1A9, and 2B7	
ecNumber	2.4.1.17	commentary	isozymes UGT1 and UGT2	
ecNumber	2.4.1.17	commentary	diverse isozymes	
ecNumber	2.4.1.17	commentary	isozyme UGT1A4	
ecNumber	2.4.1.17	commentary	isozyme UGT1A1	
ecNumber	2.4.1.17	commentary	isozyme UGT1A8	
ecNumber	2.4.1.17	commentary	isoform UGT1A8; isoform UGT1A9	
ecNumber	2.4.1.17	commentary	female and male Caucasians	
ecNumber	2.4.1.17	commentary	isozymes UGT1A and UGT2B7	
ecNumber	2.4.1.17	commentary	isozyme UGT2B17	
ecNumber	2.4.1.17	commentary	isozyme UGT1A6	
ecNumber	2.4.1.17	commentary	isozyme UGT2B7	
ecNumber	2.4.1.17	commentary	isoform UGT2B7	
ecNumber	2.4.1.17	commentary	isoform UGT1A6	
ecNumber	2.4.1.17	commentary	male athletes	
ecNumber	2.4.1.17	commentary	isoform UGT1A10	
ecNumber	2.4.1.17	commentary	isoform UGT1A9	
ecNumber	2.4.1.17	commentary	gene UGT2A2	
ecNumber	2.4.1.17	commentary		
ecNumber	2.4.1.17	commentary	isozyme UGT1A9	
ecNumber	2.4.1.17	commentary	isozymes UGT1A1, UGT1A7, UGT1A9, naturally occuring UGT1A9 mutant D256N, the latter from a japanese cancer patient	
ecNumber	2.4.1.17	commentary	recombinant	
ecNumber	2.4.1.17	commentary	isozymes UGT1A1, UGT1A6, and UGT1A9	
ecNumber	2.4.1.17	commentary	isozyme UGT1A9; isozyme UGT1A9	
ecNumber	2.4.1.17	commentary	isoform UGT1A9	
ecNumber	2.4.1.17	commentary	UGT1A9; gene UGT1A9	
ecNumber	2.4.1.17	commentary	gene UGT1A9	
ecNumber	2.4.1.17	commentary		
ecNumber	2.4.1.17	commentary	UGT1A9; UGT1A9	
ecNumber	2.4.1.17	commentary		
ecNumber	2.4.1.17	commentary	UGT2B11; gene UGT2B11	
ecNumber	2.4.1.17	commentary	isozyme UGT2B17	
ecNumber	2.4.1.17	commentary	recombinant	
ecNumber	2.4.1.17	commentary	isozyme UGT2B17; isozyme UGT2B17	
ecNumber	2.4.1.17	commentary	UGT2B17; gene UGT2B17	
ecNumber	2.4.1.17	commentary		
ecNumber	2.4.1.17	commentary	isozyme UGT2B4; isozyme UGT2B4	
ecNumber	2.4.1.17	commentary	UGT2B4; gene UGT2B4	
ecNumber	2.4.1.17	commentary		
ecNumber	2.4.1.17	commentary	isozyme UGT2B7, 2 allelic variants UGT2B7H268 and UGT2B7Y268	
ecNumber	2.4.1.17	commentary	recombinant	
ecNumber	2.4.1.17	commentary	isozyme UGT2B7	
ecNumber	2.4.1.17	commentary	isozyme UGT2B7; isozyme UGT2B7	
ecNumber	2.4.1.17	commentary	UGT2B7; gene UGT2B7	
ecNumber	2.4.1.17	commentary	gene UGT2B7	
ecNumber	2.4.1.17	commentary	UGT2B7; UGT2B7	
ecNumber	2.4.1.17	commentary		
ecNumber	2.4.1.17	commentary	overview	
ecNumber	2.4.1.17	commentary	isozyme UGT1A6; isozymes UGT1A6 and UGT1A9	
ecNumber	2.4.1.17	commentary	isozyme UGT1A6	
ecNumber	2.4.1.17	commentary	isozyme UGT1A6; diverse isozymes	
ecNumber	2.4.1.17	commentary	isozyme UGT1A6; isozyme UGT1A6	
ecNumber	2.4.1.17	commentary	UGT1A6; gene UGT1A6	
ecNumber	2.4.1.17	commentary	gene UGT1A6	
ecNumber	2.4.1.17	commentary		
ecNumber	2.4.1.17	commentary	isozyme UGT1A1	
ecNumber	2.4.1.17	commentary	recombinant	
ecNumber	2.4.1.17	commentary	isozyme UGT1A1; 17 isozymes	
ecNumber	2.4.1.17	commentary	isozyme UGT1A1; isozyme UGT1A1; isozyme UGT2B7; isozyme UGT2B7	
ecNumber	2.4.1.17	commentary	isozyme UGT1A1; isozyme UGT1A1	
ecNumber	2.4.1.17	commentary	isoform UGT1A1	
ecNumber	2.4.1.17	commentary	UGT1A1	
ecNumber	2.4.1.17	commentary	UGT1A1; gene UGT1A1	
ecNumber	2.4.1.17	commentary	gene UGT1A1	
ecNumber	2.4.1.17	commentary		
ecNumber	2.4.1.17	commentary	UGT1A1; UGT1A1	
ecNumber	2.4.1.17	commentary	isozyme UGT1A4	
ecNumber	2.4.1.17	commentary	isozyme UGT1A4; diverse isozymes	
ecNumber	2.4.1.17	commentary	isozyme UGT1A4; isozyme UGT1A4	
ecNumber	2.4.1.17	commentary	UGT1A4; gene UGT1A4	
ecNumber	2.4.1.17	commentary	gene UGT1A4	
ecNumber	2.4.1.17	commentary		
ecNumber	2.4.1.17	commentary	UGT1A4; UGT1A4	
ecNumber	2.4.1.17	commentary	recombinant	
ecNumber	2.4.1.17	commentary	isozyme UGT1A3; isozyme UGT1A3	
ecNumber	2.4.1.17	commentary	UGT1A3; gene UGT1A3	
ecNumber	2.4.1.17	commentary		
ecNumber	2.4.1.17	commentary	UGT1A5; gene UGT1A5	
ecNumber	2.4.1.17	commentary		
ecNumber	2.4.1.17	commentary	isozyme UGT2B10	
ecNumber	2.4.1.17	commentary	isozyme UGT2B10; isozyme UGT2B10	
ecNumber	2.4.1.17	commentary	isozyme UGT1A10; isozyme UGT1A10	
ecNumber	2.4.1.17	commentary	UGT2B10; gene UGT2B10	
ecNumber	2.4.1.17	commentary		
ecNumber	2.4.1.17	commentary	UGT2B10	
ecNumber	2.4.1.17	commentary	recombinant	
ecNumber	2.4.1.17	commentary	isozyme UGT2B15; isozyme UGR2B15	
ecNumber	2.4.1.17	commentary	isozyme UGT2B15; isozyme UGT2B15	
ecNumber	2.4.1.17	commentary	UGT2B15; gene UGT2B15	
ecNumber	2.4.1.17	commentary		
ecNumber	2.4.1.17	commentary	isozyme UGT2A3	
ecNumber	2.4.1.17	commentary	UGT2A3; gene UGT2A3	
ecNumber	2.4.1.17	commentary		
ecNumber	2.4.1.17	commentary	UGT2B28; gene UGT2B28	
ecNumber	2.4.1.17	commentary	isozyme UGT1A7	
ecNumber	2.4.1.17	commentary	recombinant	
ecNumber	2.4.1.17	commentary	isozyme UGT1A7; isozyme UGT1A7	
ecNumber	2.4.1.17	commentary	UGT1A7; gene UGT1A7	
ecNumber	2.4.1.17	commentary		
ecNumber	2.4.1.17	commentary	isozyme UGT1A10; isozyme UGT1A10	
ecNumber	2.4.1.17	commentary	UGT1A10; gene UGT1A10	
ecNumber	2.4.1.17	commentary		
ecNumber	2.4.1.17	commentary	isozyme UGT1A8	
ecNumber	2.4.1.17	commentary	recombinant	
ecNumber	2.4.1.17	commentary	isozyme UGT1A8; isozyme UGT1A8; isozyme UGT1A9; isozyme UGT1A9	
ecNumber	2.4.1.17	commentary	isozyme UGT1A8; isozyme UGT1A8	
ecNumber	2.4.1.17	commentary	isozyme UGT1A9; isozyme UGT1A9	
ecNumber	2.4.1.17	commentary	UGT1A8; gene UGT1A8	
ecNumber	2.4.1.17	commentary		
ecNumber	2.4.1.17	commentary	UGT2A1; gene UGT2A1	
ecNumber	2.4.1.17	commentary		
ecNumber	2.4.1.18	commentary		
ecNumber	2.4.1.19	commentary	human	
ecNumber	2.4.1.22	commentary		
ecNumber	2.4.1.25	commentary	human	
ecNumber	2.4.1.25	commentary		
ecNumber	2.4.1.37	commentary	fragment; ABO gene	
ecNumber	2.4.1.37	commentary	fragment; ABO gene	
ecNumber	2.4.1.37	commentary	fragment; ABO gene	
ecNumber	2.4.1.37	commentary	fragment; ABO gene	
ecNumber	2.4.1.37	commentary	fragment; ABO gene	
ecNumber	2.4.1.37	commentary	only four amino acids are responsible for B and A blood group enzymes R176G, G235S, L266M and G268A, the latter two amino acids are responsible for the difference in donor specificity and the first two have roles in acceptor binding and turnover	
ecNumber	2.4.1.37	commentary	genotype Wu4, P234A-mutant, heterozygot B/0; only four amino acids are responsible for B and A blood group enzymes R176G, G235S, L266M and G268A, the latter two amino acids are responsible for the difference in donor specificity and the first two have roles in acceptor binding and turnover	
ecNumber	2.4.1.37	commentary	blood group B donors	
ecNumber	2.4.1.37	commentary	recombinantly expressed in Escherichia coli	
ecNumber	2.4.1.37	commentary		
ecNumber	2.4.1.37	commentary	only four amino acids are responsible for B and A blood group enzymes R176G, G235S, L266M and G268A, the latter two amino acids are responsible for the difference in donor specificity and the first two have roles in acceptor binding and turnover	
ecNumber	2.4.1.37	commentary	recombinantly expressed in Escherichia coli	
ecNumber	2.4.1.37	commentary		
ecNumber	2.4.1.37	commentary	fragment; ABO gene	
ecNumber	2.4.1.38	commentary	expressed in Saccharomyces cerevisiae	
ecNumber	2.4.1.38	commentary	wild type and recombinant enzyme expressed in Saccharomyces cerevisiae	
ecNumber	2.4.1.38	commentary	constitutitive genes expressing two enzyme forms	
ecNumber	2.4.1.38	commentary		
ecNumber	2.4.1.38	commentary		
ecNumber	2.4.1.38	commentary		
ecNumber	2.4.1.38	commentary		
ecNumber	2.4.1.38	commentary		
ecNumber	2.4.1.40	commentary	only four amino acids are responsible for B and A blood group enzymes R176G, G235S, L266M and G268A, the latter two amino acids are responsible for the difference in donor specificity and the first two have roles in acceptor binding and turnover	
ecNumber	2.4.1.40	commentary	blood group A1 and A2	
ecNumber	2.4.1.40	commentary	gastric cancer tissue of type 0 individuals, 3 of 31 show A-antigen production	
ecNumber	2.4.1.40	commentary	blood group A	
ecNumber	2.4.1.40	commentary	blood group A1	
ecNumber	2.4.1.40	commentary	blood type A or AB; women	
ecNumber	2.4.1.40	commentary	A transferase	
ecNumber	2.4.1.40	commentary		
ecNumber	2.4.1.40	commentary	only four amino acids are responsible for B and A blood group enzymes R176G, G235S, L266M and G268A, the latter two amino acids are responsible for the difference in donor specificity and the first two have roles in acceptor binding and turnover	
ecNumber	2.4.1.40	commentary		
ecNumber	2.4.1.41	commentary	GalNAc-T1, -T2 and -T3	
ecNumber	2.4.1.41	commentary	GalNAc-T9	
ecNumber	2.4.1.41	commentary	ppGalNAc-T14 and -T2	
ecNumber	2.4.1.41	commentary	ppGalNAc-T13, -T1 and -T9	
ecNumber	2.4.1.41	commentary	recombinant GalNAc-T2 and -T4	
ecNumber	2.4.1.41	commentary	pp-GalNAc-T1, -T2, -T3 and -T4	
ecNumber	2.4.1.41	commentary	isozyme T1-T4	
ecNumber	2.4.1.41	commentary	isoforms ppGalNAcT-2 (hT2) and ppGalNAcT-10 (hT10)	
ecNumber	2.4.1.41	commentary	isozymes ppGalNAc T2 and ppGalNAc T10	
ecNumber	2.4.1.41	commentary		
ecNumber	2.4.1.41	commentary	enzyme form pp-GalNAc-T2	
ecNumber	2.4.1.41	commentary	ppGalNAc-T2 	
ecNumber	2.4.1.41	commentary	GalNAc-T2	
ecNumber	2.4.1.41	commentary	ppGalNAc T2	
ecNumber	2.4.1.41	commentary	ppGalNAcT-2	
ecNumber	2.4.1.41	commentary		
ecNumber	2.4.1.41	commentary	ppGalNAc-T1	
ecNumber	2.4.1.41	commentary	GalNAc-T1	
ecNumber	2.4.1.41	commentary		
ecNumber	2.4.1.41	commentary	ppGalNAc-T3	
ecNumber	2.4.1.41	commentary		
ecNumber	2.4.1.41	commentary		
ecNumber	2.4.1.41	commentary	enzyme form pp-GalNAc-T15	
ecNumber	2.4.1.41	commentary	GalNAc-T7	
ecNumber	2.4.1.41	commentary		
ecNumber	2.4.1.41	commentary		
ecNumber	2.4.1.41	commentary		
ecNumber	2.4.1.41	commentary	ppGalNAc-T4	
ecNumber	2.4.1.41	commentary	GalNAc-T4	
ecNumber	2.4.1.41	commentary		
ecNumber	2.4.1.41	commentary	ppGalNAc-T6	
ecNumber	2.4.1.41	commentary		
ecNumber	2.4.1.41	commentary	GalNAc-T11	
ecNumber	2.4.1.41	commentary	; GalNAc-T14	
ecNumber	2.4.1.41	commentary		
ecNumber	2.4.1.47	commentary		
ecNumber	2.4.1.50	commentary		
ecNumber	2.4.1.50	commentary		
ecNumber	2.4.1.50	commentary		
ecNumber	2.4.1.50	commentary		
ecNumber	2.4.1.50	commentary		
ecNumber	2.4.1.62	commentary		
ecNumber	2.4.1.62	commentary	isoform beta3Gal-T2	
ecNumber	2.4.1.62	commentary	isoform beta3Gal-T4	
ecNumber	2.4.1.62	commentary	isoform beta3Gal-T1; isoform beta3Gal-T3	
ecNumber	2.4.1.65	commentary	fucosyltransferase III	
ecNumber	2.4.1.65	commentary	cystic fibrosis patient	
ecNumber	2.4.1.65	commentary	at least 6 alpha1,3FucT enzymes III-VII and IX, alpha1,3/1,4FucT III is a bifunctional enzyme	
ecNumber	2.4.1.65	commentary		
ecNumber	2.4.1.65	commentary		
ecNumber	2.4.1.65	commentary	FucT3	
ecNumber	2.4.1.65	commentary		
ecNumber	2.4.1.65	commentary	FucT6	
ecNumber	2.4.1.65	commentary		
ecNumber	2.4.1.65	commentary		
ecNumber	2.4.1.65	commentary		
ecNumber	2.4.1.65	commentary		
ecNumber	2.4.1.66	commentary		
ecNumber	2.4.1.66	commentary		
ecNumber	2.4.1.68	commentary		
ecNumber	2.4.1.68	commentary	gene FUT8	
ecNumber	2.4.1.68	commentary		
ecNumber	2.4.1.69	commentary	H-type enzyme	
ecNumber	2.4.1.69	commentary	recombinant and native enzyme	
ecNumber	2.4.1.69	commentary	two fucosyltransferase 2 gene missense polymorphisms, G247S and F280S, are partly responsible for non-secretor status in a Caucasian population from Northern Portugal	
ecNumber	2.4.1.69	commentary	patients with HIV-1	
ecNumber	2.4.1.69	commentary	FUT2 gene polymorphisms in a Korean population. The se357/385 is a common secretor enzyme-deficient allele in the Korean population, and the se428, which is a common null allele in Africans and Caucasians, is quite rare	
ecNumber	2.4.1.69	commentary	expressed in CHO-K1 cells	
ecNumber	2.4.1.69	commentary		
ecNumber	2.4.1.69	commentary		
ecNumber	2.4.1.69	commentary		
ecNumber	2.4.1.69	commentary		
ecNumber	2.4.1.B72	commentary		
ecNumber	2.4.1.79	commentary		
ecNumber	2.4.1.80	commentary	gene GluT-1	
ecNumber	2.4.1.80	commentary		
ecNumber	2.4.1.80	commentary		
ecNumber	2.4.1.83	commentary		
ecNumber	2.4.1.83	commentary		
ecNumber	2.4.1.86	commentary	fetus with Tay-Sachs disease	
ecNumber	2.4.1.86	commentary		
ecNumber	2.4.1.87	commentary		
ecNumber	2.4.1.87	commentary	gene GGTA1 encoding an inactivated enzyme	
ecNumber	2.4.1.88	commentary	cosmid sequence from chromosome 9q34	
ecNumber	2.4.1.88	commentary		
ecNumber	2.4.1.88	commentary	immunoreactive sequence homologue to FS sequences, but without FS activity due to modification of catalytic domain during evolution	
ecNumber	2.4.1.88	commentary		
ecNumber	2.4.1.90	commentary	expressed in Saccharomyces cerevisiae	
ecNumber	2.4.1.90	commentary	wild type and recombinant enzyme expressed in Saccharomyces cerevisiae	
ecNumber	2.4.1.90	commentary	several isoforms	
ecNumber	2.4.1.90	commentary	constitutive genes expressing two enzyme forms	
ecNumber	2.4.1.90	commentary		
ecNumber	2.4.1.90	commentary		
ecNumber	2.4.1.90	commentary		
ecNumber	2.4.1.90	commentary		
ecNumber	2.4.1.92	commentary		
ecNumber	2.4.1.92	commentary		
ecNumber	2.4.1.92	commentary	gene B4GALNT1	
ecNumber	2.4.1.92	commentary		
ecNumber	2.4.1.94	commentary		
ecNumber	2.4.1.95	commentary	sickle cell disease patients of the Bantu beta S haplotype, mean age 12.0	
ecNumber	2.4.1.95	commentary	Taiwanese hyperbilirubinemia patients	
ecNumber	2.4.1.95	commentary		
ecNumber	2.4.1.95	commentary		
ecNumber	2.4.1.101	commentary	recombinant enzyme as fusion protein with maltose-binding protein	
ecNumber	2.4.1.101	commentary		
ecNumber	2.4.1.101	commentary		
ecNumber	2.4.1.102	commentary	gene GCNT2	
ecNumber	2.4.1.102	commentary		
ecNumber	2.4.1.102	commentary	isozyme 2	
ecNumber	2.4.1.102	commentary	gene GCNT3	
ecNumber	2.4.1.102	commentary		
ecNumber	2.4.1.102	commentary	isozyme 1	
ecNumber	2.4.1.102	commentary		
ecNumber	2.4.1.102	commentary	gene GCNT1	
ecNumber	2.4.1.102	commentary	isozyme 3	
ecNumber	2.4.1.109	commentary		
ecNumber	2.4.1.109	commentary		
ecNumber	2.4.1.109	commentary		
ecNumber	2.4.1.109	commentary	one patient with limb girdle muscular dystrophy 2K, one patient with Walker-Warburg syndrome	
ecNumber	2.4.1.117	commentary		
ecNumber	2.4.1.122	commentary	EST clone, contains full length sequence	
ecNumber	2.4.1.122	commentary		
ecNumber	2.4.1.122	commentary		
ecNumber	2.4.1.122	commentary	form 2	
ecNumber	2.4.1.122	commentary	form 1	
ecNumber	2.4.1.122	commentary		
ecNumber	2.4.1.131	commentary		
ecNumber	2.4.1.132	commentary	hALG2	
ecNumber	2.4.1.132	commentary		
ecNumber	2.4.1.132	commentary	gene ALG2	
ecNumber	2.4.1.133	commentary		
ecNumber	2.4.1.133	commentary		
ecNumber	2.4.1.133	commentary		
ecNumber	2.4.1.133	commentary	; gene B4GALT7	
ecNumber	2.4.1.133	commentary	gene B4GALT7	
ecNumber	2.4.1.134	commentary		
ecNumber	2.4.1.134	commentary		
ecNumber	2.4.1.134	commentary	; gene B3GALT6	
ecNumber	2.4.1.134	commentary		
ecNumber	2.4.1.135	commentary		
ecNumber	2.4.1.135	commentary	truncated, expression in COS-1 cell, a soluble form of GlcAT-I generated by replacing the first 43 amino acids of GlcAT-I with a cleavable insulin signal sequence and a protein A IgG-binding domain	
ecNumber	2.4.1.135	commentary		
ecNumber	2.4.1.135	commentary		
ecNumber	2.4.1.141	commentary		
ecNumber	2.4.1.142	commentary		
ecNumber	2.4.1.142	commentary		
ecNumber	2.4.1.142	commentary	gene HMT-1	
ecNumber	2.4.1.143	commentary		
ecNumber	2.4.1.144	commentary	single copy gene, no isoforms	
ecNumber	2.4.1.144	commentary	patients with chronic hepatitis and liver cirrhosis	
ecNumber	2.4.1.144	commentary	patients with extrahepatic bile duct carcinoma or benign biliary duct diseases	
ecNumber	2.4.1.144	commentary	expression in human hepatoma cells	
ecNumber	2.4.1.144	commentary	expression in mouse aorta endothelial cells	
ecNumber	2.4.1.144	commentary		
ecNumber	2.4.1.144	commentary	gene MGAT3	
ecNumber	2.4.1.144	commentary		
ecNumber	2.4.1.145	commentary	patients with extrahepatic bile duct carcinoma	
ecNumber	2.4.1.145	commentary		
ecNumber	2.4.1.145	commentary		
ecNumber	2.4.1.145	commentary	gene MGAT4A	
ecNumber	2.4.1.145	commentary	isozyme b	
ecNumber	2.4.1.145	commentary		
ecNumber	2.4.1.146	commentary		
ecNumber	2.4.1.146	commentary	fusion with enhanced green fluorescence protein, expression in CHO cells	
ecNumber	2.4.1.146	commentary		
ecNumber	2.4.1.146	commentary	gene B3GNT3	
ecNumber	2.4.1.147	commentary		
ecNumber	2.4.1.147	commentary	enzyme form beta3-Gn-T6	
ecNumber	2.4.1.147	commentary	gene B3gnt6	
ecNumber	2.4.1.148	commentary		
ecNumber	2.4.1.149	commentary		
ecNumber	2.4.1.149	commentary		
ecNumber	2.4.1.149	commentary		
ecNumber	2.4.1.150	commentary		
ecNumber	2.4.1.150	commentary	gene contains three highly similar variable exons and two constant exons, each variable exon is preceded by a distinct promoter and is separately spliced to a set of two constant exons to generate functional Gcnt2 mRNA	
ecNumber	2.4.1.152	commentary	fucosyltransferase V	
ecNumber	2.4.1.152	commentary	fusion protein: protein A coupled to the catalytic domain of FucT-V	
ecNumber	2.4.1.152	commentary	enzyme is produced by infection of Trichoplusia ni cells with recombinant baculovirus	
ecNumber	2.4.1.152	commentary	recombinant enzyme expressed in Sf-9 cells via baculovirus infection	
ecNumber	2.4.1.152	commentary	recombinant enzyme	
ecNumber	2.4.1.152	commentary	gene FUT11	
ecNumber	2.4.1.152	commentary		
ecNumber	2.4.1.152	commentary		
ecNumber	2.4.1.152	commentary		
ecNumber	2.4.1.152	commentary		
ecNumber	2.4.1.152	commentary		
ecNumber	2.4.1.152	commentary		
ecNumber	2.4.1.153	commentary		
ecNumber	2.4.1.153	commentary	normal controls and patients with cystic fibrosis and diabetes mellitus	
ecNumber	2.4.1.155	commentary	expression in human H7721 hepatocarcinoma cells	
ecNumber	2.4.1.155	commentary	expression in CHO cells	
ecNumber	2.4.1.155	commentary	induction of enzyme in hepatoma cells by treatment with retinoic acid and 1alpha2,5-dihydroxyvitamin D3, repression of enzyme by treatment with dimethyl sulfoxide or cytosine-arabinoside	
ecNumber	2.4.1.155	commentary	recombinant	
ecNumber	2.4.1.155	commentary		
ecNumber	2.4.1.155	commentary	gene ets-1	
ecNumber	2.4.1.155	commentary		
ecNumber	2.4.1.155	commentary	Chinese gastric adenocarcinoma patients, gene MGAT5	
ecNumber	2.4.1.155	commentary	gene MGAT5	
ecNumber	2.4.1.165	commentary		
ecNumber	2.4.1.165	commentary	short transkript; expression in COS-7 cells	
ecNumber	2.4.1.165	commentary		
ecNumber	2.4.1.173	commentary		
ecNumber	2.4.1.174	commentary	transfected cells are injected into the cuadal intervertebral discs of 4-month old ICR mice, analyses at day seven after the injection show, that in vivo gene delivery of chondroitin sulfate N-acetylgalactosaminyltransferase-1 increases chondroitin sulfate biosynthesis in cartilage.	
ecNumber	2.4.1.174	commentary		
ecNumber	2.4.1.174	commentary		
ecNumber	2.4.1.174	commentary	chondroitin sulfate N-acetylgalactosaminyltransferase	
ecNumber	2.4.1.174	commentary		
ecNumber	2.4.1.174	commentary	gene ChGn-1	
ecNumber	2.4.1.174	commentary	gene csgalnact1	
ecNumber	2.4.1.175	commentary		
ecNumber	2.4.1.175	commentary		
ecNumber	2.4.1.175	commentary		
ecNumber	2.4.1.175	commentary		
ecNumber	2.4.1.175	commentary	gene CHSY1	
ecNumber	2.4.1.175	commentary		
ecNumber	2.4.1.175	commentary	chondroitin N-acetylgalactosaminyltransferase II	
ecNumber	2.4.1.175	commentary	chondroitin sulfate N-acetylgalactosaminyltransferase	
ecNumber	2.4.1.175	commentary	chondroitin N-acetylgalactosaminyltransferase I, not N-acetylgalactosaminyltransferase I EC 2.4.1.174	
ecNumber	2.4.1.179	commentary		
ecNumber	2.4.1.186	commentary	the amino acid residues 301-333 in glycogenin are engaged in interaction with glycogen synthase. Glycogenin contains at least one additional interacting site for glycogen synthase beside the COOH-terminus.	
ecNumber	2.4.1.186	commentary		
ecNumber	2.4.1.186	commentary		
ecNumber	2.4.1.186	commentary	gene GYG2	
ecNumber	2.4.1.186	commentary	recreationally active males, only slight decrease of enzyme level upon exercise with fast restoring of initial level upon recreation	
ecNumber	2.4.1.186	commentary		
ecNumber	2.4.1.186	commentary	gene GYG1	
ecNumber	2.4.1.198	commentary		
ecNumber	2.4.1.198	commentary	gene PIG-P	
ecNumber	2.4.1.198	commentary	cDNA that encode a 71-amino acid protein, which is termed PIG-Y (for phosphatidylinositlglycan-class Y). Mouse and rice homologues of PIG-Y, exhibit 79% and 25% amino acid identity with human PIG-Y, respectively. The hydropathy profile of Saccharomyces cerevisiae&acute;s Eri1p is quite similar to PIG-Y and the amino acid identity is 22%. N-terminus and C-terminus face the cytoplasmic side.; from the human T lymphoma KT-3 cDNA library	
ecNumber	2.4.1.198	commentary	gene hGPI1	
ecNumber	2.4.1.198	commentary		
ecNumber	2.4.1.201	commentary	gene MGAT6	
ecNumber	2.4.1.201	commentary		
ecNumber	2.4.1.206	commentary	patients with chronic Helicobacter pylori infection	
ecNumber	2.4.1.206	commentary		
ecNumber	2.4.1.206	commentary		
ecNumber	2.4.1.212	commentary	3 isozymes HAS1, HAS2, and HAS3 encoded by genes HAS1, HAS2, and HAS3	
ecNumber	2.4.1.212	commentary	isozymes HAS1, HAS2 and HAS3	
ecNumber	2.4.1.212	commentary	isozyme HAS2	
ecNumber	2.4.1.212	commentary	gene HAS1	
ecNumber	2.4.1.212	commentary		
ecNumber	2.4.1.212	commentary	recombinant	
ecNumber	2.4.1.212	commentary		
ecNumber	2.4.1.212	commentary	isoform HAS3	
ecNumber	2.4.1.212	commentary	isozyme HAS3	
ecNumber	2.4.1.212	commentary	sequence used for preparation of siRNA	
ecNumber	2.4.1.212	commentary	isoform HAS2	
ecNumber	2.4.1.212	commentary		
ecNumber	2.4.1.212	commentary	isozyme HAS2	
ecNumber	2.4.1.212	commentary		
ecNumber	2.4.1.212	commentary	sequence used for preparation of siRNA	
ecNumber	2.4.1.212	commentary	isoform HAS1; patients with multiple myeloma and Waldenstrom macroglobulinemia	
ecNumber	2.4.1.212	commentary	isoform HAS1	
ecNumber	2.4.1.212	commentary	isozyme HAS1	
ecNumber	2.4.1.212	commentary	gene HAS1	
ecNumber	2.4.1.212	commentary	sequence used for preparation of siRNA	
ecNumber	2.4.1.214	commentary	FucT-VII	
ecNumber	2.4.1.214	commentary		
ecNumber	2.4.1.214	commentary		
ecNumber	2.4.1.221	commentary	recombinant protein expressed in COS-1 cells	
ecNumber	2.4.1.221	commentary		
ecNumber	2.4.1.221	commentary		
ecNumber	2.4.1.221	commentary	gene POFUT1	
ecNumber	2.4.1.221	commentary	wild-type POFUT2 and high mannose type DelTA21-POFUT2	
ecNumber	2.4.1.222	commentary		
ecNumber	2.4.1.222	commentary	gene MFNG	
ecNumber	2.4.1.222	commentary	gene lfng	
ecNumber	2.4.1.222	commentary	gene Rfng	
ecNumber	2.4.1.223	commentary	genes EXTL1 and EXTL3	
ecNumber	2.4.1.223	commentary	recombinant enzyme lacking first N-terminal 57 amino acids to give a soluble protein, expression in malignant fibrous histocytoma cell line	
ecNumber	2.4.1.223	commentary	recombinant enzymes EXT1 and EXT2, activity is only detectable when enzymes are coexpressed, a mixture of individually expressed enzymes is inactive	
ecNumber	2.4.1.224	commentary	enzymes EXT1 and EXT2	
ecNumber	2.4.1.224	commentary	recombinant enzymes EXT1 and EXT2 lacking transmembrane domains	
ecNumber	2.4.1.224	commentary	enzyme EXT1, EXT2 constructs from Bos taurus	
ecNumber	2.4.1.224	commentary		
ecNumber	2.4.1.224	commentary		
ecNumber	2.4.1.224	commentary	gene EXT1	
ecNumber	2.4.1.224	commentary		
ecNumber	2.4.1.224	commentary	gene ext2	
ecNumber	2.4.1.224	commentary	Mennonite population, gene EXT2	
ecNumber	2.4.1.225	commentary	enzymes EXT1 and EXT2	
ecNumber	2.4.1.225	commentary	recombinant enzymes EXT1 and EXT2 lacking transmembrane domains	
ecNumber	2.4.1.225	commentary	enzyme EXT1, EXT2 constructs from Bos taurus	
ecNumber	2.4.1.225	commentary		
ecNumber	2.4.1.225	commentary	gene ext2	
ecNumber	2.4.1.225	commentary		
ecNumber	2.4.1.225	commentary	gene EXT1	
ecNumber	2.4.1.225	commentary		
ecNumber	2.4.1.225	commentary	gene ext2	
ecNumber	2.4.1.225	commentary	Mennonite population, gene EXT2	
ecNumber	2.4.1.226	commentary		
ecNumber	2.4.1.226	commentary		
ecNumber	2.4.1.226	commentary	gene CHSY1	
ecNumber	2.4.1.226	commentary		
ecNumber	2.4.1.226	commentary	chondroitin sulfate synthase-2, i.e. CSS2; 2 enzymes: CSGlcAT-II and CSS2	
ecNumber	2.4.1.226	commentary	further cDNA: Kazusa DNA Research Institute number KIAA1402	
ecNumber	2.4.1.228	commentary	NTERA-2 cl.D1 cells, a cloned EC subline of the teratocarcinoma cell line TERA-2, during retinoic acid induced differentiation, Burkitt lymphoma Ramos cells	
ecNumber	2.4.1.228	commentary	leukaemia-myeloid cell lines: K562, KG-1, HL-60, and THP-1, lymphoma-lymphoid cell lines: Reh, Daudi, Raji, RPMI 8226, CCRF-CEM, and MOLT-4	
ecNumber	2.4.1.228	commentary	melanoma cell line SK-MEL-37	
ecNumber	2.4.1.228	commentary		
ecNumber	2.4.1.228	commentary		
ecNumber	2.4.1.228	commentary	gene A4GALT	
ecNumber	2.4.1.244	commentary		
ecNumber	2.4.1.244	commentary		
ecNumber	2.4.1.244	commentary	gene B4GALNT3	
ecNumber	2.4.1.244	commentary		
ecNumber	2.4.1.255	commentary	clone Lv4F	
ecNumber	2.4.1.255	commentary	comparison of the mouse, rat, and human ogt genes	
ecNumber	2.4.1.255	commentary		
ecNumber	2.4.1.255	commentary	clone Lv4F	
ecNumber	2.4.1.255	commentary	UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase 110 kDa subunit	
ecNumber	2.4.1.255	commentary		
ecNumber	2.4.1.255	commentary		
ecNumber	2.4.1.258	commentary		
ecNumber	2.4.1.258	commentary		
ecNumber	2.4.1.259	commentary		
ecNumber	2.4.1.259	commentary		
ecNumber	2.4.1.259	commentary	ALG9-defective (CDG-IL) patient	
ecNumber	2.4.1.260	commentary		
ecNumber	2.4.1.260	commentary		
ecNumber	2.4.1.261	commentary	ALG9-defective (CDG-IL) patient	
ecNumber	2.4.1.261	commentary		
ecNumber	2.4.1.265	commentary		
ecNumber	2.4.1.265	commentary		
ecNumber	2.4.1.267	commentary		
ecNumber	2.4.1.274	commentary		
ecNumber	2.4.1.274	commentary		
ecNumber	2.4.1.275	commentary		
ecNumber	2.4.1.312	commentary		
ecNumber	2.4.1.312	commentary		
ecNumber	2.4.1.313	commentary		
ecNumber	2.4.1.313	commentary		
ecNumber	2.4.1.344	commentary		
ecNumber	2.4.1.344	commentary		
ecNumber	2.4.2.1	commentary		
ecNumber	2.4.2.1	commentary	recombinant	
ecNumber	2.4.2.1	commentary		
ecNumber	2.4.2.2	commentary		
ecNumber	2.4.2.B2	commentary		
ecNumber	2.4.2.3	commentary		
ecNumber	2.4.2.3	commentary		
ecNumber	2.4.2.3	commentary	UP1; type 1 enzyme	
ecNumber	2.4.2.3	commentary	isozyme UPP1	
ecNumber	2.4.2.3	commentary		
ecNumber	2.4.2.4	commentary	normal and tumor tissue	
ecNumber	2.4.2.4	commentary	recombinant enyzme	
ecNumber	2.4.2.4	commentary		
ecNumber	2.4.2.4	commentary		
ecNumber	2.4.2.7	commentary	patients with partial deficiency in hypoxanthine-guanine phosphoribosyltransferase, (HPRT-) (Propositus), and control(HPRT+)	
ecNumber	2.4.2.7	commentary	Japanese patients with 2,8-dihydroxyadenine urolithiasis	
ecNumber	2.4.2.7	commentary		
ecNumber	2.4.2.7	commentary		
ecNumber	2.4.2.8	commentary	3 charge variant forms	
ecNumber	2.4.2.8	commentary	construction of 4 chimeric enzymes with segments of human and Plasmodium falciparum enzymes	
ecNumber	2.4.2.8	commentary	purified enzyme	
ecNumber	2.4.2.8	commentary	gene HPRT	
ecNumber	2.4.2.8	commentary	Japanese population	
ecNumber	2.4.2.8	commentary		
ecNumber	2.4.2.8	commentary	gene HPRT	
ecNumber	2.4.2.8	commentary		
ecNumber	2.4.2.9	commentary		
ecNumber	2.4.2.9	commentary	gene upp	
ecNumber	2.4.2.9	commentary		
ecNumber	2.4.2.10	commentary	patients with bladder carcinoma	
ecNumber	2.4.2.10	commentary		
ecNumber	2.4.2.12	commentary		
ecNumber	2.4.2.12	commentary		
ecNumber	2.4.2.14	commentary		
ecNumber	2.4.2.14	commentary		
ecNumber	2.4.2.B14	commentary		
ecNumber	2.4.2.B14	commentary		
ecNumber	2.4.2.B15	commentary		
ecNumber	2.4.2.B15	commentary		
ecNumber	2.4.2.B15	commentary		
ecNumber	2.4.2.B15	commentary		
ecNumber	2.4.2.B16	commentary		
ecNumber	2.4.2.19	commentary		
ecNumber	2.4.2.19	commentary		
ecNumber	2.4.2.26	commentary	2 isoforms XT-I and XT-II	
ecNumber	2.4.2.26	commentary		
ecNumber	2.4.2.26	commentary		
ecNumber	2.4.2.26	commentary		
ecNumber	2.4.2.28	commentary	telomeric methylthioadenosine phosphorylase gene MTAP	
ecNumber	2.4.2.28	commentary		
ecNumber	2.4.2.28	commentary	recombinant	
ecNumber	2.4.2.28	commentary		
ecNumber	2.4.2.29	commentary		
ecNumber	2.4.2.29	commentary		
ecNumber	2.4.2.30	commentary	healthy people and Parkinson patients	
ecNumber	2.4.2.30	commentary		
ecNumber	2.4.2.30	commentary	TNKS1	
ecNumber	2.4.2.30	commentary	PARP-1	
ecNumber	2.4.2.30	commentary	PARP-6	
ecNumber	2.4.2.30	commentary		
ecNumber	2.4.2.30	commentary	PARP-14	
ecNumber	2.4.2.30	commentary		
ecNumber	2.4.2.30	commentary		
ecNumber	2.4.2.30	commentary	PARP-16	
ecNumber	2.4.2.30	commentary	PARP-11	
ecNumber	2.4.2.30	commentary	PARP-2	
ecNumber	2.4.2.30	commentary	PARP-4	
ecNumber	2.4.2.30	commentary	PARP-3	
ecNumber	2.4.2.30	commentary		
ecNumber	2.4.2.31	commentary	isozymes ART1, ART3, ART4, and ART5	
ecNumber	2.4.2.31	commentary		
ecNumber	2.4.2.31	commentary		
ecNumber	2.4.2.31	commentary	ART3, fragment; gene ART3, two splicing variants different in the 5'-UTR	
ecNumber	2.4.2.31	commentary	ART3, fragments; gene ART3, two splicing variants different in the 5'-UTR	
ecNumber	2.4.2.31	commentary	ART3, fragments; gene ART3, two splicing variants different in the 5'-UTR	
ecNumber	2.4.2.31	commentary		
ecNumber	2.4.2.38	commentary		
ecNumber	2.4.2.42	commentary		
ecNumber	2.4.99.1	commentary	recombinant	
ecNumber	2.4.99.1	commentary		
ecNumber	2.4.99.1	commentary	ST6GAL1	
ecNumber	2.4.99.1	commentary		
ecNumber	2.4.99.1	commentary	ST6GAL2	
ecNumber	2.4.99.2	commentary		
ecNumber	2.4.99.3	commentary		
ecNumber	2.4.99.3	commentary	ST6GalNAc-II	
ecNumber	2.4.99.3	commentary	ST6GalNAc-I	
ecNumber	2.4.99.3	commentary	isoforms ST6GalNAc-I and ST6GalNAc-II, recombinant enzymes	
ecNumber	2.4.99.3	commentary	patients with IgA nephropathy	
ecNumber	2.4.99.3	commentary		
ecNumber	2.4.99.3	commentary	hST6GalNAc-I	
ecNumber	2.4.99.3	commentary	STM, i.e. hST6GalNAc-II	
ecNumber	2.4.99.4	commentary	healthy individuals and Wiscott-Aldrich syndrom patients	
ecNumber	2.4.99.4	commentary	ST3Gal II	
ecNumber	2.4.99.4	commentary	ST3GalI	
ecNumber	2.4.99.4	commentary	isoform ST3Gal-IV	
ecNumber	2.4.99.4	commentary		
ecNumber	2.4.99.4	commentary	ST3Gal I	
ecNumber	2.4.99.4	commentary	isoform St3Gal I	
ecNumber	2.4.99.4	commentary		
ecNumber	2.4.99.4	commentary	isoform St3Gal IV	
ecNumber	2.4.99.4	commentary	isoform St3Gal II	
ecNumber	2.4.99.6	commentary	colon carcinoma	
ecNumber	2.4.99.6	commentary	GST3GalII; GST3GalIII	
ecNumber	2.4.99.6	commentary		
ecNumber	2.4.99.6	commentary		
ecNumber	2.4.99.6	commentary	isoform ST3Gal III	
ecNumber	2.4.99.6	commentary	isoform St3Gal IV	
ecNumber	2.4.99.6	commentary	isoform ST3Gal VI	
ecNumber	2.4.99.6	commentary		
ecNumber	2.4.99.7	commentary	isoforms ST6GalNAc VI and ST6GalNAc V, recombinant enzyme	
ecNumber	2.4.99.7	commentary	isoforms ST6GalNAc III, V, and VI	
ecNumber	2.4.99.7	commentary		
ecNumber	2.4.99.7	commentary	ST6GalNAc III	
ecNumber	2.4.99.7	commentary	ST6GALNAC3, SIAT7C	
ecNumber	2.4.99.7	commentary	ST6GalNAc VI	
ecNumber	2.4.99.7	commentary	ST6GalNAc VI, ST6GALNAC VI, ST6GALNAC6	
ecNumber	2.4.99.7	commentary	ST6GALNAC5, SIAT7E	
ecNumber	2.4.99.7	commentary		
ecNumber	2.4.99.7	commentary	ST6GALNAC4, SIAT3C, SIAT7D	
ecNumber	2.4.99.8	commentary	expression in CHO cell, coexpression with calnexin suppresses enzyme-induced apoptosis	
ecNumber	2.4.99.8	commentary	recombinant protein	
ecNumber	2.4.99.8	commentary	recombinant enzyme	
ecNumber	2.4.99.8	commentary		
ecNumber	2.4.99.8	commentary		
ecNumber	2.4.99.8	commentary	gene ST8SIA1	
ecNumber	2.4.99.8	commentary		
ecNumber	2.4.99.9	commentary	5 different isozymes/mRNA variants of different lengths, overview	
ecNumber	2.4.99.9	commentary		
ecNumber	2.4.99.9	commentary	SIAT9; 5 different isozymes/mRNA variants of different lengths, overview; ST3GAL5, SIAT9; 5 different isozymes/mRNA variants of different lengths, overview	
ecNumber	2.4.99.9	commentary	gene ST3GAL5	
ecNumber	2.4.99.9	commentary		
ecNumber	2.4.99.18	commentary		
ecNumber	2.4.99.20	commentary	bifunctional ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1	
ecNumber	2.4.99.20	commentary	bifunctional enzyme that can synthesize cADPR from NAD1 as well as hydrolyze cADPR to ADP-ribose	
ecNumber	2.4.99.20	commentary		
ecNumber	2.5.1.4	commentary		
ecNumber	2.5.1.5	commentary		
ecNumber	2.5.1.6	commentary	3 isoenzymes: MAT-I, MAT-II, MAT-III	
ecNumber	2.5.1.6	commentary	isoforms MAT1A, MAT2A	
ecNumber	2.5.1.6	commentary	genes MAT1A and MAT2A, isozymes MAT I-MAT III	
ecNumber	2.5.1.6	commentary		
ecNumber	2.5.1.6	commentary	lung epithelial isoform and Jurkat cell isozyme of MAT 2A	
ecNumber	2.5.1.6	commentary		
ecNumber	2.5.1.6	commentary	isoform MAT2A	
ecNumber	2.5.1.6	commentary	isoform MAT1A	
ecNumber	2.5.1.6	commentary	MAT-II	
ecNumber	2.5.1.6	commentary		
ecNumber	2.5.1.10	commentary		
ecNumber	2.5.1.10	commentary		
ecNumber	2.5.1.16	commentary		
ecNumber	2.5.1.16	commentary		
ecNumber	2.5.1.17	commentary	2 common polymorphic variants 239K and 239M of the enzyme	
ecNumber	2.5.1.17	commentary	gene cblB	
ecNumber	2.5.1.17	commentary		
ecNumber	2.5.1.17	commentary		
ecNumber	2.5.1.18	commentary	basic and acid isoenzyme	
ecNumber	2.5.1.18	commentary	13 forms	
ecNumber	2.5.1.18	commentary	polycythaemia patients	
ecNumber	2.5.1.18	commentary	multiple forms	
ecNumber	2.5.1.18	commentary	transferase P1-1	
ecNumber	2.5.1.18	commentary	enzyme form glutathione S-transferase P1-1, recombinant	
ecNumber	2.5.1.18	commentary	alpha class GST A1-1	
ecNumber	2.5.1.18	commentary	isozyme GST P1-1	
ecNumber	2.5.1.18	commentary	GST isozymes A1-1, A2-2, M1-1, M2-2, and P1-1	
ecNumber	2.5.1.18	commentary	isozymes GSTA1-1, GSTM2-2, and GSTP1-1	
ecNumber	2.5.1.18	commentary	isozyme GSTP1	
ecNumber	2.5.1.18	commentary	male	
ecNumber	2.5.1.18	commentary	isozyme GST T1-1	
ecNumber	2.5.1.18	commentary	isozyme GSTA4-4	
ecNumber	2.5.1.18	commentary	isozymes GST A1-1 and GST A4-4	
ecNumber	2.5.1.18	commentary	isozyme GSTP1-1	
ecNumber	2.5.1.18	commentary	isozyme GSTA1-1	
ecNumber	2.5.1.18	commentary	isozyme hGSTA1-1	
ecNumber	2.5.1.18	commentary	isozymes GSTA1-1, GSTM1-1, and GSTP1-1	
ecNumber	2.5.1.18	commentary		
ecNumber	2.5.1.18	commentary		
ecNumber	2.5.1.18	commentary	isozyme GSTA4-4	
ecNumber	2.5.1.18	commentary		
ecNumber	2.5.1.18	commentary	isozyme GSTZ1-1	
ecNumber	2.5.1.18	commentary	isozyme GSTS1-1	
ecNumber	2.5.1.18	commentary		
ecNumber	2.5.1.18	commentary	isozyme GSTA1-1	
ecNumber	2.5.1.18	commentary		
ecNumber	2.5.1.18	commentary	isozyme GSTA2-2	
ecNumber	2.5.1.18	commentary		
ecNumber	2.5.1.18	commentary	isozyme GSTP1-1, encoded by a single functional GSTP gene termed GSTP1 that maps to chromosome 11q13; isozyme GSTT1-1	
ecNumber	2.5.1.18	commentary		
ecNumber	2.5.1.18	commentary	isozyme GSTM1-1	
ecNumber	2.5.1.18	commentary	isozyme GSTT2-2	
ecNumber	2.5.1.18	commentary	isozyme GSTM3-3	
ecNumber	2.5.1.18	commentary		
ecNumber	2.5.1.18	commentary	isozyme GSTM2-2	
ecNumber	2.5.1.18	commentary	theta class isozyme GST T1-1	
ecNumber	2.5.1.18	commentary	isozyme GST T1-1	
ecNumber	2.5.1.18	commentary		
ecNumber	2.5.1.18	commentary		
ecNumber	2.5.1.18	commentary	isozyme GSTM5-5	
ecNumber	2.5.1.18	commentary		
ecNumber	2.5.1.18	commentary	isozyme GSTO1-1	
ecNumber	2.5.1.18	commentary		
ecNumber	2.5.1.18	commentary	isozyme GSTM4-4	
ecNumber	2.5.1.18	commentary		
ecNumber	2.5.1.18	commentary	isozyme GSTA3-3	
ecNumber	2.5.1.18	commentary	isozyme GSTA5-5	
ecNumber	2.5.1.18	commentary	isozyme GSTO2; omega class isozymes GSTO1-1 and GSTO2	
ecNumber	2.5.1.18	commentary	isozyme GSTO2-2	
ecNumber	2.5.1.21	commentary	a French Canadian population	
ecNumber	2.5.1.21	commentary		
ecNumber	2.5.1.21	commentary	recombinant enzyme	
ecNumber	2.5.1.21	commentary		
ecNumber	2.5.1.21	commentary	gene SQS or FDFT1	
ecNumber	2.5.1.21	commentary	gene hsqs	
ecNumber	2.5.1.21	commentary	gene FDFT1	
ecNumber	2.5.1.22	commentary	patients with Snyder-Robinson X-linked recessive mental retardation syndrome	
ecNumber	2.5.1.22	commentary		
ecNumber	2.5.1.22	commentary		
ecNumber	2.5.1.26	commentary		
ecNumber	2.5.1.26	commentary	gene Agps	
ecNumber	2.5.1.26	commentary		
ecNumber	2.5.1.29	commentary	; recombinant	
ecNumber	2.5.1.29	commentary	Korean women	
ecNumber	2.5.1.29	commentary		
ecNumber	2.5.1.29	commentary		
ecNumber	2.5.1.39	commentary	isoform Coq2	
ecNumber	2.5.1.39	commentary		
ecNumber	2.5.1.39	commentary	gene COQ2	
ecNumber	2.5.1.39	commentary		
ecNumber	2.5.1.46	commentary	recombinant enzyme	
ecNumber	2.5.1.46	commentary		
ecNumber	2.5.1.46	commentary	recombinant enzyme	
ecNumber	2.5.1.46	commentary	gene Dhps	
ecNumber	2.5.1.46	commentary		
ecNumber	2.5.1.49	commentary		
ecNumber	2.5.1.49	commentary	patients with esophageal squamous cell carcinoma, Barretts esophagus-associated esophageal adenocarcinoma, cardiac carcinoma, or gastric carcinoma	
ecNumber	2.5.1.49	commentary	patients with multiple myeloma	
ecNumber	2.5.1.56	commentary	gene NANS	
ecNumber	2.5.1.57	commentary	human	
ecNumber	2.5.1.57	commentary	expression in Sf9 system	
ecNumber	2.5.1.57	commentary		
ecNumber	2.5.1.57	commentary	amino acid sequence	
ecNumber	2.5.1.57	commentary		
ecNumber	2.5.1.58	commentary	mammalian HeLa cells	
ecNumber	2.5.1.58	commentary		
ecNumber	2.5.1.58	commentary		
ecNumber	2.5.1.58	commentary	alpha-subunit	
ecNumber	2.5.1.58	commentary	beta-subunit	
ecNumber	2.5.1.59	commentary	enzyme produced in Sf9cells using baculovirus system	
ecNumber	2.5.1.59	commentary		
ecNumber	2.5.1.59	commentary	subunit alpha	
ecNumber	2.5.1.59	commentary	subunit beta	
ecNumber	2.5.1.60	commentary		
ecNumber	2.5.1.60	commentary		
ecNumber	2.5.1.61	commentary		
ecNumber	2.5.1.61	commentary	lethally irradiated acute intermittent porphyria type C57BL/6-CD45.2 mice are treated with plasmids containing human enzyme genes, that are expressed in hepatocytes	
ecNumber	2.5.1.61	commentary		
ecNumber	2.5.1.75	commentary		
ecNumber	2.5.1.75	commentary		
ecNumber	2.5.1.87	commentary		
ecNumber	2.5.1.87	commentary		
ecNumber	2.5.1.87	commentary		
ecNumber	2.5.1.91	commentary	Q5T2R2: subunit 1 (DPS1) and Q86YH6: subunit 2 (DLP1/PDSS2)	
ecNumber	2.5.1.91	commentary	subunit DPS1	
ecNumber	2.5.1.91	commentary	subunit DLP1	
ecNumber	2.5.1.96	commentary		
ecNumber	2.5.1.114	commentary		
ecNumber	2.5.1.132	commentary		
ecNumber	2.5.1.132	commentary		
ecNumber	2.5.1.141	commentary		
ecNumber	2.6.1.1	commentary	cytosolic isozyme	
ecNumber	2.6.1.1	commentary		
ecNumber	2.6.1.1	commentary		
ecNumber	2.6.1.1	commentary		
ecNumber	2.6.1.1	commentary		
ecNumber	2.6.1.2	commentary	high alanine aminotransferase activity is a marker of risk for type 2 diabetis	
ecNumber	2.6.1.2	commentary	recombinant protein	
ecNumber	2.6.1.2	commentary	; HIV/HCV co-infected patients	
ecNumber	2.6.1.2	commentary	isoform Alt1; isoform Alt2	
ecNumber	2.6.1.2	commentary	hepatitis C patients	
ecNumber	2.6.1.2	commentary		
ecNumber	2.6.1.2	commentary		
ecNumber	2.6.1.4	commentary		
ecNumber	2.6.1.4	commentary		
ecNumber	2.6.1.4	commentary		
ecNumber	2.6.1.5	commentary	enzyme is not suppressed during cell proliferation	
ecNumber	2.6.1.5	commentary		
ecNumber	2.6.1.7	commentary	kynurenine aminotransferase I and II, i.e. KAT I and KAT II, in elderly Down syndrome patients	
ecNumber	2.6.1.7	commentary	expression in Sf9 system	
ecNumber	2.6.1.7	commentary	isoform KAT II	
ecNumber	2.6.1.7	commentary		
ecNumber	2.6.1.7	commentary		
ecNumber	2.6.1.7	commentary		
ecNumber	2.6.1.7	commentary	isoform KAT II	
ecNumber	2.6.1.7	commentary		
ecNumber	2.6.1.13	commentary	patients with hyperonithinemia	
ecNumber	2.6.1.13	commentary	hereditary enzyme deficiency	
ecNumber	2.6.1.13	commentary	patient with gyrate atrophy of the choroid and retina	
ecNumber	2.6.1.13	commentary		
ecNumber	2.6.1.13	commentary		
ecNumber	2.6.1.16	commentary		
ecNumber	2.6.1.16	commentary	glutamine:fructose-6-phosphate amidotransferase isoform 1	
ecNumber	2.6.1.16	commentary	patients with type 2 diabetes	
ecNumber	2.6.1.16	commentary		
ecNumber	2.6.1.19	commentary		
ecNumber	2.6.1.19	commentary		
ecNumber	2.6.1.39	commentary	human	
ecNumber	2.6.1.39	commentary	human	
ecNumber	2.6.1.39	commentary		
ecNumber	2.6.1.40	commentary		
ecNumber	2.6.1.42	commentary	human	
ecNumber	2.6.1.42	commentary		
ecNumber	2.6.1.42	commentary	human, BCATm DNA sequence	
ecNumber	2.6.1.42	commentary	cytosolic and mitochondrial isoforms	
ecNumber	2.6.1.42	commentary		
ecNumber	2.6.1.42	commentary		
ecNumber	2.6.1.44	commentary		
ecNumber	2.6.1.44	commentary	human	
ecNumber	2.6.1.44	commentary	overexpression in Escherichia coli	
ecNumber	2.6.1.44	commentary	; patients with primary hyperoxaluria type I	
ecNumber	2.6.1.44	commentary		
ecNumber	2.6.1.44	commentary	patients with primary hyperoxaluria type 1	
ecNumber	2.6.1.44	commentary		
ecNumber	2.6.1.45	commentary		
ecNumber	2.6.1.49	commentary		
ecNumber	2.6.1.51	commentary	human	
ecNumber	2.6.1.52	commentary		
ecNumber	2.6.1.52	commentary		
ecNumber	2.6.1.58	commentary		
ecNumber	2.6.1.64	commentary	human	
ecNumber	2.6.1.64	commentary	recombinant	
ecNumber	2.6.1.64	commentary		
ecNumber	2.6.99.1	commentary		
ecNumber	2.7.1.1	commentary	multiple forms: Ia, Ib, Ic	
ecNumber	2.7.1.1	commentary	2 subtypes of hexokinase type I	
ecNumber	2.7.1.1	commentary	hexokinase types I and III	
ecNumber	2.7.1.1	commentary	recombinant hexokinase I, expressed in Escherichia coli	
ecNumber	2.7.1.1	commentary	hexokinase type III and its catalytically active recombinant carboxyl-domain	
ecNumber	2.7.1.1	commentary	recombinant hexokinase I	
ecNumber	2.7.1.1	commentary	B-cells	
ecNumber	2.7.1.1	commentary	recombinantly expressed in Escherichia coli	
ecNumber	2.7.1.1	commentary	recombinant	
ecNumber	2.7.1.1	commentary	GCK mutation (V62M) identified in two families	
ecNumber	2.7.1.1	commentary		
ecNumber	2.7.1.1	commentary	nonaggregating mutant of recombinant hexokinase I	
ecNumber	2.7.1.1	commentary		
ecNumber	2.7.1.1	commentary		
ecNumber	2.7.1.1	commentary		
ecNumber	2.7.1.2	commentary	children with congenital hyperinsulinism	
ecNumber	2.7.1.2	commentary		
ecNumber	2.7.1.2	commentary		
ecNumber	2.7.1.2	commentary		
ecNumber	2.7.1.2	commentary		
ecNumber	2.7.1.3	commentary		
ecNumber	2.7.1.3	commentary		
ecNumber	2.7.1.4	commentary		
ecNumber	2.7.1.6	commentary	Japanese patients with GALK deficiency, Caucasian patients with GALK deficiency and Japanese wild-type controls	
ecNumber	2.7.1.6	commentary	expression in Escherichia coli	
ecNumber	2.7.1.6	commentary	patients with type II galactosemia	
ecNumber	2.7.1.6	commentary	recombinant	
ecNumber	2.7.1.6	commentary		
ecNumber	2.7.1.6	commentary		
ecNumber	2.7.1.10	commentary	patients with glycogenosis	
ecNumber	2.7.1.11	commentary		
ecNumber	2.7.1.11	commentary		
ecNumber	2.7.1.11	commentary	platelet-type isoform	
ecNumber	2.7.1.11	commentary		
ecNumber	2.7.1.12	commentary	isoform 1; isoform 2	
ecNumber	2.7.1.12	commentary		
ecNumber	2.7.1.14	commentary		
ecNumber	2.7.1.14	commentary		
ecNumber	2.7.1.15	commentary		
ecNumber	2.7.1.15	commentary		
ecNumber	2.7.1.17	commentary		
ecNumber	2.7.1.17	commentary		
ecNumber	2.7.1.20	commentary	newborn	
ecNumber	2.7.1.20	commentary	recombinant	
ecNumber	2.7.1.20	commentary		
ecNumber	2.7.1.20	commentary		
ecNumber	2.7.1.21	commentary	enzyme contains a Val at position 106	
ecNumber	2.7.1.21	commentary		
ecNumber	2.7.1.21	commentary		
ecNumber	2.7.1.21	commentary		
ecNumber	2.7.1.22	commentary		
ecNumber	2.7.1.22	commentary		
ecNumber	2.7.1.23	commentary		
ecNumber	2.7.1.23	commentary		
ecNumber	2.7.1.24	commentary		
ecNumber	2.7.1.24	commentary	gene ppat/dpck, bifunctional enzyme with phosphopantetheine adenylyltransferase and dephospho-CoA kinase activities, termed CoA synthase	
ecNumber	2.7.1.25	commentary	isoforms PAPSS 1 and PAPSS 2	
ecNumber	2.7.1.25	commentary	isoforms PAPSS 1, PAPSS 2a and 2b	
ecNumber	2.7.1.25	commentary		
ecNumber	2.7.1.25	commentary	bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase	
ecNumber	2.7.1.25	commentary	PAPSS 1	
ecNumber	2.7.1.25	commentary	PAPSS1; Caucasian-American and African-American subjects	
ecNumber	2.7.1.25	commentary	isoform 1	
ecNumber	2.7.1.25	commentary		
ecNumber	2.7.1.25	commentary	isoenzyme PAPSS 2; isoenzyme PAPSS 2b, splice variant of PAPSS2, several SNPs and polymorphisms are identified with reference to PAPSS 1 and 2	
ecNumber	2.7.1.25	commentary		
ecNumber	2.7.1.26	commentary		
ecNumber	2.7.1.26	commentary		
ecNumber	2.7.1.28	commentary		
ecNumber	2.7.1.29	commentary		
ecNumber	2.7.1.30	commentary		
ecNumber	2.7.1.30	commentary		
ecNumber	2.7.1.31	commentary		
ecNumber	2.7.1.32	commentary	commentary	
ecNumber	2.7.1.32	commentary	association between gene expression and survival in patients with non-small-cell lung cancer	
ecNumber	2.7.1.32	commentary		
ecNumber	2.7.1.32	commentary	choline kinase alpha isoform	
ecNumber	2.7.1.32	commentary	subunit CKalpha	
ecNumber	2.7.1.32	commentary		
ecNumber	2.7.1.32	commentary	subunit CKbetha	
ecNumber	2.7.1.32	commentary		
ecNumber	2.7.1.33	commentary	splice variant pantothenate kinase 2, i.e. PanK2, contains mutation G521R, several isozymes e.g. iPanK2, spPanK2, mPanK2, overview	
ecNumber	2.7.1.33	commentary	multiple genes, multiple enzyme forms	
ecNumber	2.7.1.33	commentary		
ecNumber	2.7.1.33	commentary		
ecNumber	2.7.1.33	commentary	the 5' end of PANK2 gene, Hallervorden-Spatz syndrome, and a CpG island, complete sequence; enzyme form PANK2, 2 allelic variants	
ecNumber	2.7.1.33	commentary		
ecNumber	2.7.1.33	commentary		
ecNumber	2.7.1.33	commentary	isoform PanK3	
ecNumber	2.7.1.35	commentary		
ecNumber	2.7.1.35	commentary		
ecNumber	2.7.1.36	commentary	enhanced and inappropriate expression of mevalonate kinase may lead to increased metabolism of mevalonate and phosphorylation of hitherto unknown cellular proteins	
ecNumber	2.7.1.36	commentary	patients with Behcets disease	
ecNumber	2.7.1.36	commentary	patient with hyperimmunoglobulinemia D and periodic fever syndrome	
ecNumber	2.7.1.36	commentary	patients with hyperimmunoglobulinemia D and periodic fever syndrome	
ecNumber	2.7.1.36	commentary	patients with mevalonic aciduria	
ecNumber	2.7.1.36	commentary	patient wih mevalonate kinase deficiency	
ecNumber	2.7.1.36	commentary	patient with mevalonate kinase deficiency	
ecNumber	2.7.1.36	commentary		
ecNumber	2.7.1.36	commentary	french population	
ecNumber	2.7.1.36	commentary	mevalonate kinase deficiency causes mevalonic aciduria, hyperimmunoglobuinemia D and periodic fever syndrome	
ecNumber	2.7.1.36	commentary		
ecNumber	2.7.1.40	commentary	patients with colorectal adenomas	
ecNumber	2.7.1.40	commentary	isoform M2	
ecNumber	2.7.1.40	commentary	M2 isoform	
ecNumber	2.7.1.40	commentary		
ecNumber	2.7.1.40	commentary	type 1 diabetic patients with and without nephropathy	
ecNumber	2.7.1.40	commentary	isoform M2	
ecNumber	2.7.1.40	commentary		
ecNumber	2.7.1.40	commentary	four isozymes	
ecNumber	2.7.1.40	commentary		
ecNumber	2.7.1.40	commentary	isozyme L	
ecNumber	2.7.1.48	commentary		
ecNumber	2.7.1.48	commentary	isoform Uvk1	
ecNumber	2.7.1.48	commentary	uridine-cytidine kinase 2	
ecNumber	2.7.1.48	commentary		
ecNumber	2.7.1.48	commentary	uridine-cytidine kinase 1	
ecNumber	2.7.1.48	commentary		
ecNumber	2.7.1.52	commentary		
ecNumber	2.7.1.56	commentary		
ecNumber	2.7.1.59	commentary		
ecNumber	2.7.1.59	commentary		
ecNumber	2.7.1.60	commentary	hepatoma cell line HepG2	
ecNumber	2.7.1.60	commentary	patients with hereditary inclusion body myopathy	
ecNumber	2.7.1.60	commentary	Japanese patients with distal myopathy with rimmed vacuoles	
ecNumber	2.7.1.60	commentary		
ecNumber	2.7.1.60	commentary	human cell lines promyeolytic leukaemia HL-60, HeLa S3, chronic myelogenous leukaemia K-562, lymphoblastic leukaemia MOLT-4, Burkitt's lymphoma Raji, colorectal adenocarcinoma SW480, lung carcinoma A549 and melanoma G361	
ecNumber	2.7.1.60	commentary	hereditary inclusion body myopathy patients carrying M712T mutation and healthy donors	
ecNumber	2.7.1.60	commentary	; isoform 2; bifunctional UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase, isoform GNE2; isoform 3; bifunctional UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase, isoform GNE3	
ecNumber	2.7.1.60	commentary	patients with hereditary inclusion body myopathy	
ecNumber	2.7.1.60	commentary	eight isozymes hGNE1-hGNE8 from differential splicing	
ecNumber	2.7.1.60	commentary		
ecNumber	2.7.1.67	commentary	recombinant	
ecNumber	2.7.1.67	commentary	four isozymes PI4KIIIalpha and PI4KIIIbeta, and PI4KIIalpha and PI4KIIbeta	
ecNumber	2.7.1.67	commentary	isozyes PI4KA and PI4KB	
ecNumber	2.7.1.67	commentary		
ecNumber	2.7.1.67	commentary		
ecNumber	2.7.1.67	commentary		
ecNumber	2.7.1.67	commentary		
ecNumber	2.7.1.68	commentary	3 isozymes alpha, beta, and gamma	
ecNumber	2.7.1.68	commentary	enzyme form type I, 3 isozymes alpha, beta, gamma in several splicing variants	
ecNumber	2.7.1.68	commentary	isoform phosphatidylinositol 4-phosphate 5-kinase beta, type I enzyme	
ecNumber	2.7.1.68	commentary	isoform phosphatidylinositol 4-phosphate 5-kinase type Igamma	
ecNumber	2.7.1.68	commentary	three splice variants phosphatidylinositol 4-phosphate 5-kinase Igamma_v6, Igamma_v3, and Igamma_i2	
ecNumber	2.7.1.68	commentary	isozymes PIP5Kalpha, PIP5Kbeta, and PIP5Kgamma	
ecNumber	2.7.1.68	commentary		
ecNumber	2.7.1.68	commentary		
ecNumber	2.7.1.68	commentary	isozyme alpha type I; type I isozyme alpha	
ecNumber	2.7.1.68	commentary		
ecNumber	2.7.1.68	commentary		
ecNumber	2.7.1.74	commentary	B-CLL patients	
ecNumber	2.7.1.74	commentary	; patients with B-cell chronic lymphocytic leukaemia	
ecNumber	2.7.1.74	commentary	patients suffering from pancreatic cancer, survival of patients is found to be correlated to the detected enzyme level	
ecNumber	2.7.1.74	commentary	differences in mRNA levels in African and European individuals detected	
ecNumber	2.7.1.74	commentary	patients with pancreatic cancer	
ecNumber	2.7.1.74	commentary		
ecNumber	2.7.1.74	commentary		
ecNumber	2.7.1.76	commentary	newborn	
ecNumber	2.7.1.76	commentary		
ecNumber	2.7.1.78	commentary	HeLa cells	
ecNumber	2.7.1.78	commentary	bifunctional enzyme with both 5-DNA kinase and 3-DNA phosphatase activity	
ecNumber	2.7.1.78	commentary		
ecNumber	2.7.1.78	commentary		
ecNumber	2.7.1.78	commentary		
ecNumber	2.7.1.81	commentary		
ecNumber	2.7.1.82	commentary		
ecNumber	2.7.1.82	commentary		
ecNumber	2.7.1.82	commentary	gene ETNK1	
ecNumber	2.7.1.82	commentary	gene ek1; gene EKI1	
ecNumber	2.7.1.82	commentary	gene EKI1	
ecNumber	2.7.1.82	commentary	gene eki2, splicing variants eki2alpha and eki2beta; gene eki2, splicing variants eki2alpha and eki2beta	
ecNumber	2.7.1.91	commentary	Swiss 3T3 cell culture	
ecNumber	2.7.1.91	commentary	recombinant SPHK1, SPHK2	
ecNumber	2.7.1.91	commentary	SPHK1	
ecNumber	2.7.1.91	commentary	recombinant enzyme	
ecNumber	2.7.1.91	commentary	isozyme SphK1	
ecNumber	2.7.1.91	commentary	isozymes SphK1 and SphK2	
ecNumber	2.7.1.91	commentary	2 isozymes SPHK1 and SPHK2	
ecNumber	2.7.1.91	commentary	2 isozymes SPHK1 and SPHK2, several splicing variants exist, overview	
ecNumber	2.7.1.91	commentary	patients with breast cancer	
ecNumber	2.7.1.91	commentary		
ecNumber	2.7.1.91	commentary	SPHK2	
ecNumber	2.7.1.91	commentary	isozyme Sk2; 2 isozymes SK1 and SK2	
ecNumber	2.7.1.91	commentary	isozyme SPHK2; 2 isozymes SPHK1 and SPHK2, several splicing variants	
ecNumber	2.7.1.91	commentary		
ecNumber	2.7.1.91	commentary	isoform SK2	
ecNumber	2.7.1.91	commentary	isozyme SPHK2; gene SphK2	
ecNumber	2.7.1.91	commentary	sphingosine kinase isoform 2	
ecNumber	2.7.1.91	commentary	isozyme Sk1; 2 isozymes SK1 and SK2	
ecNumber	2.7.1.91	commentary	isozyme SPHK1; 2 isozymes SPHK1 and SPHK2, several splicing variants	
ecNumber	2.7.1.91	commentary	patients with non-Hodgkin lymphomas	
ecNumber	2.7.1.91	commentary	enzyme is expressed as isoform SK1a of 42.5 kDa, and isoform SK1b, a 51 kDa protein identical to SK1a, but with an 86 amino acid N-terminal extension	
ecNumber	2.7.1.91	commentary	isoform SK1	
ecNumber	2.7.1.91	commentary	isozyme SPHK1; gene SphK1	
ecNumber	2.7.1.91	commentary	sphingosine kinase isoform 1	
ecNumber	2.7.1.91	commentary		
ecNumber	2.7.1.94	commentary		
ecNumber	2.7.1.94	commentary	isozyme delta2; isozyme epsilon; isozyme eta1; isozyme gamma; isozyme kappa; isozyme theta; isozyme zeta1	
ecNumber	2.7.1.94	commentary		
ecNumber	2.7.1.94	commentary	gene agk	
ecNumber	2.7.1.95	commentary		
ecNumber	2.7.1.105	commentary	human enzyme is 95% identical with rat or bovine enzyme	
ecNumber	2.7.1.105	commentary		
ecNumber	2.7.1.105	commentary		
ecNumber	2.7.1.105	commentary	isozyme PFKFB2	
ecNumber	2.7.1.105	commentary	gene/isozyme PFKFB2	
ecNumber	2.7.1.105	commentary	recombinant	
ecNumber	2.7.1.105	commentary		
ecNumber	2.7.1.105	commentary	isozyme PFKFB1	
ecNumber	2.7.1.105	commentary	gene/isozyme Pfkfb1	
ecNumber	2.7.1.105	commentary	exon 15a and complete sequence; 10 splicing variants	
ecNumber	2.7.1.105	commentary	Pfkfb3 gene; overexpression of the Pfkfb3 gene in Mus musculus, generation of uPFK-2 transgenic line	
ecNumber	2.7.1.105	commentary		
ecNumber	2.7.1.105	commentary	isozyme PFKFB3, variant I-PFK2 is inducible	
ecNumber	2.7.1.105	commentary	gene PFKFB3	
ecNumber	2.7.1.105	commentary	gene/isozyme PFKFB3	
ecNumber	2.7.1.105	commentary		
ecNumber	2.7.1.105	commentary	bifunctional 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4	
ecNumber	2.7.1.105	commentary	isozyme PFKFB4	
ecNumber	2.7.1.105	commentary	gene/isozyme Pfkfb4	
ecNumber	2.7.1.105	commentary	gene/isozyme Pfkfb1	
ecNumber	2.7.1.106	commentary		
ecNumber	2.7.1.107	commentary	; DGKgamma	
ecNumber	2.7.1.107	commentary	DGK-theta	
ecNumber	2.7.1.107	commentary	DGKgamma	
ecNumber	2.7.1.107	commentary	isozyme theta	
ecNumber	2.7.1.107	commentary	9 different isozymes divided into 5 subtypes, alternative splicing of isozymes	
ecNumber	2.7.1.107	commentary	diacylglycerol kinase delta2	
ecNumber	2.7.1.107	commentary	patients with bipolar disorder	
ecNumber	2.7.1.107	commentary	isoform diacylglycerol kinase delta	
ecNumber	2.7.1.107	commentary		
ecNumber	2.7.1.107	commentary	isozyme iota1	
ecNumber	2.7.1.107	commentary		
ecNumber	2.7.1.107	commentary	isoform diacalglycerol kinase alpha	
ecNumber	2.7.1.107	commentary		
ecNumber	2.7.1.107	commentary	isozyme gamma; isozyme gamma	
ecNumber	2.7.1.107	commentary	diacylglycerol kinase epsilon	
ecNumber	2.7.1.107	commentary		
ecNumber	2.7.1.107	commentary	isoform diacylglycerolkinase epsilon	
ecNumber	2.7.1.107	commentary	isoform diaclyglycerol kinase epsilon	
ecNumber	2.7.1.107	commentary	isoform diacylglycerol kinase epsilon	
ecNumber	2.7.1.107	commentary	isozyme epsilon; isozyme epsilon	
ecNumber	2.7.1.107	commentary	isozyme theta	
ecNumber	2.7.1.107	commentary		
ecNumber	2.7.1.107	commentary	isoform diacylglycerolkinase zeta	
ecNumber	2.7.1.107	commentary	isoform diacalglycerol kinase zeta	
ecNumber	2.7.1.107	commentary	isozyme zeta1	
ecNumber	2.7.1.107	commentary	isoform diacylglycerol kinase delta. Female patient with a de novo balanced translocation, 46,X,t(X,2)(p11.2,q37)dn, who exhibits seizures, capillary abnormality, developmental delay, infantile hypotonia, and obesity	
ecNumber	2.7.1.107	commentary		
ecNumber	2.7.1.107	commentary	isoform diacylglycerol kinase delta	
ecNumber	2.7.1.107	commentary	isozyme delta2; isozyme delta2	
ecNumber	2.7.1.107	commentary	isozyme kappa; isozyme kappa	
ecNumber	2.7.1.107	commentary	DGKeta1 and DGKeta2	
ecNumber	2.7.1.107	commentary		
ecNumber	2.7.1.107	commentary	isozyme eta1; isozyme eta1	
ecNumber	2.7.1.107	commentary	DGKbeta	
ecNumber	2.7.1.108	commentary	clone KIAA1094 from a human brain library	
ecNumber	2.7.1.108	commentary		
ecNumber	2.7.1.108	commentary		
ecNumber	2.7.1.113	commentary	patient with mitochondrial DNA depletion syndrome	
ecNumber	2.7.1.113	commentary	; 3 patients, one with N46S/L266R double mutation who is clinically healthy at age of 10 years, 2 patients with lethal mutations who died at 2 and 3 month of age and parents and healthy controls	
ecNumber	2.7.1.113	commentary		
ecNumber	2.7.1.113	commentary	constitutive expression	
ecNumber	2.7.1.113	commentary		
ecNumber	2.7.1.127	commentary	3 isoenzymes: A and B, brain, and high-molecular weight platelet isoenzyme	
ecNumber	2.7.1.127	commentary	2 isoenzymes: A and B	
ecNumber	2.7.1.127	commentary	3 isoenzymes: A, B and C	
ecNumber	2.7.1.127	commentary	recombinant isoenzyme A overexpressed in CHO cells	
ecNumber	2.7.1.127	commentary	isoform B	
ecNumber	2.7.1.127	commentary	isozymes IP33K-A, IP33K-B, and IP33K-C	
ecNumber	2.7.1.127	commentary	isozyme IP3K-A and IP3K-B	
ecNumber	2.7.1.127	commentary	isozyme A	
ecNumber	2.7.1.127	commentary		
ecNumber	2.7.1.127	commentary		
ecNumber	2.7.1.127	commentary	; isoform inositol-1,4,5-trisphosphate 3-kinase A	
ecNumber	2.7.1.127	commentary	isoform inositol-1,4,5-trisphosphate 3-kinase A	
ecNumber	2.7.1.127	commentary	isozyme/gene ITPKA	
ecNumber	2.7.1.127	commentary	gene Itpka	
ecNumber	2.7.1.127	commentary		
ecNumber	2.7.1.127	commentary	isoform inositol-trisphosphate 3-kinase B	
ecNumber	2.7.1.127	commentary	gene Itpkb	
ecNumber	2.7.1.127	commentary	gene Itpkc	
ecNumber	2.7.1.134	commentary		
ecNumber	2.7.1.134	commentary		
ecNumber	2.7.1.137	commentary	enzyme form PI3K-C2a and PI3K-C2b	
ecNumber	2.7.1.137	commentary	class II phosphoinositide 3-kinase, PI 3-kinase C2b	
ecNumber	2.7.1.137	commentary	isozyme alpha	
ecNumber	2.7.1.137	commentary	class I isozymes	
ecNumber	2.7.1.137	commentary	class Ia phosphoinositide 3-kinase isozymes alpha, beta, gamma, and delta	
ecNumber	2.7.1.137	commentary	clinical samples from Schwedish patients	
ecNumber	2.7.1.137	commentary	gene PIK3CA encoding the catalytic subunit p110alpha of PI3K	
ecNumber	2.7.1.137	commentary	Vps34, p150, Beclin 1, Atg14, and UVRAG form two distinct class III phosphatidylinositol 3-kinase complexes	
ecNumber	2.7.1.137	commentary		
ecNumber	2.7.1.137	commentary		
ecNumber	2.7.1.137	commentary	gene PIK3R2	
ecNumber	2.7.1.137	commentary		
ecNumber	2.7.1.137	commentary		
ecNumber	2.7.1.137	commentary		
ecNumber	2.7.1.137	commentary		
ecNumber	2.7.1.137	commentary		
ecNumber	2.7.1.137	commentary	Atg14; Vps34, p150, Beclin 1, Atg14, and UVRAG form two distinct class III phosphatidylinositol 3-kinase complexes	
ecNumber	2.7.1.137	commentary	catalytic subunit type 3	
ecNumber	2.7.1.137	commentary		
ecNumber	2.7.1.137	commentary	UVRAG; Vps34, p150, Beclin 1, Atg14, and UVRAG form two distinct class III phosphatidylinositol 3-kinase complexes	
ecNumber	2.7.1.138	commentary		
ecNumber	2.7.1.138	commentary		
ecNumber	2.7.1.138	commentary	gene CERK	
ecNumber	2.7.1.140	commentary	human EST	
ecNumber	2.7.1.140	commentary	expression in HEK-293 cells	
ecNumber	2.7.1.147	commentary		
ecNumber	2.7.1.147	commentary		
ecNumber	2.7.1.149	commentary	isozyme PIP4K IIbeta	
ecNumber	2.7.1.149	commentary		
ecNumber	2.7.1.149	commentary		
ecNumber	2.7.1.149	commentary	Site-directed mutagenesis is performed on the human type IIbeta PIPkin cloned into pEGFP-C1 using QuikChange mutagenesis method, to introduce an Glu300Asp amino acid substitution into the human nuclear localisation sequence producing the equivalent chicken sequence 289-DRAEQEEMEVE(E300D)RAEDEE-306	
ecNumber	2.7.1.149	commentary		
ecNumber	2.7.1.149	commentary		
ecNumber	2.7.1.150	commentary		
ecNumber	2.7.1.150	commentary		
ecNumber	2.7.1.151	commentary	; recombinant	
ecNumber	2.7.1.151	commentary	recombinant	
ecNumber	2.7.1.151	commentary	Like the yeast enzyme, mammalian, plant and fly orthologs share the capacity for the conversion of Ins(1,4,5)P3 to Ins(1,3,4,5,6)P5. Plant and fly IPMKs recapitulate the yeast enzyme's preference for D6-hydroxyl phoshorylation followed by D3-hydroxylphosphorylation, mammalian IPMKs appear to prefer the reverse order.	
ecNumber	2.7.1.151	commentary		
ecNumber	2.7.1.151	commentary		
ecNumber	2.7.1.151	commentary	gene impk	
ecNumber	2.7.1.153	commentary	isoform p85/p110 phosphatidylinositol 3-kinase	
ecNumber	2.7.1.153	commentary	patients with acute myelogenous leukemia	
ecNumber	2.7.1.153	commentary	gene PIK3CA enocding the PI3K catalytic subunit alpha	
ecNumber	2.7.1.153	commentary	Korean population, women with polycystic ovary syndrome	
ecNumber	2.7.1.153	commentary	gene PIK3CA encoding for the catalytic subunit p110alpha of PI3K	
ecNumber	2.7.1.153	commentary		
ecNumber	2.7.1.153	commentary		
ecNumber	2.7.1.153	commentary	catalytic subunit p110, delta isoform	
ecNumber	2.7.1.153	commentary	catalytic subunit delta isoform	
ecNumber	2.7.1.153	commentary	catalytic subunit p110delta; isozyme PI3Kdelta	
ecNumber	2.7.1.153	commentary	isozyme PI3Kdelta	
ecNumber	2.7.1.153	commentary	class Ia enzyme, subunits alpha and beta; class Ia enzyme	
ecNumber	2.7.1.153	commentary	regulatory subunit alpha	
ecNumber	2.7.1.153	commentary	isozyme PI3Kalpha	
ecNumber	2.7.1.153	commentary	catalytic subunit p110, alpha isoform	
ecNumber	2.7.1.153	commentary	phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha	
ecNumber	2.7.1.153	commentary	catalytic subunit alpha isoform	
ecNumber	2.7.1.153	commentary	catalytic subunit p110alpha; isozyme PI3Kalpha	
ecNumber	2.7.1.153	commentary	gene PI3KCAgene PI3KCA	
ecNumber	2.7.1.153	commentary	isozyme PI3Kalpha	
ecNumber	2.7.1.153	commentary	class Ib enzyme, subunits alpha and beta; class Ib enzyme	
ecNumber	2.7.1.153	commentary	catalytic subunit p110, gamma isoform	
ecNumber	2.7.1.153	commentary	catalytic subunit beta isoform	
ecNumber	2.7.1.153	commentary	catalytic subunit p110beta; isozyme PI3Kbeta	
ecNumber	2.7.1.153	commentary	gene PI3KCB; gene PI3KCB	
ecNumber	2.7.1.153	commentary	p110 catalytic subunit, gamma isoform	
ecNumber	2.7.1.153	commentary	gamma isoform	
ecNumber	2.7.1.153	commentary	GFP-tag, expression in HEK cell	
ecNumber	2.7.1.153	commentary	catalytic subunit gamma isoform	
ecNumber	2.7.1.153	commentary	isozyme PI3Kgamma	
ecNumber	2.7.1.154	commentary	PI3K-C2alpha; PI3K-C2beta	
ecNumber	2.7.1.154	commentary	PI3K-C2alpha	
ecNumber	2.7.1.154	commentary	PI3K-C2beta	
ecNumber	2.7.1.154	commentary	; isozymes of class IA and IB, i.e. p85, and of class II, e.g. isozymes PI3K-C2alpha, PI3K-C2beta, and PI3K-C2gamma	
ecNumber	2.7.1.154	commentary	8 isozymes, class IA and class II, e.g. class IA p85/p110alpha or class II PI3K C2beta	
ecNumber	2.7.1.154	commentary		
ecNumber	2.7.1.154	commentary	PI3K-C2alpha	
ecNumber	2.7.1.154	commentary	class II PI3K, alpha-isoform	
ecNumber	2.7.1.154	commentary		
ecNumber	2.7.1.154	commentary	subunit alpha; gene PIK3C2A	
ecNumber	2.7.1.154	commentary	PI3K-C2beta	
ecNumber	2.7.1.154	commentary		
ecNumber	2.7.1.154	commentary	gene PIK3C2B	
ecNumber	2.7.1.154	commentary	PI3K-C2gamma	
ecNumber	2.7.1.154	commentary		
ecNumber	2.7.1.157	commentary	recombinant	
ecNumber	2.7.1.157	commentary		
ecNumber	2.7.1.157	commentary	isoform GALK2	
ecNumber	2.7.1.158	commentary		
ecNumber	2.7.1.159	commentary		
ecNumber	2.7.1.159	commentary		
ecNumber	2.7.1.160	commentary		
ecNumber	2.7.1.160	commentary		
ecNumber	2.7.1.165	commentary		
ecNumber	2.7.1.171	commentary		
ecNumber	2.7.1.171	commentary	the mean level of FN3K gene expression is significantly lower in cancer than in the corresponding normal colorectal mucosa. No difference between cancer versus normal mucosa is detected in mRNA FN3K levels stratifying for age, sex, tumour stage and histological grading	
ecNumber	2.7.1.171	commentary		
ecNumber	2.7.1.171	commentary	gene FN3K	
ecNumber	2.7.1.171	commentary		
ecNumber	2.7.1.172	commentary		
ecNumber	2.7.1.173	commentary		
ecNumber	2.7.1.173	commentary	Nrk2; Nrk2	
ecNumber	2.7.1.173	commentary	Nrk1; Nrk1	
ecNumber	2.7.1.173	commentary		
ecNumber	2.7.1.183	commentary		
ecNumber	2.7.2.3	commentary	New Guinea human variant	
ecNumber	2.7.2.3	commentary	mutant pathological variant phosphoglycerate kinase-Uppsala with R206P	
ecNumber	2.7.2.3	commentary	isozyme PGK1	
ecNumber	2.7.2.3	commentary		
ecNumber	2.7.2.3	commentary	isozyme PGK1	
ecNumber	2.7.2.3	commentary	recombinantly expressed in Escherichia coli	
ecNumber	2.7.2.3	commentary		
ecNumber	2.7.2.3	commentary	gene PGK1	
ecNumber	2.7.2.3	commentary	gene pgk2	
ecNumber	2.7.3.2	commentary	three isoforms	
ecNumber	2.7.3.2	commentary	4 isozymes encoded by 4 different genes: 2 cytosolic isozymes, a muscle-type MM-CK and a brain-type BB-CK or a heterodimer MB-CK, and 2 mitochondrial isozymes, a ubiquitous MiU-CK and a sarcomeric MiS-CK	
ecNumber	2.7.3.2	commentary	2 typical mitochondrial enzyme types, the sarcomeric and the ubiquitous, encoded by 2 different genes	
ecNumber	2.7.3.2	commentary	patients with Alzheimers disease	
ecNumber	2.7.3.2	commentary	acute myocardial infarction patient	
ecNumber	2.7.3.2	commentary	expression in Escherichia coli	
ecNumber	2.7.3.2	commentary		
ecNumber	2.7.3.2	commentary		
ecNumber	2.7.3.2	commentary		
ecNumber	2.7.3.2	commentary	gene Ckb	
ecNumber	2.7.3.2	commentary	computational approach to study the contribution of side chain residues to the very low pKa value of active site cysteine	
ecNumber	2.7.4.2	commentary		
ecNumber	2.7.4.2	commentary	the 5'-UTR and the first 30 amino acids are missing in this clone	
ecNumber	2.7.4.2	commentary	gene PMVK	
ecNumber	2.7.4.2	commentary		
ecNumber	2.7.4.3	commentary	post mortem	
ecNumber	2.7.4.3	commentary	male adult; post mortem	
ecNumber	2.7.4.3	commentary	heterozygote; post mortem	
ecNumber	2.7.4.3	commentary	AK2, fetus	
ecNumber	2.7.4.3	commentary	isoform ecto-adenylate kinase	
ecNumber	2.7.4.3	commentary	DNA repair complex components Mre11 and Rad50 show adenylate kinase activity when in complex Mre11/Rad50; Mre11/Rad50 complex, part of a DNA repair complex	
ecNumber	2.7.4.3	commentary	patients with limbic encephalitis refractory to corticosteroids, IVIg and plasma exchange	
ecNumber	2.7.4.3	commentary		
ecNumber	2.7.4.3	commentary	adenylate kinase-deficient patients with chronic hemolytic anemia; isoform 1; patients deficient in red cell adenylate kinase, suffering from chronic hemolytic anemia	
ecNumber	2.7.4.3	commentary		
ecNumber	2.7.4.3	commentary		
ecNumber	2.7.4.3	commentary		
ecNumber	2.7.4.4	commentary		
ecNumber	2.7.4.6	commentary	isoforms A and B	
ecNumber	2.7.4.6	commentary	isozyme NDPKB	
ecNumber	2.7.4.6	commentary		
ecNumber	2.7.4.6	commentary	gene NME4 encoding isozyme NDPK-D	
ecNumber	2.7.4.6	commentary		
ecNumber	2.7.4.6	commentary		
ecNumber	2.7.4.6	commentary	eight NDPKB isozymes	
ecNumber	2.7.4.6	commentary	gene NME2	
ecNumber	2.7.4.8	commentary		
ecNumber	2.7.4.8	commentary	CASK polypeptide, cf. EC 2.7.11.1	
ecNumber	2.7.4.8	commentary		
ecNumber	2.7.4.8	commentary		
ecNumber	2.7.4.8	commentary	gene GUK1	
ecNumber	2.7.4.9	commentary		
ecNumber	2.7.4.9	commentary		
ecNumber	2.7.4.10	commentary		
ecNumber	2.7.4.10	commentary		
ecNumber	2.7.4.14	commentary		
ecNumber	2.7.4.14	commentary	African-American, Caucasian-American, Han Chinese-American, and Mexican-American subjects	
ecNumber	2.7.4.14	commentary		
ecNumber	2.7.4.14	commentary	gene CMPK1	
ecNumber	2.7.4.14	commentary		
ecNumber	2.7.4.15	commentary		
ecNumber	2.7.4.21	commentary		
ecNumber	2.7.4.21	commentary		
ecNumber	2.7.4.21	commentary	isozyme PPIP5K2	
ecNumber	2.7.4.21	commentary		
ecNumber	2.7.4.21	commentary		
ecNumber	2.7.4.21	commentary	insP6 kinase 2	
ecNumber	2.7.4.21	commentary	inositol hexakisphosphate kinase 2	
ecNumber	2.7.4.21	commentary		
ecNumber	2.7.4.24	commentary		
ecNumber	2.7.4.24	commentary	VIP2	
ecNumber	2.7.4.24	commentary		
ecNumber	2.7.4.24	commentary	isoform PPIP5K2	
ecNumber	2.7.4.24	commentary	isozyme PPIP5K2	
ecNumber	2.7.4.24	commentary	VIP1	
ecNumber	2.7.4.24	commentary		
ecNumber	2.7.6.1	commentary		
ecNumber	2.7.6.1	commentary	gene PRPS1	
ecNumber	2.7.6.1	commentary	gene PRS1	
ecNumber	2.7.6.1	commentary		
ecNumber	2.7.6.2	commentary		
ecNumber	2.7.6.2	commentary		
ecNumber	2.7.6.2	commentary	gene TPK1	
ecNumber	2.7.7.1	commentary		
ecNumber	2.7.7.1	commentary	isoform NMNAT3	
ecNumber	2.7.7.1	commentary	; isozyme NMNAT3; isozyme NMNAT3	
ecNumber	2.7.7.1	commentary		
ecNumber	2.7.7.1	commentary	isoform NMAT3	
ecNumber	2.7.7.1	commentary		
ecNumber	2.7.7.1	commentary	; isozyme NMNAT2; isozyme NMNAT2	
ecNumber	2.7.7.1	commentary	isoform NMAT2	
ecNumber	2.7.7.1	commentary	isoform NMNAT2	
ecNumber	2.7.7.1	commentary	gene NMNAT2	
ecNumber	2.7.7.1	commentary		
ecNumber	2.7.7.1	commentary	isoform NMNAT1	
ecNumber	2.7.7.1	commentary	; isozyme NMNAT1; isozyme NMNAT1	
ecNumber	2.7.7.1	commentary	isoform NMAT1	
ecNumber	2.7.7.1	commentary	gene Nmnat1	
ecNumber	2.7.7.2	commentary		
ecNumber	2.7.7.2	commentary	; isoform Fads2	
ecNumber	2.7.7.2	commentary		
ecNumber	2.7.7.3	commentary	gene coaD	
ecNumber	2.7.7.3	commentary		
ecNumber	2.7.7.4	commentary	bifunctional ATP sulfurylase/adenosine 5'-phosphosulfate kinase	
ecNumber	2.7.7.4	commentary	recombinant	
ecNumber	2.7.7.4	commentary	bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 1	
ecNumber	2.7.7.4	commentary		
ecNumber	2.7.7.4	commentary	PAPS synthase 1	
ecNumber	2.7.7.4	commentary	PAPS synthase 2	
ecNumber	2.7.7.6	commentary		
ecNumber	2.7.7.7	commentary	5 cellular DNA template-dependent DNA polymerases are encoded by distinct genes: polymerase alpha, i.e. pol I, polymerase beta, only in vertebrates, polymerase gamma, required for mitochondrial DNA replication but encoded in the nucleus, polymerase delta, enzymes in mammalian cell contain tightly associated 3'-5'-exonuclease activities, 2 forms: proliferating cell nuclear antigen-dependent and a proliferating cell nuclear antigen-independent, also called DNA polymerase delta II, now named DNA polymerase epsilon, polymerase epsilon, tightly associated 3'-5'-exonuclease activity, formerly named DNA polymerase delta II	
ecNumber	2.7.7.7	commentary	gene POLG	
ecNumber	2.7.7.7	commentary		
ecNumber	2.7.7.7	commentary	gene POLN	
ecNumber	2.7.7.7	commentary		
ecNumber	2.7.7.7	commentary		
ecNumber	2.7.7.7	commentary		
ecNumber	2.7.7.7	commentary		
ecNumber	2.7.7.7	commentary		
ecNumber	2.7.7.8	commentary		
ecNumber	2.7.7.8	commentary	recombinant enzyme	
ecNumber	2.7.7.8	commentary		
ecNumber	2.7.7.8	commentary		
ecNumber	2.7.7.9	commentary	crystallized liver enzyme	
ecNumber	2.7.7.9	commentary		
ecNumber	2.7.7.9	commentary	isoform II	
ecNumber	2.7.7.9	commentary		
ecNumber	2.7.7.10	commentary		
ecNumber	2.7.7.12	commentary	3 isozymes	
ecNumber	2.7.7.12	commentary	2 different allelic variants : Duarte-1, D1, and Duarte-2, D2	
ecNumber	2.7.7.12	commentary	missense mutant N314D, Duarte allele	
ecNumber	2.7.7.12	commentary	native galactosemic Q188R mutant	
ecNumber	2.7.7.12	commentary	missense mutant N314D, Duarte allele; several galactosemic mutants	
ecNumber	2.7.7.12	commentary	native galactosemic Q188R mutant; native galactosemic R333W mutant	
ecNumber	2.7.7.12	commentary	native mutant F171S	
ecNumber	2.7.7.12	commentary	missense mutant N314D, Duarte allele; native galactosemic Q188R mutant; native galactosemic R333W mutant; native mutant F171S	
ecNumber	2.7.7.12	commentary		
ecNumber	2.7.7.12	commentary		
ecNumber	2.7.7.13	commentary		
ecNumber	2.7.7.14	commentary		
ecNumber	2.7.7.14	commentary	two splice variants, Pcyt2alpha and Pcyt2beta	
ecNumber	2.7.7.14	commentary	two splicing isozymes Pcyt2alpha and Pcyt2beta	
ecNumber	2.7.7.14	commentary		
ecNumber	2.7.7.15	commentary		
ecNumber	2.7.7.18	commentary		
ecNumber	2.7.7.18	commentary		
ecNumber	2.7.7.18	commentary	isoform NMNAT3	
ecNumber	2.7.7.18	commentary	isoform NMNAT2	
ecNumber	2.7.7.18	commentary	isoform NMNAT1	
ecNumber	2.7.7.19	commentary	2 forms of enzyme: Mn2+-activated, Mg2+-activated; HeLa infected with vaccinia virus	
ecNumber	2.7.7.19	commentary	2 forms: 1. nuclear enzyme, stimulated by Mn2+ and Mg2+, 2. cytoplasmic, dependent on Mn2+; HeLa infected with vaccinia virus	
ecNumber	2.7.7.19	commentary	2 forms from nuclear fraction: NE PAP I and II, one form from cytoplasmic fraction: S100 PAP; HeLa cells	
ecNumber	2.7.7.19	commentary	HeLa cells	
ecNumber	2.7.7.19	commentary	primary breast cancer	
ecNumber	2.7.7.19	commentary	PAP activity is attributed to the protein GLD2	
ecNumber	2.7.7.19	commentary		
ecNumber	2.7.7.19	commentary		
ecNumber	2.7.7.19	commentary		
ecNumber	2.7.7.19	commentary		
ecNumber	2.7.7.19	commentary		
ecNumber	2.7.7.19	commentary		
ecNumber	2.7.7.19	commentary		
ecNumber	2.7.7.B22	commentary		
ecNumber	2.7.7.23	commentary		
ecNumber	2.7.7.23	commentary		
ecNumber	2.7.7.30	commentary		
ecNumber	2.7.7.30	commentary		
ecNumber	2.7.7.31	commentary	commercial preparation	
ecNumber	2.7.7.31	commentary	child	
ecNumber	2.7.7.31	commentary	recombinant	
ecNumber	2.7.7.31	commentary		
ecNumber	2.7.7.31	commentary		
ecNumber	2.7.7.38	commentary	CSK gene in partial release of human chromosome 5; CSK gene in partial release of human chromosome 7	
ecNumber	2.7.7.40	commentary		
ecNumber	2.7.7.41	commentary		
ecNumber	2.7.7.41	commentary		
ecNumber	2.7.7.41	commentary		
ecNumber	2.7.7.43	commentary		
ecNumber	2.7.7.48	commentary		
ecNumber	2.7.7.49	commentary	DNA polymerase Pol gamma also catalyzes reverse transcription with a slightly higher efficiency than HIV-1 reverse transcriptase	
ecNumber	2.7.7.49	commentary	human LINE-1 ORF2, which encodes reverse transcriptase, is inserted into a baculovirus shuttle vector and expressed in SF21 cells	
ecNumber	2.7.7.49	commentary		
ecNumber	2.7.7.50	commentary	HeLa cells	
ecNumber	2.7.7.50	commentary		
ecNumber	2.7.7.51	commentary	cf. EC 3.6.1.29	
ecNumber	2.7.7.52	commentary	an unspecific enzyme form and an enzyme form specific for U6 sn-RNA	
ecNumber	2.7.7.52	commentary		
ecNumber	2.7.7.52	commentary	isoform Zcchc11, TUT4	
ecNumber	2.7.7.52	commentary	isoform Zcchc6, TUT7	
ecNumber	2.7.7.56	commentary		
ecNumber	2.7.7.72	commentary		
ecNumber	2.7.7.72	commentary		
ecNumber	2.7.7.78	commentary		
ecNumber	2.7.7.79	commentary		
ecNumber	2.7.7.80	commentary		
ecNumber	2.7.7.83	commentary		
ecNumber	2.7.7.83	commentary		
ecNumber	2.7.7.84	commentary	isozyme OAS1	
ecNumber	2.7.7.84	commentary	isozyme OAS1, two forms of isozyme OAS2, and isozyme OAS3	
ecNumber	2.7.7.84	commentary	p42 isoform of OAS1 and the p69 isoform of OAS2	
ecNumber	2.7.7.84	commentary		
ecNumber	2.7.7.84	commentary		
ecNumber	2.7.7.86	commentary		
ecNumber	2.7.7.86	commentary		
ecNumber	2.7.7.96	commentary		
ecNumber	2.7.8.1	commentary	dual-specificity enzyme, activity of EC 2.7.8.1 and EC 2.7.8.2	
ecNumber	2.7.8.1	commentary		
ecNumber	2.7.8.1	commentary		
ecNumber	2.7.8.1	commentary		
ecNumber	2.7.8.1	commentary		
ecNumber	2.7.8.2	commentary	dual-specificity enzyme, activitiy of EC 2.7.8.1 and EC 2.7.8.2	
ecNumber	2.7.8.2	commentary		
ecNumber	2.7.8.2	commentary		
ecNumber	2.7.8.2	commentary		
ecNumber	2.7.8.5	commentary		
ecNumber	2.7.8.7	commentary	human	
ecNumber	2.7.8.7	commentary		
ecNumber	2.7.8.7	commentary		
ecNumber	2.7.8.8	commentary		
ecNumber	2.7.8.11	commentary	cell line A431; human	
ecNumber	2.7.8.11	commentary	human	
ecNumber	2.7.8.11	commentary		
ecNumber	2.7.8.11	commentary	human	
ecNumber	2.7.8.15	commentary	french Canadian founder population in Saguenay-Lac-Saint-Jean (Quebec, Canada) with mucolipidosis II carrier rate at 1/39 (highest worldwide)	
ecNumber	2.7.8.15	commentary		
ecNumber	2.7.8.17	commentary		
ecNumber	2.7.8.17	commentary	alpha/beta-, and gamma-subunit encoding genes	
ecNumber	2.7.8.17	commentary		
ecNumber	2.7.8.17	commentary	gamma subunit	
ecNumber	2.7.8.19	commentary		
ecNumber	2.7.8.27	commentary	isozyme SMS2	
ecNumber	2.7.8.27	commentary	isozyme SMS1	
ecNumber	2.7.8.27	commentary	gene SMS1 encoding isozyme SMS1	
ecNumber	2.7.8.27	commentary	isozymes SMS1 and SMS2	
ecNumber	2.7.8.27	commentary		
ecNumber	2.7.8.27	commentary	SMS1; isozyme SMS1	
ecNumber	2.7.8.27	commentary	isoform SMS1	
ecNumber	2.7.8.27	commentary		
ecNumber	2.7.8.27	commentary	SMS2; isozyme SMS2	
ecNumber	2.7.8.27	commentary	isoform SMS2	
ecNumber	2.7.8.27	commentary		
ecNumber	2.7.8.29	commentary		
ecNumber	2.7.8.29	commentary		
ecNumber	2.7.8.29	commentary		
ecNumber	2.7.8.41	commentary		
ecNumber	2.7.9.3	commentary	Sps1-encoded enzyme; Sps2-encoded enzyme	
ecNumber	2.7.9.3	commentary		
ecNumber	2.7.9.3	commentary	gene selD	
ecNumber	2.7.9.3	commentary		
ecNumber	2.7.9.3	commentary	Sephs1	
ecNumber	2.7.9.3	commentary	gene selD	
ecNumber	2.7.9.3	commentary		
ecNumber	2.7.9.3	commentary	gene Sephs2	
ecNumber	2.7.9.3	commentary	Sephs2	
ecNumber	2.7.10.1	commentary	2 isozymes PDGF-alpha receptor and PDGF-beta receptor, 4 isozymes FGFR-1, FGFR-2, FGFR-3, and FGFR-4	
ecNumber	2.7.10.1	commentary	several isozymes of both ErbB receptor protein-tyrosine kinase and HER receptor protein-tyrosine kinase	
ecNumber	2.7.10.1	commentary	2 enzyme forms FGFR1 and FGFR2	
ecNumber	2.7.10.1	commentary	4 isozymes FGFR1-4	
ecNumber	2.7.10.1	commentary	Southeast Asian acute myeloid leukemia patients	
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary	ErbB1	
ecNumber	2.7.10.1	commentary	EGFR	
ecNumber	2.7.10.1	commentary	epidermal growth factor receptor tyrosine kinase	
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary	insulin-like growth factor 1 receptor	
ecNumber	2.7.10.1	commentary	IGF-1R	
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary	c-Met kinase	
ecNumber	2.7.10.1	commentary	MET	
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary	PDGFR-beta	
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary	juxtamembrane domain and catalytic domains of c-Kit receptor protein-tyrosine kinase, residues 544-935	
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary	PDGFRalpha	
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary	VEGFR-1	
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary	patients with chronic myelogenous leukemia	
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary	VEGFR-2	
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary	receptor-type tyrosine-protein kinase FLT3	
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary	EPHA4	
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary	macrophage-stimulating protein receptor	
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary	DDR1	
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.1	commentary		
ecNumber	2.7.10.2	commentary	12-year old female	
ecNumber	2.7.10.2	commentary	JAK1 and JAK2	
ecNumber	2.7.10.2	commentary	c-Abl, two splice variants, one c-Abl 1b that is N-terminally myristoylated, and another that is 19 residues shorter at the N-terminus and not known to be myristoylated	
ecNumber	2.7.10.2	commentary	Mexican patients with X-linked agammaglobulinemia	
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary	Jak2	
ecNumber	2.7.10.2	commentary	ABL1; patients with chronic myeloid leukemia	
ecNumber	2.7.10.2	commentary	ABL1	
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary	gene c-fps/fes, the feline sarcoma oncogene	
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary	YES1	
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary	SRC	
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary	FER	
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary	reference sequence for mutated Btk genes	
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary	Btk	
ecNumber	2.7.10.2	commentary	ACK1	
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary	PYK2	
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.10.2	commentary		
ecNumber	2.7.11.1	commentary	at least 3 different isozymes PKNalpha/PKN-1/PAK-1, PKNbeta, and PRK2/PKNgamma/PAK-2	
ecNumber	2.7.11.1	commentary	isozymes alpha, beta, gamma1, gamm2, gamma3, delta, and epsilon	
ecNumber	2.7.11.1	commentary	isozyme CKIdelta	
ecNumber	2.7.11.1	commentary	constitutive enzyme	
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary	isozyme PI3Kdelta	
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary	alpha-chain	
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary	subunit p110alpha	
ecNumber	2.7.11.1	commentary	isozyme PI3Kalpha	
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary	isozyme PI3Kgamma	
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary	alpha-chain	
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary	small intestine SPAK-like kinase; intestinal inflammation-associated colonic epithelial isozyme	
ecNumber	2.7.11.1	commentary	gene ULK3	
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.1	commentary		
ecNumber	2.7.11.2	commentary	isozymes PDK2 and PDK3	
ecNumber	2.7.11.2	commentary	4 different isozymes: PDK1, PDK2, PDK3, PDK4; isozyme development via gene duplication, gene locations are: PDK1 in chromosome 2, PDK2 in chromosome 17, PDK3 in chromosome Xp22, PDK4 in chromosome 7q21q22	
ecNumber	2.7.11.2	commentary	4 different isozymes: PDK1, PDK2, PDK3, PDK4	
ecNumber	2.7.11.2	commentary	isozymes PDHK1, PDHK2, PDHK3, and PDHK4	
ecNumber	2.7.11.2	commentary	isozyme PDHK2; isozyme PDHK2	
ecNumber	2.7.11.2	commentary	female and male, isozyme PDK1-PDK4	
ecNumber	2.7.11.2	commentary	isoyzmes PDK-2 and PDK-4	
ecNumber	2.7.11.2	commentary	isozyme PDK2	
ecNumber	2.7.11.2	commentary	isozyme PDK4	
ecNumber	2.7.11.2	commentary	gene PDK1, isozyme PDK1	
ecNumber	2.7.11.2	commentary	isozyme PDHK2	
ecNumber	2.7.11.2	commentary	isozymes PDK1-4	
ecNumber	2.7.11.2	commentary	isozyme PDK3	
ecNumber	2.7.11.2	commentary		
ecNumber	2.7.11.2	commentary		
ecNumber	2.7.11.2	commentary		
ecNumber	2.7.11.2	commentary		
ecNumber	2.7.11.2	commentary	isozyme 4, i.e. PDK4; isozyme PDK4	
ecNumber	2.7.11.2	commentary		
ecNumber	2.7.11.3	commentary		
ecNumber	2.7.11.4	commentary		
ecNumber	2.7.11.4	commentary		
ecNumber	2.7.11.8	commentary		
ecNumber	2.7.11.8	commentary		
ecNumber	2.7.11.8	commentary		
ecNumber	2.7.11.9	commentary		
ecNumber	2.7.11.9	commentary		
ecNumber	2.7.11.9	commentary	gene COL4A3BP	
ecNumber	2.7.11.9	commentary	isoform 1	
ecNumber	2.7.11.10	commentary	isozymes IKK1 and IKK2	
ecNumber	2.7.11.10	commentary	IKK-1 and IKK-2	
ecNumber	2.7.11.10	commentary	IKKepsilon is a noncanonical IkappaB kinase homologue	
ecNumber	2.7.11.10	commentary	IKK-alpha and IKK-beta	
ecNumber	2.7.11.10	commentary	IkappaBalpha and IkappaBbeta	
ecNumber	2.7.11.10	commentary		
ecNumber	2.7.11.10	commentary		
ecNumber	2.7.11.10	commentary		
ecNumber	2.7.11.10	commentary		
ecNumber	2.7.11.10	commentary		
ecNumber	2.7.11.11	commentary	2 isozymes PKAI and PKAII	
ecNumber	2.7.11.11	commentary	bovine catalytic subunit C and human regulatory subunits RI and RII	
ecNumber	2.7.11.11	commentary		
ecNumber	2.7.11.11	commentary		
ecNumber	2.7.11.11	commentary		
ecNumber	2.7.11.11	commentary		
ecNumber	2.7.11.11	commentary		
ecNumber	2.7.11.12	commentary	type 1alpha PKG	
ecNumber	2.7.11.12	commentary	enzyme forms cGKI, in 2 isoforms cGKIalpha and cGKIbeta, and cGKII	
ecNumber	2.7.11.12	commentary	isozyme PKG-Ialpha	
ecNumber	2.7.11.12	commentary	females	
ecNumber	2.7.11.12	commentary	two isozymes of PKGI, PKGIalpha and Ibeta	
ecNumber	2.7.11.12	commentary	PKG-Ibeta	
ecNumber	2.7.11.12	commentary	two isozymes alpha and beta of PKGI	
ecNumber	2.7.11.12	commentary	isozymes alpha and beta of type 1 PKG	
ecNumber	2.7.11.12	commentary	alpha and beta isozymes of cGKI	
ecNumber	2.7.11.12	commentary	isozyme PKG 1beta	
ecNumber	2.7.11.12	commentary	isozymes PKGIalpha and PKGIbeta	
ecNumber	2.7.11.12	commentary	isozymes PKG-Ialpha and PKG-Ibeta	
ecNumber	2.7.11.12	commentary		
ecNumber	2.7.11.12	commentary		
ecNumber	2.7.11.12	commentary		
ecNumber	2.7.11.13	commentary	isozymes PKCbetaII and PKCbetaI	
ecNumber	2.7.11.13	commentary	multiple isozymes: classical isozymes alpha, betaI, betaII, and gamma, novel isozymes delta, epsilon, eta, and theta, and atypical isozymes zeta and jota	
ecNumber	2.7.11.13	commentary	isoform PKCbetaII	
ecNumber	2.7.11.13	commentary	isozyme pKCalpha	
ecNumber	2.7.11.13	commentary	several isozymes	
ecNumber	2.7.11.13	commentary	conventional, novel, and atypical isozyme types, overview	
ecNumber	2.7.11.13	commentary		
ecNumber	2.7.11.13	commentary		
ecNumber	2.7.11.13	commentary		
ecNumber	2.7.11.13	commentary		
ecNumber	2.7.11.13	commentary		
ecNumber	2.7.11.13	commentary		
ecNumber	2.7.11.13	commentary		
ecNumber	2.7.11.13	commentary		
ecNumber	2.7.11.13	commentary		
ecNumber	2.7.11.13	commentary		
ecNumber	2.7.11.13	commentary		
ecNumber	2.7.11.13	commentary		
ecNumber	2.7.11.13	commentary		
ecNumber	2.7.11.13	commentary		
ecNumber	2.7.11.13	commentary		
ecNumber	2.7.11.14	commentary	GRK1 and its splice variant GRK1b	
ecNumber	2.7.11.14	commentary		
ecNumber	2.7.11.14	commentary	gene GRK1	
ecNumber	2.7.11.14	commentary	Japanese Oguchi disease patients, gene GRK1	
ecNumber	2.7.11.14	commentary	; adult	
ecNumber	2.7.11.14	commentary		
ecNumber	2.7.11.14	commentary		
ecNumber	2.7.11.15	commentary	enzyme exists in 2 subtypes: beta-ARK1 and 2; major isoform beta-ARK 1	
ecNumber	2.7.11.15	commentary	major isoform beta-ARK 1	
ecNumber	2.7.11.15	commentary	recombinant beta-ARK 1 holoenzyme	
ecNumber	2.7.11.15	commentary	no splicing variants of GRK2	
ecNumber	2.7.11.15	commentary		
ecNumber	2.7.11.15	commentary		
ecNumber	2.7.11.15	commentary	; beta-ARK 2, enzyme exists in 2 subtypes: beta-ARK1 and 2	
ecNumber	2.7.11.15	commentary		
ecNumber	2.7.11.16	commentary	4 splicing variants of GRK4	
ecNumber	2.7.11.16	commentary	4 splicing variants of GRK4, i.e. GRK4alpha, GRK4beta, GRK4gamma, and GRK4delta, overview	
ecNumber	2.7.11.16	commentary	Americans	
ecNumber	2.7.11.16	commentary	Han Chinese, gene GRK4	
ecNumber	2.7.11.16	commentary	multiple splice variants of GRK4 and GRK6	
ecNumber	2.7.11.16	commentary		
ecNumber	2.7.11.16	commentary	4 isoforms: GRK4alpha, GRK4beta, GRK4gamma, GRK4delta	
ecNumber	2.7.11.16	commentary	2 isoforms: GRK4A and GRK4B	
ecNumber	2.7.11.16	commentary		
ecNumber	2.7.11.16	commentary		
ecNumber	2.7.11.16	commentary		
ecNumber	2.7.11.17	commentary	isozyme CaMKIIdelta exists in two splicing variants deltaB and deltaC in the heart	
ecNumber	2.7.11.17	commentary	CaM-KII is encoded by four different genes encoding isozymes alpha-delta, alternative splicing results in 24 different enzyme variants	
ecNumber	2.7.11.17	commentary	isozyme CaM kinase IIalpha	
ecNumber	2.7.11.17	commentary	isozymes CaMKIIgamma and CaMKIIdelta	
ecNumber	2.7.11.17	commentary		
ecNumber	2.7.11.17	commentary		
ecNumber	2.7.11.17	commentary		
ecNumber	2.7.11.17	commentary	CaMK-II subunit delta	
ecNumber	2.7.11.17	commentary		
ecNumber	2.7.11.17	commentary		
ecNumber	2.7.11.17	commentary		
ecNumber	2.7.11.17	commentary	isozyme CaM-K1delta	
ecNumber	2.7.11.17	commentary	CaMKIgamma; isozyme CaMKIgamma or CLICK-III	
ecNumber	2.7.11.17	commentary		
ecNumber	2.7.11.17	commentary		
ecNumber	2.7.11.18	commentary	endothelial isozyme EC MLCK exists in different splice variants	
ecNumber	2.7.11.18	commentary	2 isozymes encoded by a single gene and translated from 2 different splicing variants	
ecNumber	2.7.11.18	commentary	cardiac/ventricular isozyme cardiac-MLCK encoded by gene MLCK3, and smooth muscle isozyme encoded by gene MLCK2	
ecNumber	2.7.11.18	commentary	gene MYLK encoding several isozymes	
ecNumber	2.7.11.18	commentary		
ecNumber	2.7.11.18	commentary	splicing variant 1, i.e. isozyme MLCK1; 2 endothelial isozymes MLCK1 and MLCK2; splicing variant 2, i.e. isozyme MLCK2; 2 endothelial isozymes MLCK1 and MLCK2	
ecNumber	2.7.11.18	commentary	smooth muscle isozyme MYLK	
ecNumber	2.7.11.18	commentary		
ecNumber	2.7.11.18	commentary		
ecNumber	2.7.11.18	commentary	skeletal/cardiac muscle isozyme MYLK2	
ecNumber	2.7.11.19	commentary	10 week old girl with severe hypertrophy of the septal and atrial walls, progressive ventricular wall thickening, girl died at the age of 5 month from aspiration pneumonia, decreased activity of phosphorylase kinase	
ecNumber	2.7.11.19	commentary		
ecNumber	2.7.11.19	commentary		
ecNumber	2.7.11.19	commentary	liver isoform, alpha subunit; patients with XLG I, with a deficiency in phosphorylase kinase activity in peripheral blood cells and liver; and with XLG II, with normal in vitro PHK activity in peripheral blood cells and with variable activity in liver	
ecNumber	2.7.11.19	commentary	the subunits of the muscle isozyme are encoded by different genes	
ecNumber	2.7.11.19	commentary		
ecNumber	2.7.11.19	commentary	gene PHKG1; the subunits of the muscle isozyme are encoded by different genes	
ecNumber	2.7.11.19	commentary		
ecNumber	2.7.11.20	commentary	male humans of about 25 years	
ecNumber	2.7.11.20	commentary		
ecNumber	2.7.11.20	commentary		
ecNumber	2.7.11.21	commentary		
ecNumber	2.7.11.21	commentary		
ecNumber	2.7.11.21	commentary		
ecNumber	2.7.11.21	commentary		
ecNumber	2.7.11.21	commentary	Plk3	
ecNumber	2.7.11.21	commentary		
ecNumber	2.7.11.21	commentary		
ecNumber	2.7.11.22	commentary	cdk1, cdk2, cdk5, cdk7, and cdk9	
ecNumber	2.7.11.22	commentary		
ecNumber	2.7.11.22	commentary		
ecNumber	2.7.11.22	commentary		
ecNumber	2.7.11.22	commentary		
ecNumber	2.7.11.22	commentary		
ecNumber	2.7.11.22	commentary		
ecNumber	2.7.11.22	commentary	alpha2-2 isozyme	
ecNumber	2.7.11.22	commentary		
ecNumber	2.7.11.22	commentary		
ecNumber	2.7.11.22	commentary		
ecNumber	2.7.11.22	commentary		
ecNumber	2.7.11.22	commentary		
ecNumber	2.7.11.22	commentary		
ecNumber	2.7.11.22	commentary		
ecNumber	2.7.11.22	commentary		
ecNumber	2.7.11.22	commentary		
ecNumber	2.7.11.22	commentary		
ecNumber	2.7.11.22	commentary		
ecNumber	2.7.11.22	commentary		
ecNumber	2.7.11.22	commentary		
ecNumber	2.7.11.22	commentary		
ecNumber	2.7.11.22	commentary		
ecNumber	2.7.11.23	commentary	isozymes TFIIH, TFIIF, and TFIIE	
ecNumber	2.7.11.23	commentary		
ecNumber	2.7.11.23	commentary	Cdk8	
ecNumber	2.7.11.23	commentary	cdk7	
ecNumber	2.7.11.23	commentary	cdk9	
ecNumber	2.7.11.23	commentary		
ecNumber	2.7.11.23	commentary	Plk3	
ecNumber	2.7.11.23	commentary		
ecNumber	2.7.11.24	commentary	isozymes p38alpha and p38beta	
ecNumber	2.7.11.24	commentary	isozyme p38alpha MAPK	
ecNumber	2.7.11.24	commentary	four p38 isoforms alpha-delta	
ecNumber	2.7.11.24	commentary		
ecNumber	2.7.11.24	commentary		
ecNumber	2.7.11.24	commentary	Erk1	
ecNumber	2.7.11.24	commentary		
ecNumber	2.7.11.24	commentary	ERK2	
ecNumber	2.7.11.24	commentary		
ecNumber	2.7.11.24	commentary		
ecNumber	2.7.11.24	commentary		
ecNumber	2.7.11.24	commentary	JNK2	
ecNumber	2.7.11.24	commentary		
ecNumber	2.7.11.24	commentary		
ecNumber	2.7.11.24	commentary		
ecNumber	2.7.11.24	commentary		
ecNumber	2.7.11.24	commentary		
ecNumber	2.7.11.24	commentary	isozyme p38 MAPKalpha	
ecNumber	2.7.11.24	commentary	isozyme p38alpha MAPK	
ecNumber	2.7.11.24	commentary		
ecNumber	2.7.11.24	commentary		
ecNumber	2.7.11.25	commentary	gene BRAF	
ecNumber	2.7.11.25	commentary		
ecNumber	2.7.11.25	commentary		
ecNumber	2.7.11.25	commentary		
ecNumber	2.7.11.25	commentary		
ecNumber	2.7.11.25	commentary	MEKK3 isozyme 1	
ecNumber	2.7.11.25	commentary		
ecNumber	2.7.11.26	commentary	human	
ecNumber	2.7.11.26	commentary	HEK 293 cells; human	
ecNumber	2.7.11.26	commentary	isozyme CKIdelta	
ecNumber	2.7.11.26	commentary		
ecNumber	2.7.11.26	commentary	isozyme alpha	
ecNumber	2.7.11.26	commentary	GSKalpha	
ecNumber	2.7.11.26	commentary	isozyme beta	
ecNumber	2.7.11.26	commentary	GSKbeta	
ecNumber	2.7.11.26	commentary		
ecNumber	2.7.11.26	commentary		
ecNumber	2.7.11.26	commentary		
ecNumber	2.7.11.27	commentary		
ecNumber	2.7.11.30	commentary	ALK4 is a type I transmembrane serine/threonine kinase receptor	
ecNumber	2.7.11.30	commentary		
ecNumber	2.7.11.30	commentary		
ecNumber	2.7.11.30	commentary		
ecNumber	2.7.11.30	commentary	gene ACVRIC, activin receptor type 1C precursor, four GenBank entries; several isoforms by alternative splicing	
ecNumber	2.7.11.31	commentary	colorectal carcinoma RKO cells; human	
ecNumber	2.7.11.31	commentary	human; IDH4, IMr90 and WI38 fibroblasts	
ecNumber	2.7.11.31	commentary	human	
ecNumber	2.7.11.31	commentary	HEK-293 cell culture	
ecNumber	2.7.11.31	commentary	HAEC cell culture; human	
ecNumber	2.7.11.31	commentary	isozymes alpha1 and alpha2	
ecNumber	2.7.11.31	commentary	patients with Cushings syndrome	
ecNumber	2.7.11.31	commentary		
ecNumber	2.7.11.31	commentary	AMPKalpha2, AMPKbeta2, and AMPKgamma3	
ecNumber	2.7.11.31	commentary		
ecNumber	2.7.11.31	commentary	AMPK subunit alpha-1a and alpha-2	
ecNumber	2.7.11.31	commentary	AMPKalpha1, AMPKbeta1, and AMPKgamma1	
ecNumber	2.7.11.31	commentary		
ecNumber	2.7.12.1	commentary	at least two splicing variants	
ecNumber	2.7.12.1	commentary		
ecNumber	2.7.12.1	commentary		
ecNumber	2.7.12.1	commentary		
ecNumber	2.7.12.1	commentary	cf. EC 2.7.10.2	
ecNumber	2.7.12.1	commentary		
ecNumber	2.7.12.1	commentary		
ecNumber	2.7.12.1	commentary		
ecNumber	2.7.12.1	commentary	adult patients with Down syndrome	
ecNumber	2.7.12.1	commentary	Homo sapiens; adult individuals with Down syndrome	
ecNumber	2.7.12.1	commentary		
ecNumber	2.7.12.1	commentary		
ecNumber	2.7.12.1	commentary		
ecNumber	2.7.12.1	commentary		
ecNumber	2.7.12.2	commentary		
ecNumber	2.7.12.2	commentary	MKK7	
ecNumber	2.7.12.2	commentary		
ecNumber	2.7.12.2	commentary	MEK2	
ecNumber	2.7.12.2	commentary		
ecNumber	2.7.12.2	commentary	MKK4	
ecNumber	2.7.12.2	commentary		
ecNumber	2.7.12.2	commentary		
ecNumber	2.7.12.2	commentary		
ecNumber	2.7.12.2	commentary	MEK1	
ecNumber	2.7.12.2	commentary		
ecNumber	2.7.12.2	commentary		
ecNumber	2.7.12.2	commentary		
ecNumber	2.7.12.2	commentary		
ecNumber	2.7.12.2	commentary		
ecNumber	2.7.12.2	commentary		
ecNumber	2.7.12.2	commentary		
ecNumber	2.8.1.1	commentary	comparison of enzyme activity with several tissues of sheep, cattle, goat, camel, horse, dog, chicken	
ecNumber	2.8.1.1	commentary	identification of functional genetic polymorphisms	
ecNumber	2.8.1.1	commentary		
ecNumber	2.8.1.2	commentary	identification of functional genetic polymorphisms	
ecNumber	2.8.1.2	commentary		
ecNumber	2.8.1.2	commentary		
ecNumber	2.8.1.B2	commentary		
ecNumber	2.8.1.7	commentary	cytosolic isoform, overexpression in Pichia pastoris	
ecNumber	2.8.1.7	commentary		
ecNumber	2.8.1.11	commentary		
ecNumber	2.8.1.11	commentary		
ecNumber	2.8.1.12	commentary		
ecNumber	2.8.1.14	commentary		
ecNumber	2.8.2.1	commentary	2 forms	
ecNumber	2.8.2.1	commentary	2 forms of P-PST: PI-PST and PII-PST	
ecNumber	2.8.2.1	commentary	2 forms of P-PST: PI-PST and PII-PST, differing in their thermostability; 2 forms: simple phenol sulfating P-PST, monoamine sulfating M-PST	
ecNumber	2.8.2.1	commentary	2 forms: thermolabile TL, thermostable TS	
ecNumber	2.8.2.1	commentary	hippocampal enzyme form H-PST	
ecNumber	2.8.2.1	commentary	SULT1A3, is a M-PST enzyme form	
ecNumber	2.8.2.1	commentary	2 forms: simple phenol sulfating P-PST, monoamine sulfating M-PST; SULT1C1 and SULT1C2	
ecNumber	2.8.2.1	commentary	2 forms: simple phenol sulfating P-PST, monoamine sulfating M-PST; SULT1A1/2, a P-PST enzyme form; SULT1A3, is a M-PST enzyme form	
ecNumber	2.8.2.1	commentary	thermostable SULT1A1 and thermolabile SULT1A3	
ecNumber	2.8.2.1	commentary	ST1A3 and ST1A5	
ecNumber	2.8.2.1	commentary	SULT1A1 allozymes 1 and 2; SULT1B1	
ecNumber	2.8.2.1	commentary	2 forms: simple phenol sulfating P-PST, monoamine sulfating M-PST	
ecNumber	2.8.2.1	commentary	SULT1A1-A3; thermostable SULT1A1 and thermolabile SULT1A3	
ecNumber	2.8.2.1	commentary	enzyme form SULT1A1, recombinant; enzyme form SULT1A3, recombinant; enzyme form SULT1E1, recombinant; enzyme form SULT2A1, recombinant	
ecNumber	2.8.2.1	commentary	enzyme form PST-P	
ecNumber	2.8.2.1	commentary	enzyme form SULT1A1	
ecNumber	2.8.2.1	commentary	enzyme form SULT1A1; enzyme form SULT1A3	
ecNumber	2.8.2.1	commentary	female and male	
ecNumber	2.8.2.1	commentary		
ecNumber	2.8.2.1	commentary	SULT1C1	
ecNumber	2.8.2.1	commentary	SULT1C	2	
ecNumber	2.8.2.1	commentary	2 forms: simple phenol sulfating P-PST, monoamine sulfating M-PST	
ecNumber	2.8.2.1	commentary	SULT1B1	
ecNumber	2.8.2.1	commentary		
ecNumber	2.8.2.1	commentary	SULT1B2	
ecNumber	2.8.2.1	commentary	SULT1C2	
ecNumber	2.8.2.1	commentary	SULT1A3, is a M-PST enzyme form	
ecNumber	2.8.2.1	commentary	; SULT1A3; SULT1A3	
ecNumber	2.8.2.1	commentary	SULT1A3	
ecNumber	2.8.2.1	commentary		
ecNumber	2.8.2.1	commentary	SULT1A1 allozymes 1 and 2	
ecNumber	2.8.2.1	commentary	SULT1A1 is a P-PST enzyme form	
ecNumber	2.8.2.1	commentary	enzyme form SULT1A1; enzyme form SULT1A3	
ecNumber	2.8.2.1	commentary	; SULT1A1; SULT1A1	
ecNumber	2.8.2.1	commentary	Japanese individuals possessing the polymorphic SULT1A1	2 allele	
ecNumber	2.8.2.1	commentary	allelic variants of SULT1A1	
ecNumber	2.8.2.1	commentary	SULT1A1; SULT1A1	
ecNumber	2.8.2.1	commentary	SULT1A1	
ecNumber	2.8.2.1	commentary		
ecNumber	2.8.2.1	commentary	SULT1A2	
ecNumber	2.8.2.1	commentary	SULT4A1	
ecNumber	2.8.2.2	commentary	human	
ecNumber	2.8.2.2	commentary	human; human, hDHEA-ST, ST2A3, SULT2A1, PDB code 1EFH	
ecNumber	2.8.2.2	commentary	recombinant enzyme expressed in Escherichia coli	
ecNumber	2.8.2.2	commentary	isoform SULT1A1; isoform SULT1A3	
ecNumber	2.8.2.2	commentary	isozymes SULT2B1a and SULT2B1b	
ecNumber	2.8.2.2	commentary		
ecNumber	2.8.2.2	commentary	human	
ecNumber	2.8.2.2	commentary	SULT1B1	
ecNumber	2.8.2.2	commentary	isozymes SULT2B1a and SULT2B1b	
ecNumber	2.8.2.2	commentary		
ecNumber	2.8.2.2	commentary		
ecNumber	2.8.2.2	commentary		
ecNumber	2.8.2.2	commentary		
ecNumber	2.8.2.2	commentary	human, SULT2A1, cDNA	
ecNumber	2.8.2.2	commentary		
ecNumber	2.8.2.3	commentary		
ecNumber	2.8.2.4	commentary	human	
ecNumber	2.8.2.4	commentary	recombinant enzyme expressed in Salmonella typhimurium	
ecNumber	2.8.2.4	commentary	isoform SULT1E1	
ecNumber	2.8.2.4	commentary	female and male	
ecNumber	2.8.2.4	commentary	women from Chile	
ecNumber	2.8.2.4	commentary	females with or without endometriosis	
ecNumber	2.8.2.4	commentary		
ecNumber	2.8.2.4	commentary	human	
ecNumber	2.8.2.4	commentary	SULT1E1	
ecNumber	2.8.2.4	commentary		
ecNumber	2.8.2.5	commentary	recombinant enzyme	
ecNumber	2.8.2.5	commentary	patient with B-cell chronic lyymphocytic leukemia	
ecNumber	2.8.2.5	commentary	isozyme C4ST3	
ecNumber	2.8.2.5	commentary	isozyme C4ST1	
ecNumber	2.8.2.5	commentary		
ecNumber	2.8.2.5	commentary	isozyme C4ST2	
ecNumber	2.8.2.7	commentary		
ecNumber	2.8.2.8	commentary	bifunctional enzyme possessing heparan sulfate N-deacetylase and N-sulfotransferase activity	
ecNumber	2.8.2.8	commentary	bifunctional enzyme possessing heparan sulfate N-deacetylase and N-sulfotransferase activity; crystal structure of sulfotransferase domain, Protein Data Bank: 1NST; enzyme form HSNST1	
ecNumber	2.8.2.8	commentary	bifunctional enzyme possessing heparan sulfate N-deacetylase and N-sulfotransferase activity; crystal structure of sulfotransferase domain, Protein Data Bank: 1NST	
ecNumber	2.8.2.8	commentary		
ecNumber	2.8.2.8	commentary	isozymes NDST1 and NDST2	
ecNumber	2.8.2.8	commentary	enzyme form NDST3, bifunctional enzyme possessing heparan sulfate N-deacetylase and N-sulfotransferase activity	
ecNumber	2.8.2.8	commentary		
ecNumber	2.8.2.8	commentary		
ecNumber	2.8.2.8	commentary	isozyme NDST4	
ecNumber	2.8.2.9	commentary		
ecNumber	2.8.2.11	commentary		
ecNumber	2.8.2.11	commentary		
ecNumber	2.8.2.14	commentary	human	
ecNumber	2.8.2.14	commentary	isoform SULT2A1	
ecNumber	2.8.2.14	commentary		
ecNumber	2.8.2.14	commentary		
ecNumber	2.8.2.15	commentary	human	
ecNumber	2.8.2.15	commentary	recombinant enzyme	
ecNumber	2.8.2.15	commentary	; two isozymes SULT2B1a and SULT2B1b	
ecNumber	2.8.2.15	commentary	SULT2A1	
ecNumber	2.8.2.15	commentary		
ecNumber	2.8.2.15	commentary	human, isoenzyme SULT2B1a; human, isoenzyme SULT2B1b	
ecNumber	2.8.2.15	commentary		
ecNumber	2.8.2.15	commentary	human, isoenzyme DHEA-ST	
ecNumber	2.8.2.15	commentary		
ecNumber	2.8.2.17	commentary	recombinant enzyme with FLAG-tag	
ecNumber	2.8.2.17	commentary	recombinant enzyme	
ecNumber	2.8.2.17	commentary	patients with a distinct form of spondyloepiphyseal dysplasia, SED Omani type	
ecNumber	2.8.2.17	commentary		
ecNumber	2.8.2.17	commentary	gene CHST3	
ecNumber	2.8.2.17	commentary		
ecNumber	2.8.2.17	commentary		
ecNumber	2.8.2.20	commentary	2 isoforms: TPST1 and TPST2	
ecNumber	2.8.2.20	commentary	isozymes TPST-1 and TPST-2	
ecNumber	2.8.2.20	commentary		
ecNumber	2.8.2.20	commentary	TPST-1; isozyme TPST-1	
ecNumber	2.8.2.20	commentary	TPST-1	
ecNumber	2.8.2.20	commentary		
ecNumber	2.8.2.20	commentary	TPST-2; isozyme TPST-2	
ecNumber	2.8.2.20	commentary		
ecNumber	2.8.2.21	commentary	corneal and intestinal isoforms of GlcNAc6ST	
ecNumber	2.8.2.21	commentary		
ecNumber	2.8.2.21	commentary	gene CHST1 encodes the keratan sulfate 6-O-sulfotransferase	
ecNumber	2.8.2.21	commentary		
ecNumber	2.8.2.22	commentary		
ecNumber	2.8.2.23	commentary		
ecNumber	2.8.2.29	commentary		
ecNumber	2.8.2.29	commentary		
ecNumber	2.8.2.30	commentary	multiple isoforms	
ecNumber	2.8.2.30	commentary		
ecNumber	2.8.2.30	commentary		
ecNumber	2.8.2.30	commentary		
ecNumber	2.8.2.33	commentary		
ecNumber	2.8.2.33	commentary	expression in COS-7 cells	
ecNumber	2.8.2.33	commentary		
ecNumber	2.8.2.34	commentary		
ecNumber	2.8.2.35	commentary		
ecNumber	2.8.2.35	commentary		
ecNumber	2.8.3.5	commentary	healthy and SCOT-deficient patients; SCOT-deficient patients	
ecNumber	2.8.3.5	commentary	SCOT-deficient patients	
ecNumber	2.8.3.5	commentary	gene SCOT	
ecNumber	2.8.3.5	commentary		
ecNumber	2.8.3.5	commentary		
ecNumber	2.8.3.5	commentary		
ecNumber	2.8.3.13	commentary		
ecNumber	2.9.1.1	commentary		
ecNumber	2.9.1.2	commentary		
ecNumber	2.9.1.2	commentary		
ecNumber	3.1.1.1	commentary	at least 4 major isoenzymes in blood monocytes	
ecNumber	3.1.1.1	commentary	monomeric and trimeric enzyme form	
ecNumber	3.1.1.1	commentary	isozymes CE-1 and CE-2	
ecNumber	3.1.1.1	commentary	isoform hormone-sensitive lipase	
ecNumber	3.1.1.1	commentary	isoform CES3, expression in baculoviral system; isoforms CES1A1, CES2	
ecNumber	3.1.1.1	commentary	isoforms hCE1, hCE2	
ecNumber	3.1.1.1	commentary	isoforms hCE1 and hCE2	
ecNumber	3.1.1.1	commentary	isoform hiCE	
ecNumber	3.1.1.1	commentary	isoform hCE1	
ecNumber	3.1.1.1	commentary	isoform CES2, several splice variants	
ecNumber	3.1.1.1	commentary	isozymes CES1 and CES2	
ecNumber	3.1.1.1	commentary	isozymes CE1 and intestinal CE	
ecNumber	3.1.1.1	commentary	Japanese population, gene CES2	
ecNumber	3.1.1.1	commentary		
ecNumber	3.1.1.1	commentary	isoform hCE2	
ecNumber	3.1.1.1	commentary	isoform hCE1	
ecNumber	3.1.1.1	commentary	isoenzyme hBr3/pTARGET and HU1/pTARGET	
ecNumber	3.1.1.1	commentary	isoforms hCE-1 and hCE-2, recombinant enzymes	
ecNumber	3.1.1.1	commentary	isoform hCE1	
ecNumber	3.1.1.1	commentary	isoforms hCE1 and hiCE	
ecNumber	3.1.1.1	commentary	isoform hiCE	
ecNumber	3.1.1.1	commentary		
ecNumber	3.1.1.2	commentary	healthy and individuals with coronary artery disease	
ecNumber	3.1.1.2	commentary		
ecNumber	3.1.1.2	commentary	variant Q192 and R192	
ecNumber	3.1.1.2	commentary	chronic hepatitis patients and control subjects	
ecNumber	3.1.1.2	commentary		
ecNumber	3.1.1.2	commentary		
ecNumber	3.1.1.2	commentary		
ecNumber	3.1.1.3	commentary	gastric lipase	
ecNumber	3.1.1.3	commentary	digestive lipases HPL and HGL, healthy male and female humans	
ecNumber	3.1.1.3	commentary	55 hyperlipidemic japanese men	
ecNumber	3.1.1.3	commentary	three bifunctional isozymes	
ecNumber	3.1.1.3	commentary	ATGL gene PNPLA2	
ecNumber	3.1.1.3	commentary	healthy persons and hypercholesterolemic patients	
ecNumber	3.1.1.3	commentary	chimeric lipase from lipoprotein lipase and hepatic lipase	
ecNumber	3.1.1.3	commentary		
ecNumber	3.1.1.3	commentary		
ecNumber	3.1.1.4	commentary	expression in Escherichia coli	
ecNumber	3.1.1.4	commentary	isozyme sPLA2IB2; isozymes sPLA2-IIA, sPLA2-V, and sPLA2-X	
ecNumber	3.1.1.4	commentary	isozymes hGIIA sPLA2, hGIB sPLA2, hGX sPLA2, and hGV sPLA2	
ecNumber	3.1.1.4	commentary	secreted human phospholipase A2, i.e. sPLA2-X	
ecNumber	3.1.1.4	commentary		
ecNumber	3.1.1.4	commentary		
ecNumber	3.1.1.4	commentary		
ecNumber	3.1.1.4	commentary		
ecNumber	3.1.1.4	commentary	cPLA2; isozyme cPLA2	
ecNumber	3.1.1.4	commentary		
ecNumber	3.1.1.4	commentary		
ecNumber	3.1.1.4	commentary		
ecNumber	3.1.1.4	commentary		
ecNumber	3.1.1.5	commentary		
ecNumber	3.1.1.5	commentary		
ecNumber	3.1.1.5	commentary		
ecNumber	3.1.1.5	commentary		
ecNumber	3.1.1.6	commentary		
ecNumber	3.1.1.7	commentary	vitiligo patients with almost absent acetylcholinesterase	
ecNumber	3.1.1.7	commentary	R-isoform, expression in Nicotiana benthamiana, or commercial preparation	
ecNumber	3.1.1.7	commentary	commercial preparation	
ecNumber	3.1.1.7	commentary	recombinant protein	
ecNumber	3.1.1.7	commentary		
ecNumber	3.1.1.7	commentary		
ecNumber	3.1.1.8	commentary	isoform serum pseudocholinesterase	
ecNumber	3.1.1.8	commentary	exogenously administered in Mus musculus	
ecNumber	3.1.1.8	commentary	native enzyme and recombinant enzyme expressed in milk of transgenic goat	
ecNumber	3.1.1.8	commentary	healthy persons and hemodialysis patients	
ecNumber	3.1.1.8	commentary	K variant of gene BCHE	
ecNumber	3.1.1.8	commentary	Brasilian population, gene BCHE	
ecNumber	3.1.1.8	commentary		
ecNumber	3.1.1.8	commentary		
ecNumber	3.1.1.13	commentary	recombinant enzyme	
ecNumber	3.1.1.13	commentary		
ecNumber	3.1.1.13	commentary		
ecNumber	3.1.1.17	commentary		
ecNumber	3.1.1.17	commentary		
ecNumber	3.1.1.23	commentary		
ecNumber	3.1.1.23	commentary		
ecNumber	3.1.1.25	commentary		
ecNumber	3.1.1.25	commentary	variant Q192 and R192	
ecNumber	3.1.1.25	commentary		
ecNumber	3.1.1.25	commentary		
ecNumber	3.1.1.25	commentary		
ecNumber	3.1.1.26	commentary	recombinant	
ecNumber	3.1.1.26	commentary		
ecNumber	3.1.1.26	commentary		
ecNumber	3.1.1.26	commentary		
ecNumber	3.1.1.28	commentary		
ecNumber	3.1.1.29	commentary		
ecNumber	3.1.1.29	commentary	colon carcinoma HeLa cells	
ecNumber	3.1.1.29	commentary		
ecNumber	3.1.1.31	commentary		
ecNumber	3.1.1.31	commentary		
ecNumber	3.1.1.32	commentary	several isozymes	
ecNumber	3.1.1.32	commentary	acid phospholipase activity	
ecNumber	3.1.1.32	commentary		
ecNumber	3.1.1.32	commentary		
ecNumber	3.1.1.32	commentary		
ecNumber	3.1.1.34	commentary	functional deficiency of enzyme in a patient with severe hypertriglyceridemia	
ecNumber	3.1.1.34	commentary	Japanese hyperlipidemic men	
ecNumber	3.1.1.34	commentary	expression in transgenic rabbit	
ecNumber	3.1.1.34	commentary	healthy males	
ecNumber	3.1.1.34	commentary		
ecNumber	3.1.1.34	commentary		
ecNumber	3.1.1.43	commentary		
ecNumber	3.1.1.45	commentary		
ecNumber	3.1.1.45	commentary		
ecNumber	3.1.1.47	commentary	children with meningitis	
ecNumber	3.1.1.47	commentary	1 extracellular, secreted plasma enzyme form and an intracellular form, devided into 4 isozyme types, differing in their primary sequences, tissue localizations, subunit compositions, and substrate preferences	
ecNumber	3.1.1.47	commentary	isozyme II	
ecNumber	3.1.1.47	commentary	patients with acute respiratory distress syndrome and control subjects, higher enzyme activity in the fluid and plasma of bronchoalveolar lavage from patients suffering from acute respiratory distress syndrome compared with the control group, lower enzyme activity in the cells of bronchoalveolar lavage from patients suffering from acute respiratory distress syndrome compared with the control group	
ecNumber	3.1.1.47	commentary	; Japanese patients with partial or complete plasma enzyme deficiency and control subjects	
ecNumber	3.1.1.47	commentary	Japanese patients with complete or partial platelet-activating factor acetylhydrolase deficiency	
ecNumber	3.1.1.47	commentary	patients suffering from chronic kidney disease and control subjects, higher enzyme activity in the chronic kidney disease patients group compared with the control group, enzyme activity is increased as a function of disease state	
ecNumber	3.1.1.47	commentary	patients suffering from metabolic syndrome and control subjects, higher enzyme activity in the metabolic syndrome patients group compared with the control group	
ecNumber	3.1.1.47	commentary	recombinantly expressed in Escherichia coli	
ecNumber	3.1.1.47	commentary		
ecNumber	3.1.1.47	commentary	isoform 1; isoform 2; isoform 3	
ecNumber	3.1.1.47	commentary		
ecNumber	3.1.1.47	commentary		
ecNumber	3.1.1.53	commentary		
ecNumber	3.1.1.53	commentary		
ecNumber	3.1.1.55	commentary	north-west indians	
ecNumber	3.1.1.55	commentary	; diabetes 2 patients and healthy individuals, higher activity in diabetes patients than in control individuals at pH 7.4, no differences at pH 5.5	
ecNumber	3.1.1.55	commentary	individuals with frailty (cognitive impairment) scores from 0.10 (young/healthy) up to 4.47	
ecNumber	3.1.1.55	commentary	Japanese subjects	
ecNumber	3.1.1.55	commentary		
ecNumber	3.1.1.56	commentary	3 isoenzymes: Es D1, Es D2-1, Es D2	
ecNumber	3.1.1.56	commentary	2 new variants of enzyme	
ecNumber	3.1.1.56	commentary	healthy individuals or patients with endogenous uveitis	
ecNumber	3.1.1.56	commentary		
ecNumber	3.1.1.60	commentary		
ecNumber	3.1.1.63	commentary		
ecNumber	3.1.1.64	commentary		
ecNumber	3.1.1.67	commentary	FAEES-III	
ecNumber	3.1.1.67	commentary		
ecNumber	3.1.1.77	commentary		
ecNumber	3.1.1.77	commentary		
ecNumber	3.1.1.79	commentary	recombinant	
ecNumber	3.1.1.79	commentary		
ecNumber	3.1.1.79	commentary	nine women and eight men, moderately trained	
ecNumber	3.1.1.79	commentary		
ecNumber	3.1.1.81	commentary	aiiA	
ecNumber	3.1.1.84	commentary		
ecNumber	3.1.1.84	commentary		
ecNumber	3.1.1.89	commentary		
ecNumber	3.1.1.89	commentary		
ecNumber	3.1.1.93	commentary		
ecNumber	3.1.1.93	commentary		
ecNumber	3.1.1.96	commentary		
ecNumber	3.1.1.97	commentary		
ecNumber	3.1.1.98	commentary		
ecNumber	3.1.2.1	commentary		
ecNumber	3.1.2.1	commentary		
ecNumber	3.1.2.2	commentary	isozymes CTE-I and MTE-I	
ecNumber	3.1.2.2	commentary	thioesterase II	
ecNumber	3.1.2.2	commentary		
ecNumber	3.1.2.2	commentary	human brain long-chain acyl-CoA hydrolase hBACH	
ecNumber	3.1.2.2	commentary	brain-specific enzyme, several isoforms	
ecNumber	3.1.2.2	commentary	hTE; should be renamed as PTE I	
ecNumber	3.1.2.2	commentary		
ecNumber	3.1.2.2	commentary		
ecNumber	3.1.2.2	commentary		
ecNumber	3.1.2.2	commentary		
ecNumber	3.1.2.4	commentary		
ecNumber	3.1.2.4	commentary	mitochondrial precursor	
ecNumber	3.1.2.4	commentary		
ecNumber	3.1.2.6	commentary	HAGH gene encodes both cytosolic and mitochondrial forms of glyoxalase II	
ecNumber	3.1.2.6	commentary	recombinant cytosolic isozyme expressed in Escherichia coli	
ecNumber	3.1.2.6	commentary	purified recombinant cytosolic isozyme	
ecNumber	3.1.2.6	commentary		
ecNumber	3.1.2.6	commentary	cytosolic and mitochondrial isozyme, both encoded by gene HAGH for hydroxyacylglutathione hydrolase	
ecNumber	3.1.2.6	commentary		
ecNumber	3.1.2.7	commentary		
ecNumber	3.1.2.11	commentary		
ecNumber	3.1.2.12	commentary		
ecNumber	3.1.2.13	commentary		
ecNumber	3.1.2.20	commentary	isozymes CTE-I and MTE-I	
ecNumber	3.1.2.20	commentary	thioesterase II	
ecNumber	3.1.2.20	commentary	patients with lowered type-II acyl-CoA thioesterase protein and activity in human skin fibroblasts	
ecNumber	3.1.2.20	commentary		
ecNumber	3.1.2.20	commentary	human brain long-chain acyl-CoA hydrolase hBACH	
ecNumber	3.1.2.20	commentary	hTE; should be renamed as PTE I	
ecNumber	3.1.2.20	commentary		
ecNumber	3.1.2.20	commentary		
ecNumber	3.1.2.20	commentary		
ecNumber	3.1.2.22	commentary	lysosomal enzyme forms PPT1	
ecNumber	3.1.2.22	commentary	2 lysosomal enzyme forms PPT1 and PPT2	
ecNumber	3.1.2.22	commentary		
ecNumber	3.1.2.22	commentary		
ecNumber	3.1.2.22	commentary	precursor	
ecNumber	3.1.2.22	commentary		
ecNumber	3.1.2.27	commentary		
ecNumber	3.1.3.1	commentary	secreted alkaline phosphatase SEAP containing a single N-glycan chain, a model protein for investigation of glycosylation pattern	
ecNumber	3.1.3.1	commentary	4 isozyme types: 1. nonspecific liver/bone/kidney, which is also present in osteoblast and neutrophilic granulocytes, 2. intestinal, 3. placental, 4. germ-cell	
ecNumber	3.1.3.1	commentary	several isozymes	
ecNumber	3.1.3.1	commentary	at least 3 isoenzymes: placental, intestinal and tissue non-specific	
ecNumber	3.1.3.1	commentary		
ecNumber	3.1.3.1	commentary	precursor	
ecNumber	3.1.3.1	commentary		
ecNumber	3.1.3.1	commentary	humanplacenta alkaline phosphatase PLAP	
ecNumber	3.1.3.1	commentary		
ecNumber	3.1.3.2	commentary	tartrate-resistant acid phosphatase isoforms 5a and 5b	
ecNumber	3.1.3.2	commentary		
ecNumber	3.1.3.2	commentary		
ecNumber	3.1.3.2	commentary		
ecNumber	3.1.3.3	commentary		
ecNumber	3.1.3.4	commentary	isozymes LPP1-3	
ecNumber	3.1.3.4	commentary	isozymes LPP1, LPP-2, and LPP-3	
ecNumber	3.1.3.4	commentary	transcript PAP2d_v2, PAP2 protein; PAP2d, transcript PAP2d_v2	
ecNumber	3.1.3.4	commentary	isozymes LPP1-3, several splicing variants of LPP1	
ecNumber	3.1.3.4	commentary	isozymes PAP-1 and PAP-2	
ecNumber	3.1.3.4	commentary	gene PAP2a	
ecNumber	3.1.3.4	commentary	genes Lpin1, Lpin2, and Lpin3	
ecNumber	3.1.3.4	commentary		
ecNumber	3.1.3.4	commentary		
ecNumber	3.1.3.4	commentary		
ecNumber	3.1.3.4	commentary	transcript PAP2d_v1, PAP2 protein fragment; PAP2d, transcript PAP2d_v1	
ecNumber	3.1.3.4	commentary	DPPL2; isozyme DPPL2	
ecNumber	3.1.3.4	commentary	LPR-3; LPR-3	
ecNumber	3.1.3.4	commentary	PRG-1 or LPR-4; PRG-1 or LPR-4	
ecNumber	3.1.3.4	commentary	DPPL1; isozyme DPPL1	
ecNumber	3.1.3.4	commentary	PRG-3 or LPR-1; isozyme PRG-3 or LPR-1	
ecNumber	3.1.3.4	commentary	LPR1	
ecNumber	3.1.3.4	commentary	LPR-2 or PRG-4; PRG-4 or LPR-2	
ecNumber	3.1.3.B4	commentary		
ecNumber	3.1.3.5	commentary	ecto- and cytosolic 5'-nucleotidase isoform	
ecNumber	3.1.3.5	commentary	patients with acute lymphoblastic leukemia during 6-mercaptopurine treatment	
ecNumber	3.1.3.5	commentary	gene NT5E at 6q14-q21 encodes CD73	
ecNumber	3.1.3.5	commentary	ecto-5'-nucleotidase	
ecNumber	3.1.3.5	commentary		
ecNumber	3.1.3.5	commentary		
ecNumber	3.1.3.5	commentary	isoform cytosolic 5'-nucleotidase II, expression in Escherichia coli	
ecNumber	3.1.3.5	commentary		
ecNumber	3.1.3.5	commentary		
ecNumber	3.1.3.5	commentary		
ecNumber	3.1.3.5	commentary		
ecNumber	3.1.3.7	commentary		
ecNumber	3.1.3.7	commentary	GenBank AF125042	
ecNumber	3.1.3.7	commentary	recombinantly expressed in yeast	
ecNumber	3.1.3.9	commentary	; type 1 diabetes individuals and individuals with a DR0301 or DR0401 haplotype, which are disease susceptible	
ecNumber	3.1.3.9	commentary		
ecNumber	3.1.3.9	commentary	; individuals from Argentina	
ecNumber	3.1.3.9	commentary		
ecNumber	3.1.3.9	commentary		
ecNumber	3.1.3.9	commentary		
ecNumber	3.1.3.11	commentary	; cancer patients enrolled in phase I clinical trial of calcitriol and carboplatin	
ecNumber	3.1.3.11	commentary		
ecNumber	3.1.3.11	commentary	isoform FBP2	
ecNumber	3.1.3.11	commentary	liver and muscle isoforms	
ecNumber	3.1.3.11	commentary		
ecNumber	3.1.3.16	commentary	isozyme PP2Cdelta	
ecNumber	3.1.3.16	commentary	several isozymes, classification, overview	
ecNumber	3.1.3.16	commentary	isozymes PP1alpha, PP1beta, and PP1gamma1	
ecNumber	3.1.3.16	commentary	individuals with Down syndrome	
ecNumber	3.1.3.16	commentary		
ecNumber	3.1.3.16	commentary		
ecNumber	3.1.3.16	commentary		
ecNumber	3.1.3.16	commentary		
ecNumber	3.1.3.16	commentary		
ecNumber	3.1.3.16	commentary		
ecNumber	3.1.3.16	commentary	catalytic subunit	
ecNumber	3.1.3.16	commentary	isoform PPP1CC	
ecNumber	3.1.3.16	commentary		
ecNumber	3.1.3.16	commentary		
ecNumber	3.1.3.16	commentary		
ecNumber	3.1.3.16	commentary	isoform PPP1CA	
ecNumber	3.1.3.16	commentary	isoform PPP1CB	
ecNumber	3.1.3.16	commentary		
ecNumber	3.1.3.16	commentary		
ecNumber	3.1.3.16	commentary		
ecNumber	3.1.3.16	commentary	; isozyme PP2Cepsilon	
ecNumber	3.1.3.16	commentary	mitochondrial precursor	
ecNumber	3.1.3.16	commentary		
ecNumber	3.1.3.16	commentary	protein phosphatase 3 regulatory subunit B beta isoform; gene PPP3RL, two isozymes PPP3R1 and PPP3R2	
ecNumber	3.1.3.16	commentary		
ecNumber	3.1.3.16	commentary		
ecNumber	3.1.3.17	commentary		
ecNumber	3.1.3.18	commentary		
ecNumber	3.1.3.25	commentary		
ecNumber	3.1.3.25	commentary	gene IMPA2	
ecNumber	3.1.3.25	commentary		
ecNumber	3.1.3.26	commentary	The enzyme may be a 3-phytase (EC 3.1.3.8), or a 4-phytase (synonym 6-phytase, EC 3.1.3.26). The product of the hydrolysis of myo-inositol hexakisphosphate to 1D-myo-inositol 1,2,4,5,6-pentakisphosphate or alternatively 1D-myo-inositol 1,2,3,5,6-pentakisphosphate has not been identified.	
ecNumber	3.1.3.29	commentary		
ecNumber	3.1.3.31	commentary		
ecNumber	3.1.3.31	commentary		
ecNumber	3.1.3.32	commentary		
ecNumber	3.1.3.32	commentary	bifunctional, c.f. EC 2.7.1.78; polyp prevention trial participants	
ecNumber	3.1.3.32	commentary		
ecNumber	3.1.3.34	commentary		
ecNumber	3.1.3.36	commentary	a Ca2+-dependent enzyme and a Mg2+-dependent enzyme	
ecNumber	3.1.3.36	commentary		
ecNumber	3.1.3.36	commentary		
ecNumber	3.1.3.36	commentary	isoform INPP5B	
ecNumber	3.1.3.36	commentary		
ecNumber	3.1.3.36	commentary	isoform OCRL	
ecNumber	3.1.3.36	commentary		
ecNumber	3.1.3.42	commentary		
ecNumber	3.1.3.43	commentary		
ecNumber	3.1.3.43	commentary		
ecNumber	3.1.3.43	commentary		
ecNumber	3.1.3.46	commentary	bifunctional enzyme	
ecNumber	3.1.3.46	commentary	isozymes PFKFB-4 and PFKFB-3	
ecNumber	3.1.3.46	commentary	isozymes PFKFB1-4	
ecNumber	3.1.3.46	commentary		
ecNumber	3.1.3.46	commentary	heart isozyme PFKFB2; genes PFKFB1-4, four isozymes	
ecNumber	3.1.3.46	commentary		
ecNumber	3.1.3.46	commentary		
ecNumber	3.1.3.46	commentary	liver isozyme PFKFB1; genes PFKFB1-4, four isozymes	
ecNumber	3.1.3.46	commentary	isozymes PFKFB1-4; recombinant	
ecNumber	3.1.3.46	commentary	brain/placenta isozyme PFKFB3; genes PFKFB1-4, four isozymes	
ecNumber	3.1.3.46	commentary		
ecNumber	3.1.3.46	commentary	testis isozyme PFKFB4; genes PFKFB1-4, four isozymes	
ecNumber	3.1.3.46	commentary	PFKFB4 gene, promoter region, and 5' untranslated region, partial sequence; minor splice isozyme PFKFB-4, major isozyme PFKFB-3	
ecNumber	3.1.3.46	commentary		
ecNumber	3.1.3.46	commentary	bifunctional 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase, six different isoforms	
ecNumber	3.1.3.48	commentary	recombinant protein expressed in various human cell lines	
ecNumber	3.1.3.48	commentary	two isozymes	
ecNumber	3.1.3.48	commentary	classification of subfamilies, overview	
ecNumber	3.1.3.48	commentary	isozymes PTP1B, PTPalpha	
ecNumber	3.1.3.48	commentary	isozyme PTP1B	
ecNumber	3.1.3.48	commentary	recombinant enzyme	
ecNumber	3.1.3.48	commentary	isoforms PTP1B, CD45, comercial preparations	
ecNumber	3.1.3.48	commentary	isoform PTP1B, recombinant enzyme	
ecNumber	3.1.3.48	commentary	isoform PTP1B	
ecNumber	3.1.3.48	commentary	comercial preparation	
ecNumber	3.1.3.48	commentary	isoforms PTP1B, CD45, PTPalpha, LAR	
ecNumber	3.1.3.48	commentary	transgenic expression in mice muscle	
ecNumber	3.1.3.48	commentary	recombinant enzyme, expression in Escherichia coli and L cell	
ecNumber	3.1.3.48	commentary	isoform Receptor-type protein-tyrosine phosphatase-kappa	
ecNumber	3.1.3.48	commentary	isoform PTPN22, expressed exclusively in cells of hematopoietic origin	
ecNumber	3.1.3.48	commentary	isoform PTP-1B and TCPTP	
ecNumber	3.1.3.48	commentary	isoform CD45	
ecNumber	3.1.3.48	commentary	protein isoform PTP1B	
ecNumber	3.1.3.48	commentary	gene PTPN22	
ecNumber	3.1.3.48	commentary	phosphatase subtype 1A and 1B	
ecNumber	3.1.3.48	commentary	receptor-type protein tyrosine phosphatase CD148	
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary	isoforms PTPB1, PTPH1	
ecNumber	3.1.3.48	commentary	recombinant enzyme PTP1B	
ecNumber	3.1.3.48	commentary	isoforms PTP1B and PTPbeta	
ecNumber	3.1.3.48	commentary	isoform PTP1B, amino acids 1-400, catalytic domain plus 80-amino acid C-terminal tail	
ecNumber	3.1.3.48	commentary	isoform PTP1B	
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary	two isozymes of LMW-PTP, and PTP-1B	
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary	isozyme SHP-1	
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary	Cdc25B	
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary	Cdc25C	
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary	PTPN7	
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary	PTPN5	
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary	GenBank, EMBL Data Bank L07527	
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary	PTPRR	
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary	MKP-3	
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary	epsilon isoform	
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary	MKP-4	
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary		
ecNumber	3.1.3.48	commentary	MKP-5	
ecNumber	3.1.3.51	commentary		
ecNumber	3.1.3.52	commentary		
ecNumber	3.1.3.53	commentary	PP-1 and PP-2A	
ecNumber	3.1.3.53	commentary	myosin-associated PP-1M	
ecNumber	3.1.3.53	commentary	MLCPPase, member of type 1 phosphatases	
ecNumber	3.1.3.53	commentary	isoforms of enzyme targeting subunit, MYPT 1	
ecNumber	3.1.3.53	commentary		
ecNumber	3.1.3.53	commentary		
ecNumber	3.1.3.53	commentary	heart-specific small regulatory subunit isoform hHS-M21 A of MLCP; heart-specific small regulatory subunit isoform hHS-M21 B of MLCP	
ecNumber	3.1.3.55	commentary		
ecNumber	3.1.3.56	commentary	IMR-32 neuroblastoma cells	
ecNumber	3.1.3.56	commentary	SH-SY5Y neuroblastoma cells	
ecNumber	3.1.3.56	commentary		
ecNumber	3.1.3.56	commentary	isoform SHIP2	
ecNumber	3.1.3.56	commentary		
ecNumber	3.1.3.57	commentary		
ecNumber	3.1.3.62	commentary		
ecNumber	3.1.3.62	commentary		
ecNumber	3.1.3.62	commentary	(HSA)MINPP1	
ecNumber	3.1.3.64	commentary	myotubularins MTM1 and MTMR6	
ecNumber	3.1.3.64	commentary	gene mtmr2	
ecNumber	3.1.3.64	commentary		
ecNumber	3.1.3.64	commentary		
ecNumber	3.1.3.64	commentary		
ecNumber	3.1.3.64	commentary		
ecNumber	3.1.3.64	commentary	adapter subunit 3-PAP of phosphatidylinositol 3-phosphate phosphatase	
ecNumber	3.1.3.66	commentary	gene INPP4B	
ecNumber	3.1.3.66	commentary		
ecNumber	3.1.3.66	commentary	inositol polyphosphate 4-phosphatase type II	
ecNumber	3.1.3.66	commentary		
ecNumber	3.1.3.67	commentary		
ecNumber	3.1.3.74	commentary		
ecNumber	3.1.3.74	commentary		
ecNumber	3.1.3.75	commentary		
ecNumber	3.1.3.75	commentary		
ecNumber	3.1.3.75	commentary	PHOSPHO1	
ecNumber	3.1.3.76	commentary	gene EPXH2	
ecNumber	3.1.3.76	commentary	gene EPHX2	
ecNumber	3.1.3.76	commentary		
ecNumber	3.1.3.77	commentary		
ecNumber	3.1.3.77	commentary		
ecNumber	3.1.3.78	commentary		
ecNumber	3.1.3.78	commentary	two isozyme I	
ecNumber	3.1.3.78	commentary	isozyme II	
ecNumber	3.1.3.80	commentary		
ecNumber	3.1.3.81	commentary	DPPL2; isozyme DPPL2	
ecNumber	3.1.3.81	commentary	DPPL1; isozyme DPPL1	
ecNumber	3.1.3.86	commentary		
ecNumber	3.1.3.86	commentary	isoform SHIP2	
ecNumber	3.1.3.86	commentary	isoform SHIP1	
ecNumber	3.1.3.91	commentary		
ecNumber	3.1.3.94	commentary		
ecNumber	3.1.3.95	commentary		
ecNumber	3.1.3.95	commentary	isoform MTM1	
ecNumber	3.1.3.95	commentary	isoform MTMR2	
ecNumber	3.1.3.95	commentary		
ecNumber	3.1.3.95	commentary	isoform MTMR8	
ecNumber	3.1.3.95	commentary	isoform MTMR6	
ecNumber	3.1.3.96	commentary		
ecNumber	3.1.4.1	commentary	fetal, origin of the fetal serum PDEase might be a soluble form of human PC-1, a plasma cell membrane glycoprotein, with a molecular weight of 130000 Da, which possesses alkaline phosphodiesterase I and nucleotide pyrophosphatase activity	
ecNumber	3.1.4.1	commentary	patients with neurofibromatosis: over-expression of alkaline phosphodiesterase I	
ecNumber	3.1.4.1	commentary	PC-1	
ecNumber	3.1.4.1	commentary	patients with uterine cervix neoplasia	
ecNumber	3.1.4.1	commentary		
ecNumber	3.1.4.1	commentary	gene SMPDL3A	
ecNumber	3.1.4.1	commentary		
ecNumber	3.1.4.2	commentary		
ecNumber	3.1.4.3	commentary	isozyme PLC-Cbeta	
ecNumber	3.1.4.3	commentary	isozyme PLC-beta2	
ecNumber	3.1.4.3	commentary	; two isoforms	
ecNumber	3.1.4.3	commentary	isoform PC-PLC	
ecNumber	3.1.4.3	commentary	isoforms phosphatidylcholine-specific phospholipase C, i.e. PC-PLC, and phosphatidylinositol-specific phospholipase C, i.e. PI-PLC	
ecNumber	3.1.4.3	commentary		
ecNumber	3.1.4.3	commentary		
ecNumber	3.1.4.4	commentary	isozymes PLD1, PLD2	
ecNumber	3.1.4.4	commentary	recombinant	
ecNumber	3.1.4.4	commentary	isoform PL D1	
ecNumber	3.1.4.4	commentary	N-acylethanolamine-specific phospholipase D, NAPE-PLD	
ecNumber	3.1.4.4	commentary	isoform PLD2	
ecNumber	3.1.4.4	commentary	isozymes PLD1b and PLD2a	
ecNumber	3.1.4.4	commentary	isozynmes PLD1 and PLD2	
ecNumber	3.1.4.4	commentary	isozymes PLD1 and PLD2, and two splice variants of PLD1, PLD1a and PLD1b	
ecNumber	3.1.4.4	commentary	isozymes PLD1 and PLD2	
ecNumber	3.1.4.4	commentary	isozyme PLD2	
ecNumber	3.1.4.4	commentary		
ecNumber	3.1.4.4	commentary	two splice variants, PLD1 and PLD2	
ecNumber	3.1.4.4	commentary	isoform D2	
ecNumber	3.1.4.4	commentary		
ecNumber	3.1.4.4	commentary	PLD2; isozyme PLD2alpha	
ecNumber	3.1.4.4	commentary	isozymes PLD1 and PLD2, PLD2 has three splice variants, PLD2a, 2b, and 2c	
ecNumber	3.1.4.4	commentary	PLD2; isozyme PLD2	
ecNumber	3.1.4.4	commentary	isozyme PLD1	
ecNumber	3.1.4.4	commentary	isoform PLD1	
ecNumber	3.1.4.4	commentary	PLD1; isozymes PLD1beta and PLD2alpha	
ecNumber	3.1.4.4	commentary	PLD1; isozyme PLD1	
ecNumber	3.1.4.4	commentary		
ecNumber	3.1.4.11	commentary	four PLC delta isoenzymes: PLC delta1-4	
ecNumber	3.1.4.11	commentary	PLC-epsilon	
ecNumber	3.1.4.11	commentary	PLCgamma2	
ecNumber	3.1.4.11	commentary	breast cancer patients	
ecNumber	3.1.4.11	commentary		
ecNumber	3.1.4.11	commentary	PLCgamma2	
ecNumber	3.1.4.11	commentary		
ecNumber	3.1.4.11	commentary		
ecNumber	3.1.4.11	commentary	myelodysplastic syndromes (MDS) patients	
ecNumber	3.1.4.11	commentary		
ecNumber	3.1.4.11	commentary		
ecNumber	3.1.4.11	commentary		
ecNumber	3.1.4.11	commentary	myelodysplastic syndromes (MDS) patients	
ecNumber	3.1.4.11	commentary		
ecNumber	3.1.4.11	commentary	PLCbeta1a; two isoforms of PLCbeta1, a and b; PLCbeta1b; two isoforms of PLCbeta1, a and b	
ecNumber	3.1.4.11	commentary		
ecNumber	3.1.4.11	commentary	myelodysplastic syndromes (MDS) patients	
ecNumber	3.1.4.11	commentary	PLCbeta1a and PLCbeta1b	
ecNumber	3.1.4.11	commentary		
ecNumber	3.1.4.12	commentary	acid sphingomyelinase, splicing form ASM-5; gene SMPD1	
ecNumber	3.1.4.12	commentary	acid sphingomyelinase, splicing form ASM-6; gene SMPD1	
ecNumber	3.1.4.12	commentary	acid sphingomyelinase, splicing form ASM-7; gene SMPD1	
ecNumber	3.1.4.12	commentary	controls and patients with different variants of Gaucher disease	
ecNumber	3.1.4.12	commentary	Niemann-Pick disease patients	
ecNumber	3.1.4.12	commentary	haSMase deficiency due to mutations in haSMase gene leads to Niemann-Pick disease, an autosomal recessive sphingolipidosis	
ecNumber	3.1.4.12	commentary	one form of Niemann-Pick disease is caused by a deficiency of acid sphingomyelinase	
ecNumber	3.1.4.12	commentary	; nSMase2 expression is up-regulated during cell growth	
ecNumber	3.1.4.12	commentary	patients with atopic dermatitis	
ecNumber	3.1.4.12	commentary	acid sphingomyelinase, gene SMPD-1	
ecNumber	3.1.4.12	commentary	isozymes nSMase2 and nSMase1	
ecNumber	3.1.4.12	commentary	healthy individuals and patient with chronic heart failure	
ecNumber	3.1.4.12	commentary		
ecNumber	3.1.4.12	commentary	gene SMPD1	
ecNumber	3.1.4.12	commentary		
ecNumber	3.1.4.12	commentary	nSMase1 or smpd2; nSMase1 or smpd2	
ecNumber	3.1.4.12	commentary	gene SMPD1	
ecNumber	3.1.4.12	commentary	acid sphingomyelinase, splicing forms ASM-1 to ASM-4; gene SMPD1	
ecNumber	3.1.4.12	commentary		
ecNumber	3.1.4.12	commentary	gene ENPP7; gene ENPP7	
ecNumber	3.1.4.12	commentary	gene SMPD1	
ecNumber	3.1.4.12	commentary		
ecNumber	3.1.4.12	commentary		
ecNumber	3.1.4.12	commentary	nSMase2; nSMase2	
ecNumber	3.1.4.17	commentary	isoform PDE1C	
ecNumber	3.1.4.17	commentary	PDE1; PDE11; PDE2	
ecNumber	3.1.4.17	commentary	isoforms PDE3, PDE1A	
ecNumber	3.1.4.17	commentary	splice variants A1, A2, A3, A4 of isoform PDE11	
ecNumber	3.1.4.17	commentary	isoforms PDE2A, PDE3A	
ecNumber	3.1.4.17	commentary	isoform PDE11	
ecNumber	3.1.4.17	commentary	isoform PDE1B2	
ecNumber	3.1.4.17	commentary	isoform PDE1	
ecNumber	3.1.4.17	commentary		
ecNumber	3.1.4.17	commentary	PDE2A	
ecNumber	3.1.4.17	commentary		
ecNumber	3.1.4.17	commentary	PDE1A	
ecNumber	3.1.4.17	commentary		
ecNumber	3.1.4.17	commentary	PDE1B	
ecNumber	3.1.4.17	commentary	PDE3B	
ecNumber	3.1.4.17	commentary	PDE1C	
ecNumber	3.1.4.17	commentary	PDE3A	
ecNumber	3.1.4.17	commentary	isozyme PDE11A2; isozyme PDE11A3	
ecNumber	3.1.4.17	commentary	isoform PDE11A4	
ecNumber	3.1.4.17	commentary	PDE11A	
ecNumber	3.1.4.17	commentary	isoform PDE10A1	
ecNumber	3.1.4.17	commentary	PDE10A	
ecNumber	3.1.4.35	commentary	isoenzymes PDE5A1, PDE5A2 and PDE5A3	
ecNumber	3.1.4.35	commentary	recombinant and native	
ecNumber	3.1.4.35	commentary	PDE5; PDE9	
ecNumber	3.1.4.35	commentary	recombinant PDE5A1	
ecNumber	3.1.4.35	commentary	; isoform PDE5	
ecNumber	3.1.4.35	commentary	isoforms PDE5, three splice variants: PDE5A1, PDE5A2, PDE5A3. Enzyme promoters are sensitive to cGMP or cAMP stimulation	
ecNumber	3.1.4.35	commentary	isoform PDE5	
ecNumber	3.1.4.35	commentary	isoform PDE6	
ecNumber	3.1.4.35	commentary		
ecNumber	3.1.4.35	commentary	splice variants PDE5A1 and PDE5A2	
ecNumber	3.1.4.35	commentary		
ecNumber	3.1.4.35	commentary	isoform PDE5A1	
ecNumber	3.1.4.35	commentary	isoform PDE5A	
ecNumber	3.1.4.35	commentary	PDE5A	
ecNumber	3.1.4.35	commentary	splice variants PDE9A5 and PDE9A1	
ecNumber	3.1.4.35	commentary	PDE9A	
ecNumber	3.1.4.37	commentary	overview	
ecNumber	3.1.4.37	commentary		
ecNumber	3.1.4.37	commentary	two isozymes, difference between the variants is the presence of a 20-amino-acid N-terminal mitochondrial targeting sequence in the 48-kDa isoform II, which is removed after mitochondrial import to produce a truncated 46-kDa variant that corresponds to the cytosolic isoform I of 400 amino-acids, gene CNP1	
ecNumber	3.1.4.37	commentary		
ecNumber	3.1.4.37	commentary	isoforms CNP1 and CNP2	
ecNumber	3.1.4.38	commentary		
ecNumber	3.1.4.39	commentary	isozymes ATXalpa-ATXdelta	
ecNumber	3.1.4.39	commentary		
ecNumber	3.1.4.39	commentary	gamma isoform	
ecNumber	3.1.4.39	commentary		
ecNumber	3.1.4.40	commentary		
ecNumber	3.1.4.44	commentary		
ecNumber	3.1.4.45	commentary	soluble form where transmembrane and cytoplasmic domains were replaced with the HPC4 epitope	
ecNumber	3.1.4.45	commentary	gene NAGPA, two splice forms	
ecNumber	3.1.4.45	commentary		
ecNumber	3.1.4.45	commentary		
ecNumber	3.1.4.46	commentary		
ecNumber	3.1.4.46	commentary	GDE2 (also named GDPD5)	
ecNumber	3.1.4.46	commentary		
ecNumber	3.1.4.46	commentary		
ecNumber	3.1.4.46	commentary		
ecNumber	3.1.4.50	commentary	healthy adults and patients with chronic myeloid leukemia	
ecNumber	3.1.4.50	commentary		
ecNumber	3.1.4.50	commentary	precursor	
ecNumber	3.1.4.53	commentary	PDE7A, recombinant protein, N-terminally truncated	
ecNumber	3.1.4.53	commentary	PDE4; PDE7; PDE8	
ecNumber	3.1.4.53	commentary	; isoform PDE4	
ecNumber	3.1.4.53	commentary	patients with idiopathic pulmonary arterial hypertension or secondary pulmonary hypertension	
ecNumber	3.1.4.53	commentary	isoforms PDE4D3 and PDE4D5	
ecNumber	3.1.4.53	commentary	isoform PDE4B2B; isoform PDE4C2	
ecNumber	3.1.4.53	commentary	isoform PDE4D5	
ecNumber	3.1.4.53	commentary	isoform PDE4D2	
ecNumber	3.1.4.53	commentary	isoform PDE4	
ecNumber	3.1.4.53	commentary		
ecNumber	3.1.4.53	commentary		
ecNumber	3.1.4.53	commentary	PDE8A	
ecNumber	3.1.4.53	commentary		
ecNumber	3.1.4.53	commentary	PDE8B	
ecNumber	3.1.4.53	commentary	isoform PDE4A10	
ecNumber	3.1.4.53	commentary	; isoform PDE4A8	
ecNumber	3.1.4.53	commentary		
ecNumber	3.1.4.53	commentary	PDE4A	
ecNumber	3.1.4.53	commentary	isoform PDE4B5, variant of PDE4B with a different 5'-terminus	
ecNumber	3.1.4.53	commentary	PDE4B	
ecNumber	3.1.4.53	commentary		
ecNumber	3.1.4.53	commentary		
ecNumber	3.1.4.53	commentary	PDE4C	
ecNumber	3.1.4.53	commentary	isoform PDE4D2	
ecNumber	3.1.4.53	commentary	PDE4D	
ecNumber	3.1.4.53	commentary		
ecNumber	3.1.4.53	commentary	PDE7A; PDE7A2	
ecNumber	3.1.4.53	commentary	PDE7A	
ecNumber	3.1.4.53	commentary		
ecNumber	3.1.4.53	commentary		
ecNumber	3.1.4.53	commentary	PDE7B	
ecNumber	3.1.4.54	commentary		
ecNumber	3.1.4.54	commentary		
ecNumber	3.1.4.58	commentary		
ecNumber	3.1.5.B1	commentary		
ecNumber	3.1.5.B1	commentary		
ecNumber	3.1.6.1	commentary	patients with cerebral palsy	
ecNumber	3.1.6.1	commentary	women at 41 and 42 weeks of gestation	
ecNumber	3.1.6.1	commentary		
ecNumber	3.1.6.1	commentary		
ecNumber	3.1.6.1	commentary		
ecNumber	3.1.6.1	commentary		
ecNumber	3.1.6.2	commentary	2 forms of arylsulfatase C: slow form, fast form, only slow form is associated with sterol sulfatase activity; fast form in patients with X-linked ichthyosis	
ecNumber	3.1.6.2	commentary	women	
ecNumber	3.1.6.2	commentary	patients with endometrial carcinoma	
ecNumber	3.1.6.2	commentary	patients with endometriosis	
ecNumber	3.1.6.2	commentary	expression in COS-1 cell	
ecNumber	3.1.6.2	commentary	native enzyme and recombinant enzyme from CHO cells	
ecNumber	3.1.6.2	commentary	recombinant enzyme	
ecNumber	3.1.6.2	commentary	enzyme does not copurify with oestrone sulfate sulfohydrolase	
ecNumber	3.1.6.2	commentary	patients with estrogen-receptor positive metastatic breast cancer	
ecNumber	3.1.6.2	commentary	colon carcinoma cells	
ecNumber	3.1.6.2	commentary		
ecNumber	3.1.6.2	commentary		
ecNumber	3.1.6.4	commentary	patients with mucopolysaccharidosis IVA	
ecNumber	3.1.6.4	commentary	six tunisian individuals from four families	
ecNumber	3.1.6.4	commentary		
ecNumber	3.1.6.4	commentary	precursor	
ecNumber	3.1.6.4	commentary		
ecNumber	3.1.6.8	commentary	81 woman, including 28 healthy woman, 29 woman with benign breast disease and 24 patients with primary breast cancer	
ecNumber	3.1.6.8	commentary	plasmid encoding human arylsulfatase A was expressed in arylsulfatase A-deficient mice, HEK-293 cells, HeLa cells and COS-7 cells	
ecNumber	3.1.6.8	commentary	females with breast cancer	
ecNumber	3.1.6.8	commentary		
ecNumber	3.1.6.8	commentary		
ecNumber	3.1.6.12	commentary	mutant enzyme Y210C detected in 10% of the patients with mucopolysaccharidosis type VI	
ecNumber	3.1.6.12	commentary		
ecNumber	3.1.6.12	commentary	; precursor	
ecNumber	3.1.6.12	commentary		
ecNumber	3.1.6.12	commentary		
ecNumber	3.1.6.13	commentary	2 forms: A, B	
ecNumber	3.1.6.13	commentary	several molecular species	
ecNumber	3.1.6.13	commentary	multiple forms: A, B, C	
ecNumber	3.1.6.13	commentary	almost total absence of iduronate-2-sulfatase in patients with mucopolysaccharidosis type II compared with control	
ecNumber	3.1.6.13	commentary	Taiwanese patients with mucopolysaccharidosis type II	
ecNumber	3.1.6.13	commentary	patients with mucopolysaccharidosis type II	
ecNumber	3.1.6.13	commentary	Portuguese patients with mucopolysaccharidosis type II	
ecNumber	3.1.6.13	commentary	patients with mucopolysaccharidosis type II, i.e. Hunter disease	
ecNumber	3.1.6.13	commentary	patients with mucopolysaccharidosis II	
ecNumber	3.1.6.13	commentary		
ecNumber	3.1.6.13	commentary		
ecNumber	3.1.6.14	commentary	2 major forms: A, B , 2 minor form: C and D	
ecNumber	3.1.6.14	commentary	patient with a single base pair deletion which causes a frameshift and premature termination of the protein	
ecNumber	3.1.6.14	commentary		
ecNumber	3.1.6.14	commentary	precursor	
ecNumber	3.1.6.15	commentary		
ecNumber	3.1.6.18	commentary		
ecNumber	3.1.7.2	commentary		
ecNumber	3.1.8.1	commentary	; isoform PON1	
ecNumber	3.1.8.1	commentary	PON1 expressed in CHO cells	
ecNumber	3.1.8.1	commentary	isozyme PON2; paraoxonase PON2	
ecNumber	3.1.8.1	commentary	PON L or M form expressed in CHO cells	
ecNumber	3.1.8.1	commentary	PON1 type Q	
ecNumber	3.1.8.1	commentary	polymorphism of enzyme	
ecNumber	3.1.8.1	commentary	gene PON1, two naturally occuring allelic variant isozymes L55R192 PON1 and L55Q192 PON1	
ecNumber	3.1.8.1	commentary	; isoform hPON1	
ecNumber	3.1.8.1	commentary	isozymes PON1-PON3	
ecNumber	3.1.8.1	commentary	isoform PON1	
ecNumber	3.1.8.1	commentary	children with autism, isoform PON1	
ecNumber	3.1.8.1	commentary	individuals of both sexes and different age, overview	
ecNumber	3.1.8.1	commentary	hyperlipoproteinemia type IIa and IIb patients	
ecNumber	3.1.8.1	commentary	healthy and Helicobacter pylori infected individuals	
ecNumber	3.1.8.1	commentary		
ecNumber	3.1.8.1	commentary	variant Q192 and R192	
ecNumber	3.1.8.1	commentary	isozymes PON1-3	
ecNumber	3.1.8.1	commentary	chronic hepatitis patients and control subjects	
ecNumber	3.1.8.1	commentary		
ecNumber	3.1.8.1	commentary		
ecNumber	3.1.8.1	commentary		
ecNumber	3.1.8.2	commentary	bifunctional enzyme exhibiting additionally prolidase activity, E.C. 3.4.13.9	
ecNumber	3.1.8.2	commentary		
ecNumber	3.1.11.1	commentary	several enzyme forms in the cell	
ecNumber	3.1.11.1	commentary		
ecNumber	3.1.11.1	commentary		
ecNumber	3.1.11.2	commentary		
ecNumber	3.1.11.7	commentary		
ecNumber	3.1.11.7	commentary		
ecNumber	3.1.11.8	commentary		
ecNumber	3.1.11.8	commentary		
ecNumber	3.1.13.1	commentary	human ERI-1, orthologue to Caenorhabditis elegans ERI-1	
ecNumber	3.1.13.1	commentary		
ecNumber	3.1.13.2	commentary		
ecNumber	3.1.13.3	commentary		
ecNumber	3.1.13.3	commentary		
ecNumber	3.1.13.4	commentary	gene PARN	
ecNumber	3.1.13.4	commentary		
ecNumber	3.1.13.4	commentary		
ecNumber	3.1.13.4	commentary	catalytic subunit hPAN2, regulatory subunit hPAN3: Q76E13; catalytic subunit hPAN2, regulatory subunit hPAN3	
ecNumber	3.1.13.4	commentary		
ecNumber	3.1.16.1	commentary		
ecNumber	3.1.21.1	commentary	dornase alpha, recombinant enzyme	
ecNumber	3.1.21.1	commentary	Japanese population	
ecNumber	3.1.21.1	commentary		
ecNumber	3.1.21.1	commentary	different enzyme types of the human DNase I family: DNase I, DNase X, DNase lambda, and DNASIL2	
ecNumber	3.1.21.1	commentary		
ecNumber	3.1.21.7	commentary	HeLa cells	
ecNumber	3.1.21.7	commentary		
ecNumber	3.1.22.1	commentary	polymorphisms associated with risk of renal disorder among systemic lupus erythematosus patients	
ecNumber	3.1.22.1	commentary	isoform DNase IIalpha	
ecNumber	3.1.22.1	commentary		
ecNumber	3.1.22.1	commentary	extensive database search to find sequence homology, which may allow a better analysis of critical residues	
ecNumber	3.1.22.1	commentary		
ecNumber	3.1.22.1	commentary	enzyme activity is reported in all of the human cell lines examined	
ecNumber	3.1.22.1	commentary		
ecNumber	3.1.22.4	commentary		
ecNumber	3.1.25.1	commentary		
ecNumber	3.1.26.3	commentary	Dicer, a class III RNase III containing an N-terminal ATP-dependent RNA helicase domain, a PAZ motif, and 2 C-terminal endonuclease domains followed by a single dsRNA binding domain	
ecNumber	3.1.26.3	commentary	class 2 RNase III enzyme	
ecNumber	3.1.26.3	commentary		
ecNumber	3.1.26.3	commentary		
ecNumber	3.1.26.3	commentary		
ecNumber	3.1.26.4	commentary	type 1 and type 2 enzymes	
ecNumber	3.1.26.4	commentary	type 2 enzyme	
ecNumber	3.1.26.4	commentary	type 1 enzyme	
ecNumber	3.1.26.4	commentary	RNase H1 is a type 2 enzyme	
ecNumber	3.1.26.4	commentary	isoform RNase H2	
ecNumber	3.1.26.4	commentary		
ecNumber	3.1.26.4	commentary		
ecNumber	3.1.26.4	commentary	subunit H2B; isoform RNase H2	
ecNumber	3.1.26.4	commentary	subunit H2C; isoform RNase H2	
ecNumber	3.1.26.5	commentary		
ecNumber	3.1.26.10	commentary	human	
ecNumber	3.1.26.11	commentary	distribution of short and long forms of tRNase Z reviewed	
ecNumber	3.1.26.11	commentary	tRNase Z and other members of the metallo-beta-lactamase family reviewed	
ecNumber	3.1.26.11	commentary	tRNase Z, overview	
ecNumber	3.1.26.11	commentary	genes ELAC1 and ELAC2, two isozymes	
ecNumber	3.1.26.11	commentary	gene ELAC2	
ecNumber	3.1.26.11	commentary		
ecNumber	3.1.26.11	commentary		
ecNumber	3.1.26.11	commentary		
ecNumber	3.1.27.1	commentary	gene RNASET2	
ecNumber	3.1.27.1	commentary		
ecNumber	3.1.27.1	commentary		
ecNumber	3.1.27.1	commentary		
ecNumber	3.1.27.5	commentary	; isozymes RNases 1, 2, 3, 4, and 5	
ecNumber	3.1.27.5	commentary		
ecNumber	3.1.27.5	commentary	; comparison of pancreatic ribonuclease and ribonuclease A	
ecNumber	3.1.27.5	commentary		
ecNumber	3.1.27.8	commentary		
ecNumber	3.1.30.1	commentary		
ecNumber	3.1.30.2	commentary		
ecNumber	3.1.31.1	commentary		
ecNumber	3.1.31.1	commentary		
ecNumber	3.1.99.B1	commentary		
ecNumber	3.2.1.1	commentary		
ecNumber	3.2.1.1	commentary	AMY1A; isozyme AMY1A	
ecNumber	3.2.1.1	commentary		
ecNumber	3.2.1.1	commentary		
ecNumber	3.2.1.3	commentary		
ecNumber	3.2.1.3	commentary		
ecNumber	3.2.1.10	commentary		
ecNumber	3.2.1.10	commentary	GH31 module subject to phylogenetic analysis	
ecNumber	3.2.1.10	commentary		
ecNumber	3.2.1.14	commentary		
ecNumber	3.2.1.14	commentary	precursor; gene CHIA	
ecNumber	3.2.1.14	commentary		
ecNumber	3.2.1.17	commentary	gene expression in: Saccharomyces cerevisiae	
ecNumber	3.2.1.17	commentary	expression of recombinant Ca2+-binding lysozyme in Aspergillus niger	
ecNumber	3.2.1.17	commentary	gene hlyz	
ecNumber	3.2.1.17	commentary		
ecNumber	3.2.1.17	commentary		
ecNumber	3.2.1.17	commentary		
ecNumber	3.2.1.18	commentary	3 isozymes Neu-1, Neu-2, and Neu-3	
ecNumber	3.2.1.18	commentary	gene neu-1	
ecNumber	3.2.1.18	commentary	isoform Neu3	
ecNumber	3.2.1.18	commentary	acute ill patients with and without sepsis	
ecNumber	3.2.1.18	commentary	isozyme NEU3	
ecNumber	3.2.1.18	commentary	isozyme NEU2	
ecNumber	3.2.1.18	commentary		
ecNumber	3.2.1.18	commentary		
ecNumber	3.2.1.18	commentary	isoform Neu1	
ecNumber	3.2.1.18	commentary		
ecNumber	3.2.1.18	commentary		
ecNumber	3.2.1.18	commentary		
ecNumber	3.2.1.20	commentary	alpha-glucosidase AB and alpha-glucosidase C	
ecNumber	3.2.1.20	commentary	patients with infantile Pompe disease	
ecNumber	3.2.1.20	commentary		
ecNumber	3.2.1.20	commentary		
ecNumber	3.2.1.20	commentary		
ecNumber	3.2.1.21	commentary	healthy humans and Gaucher's disease patients	
ecNumber	3.2.1.21	commentary		
ecNumber	3.2.1.21	commentary		
ecNumber	3.2.1.22	commentary	male patients with Fabry disease	
ecNumber	3.2.1.22	commentary	patients with sporadic Parkinson's disease	
ecNumber	3.2.1.22	commentary	patients with Fabry disease	
ecNumber	3.2.1.22	commentary		
ecNumber	3.2.1.22	commentary		
ecNumber	3.2.1.23	commentary	patients with GM1 gangliosidosis	
ecNumber	3.2.1.23	commentary		
ecNumber	3.2.1.24	commentary	2 isoforms, alpha-mannosidase A, B	
ecNumber	3.2.1.24	commentary	2 isoforms of neutral alpha-mannosidase	
ecNumber	3.2.1.24	commentary		
ecNumber	3.2.1.24	commentary	MA2B1_HUMAN	
ecNumber	3.2.1.24	commentary		
ecNumber	3.2.1.24	commentary		
ecNumber	3.2.1.25	commentary		
ecNumber	3.2.1.25	commentary		
ecNumber	3.2.1.25	commentary	patient with beta-mannosodosis, an inborn lysosomal storage disorder	
ecNumber	3.2.1.28	commentary		
ecNumber	3.2.1.28	commentary		
ecNumber	3.2.1.31	commentary	male adults	
ecNumber	3.2.1.31	commentary		
ecNumber	3.2.1.33	commentary		
ecNumber	3.2.1.33	commentary	patients with type I and type III glycogen storage disease and control patient	
ecNumber	3.2.1.33	commentary	healthy and patient with type III glycogen storage disease	
ecNumber	3.2.1.33	commentary	patients with Glycogen Storage Disease Type III. Bifunctional amylo-1,6-glucosidase and 4-alpha-glucanotransferase, protein possesses two separate domains for the transferase and glucosidase activities	
ecNumber	3.2.1.35	commentary	wild-type isozyme HYAL1	
ecNumber	3.2.1.35	commentary	isozymes Hyal1-Hyal4, and HPH-20, or SPAM1	
ecNumber	3.2.1.35	commentary		
ecNumber	3.2.1.35	commentary	isozyme splice variant HYAL3v1; isozyme splice variant HYAL3v2; isozyme splice variant HYAL3v3; wild-type isozyme HYAL3wt	
ecNumber	3.2.1.35	commentary	; expression in human bronchial epithelial cell (HBE)	
ecNumber	3.2.1.35	commentary		
ecNumber	3.2.1.35	commentary	gene mgea5, bifunctional enzyme possessing hyaluronidase and beta-N-acetylglucoaminidase activities	
ecNumber	3.2.1.35	commentary	isozyme splice variant HYAL1v1; isozyme splice variant HYAL1v2; isozyme splice variant HYAL1v3; isozyme splice variant HYAL1v4; isozyme splice variant HYAL1v5	
ecNumber	3.2.1.35	commentary	hyaluronidase-1 precursor	
ecNumber	3.2.1.35	commentary	; expression in human bronchial epithelial cell (HBE)	
ecNumber	3.2.1.35	commentary	HYAL1 gene of the the LUCA region	
ecNumber	3.2.1.35	commentary		
ecNumber	3.2.1.35	commentary	; expression in human bronchial epithelial cell (HBE)	
ecNumber	3.2.1.35	commentary	HYAL2 gene of the the LUCA region	
ecNumber	3.2.1.35	commentary		
ecNumber	3.2.1.35	commentary		
ecNumber	3.2.1.45	commentary	methods of enzyme determination; overview	
ecNumber	3.2.1.45	commentary	overview	
ecNumber	3.2.1.45	commentary	normal and Gaucher disease enzyme	
ecNumber	3.2.1.45	commentary	patients with Gaucher disease	
ecNumber	3.2.1.45	commentary	Gaucher patients	
ecNumber	3.2.1.45	commentary	Gaucher disease-associated glucocerebroside variants N370S and G202R	
ecNumber	3.2.1.45	commentary	patients with Psoriasis vulgaris	
ecNumber	3.2.1.45	commentary	patients with Parkinson's disease and patients with demetia with Lewis bodies	
ecNumber	3.2.1.45	commentary	Turkish patients with Gaucher disease	
ecNumber	3.2.1.45	commentary	children with chronic neuronopathic Gaucher disease	
ecNumber	3.2.1.45	commentary		
ecNumber	3.2.1.45	commentary	normal and Gaucher disease enzyme	
ecNumber	3.2.1.45	commentary		
ecNumber	3.2.1.45	commentary		
ecNumber	3.2.1.46	commentary	mutant enzyme /Krabbe disease; normal enzyme	
ecNumber	3.2.1.46	commentary	Lesch-Nyhan cells	
ecNumber	3.2.1.46	commentary	mutant enzyme /Krabbe disease	
ecNumber	3.2.1.46	commentary		
ecNumber	3.2.1.47	commentary	2 forms, non-interconvertible: form A-1, form A-2	
ecNumber	3.2.1.47	commentary	multiple forms: A, B	
ecNumber	3.2.1.47	commentary		
ecNumber	3.2.1.48	commentary	human, sucrase/isomaltase molecule is an hybrid consisting of 2 distinct alpha-glucosidases	
ecNumber	3.2.1.48	commentary	sucrase-isomaltase in adult human colon and colonic polyps	
ecNumber	3.2.1.48	commentary	bifunctional sucrase-isomaltase from patients with congenital sucrase-isomaltase deficiency	
ecNumber	3.2.1.48	commentary		
ecNumber	3.2.1.48	commentary		
ecNumber	3.2.1.48	commentary	cf. EC 3.2.1.10	
ecNumber	3.2.1.49	commentary		
ecNumber	3.2.1.49	commentary		
ecNumber	3.2.1.50	commentary		
ecNumber	3.2.1.50	commentary		
ecNumber	3.2.1.51	commentary		
ecNumber	3.2.1.51	commentary	isoform FucA2	
ecNumber	3.2.1.51	commentary	tissue alpha-L-fucosidase precursor	
ecNumber	3.2.1.51	commentary	precursor; comparative and phylogenetic analysis of alpha-L-fucosidase genes	
ecNumber	3.2.1.51	commentary		
ecNumber	3.2.1.51	commentary	precursor; comparative and phylogenetic analysis of alpha-L-fucosidase genes	
ecNumber	3.2.1.52	commentary	healthy persons and mucolipidosis patients	
ecNumber	3.2.1.52	commentary	patient with Sandhoffs disease	
ecNumber	3.2.1.52	commentary	patient with GM2-gangliosidosis B1 variant	
ecNumber	3.2.1.52	commentary	patients with GM2-gangliosidosis B1 variant from the north of Portugal	
ecNumber	3.2.1.52	commentary	patients with Tay-Sachs-disease	
ecNumber	3.2.1.52	commentary	newborns	
ecNumber	3.2.1.52	commentary	patients with I-cell disease and healthy persons	
ecNumber	3.2.1.52	commentary	pregnant women	
ecNumber	3.2.1.52	commentary	inhibition assay of human beta-N-acetyglucosaminidase by an analogue of 6-epi-valienamine	
ecNumber	3.2.1.52	commentary		
ecNumber	3.2.1.52	commentary	isozyme Hex B	
ecNumber	3.2.1.52	commentary		
ecNumber	3.2.1.53	commentary		
ecNumber	3.2.1.62	commentary		
ecNumber	3.2.1.68	commentary		
ecNumber	3.2.1.76	commentary	gene IDUA	
ecNumber	3.2.1.76	commentary		
ecNumber	3.2.1.76	commentary	precursor	
ecNumber	3.2.1.76	commentary		
ecNumber	3.2.1.84	commentary	two isoforms derived by alternative spicing, isofoms 2 contains a 22 amino acid insert	
ecNumber	3.2.1.84	commentary		
ecNumber	3.2.1.84	commentary	; beta subunit	
ecNumber	3.2.1.84	commentary		
ecNumber	3.2.1.84	commentary	; alpha1 isofrom of the alpha subunit, isoforms are formed by alternative splicing; alpha2 isoform of the alpha subunit, contains a 66 bp insert, isoforms are formed by alternative splicing	
ecNumber	3.2.1.96	commentary		
ecNumber	3.2.1.96	commentary		
ecNumber	3.2.1.103	commentary		
ecNumber	3.2.1.106	commentary		
ecNumber	3.2.1.108	commentary		
ecNumber	3.2.1.108	commentary		
ecNumber	3.2.1.113	commentary	expression in Escherichia coli	
ecNumber	3.2.1.113	commentary		
ecNumber	3.2.1.113	commentary		
ecNumber	3.2.1.113	commentary		
ecNumber	3.2.1.113	commentary	recombinant	
ecNumber	3.2.1.113	commentary		
ecNumber	3.2.1.114	commentary	alpha-mannosidase II and IIx	
ecNumber	3.2.1.114	commentary		
ecNumber	3.2.1.117	commentary		
ecNumber	3.2.1.118	commentary		
ecNumber	3.2.1.127	commentary		
ecNumber	3.2.1.130	commentary		
ecNumber	3.2.1.130	commentary		
ecNumber	3.2.1.143	commentary	recombinant protein with GFP- or Myc-tag, subcellular distribution of enzmye changes dramatically during cell cycle	
ecNumber	3.2.1.143	commentary	identification of enzyme-interacting proteins by mass spectometric analysis of enzyme pulled down proteins	
ecNumber	3.2.1.143	commentary	; GFP fusion protein	
ecNumber	3.2.1.143	commentary	splicing variants hPARG60 and hPARG55. HPARG55 is expressed through alternative translation initiation from hPARG60 transcripts	
ecNumber	3.2.1.143	commentary	isoform ARH3	
ecNumber	3.2.1.143	commentary	human cervical carcinoma cells HeLa-S3	
ecNumber	3.2.1.143	commentary	isoform PARG59	
ecNumber	3.2.1.143	commentary		
ecNumber	3.2.1.143	commentary		
ecNumber	3.2.1.143	commentary	two splice variants of enzyme mRNA leading to isoforms of 102 kDa, hPARG102, and of 99 kDA, hPARG99, in addition to full-length protein hPARG111	
ecNumber	3.2.1.143	commentary		
ecNumber	3.2.1.143	commentary		
ecNumber	3.2.1.147	commentary		
ecNumber	3.2.1.163	commentary	core-specific alpha1,6-mannosidase	
ecNumber	3.2.1.163	commentary		
ecNumber	3.2.1.166	commentary	single gene	
ecNumber	3.2.1.166	commentary		
ecNumber	3.2.1.166	commentary	recombinant	
ecNumber	3.2.1.166	commentary		
ecNumber	3.2.1.169	commentary		
ecNumber	3.2.1.169	commentary		
ecNumber	3.2.1.183	commentary		
ecNumber	3.2.1.183	commentary	eight isoforms, hGNE1-hGNE8	
ecNumber	3.2.2.1	commentary		
ecNumber	3.2.2.3	commentary		
ecNumber	3.2.2.5	commentary	the extracellular domain of the leukocyte single transmembrane cell surface antigen CD38 shows NADase activity	
ecNumber	3.2.2.5	commentary	isoform CD38	
ecNumber	3.2.2.5	commentary		
ecNumber	3.2.2.5	commentary	isoform CD38	
ecNumber	3.2.2.5	commentary		
ecNumber	3.2.2.6	commentary		
ecNumber	3.2.2.6	commentary		
ecNumber	3.2.2.10	commentary		
ecNumber	3.2.2.11	commentary	human	
ecNumber	3.2.2.15	commentary	human, normal and progeroid cells	
ecNumber	3.2.2.15	commentary	HeLa cells	
ecNumber	3.2.2.16	commentary	human	
ecNumber	3.2.2.19	commentary		
ecNumber	3.2.2.19	commentary	hARH1	
ecNumber	3.2.2.20	commentary	human, U2-osteosarcoma, MCF-7	
ecNumber	3.2.2.20	commentary		
ecNumber	3.2.2.21	commentary	human	
ecNumber	3.2.2.21	commentary	human; MDA-MB231	
ecNumber	3.2.2.21	commentary		
ecNumber	3.2.2.21	commentary		
ecNumber	3.2.2.23	commentary	isoform hOGG1	
ecNumber	3.2.2.23	commentary	isoform Ogg1	
ecNumber	3.2.2.23	commentary	isoform Ogg1, patients with gastric cancer	
ecNumber	3.2.2.23	commentary	children with Down's syndrome	
ecNumber	3.2.2.23	commentary	white-collar active smokers and passive smokers at workplace	
ecNumber	3.2.2.23	commentary		
ecNumber	3.2.2.23	commentary		
ecNumber	3.2.2.23	commentary	human nei homolog NEH2	
ecNumber	3.2.2.23	commentary	human nei homolog NEH1	
ecNumber	3.2.2.27	commentary	mitochondrial UNG1 and nuclear UNG2 are both encoded by the UNG gene	
ecNumber	3.2.2.27	commentary		
ecNumber	3.2.2.27	commentary		
ecNumber	3.2.2.27	commentary		
ecNumber	3.2.2.27	commentary	UNG2	
ecNumber	3.2.2.27	commentary	SMUG1	
ecNumber	3.2.2.27	commentary		
ecNumber	3.2.2.29	commentary		
ecNumber	3.2.2.29	commentary	recombinant	
ecNumber	3.2.2.29	commentary		
ecNumber	3.3.1.1	commentary	polymorphism has no effect on the total plasma homocysteine	
ecNumber	3.3.1.1	commentary	recombinant	
ecNumber	3.3.1.1	commentary		
ecNumber	3.3.1.1	commentary	recombinant enzyme	
ecNumber	3.3.1.1	commentary		
ecNumber	3.3.2.1	commentary		
ecNumber	3.3.2.6	commentary	recombinant	
ecNumber	3.3.2.6	commentary	the enzyme is encoded in the lta4h locus	
ecNumber	3.3.2.6	commentary		
ecNumber	3.3.2.6	commentary		
ecNumber	3.3.2.9	commentary	healthy humans and patients with Alzheimer's disease	
ecNumber	3.3.2.9	commentary	female and male at different ages	
ecNumber	3.3.2.9	commentary	isoform EPHX1, patients with a first acute non-fatal myocardial infarction	
ecNumber	3.3.2.9	commentary	patients with prostate cancer	
ecNumber	3.3.2.9	commentary	male Turkish population	
ecNumber	3.3.2.9	commentary	isoform EPHX1, children with asthma	
ecNumber	3.3.2.9	commentary	patients with epilepsy	
ecNumber	3.3.2.9	commentary	Indian hepatocellular carcinoma patients	
ecNumber	3.3.2.9	commentary	Danish population	
ecNumber	3.3.2.9	commentary	gene EPHX1	
ecNumber	3.3.2.9	commentary		
ecNumber	3.3.2.9	commentary	mEH is single gene-encoded	
ecNumber	3.3.2.9	commentary	non-small cell lung cancer patients	
ecNumber	3.3.2.9	commentary		
ecNumber	3.3.2.10	commentary	; gene EPXH2	
ecNumber	3.3.2.10	commentary	gene EPHX2	
ecNumber	3.3.2.10	commentary	bifunctional epoxide hydrolase/phosphatase	
ecNumber	3.3.2.10	commentary		
ecNumber	3.3.2.10	commentary	gene EPHX2	
ecNumber	3.3.2.10	commentary		
ecNumber	3.3.2.11	commentary		
ecNumber	3.4.11.1	commentary	isozyme ERAP1; isozyme ERAP2	
ecNumber	3.4.11.1	commentary	patients with duodenal ulcer	
ecNumber	3.4.11.1	commentary		
ecNumber	3.4.11.1	commentary	two isozyme ERAP2	
ecNumber	3.4.11.1	commentary		
ecNumber	3.4.11.1	commentary		
ecNumber	3.4.11.2	commentary	alcohol-dependent patients	
ecNumber	3.4.11.2	commentary	leukemic patient	
ecNumber	3.4.11.2	commentary	isoform CD13, expression in patients with non-small cell lung cancer	
ecNumber	3.4.11.2	commentary	isoform CD13	
ecNumber	3.4.11.2	commentary	isoform CD13, patients allergic to grass pollen, birch pollen, or house dust mites	
ecNumber	3.4.11.2	commentary		
ecNumber	3.4.11.2	commentary		
ecNumber	3.4.11.3	commentary	2 isoenzymes: SP I, SP II	
ecNumber	3.4.11.3	commentary	2 forms: I, II	
ecNumber	3.4.11.3	commentary	produced during pregnancy	
ecNumber	3.4.11.3	commentary	two forms CAP-I and CAP-II	
ecNumber	3.4.11.3	commentary	patients with Parkinson's disease	
ecNumber	3.4.11.3	commentary	isoform IRAP is identical to angiotensin IV receptor	
ecNumber	3.4.11.3	commentary		
ecNumber	3.4.11.3	commentary		
ecNumber	3.4.11.4	commentary		
ecNumber	3.4.11.5	commentary		
ecNumber	3.4.11.6	commentary	gene rnpep	
ecNumber	3.4.11.6	commentary		
ecNumber	3.4.11.6	commentary		
ecNumber	3.4.11.7	commentary		
ecNumber	3.4.11.9	commentary		
ecNumber	3.4.11.9	commentary		
ecNumber	3.4.11.9	commentary		
ecNumber	3.4.11.14	commentary	heroin addicts	
ecNumber	3.4.11.14	commentary		
ecNumber	3.4.11.16	commentary		
ecNumber	3.4.11.18	commentary	methionine aminopeptidase type 2	
ecNumber	3.4.11.18	commentary	type I enzyme, expressed in Escherichia coli	
ecNumber	3.4.11.18	commentary	MetAP1 isoform	
ecNumber	3.4.11.18	commentary	enzyme type II, patients with human colorectal adenocarcinomas	
ecNumber	3.4.11.18	commentary	patient with high-risk neuroblastoma	
ecNumber	3.4.11.18	commentary	type I isoform	
ecNumber	3.4.11.18	commentary	type I and type II enzyme	
ecNumber	3.4.11.18	commentary	isoform &micro;etAP2	
ecNumber	3.4.11.18	commentary	; colon cancer cell lines and patiens with colon tumors	
ecNumber	3.4.11.18	commentary	patients with rheumatoid arthritis	
ecNumber	3.4.11.18	commentary		
ecNumber	3.4.11.18	commentary	type II enzyme, Mn(II)-form	
ecNumber	3.4.11.18	commentary		
ecNumber	3.4.11.18	commentary	MetAP2	
ecNumber	3.4.11.18	commentary	isoform MetAP2	
ecNumber	3.4.11.18	commentary	MetAP1	
ecNumber	3.4.11.18	commentary		
ecNumber	3.4.11.18	commentary	mitochondrial precursor	
ecNumber	3.4.11.21	commentary		
ecNumber	3.4.11.21	commentary		
ecNumber	3.4.11.22	commentary		
ecNumber	3.4.11.22	commentary		
ecNumber	3.4.13.9	commentary	comparison of normal human and a patient with prolidase deficiency	
ecNumber	3.4.13.9	commentary	expression in Saccharomyces cerevisiae	
ecNumber	3.4.13.9	commentary	patients with postmenopausal osteoporosis	
ecNumber	3.4.13.9	commentary	expression in Saccharomyces cerevisiae, bifunctional enzyme with both dipeptidase and organophosphorus acid anhydrolase activity	
ecNumber	3.4.13.9	commentary	comparison of isoforms prolidase I and prolidase II and isoform from patient with enzyme deficiency	
ecNumber	3.4.13.9	commentary	patient with enzyme deficiency	
ecNumber	3.4.13.9	commentary	patients with enzyme deficiency	
ecNumber	3.4.13.9	commentary	regulation of enzyme activity and collagen biosynthesis may involve beta1-integrin-dependent signaling	
ecNumber	3.4.13.9	commentary	; gene PEPD	
ecNumber	3.4.13.9	commentary	healthy individuals and patients with pleural tuberculosis	
ecNumber	3.4.13.9	commentary	; patients with non-alcoholic steatohepatitis	
ecNumber	3.4.13.9	commentary	patients with thalassemia major	
ecNumber	3.4.13.9	commentary	healthy pregnant women and pregnant women with intrauterine growth restricted infants	
ecNumber	3.4.13.9	commentary		
ecNumber	3.4.13.9	commentary		
ecNumber	3.4.13.18	commentary		
ecNumber	3.4.13.18	commentary		
ecNumber	3.4.13.19	commentary	prolinase and non-specific dipeptidase in human kidney are due to a single enzyme	
ecNumber	3.4.13.19	commentary		
ecNumber	3.4.13.19	commentary		
ecNumber	3.4.13.20	commentary	little or no activity in children below 10 months in age thereafter, the average concentration increases gradually to reach the adult range at the age 13-15	
ecNumber	3.4.13.20	commentary	enzyme activities in patients with idiopathic epilepsy and motor neurone disease are similar to the control group. Reduced serum carnosinase activity is observed in patients with multiple sclerosis and patients following a cerebrovascular accident	
ecNumber	3.4.13.20	commentary	diabetic patients with the CDDP1 Mannheim variant are less susceptible for nephropathy	
ecNumber	3.4.13.20	commentary	patients with Alzheimer's disease and with mixed dementia	
ecNumber	3.4.13.20	commentary	; isoform CDNP1	
ecNumber	3.4.13.20	commentary		
ecNumber	3.4.13.20	commentary		
ecNumber	3.4.14.1	commentary	recombinant	
ecNumber	3.4.14.1	commentary		
ecNumber	3.4.14.1	commentary		
ecNumber	3.4.14.2	commentary	patients with Sjorgren's syndrome and healthy subjects	
ecNumber	3.4.14.2	commentary		
ecNumber	3.4.14.2	commentary		
ecNumber	3.4.14.4	commentary		
ecNumber	3.4.14.4	commentary		
ecNumber	3.4.14.5	commentary	recombinant wild-type enzyme	
ecNumber	3.4.14.5	commentary	patients with type 2 diabetes mellitus	
ecNumber	3.4.14.5	commentary	recombinant	
ecNumber	3.4.14.5	commentary	patients with type 2 diabetes	
ecNumber	3.4.14.5	commentary		
ecNumber	3.4.14.5	commentary	T-cell enzyme	
ecNumber	3.4.14.5	commentary	multifunctional enzyme	
ecNumber	3.4.14.5	commentary	recombinant	
ecNumber	3.4.14.5	commentary	recombinant enzyme	
ecNumber	3.4.14.5	commentary		
ecNumber	3.4.14.6	commentary		
ecNumber	3.4.14.9	commentary		
ecNumber	3.4.14.9	commentary	precursor	
ecNumber	3.4.14.9	commentary		
ecNumber	3.4.14.10	commentary		
ecNumber	3.4.14.10	commentary		
ecNumber	3.4.15.1	commentary	recombinant	
ecNumber	3.4.15.1	commentary	patients with congestive heart failure	
ecNumber	3.4.15.1	commentary	individual biomechanical muscle properties correlate with ACE I/D gene polymorphism	
ecNumber	3.4.15.1	commentary	patients taking angiotensin-converting enzyme inhibitor therapy	
ecNumber	3.4.15.1	commentary	children and young people with IgA nephropathy and moderate proteinuria	
ecNumber	3.4.15.1	commentary	hypertensive patients of African ancestry	
ecNumber	3.4.15.1	commentary	patients with heart failure	
ecNumber	3.4.15.1	commentary	Saudi population from Qassim region	
ecNumber	3.4.15.1	commentary	somatic and germinal isozymes, sACE and gACE	
ecNumber	3.4.15.1	commentary	somatic ACE isozyme	
ecNumber	3.4.15.1	commentary	4842 adult renal transplantation patients from Spain of different operation years	
ecNumber	3.4.15.1	commentary	wild-type enzyme and mutants in which one active site has been inactivated by site-directed mutagenesis	
ecNumber	3.4.15.1	commentary		
ecNumber	3.4.15.1	commentary	testis-specific isoform precursor	
ecNumber	3.4.15.1	commentary	recombinant ACE construct tACEDELTA36NJ	
ecNumber	3.4.15.1	commentary	precursor	
ecNumber	3.4.15.1	commentary		
ecNumber	3.4.15.1	commentary	precursor	
ecNumber	3.4.15.1	commentary		
ecNumber	3.4.16.2	commentary		
ecNumber	3.4.16.2	commentary		
ecNumber	3.4.16.5	commentary		
ecNumber	3.4.16.5	commentary		
ecNumber	3.4.16.6	commentary		
ecNumber	3.4.17.1	commentary		
ecNumber	3.4.17.1	commentary		
ecNumber	3.4.17.1	commentary		
ecNumber	3.4.17.2	commentary		
ecNumber	3.4.17.2	commentary		
ecNumber	3.4.17.3	commentary	the enzyme exists in two forms: carboxypeptidase N1, and carboxypeptidase N2 which can be differentiated by their activities towards hippuryl-L-Arg and hippuryl-L-Lys	
ecNumber	3.4.17.3	commentary		
ecNumber	3.4.17.3	commentary		
ecNumber	3.4.17.B6	commentary		
ecNumber	3.4.17.B6	commentary		
ecNumber	3.4.17.10	commentary	different genetic variants	
ecNumber	3.4.17.10	commentary		
ecNumber	3.4.17.10	commentary		
ecNumber	3.4.17.11	commentary		
ecNumber	3.4.17.11	commentary	human cancer cell lines are targeted by a vector carrying the CPG2 gene, CPG2 gene originates from different organism	
ecNumber	3.4.17.12	commentary		
ecNumber	3.4.17.12	commentary		
ecNumber	3.4.17.15	commentary		
ecNumber	3.4.17.15	commentary		
ecNumber	3.4.17.16	commentary		
ecNumber	3.4.17.17	commentary		
ecNumber	3.4.17.20	commentary	; variant A147/I325; variant A147/T325; variant T147/I325; variant T147/T325	
ecNumber	3.4.17.20	commentary	polymorphism: A/T147, A/G152, A/G438, C/T530, C/T1053, T/G1102, A/G690, T/C1925	
ecNumber	3.4.17.20	commentary	wild-type isozymes A147/T325 and A147/I325	
ecNumber	3.4.17.20	commentary	genotypes 1040CC and 1040TT	
ecNumber	3.4.17.20	commentary	isozyme T147/T325	
ecNumber	3.4.17.20	commentary	two isozymes T325 and I325	
ecNumber	3.4.17.20	commentary	women with normal and complicated pregnancies	
ecNumber	3.4.17.20	commentary		
ecNumber	3.4.17.20	commentary		
ecNumber	3.4.17.20	commentary		
ecNumber	3.4.17.21	commentary	male	
ecNumber	3.4.17.21	commentary	bifunctional enzyme	
ecNumber	3.4.17.21	commentary	bifunctional enzyme, gene PMSA	
ecNumber	3.4.17.21	commentary	persons of both sexes and different ages with schizophrenia	
ecNumber	3.4.17.21	commentary		
ecNumber	3.4.17.21	commentary		
ecNumber	3.4.17.22	commentary		
ecNumber	3.4.17.22	commentary		
ecNumber	3.4.17.23	commentary	recombinant	
ecNumber	3.4.17.23	commentary		
ecNumber	3.4.17.23	commentary	angiotensin-converting enzyme 2 precursor	
ecNumber	3.4.17.23	commentary	precursor	
ecNumber	3.4.17.23	commentary	patients with hypertensive cardiopathy and nephropathy	
ecNumber	3.4.17.23	commentary		
ecNumber	3.4.18.1	commentary	patients infected with Helicobacter pylori	
ecNumber	3.4.18.1	commentary		
ecNumber	3.4.18.1	commentary	gene CTSZ, South African coloured population in metropolitan Cape Town, South Africa	
ecNumber	3.4.18.1	commentary		
ecNumber	3.4.19.1	commentary		
ecNumber	3.4.19.3	commentary		
ecNumber	3.4.19.3	commentary	recombinant	
ecNumber	3.4.19.3	commentary		
ecNumber	3.4.19.5	commentary		
ecNumber	3.4.19.9	commentary	two separate folate conjugase activities in jejunal mucosa: one membrane-bound and concentrated in the brush-border and the other soluble and intracellular	
ecNumber	3.4.19.9	commentary	patients with chronic myeloid leukemia	
ecNumber	3.4.19.9	commentary	Japanese healthy individuals	
ecNumber	3.4.19.9	commentary	single gene and single spliced mRNA	
ecNumber	3.4.19.9	commentary		
ecNumber	3.4.19.9	commentary		
ecNumber	3.4.19.12	commentary	UCH-L1, SwissProt: P09936, PIR: A25865, UCH-L3, SwissProt: P15374, PIR: A40085	
ecNumber	3.4.19.12	commentary	; isozymes L1, L2, and L3	
ecNumber	3.4.19.12	commentary	isozymes ISOT-S and ISOT-L	
ecNumber	3.4.19.12	commentary	; two isozymes UCH-L1 and UCH-L3	
ecNumber	3.4.19.12	commentary	3 isozymes of UCH-L1	
ecNumber	3.4.19.12	commentary	Taiwanese population, gene rs5030732	
ecNumber	3.4.19.12	commentary	gene uchl1	
ecNumber	3.4.19.12	commentary		
ecNumber	3.4.19.12	commentary	isozyme L1	
ecNumber	3.4.19.12	commentary	gene uch-L1	
ecNumber	3.4.19.12	commentary	gene rs5030732	
ecNumber	3.4.19.12	commentary	gene UCHL1; gene uchl1	
ecNumber	3.4.19.12	commentary	isoform UCHL1	
ecNumber	3.4.19.12	commentary		
ecNumber	3.4.19.12	commentary	expressed in Escherichia coli	
ecNumber	3.4.19.12	commentary		
ecNumber	3.4.19.12	commentary	UBPY	
ecNumber	3.4.19.12	commentary		
ecNumber	3.4.19.12	commentary		
ecNumber	3.4.19.12	commentary		
ecNumber	3.4.19.12	commentary	gene usp21, dual substrate specificity for ubiquitin- and NEDD8-conjugates	
ecNumber	3.4.19.12	commentary		
ecNumber	3.4.19.13	commentary		
ecNumber	3.4.19.13	commentary		
ecNumber	3.4.19.13	commentary		
ecNumber	3.4.19.14	commentary		
ecNumber	3.4.21.1	commentary		
ecNumber	3.4.21.B1	commentary		
ecNumber	3.4.21.B1	commentary		
ecNumber	3.4.21.2	commentary		
ecNumber	3.4.21.2	commentary		
ecNumber	3.4.21.B2	commentary		
ecNumber	3.4.21.B2	commentary		
ecNumber	3.4.21.B3	commentary		
ecNumber	3.4.21.4	commentary	isoform trypsin-2	
ecNumber	3.4.21.4	commentary	pancreatic isoforms cationic trypsin, anionic trypsin, and mesotrypsin	
ecNumber	3.4.21.4	commentary	isozymes trypsin-1, -2, -C and -3	
ecNumber	3.4.21.4	commentary		
ecNumber	3.4.21.B4	commentary		
ecNumber	3.4.21.B4	commentary		
ecNumber	3.4.21.5	commentary	prothrombin	
ecNumber	3.4.21.5	commentary	human mutant with homozygous dysprothrombinemia with a low level of coagulation activity, prothrombin Perija	
ecNumber	3.4.21.5	commentary	enzyme from platelet-poor plasma of 2 humans with congenital afibrinogenemia, termed MC and KU	
ecNumber	3.4.21.5	commentary	comercial preparation	
ecNumber	3.4.21.5	commentary	recombinant prethrombin-2	
ecNumber	3.4.21.5	commentary	thrombin and anhydrothrombin chemically modified by glycine ethyl ester	
ecNumber	3.4.21.5	commentary	commercial preparation	
ecNumber	3.4.21.5	commentary	patients with first spontaneous venous thromboembolism	
ecNumber	3.4.21.5	commentary	gamma-thrombin, commercial preparation	
ecNumber	3.4.21.5	commentary	unilateral total knee arthroplasty patients	
ecNumber	3.4.21.5	commentary	commercial product	
ecNumber	3.4.21.5	commentary	patients with heparin-induced thrombocytopenia	
ecNumber	3.4.21.5	commentary	isoform alpha-thrombin	
ecNumber	3.4.21.5	commentary	patients with acute ST-segment elevation myocardial infarction	
ecNumber	3.4.21.5	commentary		
ecNumber	3.4.21.5	commentary	commercial preparation	
ecNumber	3.4.21.5	commentary		
ecNumber	3.4.21.6	commentary	enzyme modified with [5-(dimethylamino)-1-naphthalenesulfonyl]glutamylglycylarginyl chloromethyl ketone	
ecNumber	3.4.21.6	commentary	prothrombinase, enzyme complex consisting of factor Xa and factor Va, assembled in a calcium-dependent manner on the surface of phospholipid membranes	
ecNumber	3.4.21.6	commentary	patients undergoing elective total knee replacement	
ecNumber	3.4.21.6	commentary	male Chinese individuals	
ecNumber	3.4.21.6	commentary	recombinant and inactive factor Xa(Asp322Asn,Ser419Ala)	
ecNumber	3.4.21.6	commentary		
ecNumber	3.4.21.6	commentary	chymotrypsin treated factor Xa, i.e. des-Gla(1-44), lacking the Gla domain	
ecNumber	3.4.21.6	commentary		
ecNumber	3.4.21.6	commentary	enzyme from which the residues 1-44 of the light chain have been removed	
ecNumber	3.4.21.B6	commentary		
ecNumber	3.4.21.B6	commentary	; precursor	
ecNumber	3.4.21.B6	commentary		
ecNumber	3.4.21.B6	commentary	gene PRSS8	
ecNumber	3.4.21.7	commentary	human plasmin binds to the extracellular alpha-enolase Eno of Streptococcus pneumoniae	
ecNumber	3.4.21.7	commentary	patients with a history of systemic reaction to Hymenoptera and Diptera venom	
ecNumber	3.4.21.7	commentary	commercial product	
ecNumber	3.4.21.7	commentary	patients with systemic reactions to Hymenoptera stings	
ecNumber	3.4.21.7	commentary	various forms of enzyme: Glu1-plasmin, Lys77-plasmin, Val442-plasmin, Val561-plasmin	
ecNumber	3.4.21.7	commentary		
ecNumber	3.4.21.7	commentary	plasminogen; gene PLG	
ecNumber	3.4.21.7	commentary		
ecNumber	3.4.21.B7	commentary		
ecNumber	3.4.21.B7	commentary		
ecNumber	3.4.21.9	commentary	2 isoenzymes	
ecNumber	3.4.21.9	commentary		
ecNumber	3.4.21.9	commentary	light chain	
ecNumber	3.4.21.9	commentary		
ecNumber	3.4.21.10	commentary	infertile couples	
ecNumber	3.4.21.10	commentary	patients with unexplained infertility and infertile males with low motility of semen	
ecNumber	3.4.21.10	commentary	recombinant protein	
ecNumber	3.4.21.10	commentary	infertile and fertile Nigerian men, fertile men are found to have higher acrosin activity in spermatozoa than infertile men, lower enzyme activity is found to correlate with increased morphological changes in the spermatozoa	
ecNumber	3.4.21.10	commentary		
ecNumber	3.4.21.10	commentary	precursor	
ecNumber	3.4.21.B10	commentary		
ecNumber	3.4.21.B10	commentary	gene KLK6 or PRSS9	
ecNumber	3.4.21.B10	commentary	precursor	
ecNumber	3.4.21.B10	commentary		
ecNumber	3.4.21.B10	commentary	gene KLK6	
ecNumber	3.4.21.B12	commentary	patients with epithelial ovarian carcinoma	
ecNumber	3.4.21.B12	commentary	expressed in Pichia pastoris	
ecNumber	3.4.21.B12	commentary		
ecNumber	3.4.21.B12	commentary	kallikrein 4 precursor	
ecNumber	3.4.21.B12	commentary	gene KLK-L1; gene prostase	
ecNumber	3.4.21.B12	commentary	gene KLK4	
ecNumber	3.4.21.B12	commentary	gene prostase	
ecNumber	3.4.21.B12	commentary	gene PRSS17	
ecNumber	3.4.21.B12	commentary	precursor	
ecNumber	3.4.21.B12	commentary		
ecNumber	3.4.21.B12	commentary		
ecNumber	3.4.21.20	commentary		
ecNumber	3.4.21.20	commentary	precursor	
ecNumber	3.4.21.20	commentary		
ecNumber	3.4.21.21	commentary		
ecNumber	3.4.21.21	commentary		
ecNumber	3.4.21.22	commentary		
ecNumber	3.4.21.22	commentary		
ecNumber	3.4.21.B24	commentary		
ecNumber	3.4.21.B24	commentary		
ecNumber	3.4.21.B24	commentary		
ecNumber	3.4.21.B25	commentary		
ecNumber	3.4.21.B25	commentary		
ecNumber	3.4.21.B25	commentary		
ecNumber	3.4.21.26	commentary	recombinant enzyme	
ecNumber	3.4.21.26	commentary	patients with Alzheimers disease	
ecNumber	3.4.21.26	commentary	female and male Caucasian individuals	
ecNumber	3.4.21.26	commentary	gene prep	
ecNumber	3.4.21.26	commentary	2 isoenzymes	
ecNumber	3.4.21.26	commentary		
ecNumber	3.4.21.26	commentary		
ecNumber	3.4.21.26	commentary	splice variant PREPL A lacking peptidase activity	
ecNumber	3.4.21.B26	commentary		
ecNumber	3.4.21.B26	commentary		
ecNumber	3.4.21.27	commentary	patients with coronary artery disease	
ecNumber	3.4.21.27	commentary		
ecNumber	3.4.21.27	commentary	korean woman with hereditary factor XI deficiency	
ecNumber	3.4.21.27	commentary		
ecNumber	3.4.21.B27	commentary		
ecNumber	3.4.21.B27	commentary	precursor	
ecNumber	3.4.21.B27	commentary		
ecNumber	3.4.21.B28	commentary		
ecNumber	3.4.21.B28	commentary		
ecNumber	3.4.21.B28	commentary		
ecNumber	3.4.21.34	commentary	purified enzyme	
ecNumber	3.4.21.34	commentary	patients with pemphigus foliaceus (autoimmune blistering disease) and control	
ecNumber	3.4.21.34	commentary	kallikrein I, kallikrein II	
ecNumber	3.4.21.34	commentary		
ecNumber	3.4.21.34	commentary	gene KLK3 or KLKB1, plasma kallikrein precursor	
ecNumber	3.4.21.34	commentary		
ecNumber	3.4.21.34	commentary		
ecNumber	3.4.21.35	commentary	glandular kallikrein; kallikrein genes are located in a cluster on chromosome 19q13.4	
ecNumber	3.4.21.35	commentary	patients with pemphigus foliaceus (autoimmune blistering disease) and control	
ecNumber	3.4.21.35	commentary	men with localized prostate cancer	
ecNumber	3.4.21.35	commentary		
ecNumber	3.4.21.35	commentary	glandular kallikrein 1 precursor	
ecNumber	3.4.21.35	commentary	gene KLK1	
ecNumber	3.4.21.35	commentary	precursor	
ecNumber	3.4.21.35	commentary		
ecNumber	3.4.21.35	commentary		
ecNumber	3.4.21.36	commentary	elastase 1 and 2	
ecNumber	3.4.21.36	commentary		
ecNumber	3.4.21.36	commentary		
ecNumber	3.4.21.37	commentary	cystic fibrosis patients suffering from chronic Pseudomonas aeruginosa lung infection	
ecNumber	3.4.21.37	commentary	patients with cystic fibrosis	
ecNumber	3.4.21.37	commentary	healthy individuals and patients with cyclic neutropenia	
ecNumber	3.4.21.37	commentary	healthy individuals and patients with chronic obstructive pulmonary disease	
ecNumber	3.4.21.37	commentary	Japanese population	
ecNumber	3.4.21.37	commentary		
ecNumber	3.4.21.37	commentary	gene ela2	
ecNumber	3.4.21.37	commentary		
ecNumber	3.4.21.38	commentary	patients with antiphospholipid syndrome and late-pregnancy complications	
ecNumber	3.4.21.38	commentary	male patients with hypercholesterolemia	
ecNumber	3.4.21.38	commentary	patients treated with fibrinolytic agents	
ecNumber	3.4.21.38	commentary	patients having suffered venous thrombosis	
ecNumber	3.4.21.38	commentary		
ecNumber	3.4.21.38	commentary	coagulation factor XII, precursor; patients with acute ST-elevation myocardial infarction (STEMI), treated with thrombolytic therapy	
ecNumber	3.4.21.38	commentary		
ecNumber	3.4.21.39	commentary	patients with macular holes, proliferative diabetic retinopathy, idiopathic epiretinal membrane, or rhegmatogenous retinal detachment	
ecNumber	3.4.21.39	commentary	patients treated for breast cancer with surgery and radiotherapy	
ecNumber	3.4.21.39	commentary		
ecNumber	3.4.21.39	commentary		
ecNumber	3.4.21.B39	commentary		
ecNumber	3.4.21.B39	commentary	gene KLK5; gene KLK5 or SCTE	
ecNumber	3.4.21.B39	commentary	can be processed to active enzyme from inactive precursor by trypsin; gene KLK5 or SCTE	
ecNumber	3.4.21.B39	commentary	gene KLK5 or SCTE	
ecNumber	3.4.21.B39	commentary		
ecNumber	3.4.21.B39	commentary	gene KLK5	
ecNumber	3.4.21.B40	commentary	3 different transcripts due to different start codons	
ecNumber	3.4.21.B40	commentary	gene KLK-L3 or KLK9; precursor	
ecNumber	3.4.21.B40	commentary	gene KLK-L3 or KLK9	
ecNumber	3.4.21.41	commentary		
ecNumber	3.4.21.41	commentary		
ecNumber	3.4.21.B41	commentary		
ecNumber	3.4.21.B41	commentary	gene KLK10 or PRRSL or NES1	
ecNumber	3.4.21.B41	commentary	KLK10	
ecNumber	3.4.21.B41	commentary		
ecNumber	3.4.21.B41	commentary	gene KLK10	
ecNumber	3.4.21.B41	commentary	gene KLK10	
ecNumber	3.4.21.42	commentary		
ecNumber	3.4.21.42	commentary	Japanese family	
ecNumber	3.4.21.42	commentary		
ecNumber	3.4.21.B42	commentary		
ecNumber	3.4.21.B42	commentary	brain-type isozyme; prostate-type isozyme; splicing variant 1; splicing variant 2	
ecNumber	3.4.21.B42	commentary		
ecNumber	3.4.21.43	commentary	2 distinct C3 convertases generated by 2 seperate enzyme cascade systems	
ecNumber	3.4.21.43	commentary		
ecNumber	3.4.21.43	commentary		
ecNumber	3.4.21.B43	commentary		
ecNumber	3.4.21.B43	commentary	gene KLK12	
ecNumber	3.4.21.B43	commentary		
ecNumber	3.4.21.45	commentary	patients with hemolytic uremic syndrome	
ecNumber	3.4.21.45	commentary	Caucasian individuals	
ecNumber	3.4.21.45	commentary	gene CFI	
ecNumber	3.4.21.45	commentary		
ecNumber	3.4.21.45	commentary	encoded by CFI gene	
ecNumber	3.4.21.45	commentary		
ecNumber	3.4.21.B45	commentary	patients with invasive breast cancer	
ecNumber	3.4.21.B45	commentary		
ecNumber	3.4.21.B45	commentary	gene KLK14 or KLK-L6	
ecNumber	3.4.21.B45	commentary		
ecNumber	3.4.21.46	commentary	two children with meningococcal septic shock	
ecNumber	3.4.21.46	commentary	chronic renal failure patients with arteriosklerosis obliterans	
ecNumber	3.4.21.46	commentary		
ecNumber	3.4.21.46	commentary		
ecNumber	3.4.21.46	commentary	complement factor D precursor; asymptomatic malaria patients from Papua New Guinea	
ecNumber	3.4.21.46	commentary		
ecNumber	3.4.21.47	commentary	comercial preparation	
ecNumber	3.4.21.47	commentary	component C2-deficient patient	
ecNumber	3.4.21.47	commentary	recombinant enzyme component C3	
ecNumber	3.4.21.47	commentary		
ecNumber	3.4.21.47	commentary		
ecNumber	3.4.21.47	commentary		
ecNumber	3.4.21.B48	commentary		
ecNumber	3.4.21.50	commentary		
ecNumber	3.4.21.53	commentary	human	
ecNumber	3.4.21.53	commentary	human,WI-38 VA-13 cell line	
ecNumber	3.4.21.53	commentary	; human	
ecNumber	3.4.21.53	commentary	gene Lonp1	
ecNumber	3.4.21.53	commentary		
ecNumber	3.4.21.53	commentary	human	
ecNumber	3.4.21.53	commentary		
ecNumber	3.4.21.59	commentary	human	
ecNumber	3.4.21.59	commentary	several enzyme forms	
ecNumber	3.4.21.59	commentary	three distinct catalytic forms of human tryptase-beta	
ecNumber	3.4.21.59	commentary	genes TPSAB 1 and TPSB2	
ecNumber	3.4.21.59	commentary		
ecNumber	3.4.21.59	commentary		
ecNumber	3.4.21.59	commentary		
ecNumber	3.4.21.B59	commentary		
ecNumber	3.4.21.60	commentary		
ecNumber	3.4.21.61	commentary		
ecNumber	3.4.21.61	commentary		
ecNumber	3.4.21.64	commentary		
ecNumber	3.4.21.67	commentary	secreted soluble form of isozyme-1, SK-1, recombinant protein	
ecNumber	3.4.21.68	commentary	construction of a one-chain recombinant tissue-type plasminogen activator analogue in which Arg275 is changed to Gly by site-directed mutagenesis	
ecNumber	3.4.21.68	commentary	Boehringer Mannheim	
ecNumber	3.4.21.68	commentary	commercial preparation from Sigma Chemical	
ecNumber	3.4.21.68	commentary	recombinant kringle 1 domain from tissue-type plasminogen activator expressed in Escherichia coli	
ecNumber	3.4.21.68	commentary	recombinant domain-deletion mutant BM 06.022	
ecNumber	3.4.21.68	commentary	recombinant protease and BM 06.022 proteins expressed in Escherichia coli	
ecNumber	3.4.21.68	commentary	Genentech	
ecNumber	3.4.21.68	commentary	glycosylation variant of human tPA	
ecNumber	3.4.21.68	commentary	recombinant protein, expressed in JMI-229 cell line of rat	
ecNumber	3.4.21.68	commentary	human	
ecNumber	3.4.21.68	commentary	gene K2S	
ecNumber	3.4.21.68	commentary	; gene t-PA	
ecNumber	3.4.21.68	commentary		
ecNumber	3.4.21.68	commentary		
ecNumber	3.4.21.69	commentary	human	
ecNumber	3.4.21.69	commentary	recombinant enzyme	
ecNumber	3.4.21.69	commentary	commercial preparation from Enzyme Research Laboratories, South Bend, USA	
ecNumber	3.4.21.69	commentary	recombinant protein	
ecNumber	3.4.21.69	commentary	inflammatory bowel disease patients	
ecNumber	3.4.21.69	commentary	gene PROC	
ecNumber	3.4.21.69	commentary		
ecNumber	3.4.21.69	commentary	human	
ecNumber	3.4.21.70	commentary		
ecNumber	3.4.21.71	commentary		
ecNumber	3.4.21.73	commentary	recombinant plasmin-resistant mutant of single-chain uPA obtained by site-specific mutagenesis of Lys158 to Glu	
ecNumber	3.4.21.73	commentary	single chain form	
ecNumber	3.4.21.73	commentary	commercial preparation of low-molecular weight uPA from American Diagnostica	
ecNumber	3.4.21.73	commentary	recombinant 54000 MW scuPA, plasmin-resistant rscuPA with Lys158 mutagenized to Glu and a 32000 MW form of rscuPA consisting of Leu144-Leu411 are obtained by expression of cDNA in Chinese hamster ovary cells	
ecNumber	3.4.21.73	commentary	from Sandoz, N&uuml;rnberg	
ecNumber	3.4.21.73	commentary	Calbiochem	
ecNumber	3.4.21.73	commentary	recombinant single chain urokinase-type plasminogen activator is home-made by expression of uPA cDNA in Chinese hamster ovary cells	
ecNumber	3.4.21.73	commentary	uPA from Serono and low-molecular weight uPa from Le Petit	
ecNumber	3.4.21.73	commentary	nonphosphorylated and phosphorylated on serine	
ecNumber	3.4.21.73	commentary	high-molecular weight uPA expressed in SP2/0 cell culture from Abbott Biotech; low-molecular weight uPA, Abbokinase, from Abbott Labs, North Chicago	
ecNumber	3.4.21.73	commentary	single-chain uPA	
ecNumber	3.4.21.73	commentary	human	
ecNumber	3.4.21.73	commentary	commercial preparation from Sigma Aldrich	
ecNumber	3.4.21.73	commentary	recombinant amino-terminal fragment S1-E143 expressed in Pichia pastoris	
ecNumber	3.4.21.73	commentary	patients with Quebec platelet disease	
ecNumber	3.4.21.73	commentary	patients with colorectal cancer	
ecNumber	3.4.21.73	commentary	patients with common variable immunodeficiency	
ecNumber	3.4.21.73	commentary	patients with allergic asthma	
ecNumber	3.4.21.73	commentary	patients with acute and chronic hepatitis B	
ecNumber	3.4.21.73	commentary		
ecNumber	3.4.21.73	commentary		
ecNumber	3.4.21.75	commentary	rat somatomammotroph cell line, GH4C1 infected with vaccinia virus recombinants of human PC1	
ecNumber	3.4.21.75	commentary	overview	
ecNumber	3.4.21.75	commentary	human	
ecNumber	3.4.21.75	commentary	recombinant	
ecNumber	3.4.21.75	commentary		
ecNumber	3.4.21.75	commentary		
ecNumber	3.4.21.76	commentary	healthy	
ecNumber	3.4.21.76	commentary	Wegener's granulomatosis	
ecNumber	3.4.21.76	commentary	human	
ecNumber	3.4.21.76	commentary		
ecNumber	3.4.21.76	commentary		
ecNumber	3.4.21.77	commentary	2 isozyme of the zymogen with different pI, several isoforms with different pIs of the mature enzyme	
ecNumber	3.4.21.77	commentary	isoform tissue kallikrein 4, hK4	
ecNumber	3.4.21.77	commentary	isoform prostate specific antigen	
ecNumber	3.4.21.77	commentary	American veterans before diagnosis of prostate cancer	
ecNumber	3.4.21.77	commentary		
ecNumber	3.4.21.77	commentary	enzyme precursor; gene KLK3 or APS	
ecNumber	3.4.21.77	commentary		
ecNumber	3.4.21.78	commentary	human	
ecNumber	3.4.21.78	commentary	patients with amyotrophic lateral sclerosis	
ecNumber	3.4.21.78	commentary		
ecNumber	3.4.21.78	commentary	affected individuals of familial chilblain lupus, an autosomal-dominant genodermatosis that is manifested in early childhood with ulcerating acral skin lesions associated with arthralgias and circulating antinuclear antibodies	
ecNumber	3.4.21.78	commentary		
ecNumber	3.4.21.78	commentary		
ecNumber	3.4.21.79	commentary	human, YT cells, autonomously proliferating NK line, devoid of granzyme A and K	
ecNumber	3.4.21.79	commentary	human	
ecNumber	3.4.21.79	commentary	expression in Pichia pastoris	
ecNumber	3.4.21.79	commentary	encoded by RAH allele	
ecNumber	3.4.21.79	commentary	recombinant expression	
ecNumber	3.4.21.79	commentary	HIV-positive patients and healthy controls	
ecNumber	3.4.21.79	commentary	patients with systemic lupus erythematosus	
ecNumber	3.4.21.79	commentary	patients with amyotrophic lateral sclerosis	
ecNumber	3.4.21.79	commentary		
ecNumber	3.4.21.79	commentary		
ecNumber	3.4.21.89	commentary	coexpression of human signal peptide peptidase with hepatitis C virus core protein in Pichia pastoris	
ecNumber	3.4.21.89	commentary		
ecNumber	3.4.21.89	commentary	human	
ecNumber	3.4.21.92	commentary		
ecNumber	3.4.21.92	commentary		
ecNumber	3.4.21.93	commentary	6 year old boy of Libyan origin	
ecNumber	3.4.21.93	commentary		
ecNumber	3.4.21.93	commentary		
ecNumber	3.4.21.94	commentary	human	
ecNumber	3.4.21.94	commentary		
ecNumber	3.4.21.104	commentary	Danish adult twins, monozygotic and dizygotic twin pairs	
ecNumber	3.4.21.104	commentary	healthy individuals and schizophrenia patients	
ecNumber	3.4.21.104	commentary		
ecNumber	3.4.21.104	commentary		
ecNumber	3.4.21.104	commentary		
ecNumber	3.4.21.105	commentary		
ecNumber	3.4.21.105	commentary		
ecNumber	3.4.21.105	commentary		
ecNumber	3.4.21.105	commentary		
ecNumber	3.4.21.105	commentary	recombinant enzyme expressed in Escherichia coli	
ecNumber	3.4.21.106	commentary		
ecNumber	3.4.21.106	commentary	chinese patient with hepatocellular carcinoma combined hepatitis B virus infection, strain WhuTJ-37	
ecNumber	3.4.21.106	commentary		
ecNumber	3.4.21.107	commentary		
ecNumber	3.4.21.108	commentary	518 Parkinson's disease patients	
ecNumber	3.4.21.108	commentary		
ecNumber	3.4.21.108	commentary		
ecNumber	3.4.21.108	commentary		
ecNumber	3.4.21.109	commentary	gene ST14, i.e. suppression of tumorgenecity14	
ecNumber	3.4.21.109	commentary	gene ST14	
ecNumber	3.4.21.109	commentary	Chinese women	
ecNumber	3.4.21.109	commentary		
ecNumber	3.4.21.109	commentary	matriptase and matriptase-2	
ecNumber	3.4.21.109	commentary	gene TMPRSS6	
ecNumber	3.4.21.109	commentary		
ecNumber	3.4.21.109	commentary	gene ST14	
ecNumber	3.4.21.109	commentary		
ecNumber	3.4.21.112	commentary	secreted soluble form of isozyme-1, SK-1, recombinant protein	
ecNumber	3.4.21.112	commentary		
ecNumber	3.4.21.112	commentary		
ecNumber	3.4.21.117	commentary	gene KLK7	
ecNumber	3.4.21.117	commentary	two different KLK7 transcripts, KLK7-253 and KLK7-181	
ecNumber	3.4.21.117	commentary		
ecNumber	3.4.21.117	commentary	gene KLK7, RNA sequence	
ecNumber	3.4.21.117	commentary	gene KLK7 or PRSS6, genomic sequence	
ecNumber	3.4.21.117	commentary	; gene KLK7	
ecNumber	3.4.21.117	commentary	precursor	
ecNumber	3.4.21.117	commentary	gene KLK7	
ecNumber	3.4.21.117	commentary		
ecNumber	3.4.21.118	commentary	patients with ovarian cancer	
ecNumber	3.4.21.118	commentary		
ecNumber	3.4.21.118	commentary	gene KLK8 or PRSS19 or NRPN; precursor; TADG14	
ecNumber	3.4.21.118	commentary	TADG14	
ecNumber	3.4.21.118	commentary	gene KLK8	
ecNumber	3.4.21.118	commentary	recombinant enzyme	
ecNumber	3.4.21.118	commentary	active recombinant ezyme	
ecNumber	3.4.21.118	commentary	type II splice form, expressed in hominoids but not in lesser apes or Old World monkeys	
ecNumber	3.4.21.118	commentary		
ecNumber	3.4.21.119	commentary	recombinant enzyme	
ecNumber	3.4.21.119	commentary	patients with ovarian carcinoma	
ecNumber	3.4.21.119	commentary		
ecNumber	3.4.21.119	commentary	GenBank: AF135024; kallikrein-like gene 4, i.e. KLK-L4	
ecNumber	3.4.21.119	commentary		
ecNumber	3.4.21.119	commentary	gene KLK13	
ecNumber	3.4.21.120	commentary		
ecNumber	3.4.22.1	commentary	recombinant proenzyme	
ecNumber	3.4.22.1	commentary	recombinant protein	
ecNumber	3.4.22.1	commentary	recombinant enzyme	
ecNumber	3.4.22.1	commentary	commercial preparation	
ecNumber	3.4.22.1	commentary	healthy women and patients with pelvic inflammatory disease	
ecNumber	3.4.22.1	commentary		
ecNumber	3.4.22.1	commentary	gene CATB or CTSB	
ecNumber	3.4.22.1	commentary		
ecNumber	3.4.22.B6	commentary		
ecNumber	3.4.22.15	commentary	patients with coronary heart disease	
ecNumber	3.4.22.15	commentary	infected with Anaplasma phagocytophilum	
ecNumber	3.4.22.15	commentary	patients with colorectal cancer	
ecNumber	3.4.22.15	commentary		
ecNumber	3.4.22.15	commentary	procathepsin L	
ecNumber	3.4.22.15	commentary		
ecNumber	3.4.22.15	commentary		
ecNumber	3.4.22.16	commentary	recombinant protein lacking the mini chain	
ecNumber	3.4.22.16	commentary		
ecNumber	3.4.22.16	commentary		
ecNumber	3.4.22.B24	commentary		
ecNumber	3.4.22.B24	commentary		
ecNumber	3.4.22.B25	commentary		
ecNumber	3.4.22.B25	commentary		
ecNumber	3.4.22.26	commentary	healthy persons and patients with adenocarcinomas	
ecNumber	3.4.22.26	commentary	healthy women and genital cancer patients	
ecNumber	3.4.22.26	commentary		
ecNumber	3.4.22.B26	commentary		
ecNumber	3.4.22.27	commentary		
ecNumber	3.4.22.27	commentary	tag single polymorphism at location 147,540,467, intronic A/G exchange; tag single polymorphism at location 147,540,612, exon 4 A/G exchange; tag single polymorphism at location 147,551,270, location at 5'-UTR, T/C exchange; tag single polymorphism at location 147,562,986, genomic C/T exchange; tag single polymorphism at location 47,560,484, genomic T/G exchange	
ecNumber	3.4.22.27	commentary	reference no. rs7534124, A/G type single strand conformation polymorphism	
ecNumber	3.4.22.27	commentary		
ecNumber	3.4.22.B27	commentary		
ecNumber	3.4.22.B27	commentary		
ecNumber	3.4.22.B27	commentary		
ecNumber	3.4.22.29	commentary		
ecNumber	3.4.22.B29	commentary		
ecNumber	3.4.22.B29	commentary		
ecNumber	3.4.22.B30	commentary		
ecNumber	3.4.22.B30	commentary	gene CAPN10	
ecNumber	3.4.22.B30	commentary		
ecNumber	3.4.22.B31	commentary		
ecNumber	3.4.22.34	commentary		
ecNumber	3.4.22.34	commentary	; Homo sapiens	
ecNumber	3.4.22.34	commentary	Homo sapiens	
ecNumber	3.4.22.34	commentary		
ecNumber	3.4.22.36	commentary	recombinant	
ecNumber	3.4.22.36	commentary		
ecNumber	3.4.22.36	commentary		
ecNumber	3.4.22.38	commentary	recombinant enzymes, expressed in Sf21 cells, baculovirus-infected, wild-type and mutant enzyme in which Cys139 is changed to Ser	
ecNumber	3.4.22.38	commentary	expressed in Sf9 cells with Autographa californica nuclear polyhedrosis virus	
ecNumber	3.4.22.38	commentary	recombinant	
ecNumber	3.4.22.38	commentary	humanized rabbit enzyme is used	
ecNumber	3.4.22.38	commentary	gene Ctsk	
ecNumber	3.4.22.38	commentary		
ecNumber	3.4.22.38	commentary		
ecNumber	3.4.22.40	commentary		
ecNumber	3.4.22.40	commentary	encoded by Blmh gene; patient study, testicular germ-cell cancer	
ecNumber	3.4.22.41	commentary	accession number AF132894	
ecNumber	3.4.22.41	commentary	mexican women	
ecNumber	3.4.22.41	commentary	production of cathepsin F is increased by stimulation of cells with angiotensin, level of lysosomal enzyme remains unaffected but more enzyme is secreted	
ecNumber	3.4.22.41	commentary		
ecNumber	3.4.22.41	commentary	accession numbers AJ007331, AJ131851	
ecNumber	3.4.22.41	commentary	accession number AF088886	
ecNumber	3.4.22.41	commentary	accession number AF071748, AF071749	
ecNumber	3.4.22.42	commentary		
ecNumber	3.4.22.43	commentary		
ecNumber	3.4.22.43	commentary		
ecNumber	3.4.22.49	commentary	gene hESP	
ecNumber	3.4.22.49	commentary		
ecNumber	3.4.22.49	commentary		
ecNumber	3.4.22.52	commentary		
ecNumber	3.4.22.52	commentary	calpain-1 catalytic subunit	
ecNumber	3.4.22.52	commentary		
ecNumber	3.4.22.53	commentary		
ecNumber	3.4.22.53	commentary		
ecNumber	3.4.22.53	commentary	calpain-1 catalytic subunit	
ecNumber	3.4.22.53	commentary		
ecNumber	3.4.22.54	commentary	recombinant	
ecNumber	3.4.22.54	commentary	limb-girdle muscular dystrophy type 2A patients	
ecNumber	3.4.22.54	commentary	model of calpain 3 by crystal structures of human calpain2 and calpastatin-inhibited rat calpain2	
ecNumber	3.4.22.54	commentary		
ecNumber	3.4.22.54	commentary	alternative splicing: I: isoform ID P20807-1, this is the isoform sequence displayed in this entry. II: isoform IDP20807-2, features which should be applied to build the isoform sequence: VSP_005227, VSP_005228. III: isoform ID P20807-3, features which should be applied to build the isoform sequence: VSP_005229. IV: isoform ID P20807-4, features which should be applied to build the isoform sequence: VSP_007813	
ecNumber	3.4.22.54	commentary	expressed in COS-7 cells	
ecNumber	3.4.22.54	commentary		
ecNumber	3.4.22.55	commentary		
ecNumber	3.4.22.55	commentary		
ecNumber	3.4.22.56	commentary	recombinant enzyme expressed in Escherichia coli	
ecNumber	3.4.22.56	commentary	commercial preparation, recombinant full-length enzyme expressed in Escherichia coli	
ecNumber	3.4.22.56	commentary	recombinant catalytic domain of enzyme	
ecNumber	3.4.22.56	commentary	recombinant enzyme	
ecNumber	3.4.22.56	commentary	gene CASP3	
ecNumber	3.4.22.56	commentary		
ecNumber	3.4.22.56	commentary	recombinant enzyme	
ecNumber	3.4.22.56	commentary		
ecNumber	3.4.22.57	commentary		
ecNumber	3.4.22.57	commentary		
ecNumber	3.4.22.57	commentary	TRAF6-caspase-4 interaction, triggered by LPS, leads to NFkappaB-dependent transcriptional up-regulation and secretion of important cytokines and chemokines in innate immune signaling in human monocytic cells	
ecNumber	3.4.22.58	commentary		
ecNumber	3.4.22.58	commentary		
ecNumber	3.4.22.59	commentary	gene CASP6	
ecNumber	3.4.22.59	commentary		
ecNumber	3.4.22.59	commentary		
ecNumber	3.4.22.60	commentary	GenBank Acc. No NM 001227	
ecNumber	3.4.22.60	commentary	gene CASP-7	
ecNumber	3.4.22.60	commentary		
ecNumber	3.4.22.60	commentary		
ecNumber	3.4.22.B60	commentary		
ecNumber	3.4.22.61	commentary	; gene CASP8	
ecNumber	3.4.22.61	commentary	gene CASP8	
ecNumber	3.4.22.61	commentary		
ecNumber	3.4.22.61	commentary	recombinant enzyme expressed in Escherichia coli	
ecNumber	3.4.22.61	commentary	?	
ecNumber	3.4.22.61	commentary		
ecNumber	3.4.22.62	commentary		
ecNumber	3.4.22.62	commentary	multiple sclerosis (MS) patients	
ecNumber	3.4.22.62	commentary		
ecNumber	3.4.22.63	commentary		
ecNumber	3.4.22.63	commentary		
ecNumber	3.4.22.64	commentary		
ecNumber	3.4.22.68	commentary		
ecNumber	3.4.22.B70	commentary		
ecNumber	3.4.22.B70	commentary		
ecNumber	3.4.22.B70	commentary		
ecNumber	3.4.22.B71	commentary		
ecNumber	3.4.22.B71	commentary		
ecNumber	3.4.22.B72	commentary		
ecNumber	3.4.22.B72	commentary		
ecNumber	3.4.22.B73	commentary		
ecNumber	3.4.22.B73	commentary		
ecNumber	3.4.22.B74	commentary		
ecNumber	3.4.22.B74	commentary		
ecNumber	3.4.22.B75	commentary	two splicing variants, a short SENP7 splice variant SENP7S and a long transcript SENP7L	
ecNumber	3.4.22.B75	commentary		
ecNumber	3.4.22.B75	commentary		
ecNumber	3.4.23.1	commentary		
ecNumber	3.4.23.B1	commentary	recombinant	
ecNumber	3.4.23.B1	commentary		
ecNumber	3.4.23.B1	commentary		
ecNumber	3.4.23.3	commentary		
ecNumber	3.4.23.3	commentary		
ecNumber	3.4.23.4	commentary		
ecNumber	3.4.23.5	commentary	commercial preparation	
ecNumber	3.4.23.5	commentary		
ecNumber	3.4.23.5	commentary	; natural variant A58V	
ecNumber	3.4.23.5	commentary		
ecNumber	3.4.23.15	commentary	healthy persons and hypertensive patients	
ecNumber	3.4.23.15	commentary	healthy persons, hypertensive patients, and patients with aldosterone- and/or cortisol secreting adenomas	
ecNumber	3.4.23.15	commentary	recombinant	
ecNumber	3.4.23.15	commentary	patients with biopsy-confirmed post-transplant glomerulonephritis	
ecNumber	3.4.23.15	commentary	patients with hypertension	
ecNumber	3.4.23.15	commentary		
ecNumber	3.4.23.15	commentary		
ecNumber	3.4.23.15	commentary		
ecNumber	3.4.23.B24	commentary		
ecNumber	3.4.23.34	commentary	human, cell line T1	
ecNumber	3.4.23.34	commentary	human	
ecNumber	3.4.23.34	commentary		
ecNumber	3.4.23.34	commentary		
ecNumber	3.4.23.45	commentary	healthy and trisomy 21 patients	
ecNumber	3.4.23.45	commentary	3 different forms: A,B and C; healthy and trisomy 21 patients	
ecNumber	3.4.23.45	commentary	patients with myopathies	
ecNumber	3.4.23.45	commentary	enzyme level is decreased in Alzheimers disease patients	
ecNumber	3.4.23.45	commentary	patients with Alzheimers disease, BACE1 and BACE2 levels are found to be decreased in Alzheimers disease patients	
ecNumber	3.4.23.45	commentary	patients with Down syndrome and control individuals, protein levels between the groups do not differ significantly	
ecNumber	3.4.23.45	commentary	patients with Down syndrome, slightly increased mRNA levels but protein level is identical to normal individuals	
ecNumber	3.4.23.45	commentary		
ecNumber	3.4.23.45	commentary	form A; form B; form C	
ecNumber	3.4.23.45	commentary	healthy and trisomy 21 patients	
ecNumber	3.4.23.45	commentary	precursor protein	
ecNumber	3.4.23.45	commentary		
ecNumber	3.4.23.46	commentary	; sporadic Alzheimer's disease patients	
ecNumber	3.4.23.46	commentary		
ecNumber	3.4.23.46	commentary		
ecNumber	3.4.23.50	commentary	HERV K10, belongs to the human endogenous retrovirus K group	
ecNumber	3.4.23.50	commentary	HERV-K, provirus HML-5	
ecNumber	3.4.23.50	commentary		
ecNumber	3.4.23.50	commentary		
ecNumber	3.4.24.B3	commentary	Taiwanese population	
ecNumber	3.4.24.B3	commentary		
ecNumber	3.4.24.B3	commentary	precursor	
ecNumber	3.4.24.B3	commentary	Korean population	
ecNumber	3.4.24.B4	commentary	patients with cutaneous malignant melanoma	
ecNumber	3.4.24.B4	commentary		
ecNumber	3.4.24.B4	commentary	recombinant procollagnase expressed in NSO mouse myeloma cells and secreted to the medium	
ecNumber	3.4.24.B4	commentary	gene Mmp13	
ecNumber	3.4.24.B4	commentary		
ecNumber	3.4.24.B5	commentary	membrane-type-2 matrix metalloprotease	
ecNumber	3.4.24.B5	commentary	membrane-type-1, -type-2 and -type-3 matrix metalloproteases	
ecNumber	3.4.24.B5	commentary		
ecNumber	3.4.24.B5	commentary	membrane-type-1, -type -2 and -type-3 matrix metalloproteases	
ecNumber	3.4.24.B5	commentary	precursor	
ecNumber	3.4.24.B5	commentary		
ecNumber	3.4.24.B6	commentary		
ecNumber	3.4.24.B6	commentary	recombinant enzyme	
ecNumber	3.4.24.B6	commentary		
ecNumber	3.4.24.7	commentary	HSFC	
ecNumber	3.4.24.7	commentary	DNA repair-deficient/cancer-prone xeroderma pigmentosum group C patients, Caucasian and Black	
ecNumber	3.4.24.7	commentary	vernal keratoconjunctivitis patients	
ecNumber	3.4.24.7	commentary	recipients of heart transplantation	
ecNumber	3.4.24.7	commentary	patients with primary epithelial ovarian tumors	
ecNumber	3.4.24.7	commentary	patients with atrial fibrillation	
ecNumber	3.4.24.7	commentary	patients with chronic venous insufficiency	
ecNumber	3.4.24.7	commentary		
ecNumber	3.4.24.7	commentary	patients with pediatric acute lung injury	
ecNumber	3.4.24.7	commentary		
ecNumber	3.4.24.B7	commentary	enzyme proform contains a unique cystene switch sequence Pro-His81-Cys-Gly-Xaa-Xaa-Asp	
ecNumber	3.4.24.B7	commentary		
ecNumber	3.4.24.B7	commentary	enzyme shares minimal domain organisation and a threonine residue adjacent to the zinc-binding site with matrilysin	
ecNumber	3.4.24.B7	commentary		
ecNumber	3.4.24.B8	commentary		
ecNumber	3.4.24.B9	commentary	patients with gastric cancer	
ecNumber	3.4.24.B9	commentary	female and male sporadic Alzheimer's disease patients	
ecNumber	3.4.24.B9	commentary		
ecNumber	3.4.24.B9	commentary		
ecNumber	3.4.24.B9	commentary	native short form of ADAM9 lacking the transmembrane and the cytoplasmic domains due to a deletion in the EGF-like domain	
ecNumber	3.4.24.B10	commentary		
ecNumber	3.4.24.B10	commentary	precursor	
ecNumber	3.4.24.B10	commentary		
ecNumber	3.4.24.11	commentary	transgenic expression in mouse	
ecNumber	3.4.24.11	commentary	patients with prostate cancer	
ecNumber	3.4.24.11	commentary	expression in Drosophila melanogaster	
ecNumber	3.4.24.11	commentary	expression in mouse	
ecNumber	3.4.24.11	commentary		
ecNumber	3.4.24.11	commentary		
ecNumber	3.4.24.B11	commentary	recombinant enzyme	
ecNumber	3.4.24.B11	commentary		
ecNumber	3.4.24.B11	commentary		
ecNumber	3.4.24.B11	commentary	single copy gene	
ecNumber	3.4.24.B11	commentary	ATS1_HUMAN	
ecNumber	3.4.24.B11	commentary		
ecNumber	3.4.24.B12	commentary	; recombinant	
ecNumber	3.4.24.B12	commentary	recombinantly expressed in Escherichia coli	
ecNumber	3.4.24.B12	commentary		
ecNumber	3.4.24.B12	commentary		
ecNumber	3.4.24.B12	commentary	precursor	
ecNumber	3.4.24.B12	commentary		
ecNumber	3.4.24.14	commentary		
ecNumber	3.4.24.14	commentary	gene ADAMTS3; gene ADAMTS3	
ecNumber	3.4.24.14	commentary	gene ADAMTS2; gene ADAMTS2	
ecNumber	3.4.24.14	commentary	gene ADAMTS14; gene ADAMTS14	
ecNumber	3.4.24.B14	commentary		
ecNumber	3.4.24.B14	commentary	soluble form, NEP2(s)	
ecNumber	3.4.24.B14	commentary		
ecNumber	3.4.24.15	commentary		
ecNumber	3.4.24.15	commentary		
ecNumber	3.4.24.B15	commentary	gene PHEX	
ecNumber	3.4.24.B15	commentary		
ecNumber	3.4.24.B15	commentary		
ecNumber	3.4.24.16	commentary		
ecNumber	3.4.24.17	commentary	expression in Escherichia coli; prostromelysin (treatment with (aminophenyl)mercuric acetate results in activation)	
ecNumber	3.4.24.17	commentary	expression in Escherichia coli	
ecNumber	3.4.24.17	commentary	catalytic domain lacking both propeptide and C-terminal fragment; expression in Escherichia coli	
ecNumber	3.4.24.17	commentary	prostromelysin expressed in a mouse fibroblast cell line C127 (self activation by incubation at 55&deg;C to a 45000 MW and a 28000 MW form)	
ecNumber	3.4.24.17	commentary	human	
ecNumber	3.4.24.17	commentary	patients with active untreated adult onset Stills disease	
ecNumber	3.4.24.17	commentary	truncated protein lacking C-terminus	
ecNumber	3.4.24.17	commentary	patients with cutaneous malignant melanoma	
ecNumber	3.4.24.17	commentary	women with or without endometriosis	
ecNumber	3.4.24.17	commentary	Koreans including Helicobacter pylori-infected subjects and Helicobacter pylori-negative controls	
ecNumber	3.4.24.17	commentary		
ecNumber	3.4.24.17	commentary		
ecNumber	3.4.24.17	commentary	gene MMP3	
ecNumber	3.4.24.17	commentary	human	
ecNumber	3.4.24.18	commentary	PPH	
ecNumber	3.4.24.18	commentary	patients with diabetes mellitus	
ecNumber	3.4.24.18	commentary	gene MEP1A	
ecNumber	3.4.24.18	commentary		
ecNumber	3.4.24.18	commentary		
ecNumber	3.4.24.18	commentary	subunit alpha	
ecNumber	3.4.24.18	commentary	subunit beta	
ecNumber	3.4.24.B18	commentary		
ecNumber	3.4.24.B18	commentary		
ecNumber	3.4.24.B18	commentary	paraplegin subunit	
ecNumber	3.4.24.B18	commentary	PDB enty 2qz4, gene identification code 116242796	
ecNumber	3.4.24.B18	commentary		
ecNumber	3.4.24.19	commentary	recombinantly expressed in CHO cells	
ecNumber	3.4.24.19	commentary		
ecNumber	3.4.24.19	commentary	human	
ecNumber	3.4.24.19	commentary		
ecNumber	3.4.24.22	commentary	catalytic domain, expression in Escherichia coli	
ecNumber	3.4.24.22	commentary	patients with gastric cancer	
ecNumber	3.4.24.22	commentary	patients with ischemic colitis	
ecNumber	3.4.24.22	commentary		
ecNumber	3.4.24.22	commentary		
ecNumber	3.4.24.22	commentary		
ecNumber	3.4.24.22	commentary		
ecNumber	3.4.24.23	commentary	expression in COS cells	
ecNumber	3.4.24.23	commentary	expression in Escherichia coli	
ecNumber	3.4.24.23	commentary	expression by transfected mouse myeloma cells; expression in Escherichia coli	
ecNumber	3.4.24.23	commentary	fusion protein of glutathione S-transferase and human promatrilysin	
ecNumber	3.4.24.23	commentary	human	
ecNumber	3.4.24.23	commentary	expression in MCF-7 breast cancer cell. Overexpression of enzyme leads to increased invasion and gelatinase activation	
ecNumber	3.4.24.23	commentary	expression in polarized MDCK cell and HCA-7 and Caco2 colon cancer cell lines	
ecNumber	3.4.24.23	commentary	recombinant enzyme	
ecNumber	3.4.24.23	commentary	recombinant enzyme, commercial preparation	
ecNumber	3.4.24.23	commentary	patients with ischemic colitis	
ecNumber	3.4.24.23	commentary	patients with pT3 rectosigmoid cancer	
ecNumber	3.4.24.23	commentary	Brasilian population	
ecNumber	3.4.24.23	commentary	Finnish population	
ecNumber	3.4.24.23	commentary	gene rs11568818	
ecNumber	3.4.24.23	commentary	Taiwanese population	
ecNumber	3.4.24.23	commentary	Egyptian women	
ecNumber	3.4.24.23	commentary	Japanese population	
ecNumber	3.4.24.23	commentary		
ecNumber	3.4.24.23	commentary	patients with colorectal cancer	
ecNumber	3.4.24.23	commentary	curatively resected colorectal cancer patients	
ecNumber	3.4.24.23	commentary	gene MMP7	
ecNumber	3.4.24.23	commentary		
ecNumber	3.4.24.24	commentary	recombinant enzyme expressed in NSO mouse myeloma cells	
ecNumber	3.4.24.24	commentary	recombinant enzyme expressed in a Vaccinia virus-mammalian cell expression system	
ecNumber	3.4.24.24	commentary	recombinant wild-type from a myeloma cell expression system	
ecNumber	3.4.24.24	commentary	expression in Escherichia coli	
ecNumber	3.4.24.24	commentary	synthetic gene in which two polypeptide fragments of the catalytic domain are joined with the deletion of the 19000 MW fibronectin-like insert of the catalytic domain, expressed in Escherichia coli	
ecNumber	3.4.24.24	commentary	human	
ecNumber	3.4.24.24	commentary	patients with degenerative disc disease	
ecNumber	3.4.24.24	commentary	patients with pleural effusions, such as malignant pleural effusion, breast carcinoma or lung carcinoma	
ecNumber	3.4.24.24	commentary	patients with benign prostate hyperplasia or prostate cancer	
ecNumber	3.4.24.24	commentary	patients with oral squamous cell carcinomas	
ecNumber	3.4.24.24	commentary	recombinant enzyme	
ecNumber	3.4.24.24	commentary	patients with bladder cancer	
ecNumber	3.4.24.24	commentary	MMP-2 is a constitutive enzyme	
ecNumber	3.4.24.24	commentary		
ecNumber	3.4.24.24	commentary	human	
ecNumber	3.4.24.24	commentary		
ecNumber	3.4.24.27	commentary		
ecNumber	3.4.24.B27	commentary		
ecNumber	3.4.24.B28	commentary		
ecNumber	3.4.24.B28	commentary		
ecNumber	3.4.24.34	commentary	human	
ecNumber	3.4.24.34	commentary		
ecNumber	3.4.24.34	commentary	human	
ecNumber	3.4.24.34	commentary		
ecNumber	3.4.24.35	commentary	human	
ecNumber	3.4.24.35	commentary	glaucoma patients with leaking or overhanging blebs	
ecNumber	3.4.24.35	commentary	patients with proliferative diabetic retinopathy	
ecNumber	3.4.24.35	commentary	patients with sympathetic ophthalmia	
ecNumber	3.4.24.35	commentary	recombinant enzyme	
ecNumber	3.4.24.35	commentary	patients with pleural effusions, such as malignant pleural effusion, breast carcinoma or lung carcinoma	
ecNumber	3.4.24.35	commentary	patients with epidermolysis bullosa acquisita and bullous pemphigoid	
ecNumber	3.4.24.35	commentary	children with aseptic and bacterial meningitis	
ecNumber	3.4.24.35	commentary	patients with bladder cancer	
ecNumber	3.4.24.35	commentary	patients with benign prostate hyperplasia, localized prostate cancer or metastatic disease	
ecNumber	3.4.24.35	commentary	patients with vascular dementia and Alzheimer disease	
ecNumber	3.4.24.35	commentary		
ecNumber	3.4.24.35	commentary	gene MMP9	
ecNumber	3.4.24.35	commentary		
ecNumber	3.4.24.35	commentary	human	
ecNumber	3.4.24.46	commentary	recombinant disintegrin domain of enzyme	
ecNumber	3.4.24.56	commentary	human	
ecNumber	3.4.24.56	commentary	healthy individuals and patients with Alzheimers disease with cerebral amyloid angiopathy	
ecNumber	3.4.24.56	commentary	patients with diabetes	
ecNumber	3.4.24.56	commentary	chromosome 10-linked Alzheimer disease families	
ecNumber	3.4.24.56	commentary	Finnish population	
ecNumber	3.4.24.56	commentary	patients with sporadic and familial Alzheimer's disease	
ecNumber	3.4.24.56	commentary	Chinese Han populations	
ecNumber	3.4.24.56	commentary	Chinese population	
ecNumber	3.4.24.56	commentary		
ecNumber	3.4.24.56	commentary	isoform IDE-15a using the canonical exon 15a; identification of six distinct enzyme transcripts, in isoform IDE-15b exon 15b replaces the canonical exon 15a	
ecNumber	3.4.24.56	commentary		
ecNumber	3.4.24.56	commentary	cf. EC 3.4.23.45	
ecNumber	3.4.24.57	commentary		
ecNumber	3.4.24.59	commentary		
ecNumber	3.4.24.60	commentary		
ecNumber	3.4.24.61	commentary		
ecNumber	3.4.24.61	commentary		
ecNumber	3.4.24.62	commentary		
ecNumber	3.4.24.63	commentary		
ecNumber	3.4.24.63	commentary	gene MEP1B	
ecNumber	3.4.24.63	commentary		
ecNumber	3.4.24.64	commentary		
ecNumber	3.4.24.65	commentary	human	
ecNumber	3.4.24.65	commentary	MMP-12 expressed in Oryctolagus cuniculus	
ecNumber	3.4.24.65	commentary	recombinant	
ecNumber	3.4.24.65	commentary		
ecNumber	3.4.24.65	commentary		
ecNumber	3.4.24.65	commentary	human	
ecNumber	3.4.24.71	commentary	human	
ecNumber	3.4.24.71	commentary	isozymes ECE-1a, ECE-1b, ECE-1c, and ECE-1d	
ecNumber	3.4.24.71	commentary	4 isozymes ECE-1a-d	
ecNumber	3.4.24.71	commentary	isozymes ECE-1a-d	
ecNumber	3.4.24.71	commentary	4 isoforms of endothelin-converting enzyme-1, ECE-1a-d	
ecNumber	3.4.24.71	commentary	Chinese population, ECE1 shows four isoforms, ECE-1a, ECE-1b, ECE-1c and ECE-1d, gene ECE-1b	
ecNumber	3.4.24.71	commentary	4 variants of isozyme ECE-1, ECE-1a, 1b, 1c and 1d	
ecNumber	3.4.24.71	commentary		
ecNumber	3.4.24.71	commentary		
ecNumber	3.4.24.72	commentary		
ecNumber	3.4.24.79	commentary	healthy individuals and patients with symptomatic atherosclerotic, i.e. chronic limb ischemia	
ecNumber	3.4.24.79	commentary	isozymes PAPP-A and PAPP-A2	
ecNumber	3.4.24.79	commentary		
ecNumber	3.4.24.79	commentary		
ecNumber	3.4.24.80	commentary		
ecNumber	3.4.24.80	commentary	cDNA fragment coding for peptide Ala21-Ser538 of the full-length MT1-MMP	
ecNumber	3.4.24.80	commentary		
ecNumber	3.4.24.81	commentary	cell line	
ecNumber	3.4.24.81	commentary		
ecNumber	3.4.24.81	commentary	precursor	
ecNumber	3.4.24.81	commentary		
ecNumber	3.4.24.82	commentary	ADAMTS-1 also cleaves versican and aggrecane	
ecNumber	3.4.24.82	commentary	aggrecanase-2, i.e. ADAMTS-5	
ecNumber	3.4.24.82	commentary	ADAMTS stands for: a disintegrin and metalloproteinase with thrombospondin motifs	
ecNumber	3.4.24.82	commentary	ADAMTS stands for: a disintegrin and metalloproteinase with thrombospondin motifs; aggrecanase-2, i.e. ADAMTS-5	
ecNumber	3.4.24.82	commentary	; recombinant	
ecNumber	3.4.24.82	commentary	recombinantly expressed in Escherichia coli	
ecNumber	3.4.24.82	commentary		
ecNumber	3.4.24.82	commentary	aggrecanase-1 i.e. ADAMTS-4	
ecNumber	3.4.24.82	commentary		
ecNumber	3.4.24.82	commentary		
ecNumber	3.4.24.84	commentary		
ecNumber	3.4.24.84	commentary		
ecNumber	3.4.24.85	commentary	recombinant enzyme	
ecNumber	3.4.24.85	commentary		
ecNumber	3.4.24.85	commentary	s2p cloned	
ecNumber	3.4.24.86	commentary	human; human monocytic cell line THP-1	
ecNumber	3.4.24.86	commentary	human; MonoMac 6 cells	
ecNumber	3.4.24.86	commentary	human	
ecNumber	3.4.24.86	commentary	HeLa cells; human	
ecNumber	3.4.24.86	commentary	HeLa cells; human; human monocytic cell line THP-1	
ecNumber	3.4.24.86	commentary	accession number for cytoplasmic domain coding sequence	
ecNumber	3.4.24.86	commentary	human monocytic cell line THP-1	
ecNumber	3.4.24.86	commentary	MonoMac 6 cells; Ntera2/cl.D1, human embryonal carcinoma cell line	
ecNumber	3.4.24.86	commentary	HEK293 cells	
ecNumber	3.4.24.86	commentary	HUVECs	
ecNumber	3.4.24.86	commentary	MonoMac 6 cells	
ecNumber	3.4.24.86	commentary	HEK293 cells; human monocytic cell line THP-1; SH-SY5Y	
ecNumber	3.4.24.86	commentary	recombinant	
ecNumber	3.4.24.86	commentary		
ecNumber	3.4.24.86	commentary		
ecNumber	3.4.24.87	commentary	enzyme is a member of the ADAMTS metalloprotease family, disintegrin and metalloproteinase with thrombospondin type I motif	
ecNumber	3.4.24.87	commentary	genetic analysis of a woman with a family history of chronic recurrent thrombotic thrombocytopenic purpurea and undetectable plasma levels of ADAMTS13 reveals two missense mutations in the heterozygous state: Val88Met substitution in the metalloprotease domain and Gly1239Val substitution in the first CUB domain of ADAMTS13	
ecNumber	3.4.24.87	commentary	ADAMTS13 Val900 polymorphic form	
ecNumber	3.4.24.87	commentary	paroxysmal and chronic atrial fibrillation patients and healthy controls	
ecNumber	3.4.24.87	commentary	diabetic patients and healthy persons	
ecNumber	3.4.24.87	commentary		
ecNumber	3.4.24.87	commentary	ADAMTS-13 precursor	
ecNumber	3.4.24.87	commentary	recombinant	
ecNumber	3.4.24.87	commentary		
ecNumber	3.4.25.1	commentary	expressed in Escherichia coli	
ecNumber	3.4.25.1	commentary		
ecNumber	3.4.25.1	commentary	(subunit alpha 4), P49720 (subunit beta 3), P28072 (subunit beta 6), P25786 (subunit alpha 1), P25787 (subunit alpha 2), P28066 (subunit alpha 5), P60900 (subunit alpha 6), O14818 (subunit alpha 7), P20618 (subunit beta 1), P49721 (subunit beta 2), P28070 (subunit beta 4), P28074 (subunit beta 5), Q99436 (subunit beta 7), P25788 (subunit alpha 3)	
ecNumber	3.4.99.B1	commentary		
ecNumber	3.4.99.B1	commentary		
ecNumber	3.5.1.1	commentary		
ecNumber	3.5.1.1	commentary	children up to 18 years	
ecNumber	3.5.1.1	commentary		
ecNumber	3.5.1.2	commentary	two isozymes, glutaminase K and L, i.e. LGA and KGA	
ecNumber	3.5.1.2	commentary	phosphate-activated isozyme, kidney type isozyme K-PAG and the hepatic type isozyme L-PAG	
ecNumber	3.5.1.2	commentary	two isozymes, glutaminase K and L, i.e. LGA and KGA, or liver-type isozyme and kidney-type isozyme	
ecNumber	3.5.1.2	commentary	isozyme GLS2	
ecNumber	3.5.1.2	commentary	kidney-type glutaminase, KGA or GLS1, glutaminase C, GAC, a splice variant of the gene gls encoding GLS1, and liver-type glutaminase GLS2	
ecNumber	3.5.1.2	commentary	kidney-type glutaminase isoform KGA	
ecNumber	3.5.1.2	commentary		
ecNumber	3.5.1.2	commentary		
ecNumber	3.5.1.2	commentary	kidney-type glutaminase isozyme	
ecNumber	3.5.1.2	commentary	GAC; GAC, a splice variant of isozyme GLS1; GLS1; isozyme GLS1	
ecNumber	3.5.1.2	commentary		
ecNumber	3.5.1.3	commentary	human	
ecNumber	3.5.1.3	commentary		
ecNumber	3.5.1.4	commentary	healthy male individuals	
ecNumber	3.5.1.4	commentary	recombinantly expressed in COS-7 cells	
ecNumber	3.5.1.4	commentary		
ecNumber	3.5.1.4	commentary		
ecNumber	3.5.1.4	commentary	from COS-7 cells transfected with human FAAH-1	
ecNumber	3.5.1.4	commentary		
ecNumber	3.5.1.4	commentary	from COS-7 cells transfected with human FAAH-1	
ecNumber	3.5.1.6	commentary	human	
ecNumber	3.5.1.6	commentary		
ecNumber	3.5.1.6	commentary	gene UPB1	
ecNumber	3.5.1.6	commentary		
ecNumber	3.5.1.6	commentary	gene UPB1	
ecNumber	3.5.1.12	commentary	human	
ecNumber	3.5.1.12	commentary	Hungarian population	
ecNumber	3.5.1.12	commentary		
ecNumber	3.5.1.12	commentary	hepatic glycogen storage disease patients from Argentina	
ecNumber	3.5.1.12	commentary		
ecNumber	3.5.1.12	commentary	gene BTD	
ecNumber	3.5.1.13	commentary		
ecNumber	3.5.1.14	commentary	human	
ecNumber	3.5.1.14	commentary		
ecNumber	3.5.1.14	commentary		
ecNumber	3.5.1.15	commentary	human	
ecNumber	3.5.1.15	commentary		
ecNumber	3.5.1.15	commentary		
ecNumber	3.5.1.15	commentary	gene ASPA	
ecNumber	3.5.1.15	commentary	gene acy2 or ASPA	
ecNumber	3.5.1.20	commentary	human	
ecNumber	3.5.1.23	commentary	five isozymes: acid ceramidase, neutral ceramidase, and three alkaline ceramidases ACER1, ACER2, and ACER3	
ecNumber	3.5.1.23	commentary	ACER1-3	
ecNumber	3.5.1.23	commentary		
ecNumber	3.5.1.23	commentary	precursor	
ecNumber	3.5.1.23	commentary	acid ceramidase ASAH1	
ecNumber	3.5.1.23	commentary	gene ASAH1	
ecNumber	3.5.1.23	commentary		
ecNumber	3.5.1.23	commentary	five isozymes: acid, neutral, phytoalkaline, and alkaline-1 and -2 isozymes	
ecNumber	3.5.1.23	commentary		
ecNumber	3.5.1.23	commentary		
ecNumber	3.5.1.23	commentary	alkaline ceramidase ASAH3	
ecNumber	3.5.1.23	commentary	N-CDase	
ecNumber	3.5.1.23	commentary	neutral ceramidase ASAH2	
ecNumber	3.5.1.23	commentary		
ecNumber	3.5.1.23	commentary		
ecNumber	3.5.1.25	commentary		
ecNumber	3.5.1.26	commentary		
ecNumber	3.5.1.26	commentary		
ecNumber	3.5.1.26	commentary	AGA; gene AGA	
ecNumber	3.5.1.28	commentary		
ecNumber	3.5.1.28	commentary		
ecNumber	3.5.1.28	commentary	PGLYRP2; gene pglyrp2	
ecNumber	3.5.1.31	commentary		
ecNumber	3.5.1.42	commentary		
ecNumber	3.5.1.48	commentary		
ecNumber	3.5.1.52	commentary		
ecNumber	3.5.1.60	commentary		
ecNumber	3.5.1.60	commentary		
ecNumber	3.5.1.88	commentary		
ecNumber	3.5.1.88	commentary		
ecNumber	3.5.1.89	commentary		
ecNumber	3.5.1.89	commentary		
ecNumber	3.5.1.92	commentary		
ecNumber	3.5.1.92	commentary		
ecNumber	3.5.1.92	commentary		
ecNumber	3.5.1.92	commentary		
ecNumber	3.5.1.98	commentary	isoform HDAC1	
ecNumber	3.5.1.98	commentary	isoforms HDAC1 and HDAC2	
ecNumber	3.5.1.98	commentary	patients with chronic obstructive pulmonary disease	
ecNumber	3.5.1.98	commentary		
ecNumber	3.5.1.98	commentary	isoform HDAC-A	
ecNumber	3.5.1.98	commentary	isoform HDAC4	
ecNumber	3.5.1.98	commentary		
ecNumber	3.5.1.98	commentary	isozyme HDAC1	
ecNumber	3.5.1.98	commentary		
ecNumber	3.5.1.98	commentary	isoform HDAC7, class II enzyme, and isoform HDAC3, class I enzyme	
ecNumber	3.5.1.98	commentary		
ecNumber	3.5.1.98	commentary		
ecNumber	3.5.1.98	commentary	isoform HDAC10, enzyme is most similar to isoform HDAC6	
ecNumber	3.5.1.98	commentary	isoform HDAC10, class II enzyme	
ecNumber	3.5.1.98	commentary	isoform HDAC11	
ecNumber	3.5.1.98	commentary	isoform HDAC8	
ecNumber	3.5.1.98	commentary	isoform HDAC8, class I enzyme	
ecNumber	3.5.1.98	commentary	isoforms HDAC1, HDAC3, HDAC8	
ecNumber	3.5.1.98	commentary	histone deacetylase 8	
ecNumber	3.5.1.98	commentary	isozyme HDAC8	
ecNumber	3.5.1.98	commentary		
ecNumber	3.5.1.98	commentary	isoform HDAC6, contains two potentially functional catalytic domains	
ecNumber	3.5.1.98	commentary		
ecNumber	3.5.1.98	commentary	isozyme HDAC6	
ecNumber	3.5.1.98	commentary	isoform HDAC9, class II enzyme with several alternatively spliced isoforms	
ecNumber	3.5.1.99	commentary	recombinant	
ecNumber	3.5.1.99	commentary		
ecNumber	3.5.1.99	commentary		
ecNumber	3.5.1.99	commentary		
ecNumber	3.5.1.109	commentary	patients with atopic dermatitis	
ecNumber	3.5.1.109	commentary		
ecNumber	3.5.1.114	commentary		
ecNumber	3.5.1.121	commentary		
ecNumber	3.5.1.122	commentary		
ecNumber	3.5.1.124	commentary		
ecNumber	3.5.2.2	commentary	human	
ecNumber	3.5.2.2	commentary		
ecNumber	3.5.2.3	commentary		
ecNumber	3.5.2.3	commentary		
ecNumber	3.5.2.9	commentary	human	
ecNumber	3.5.2.9	commentary	breast cancer cell line MCF7; human	
ecNumber	3.5.2.9	commentary		
ecNumber	3.5.2.9	commentary		
ecNumber	3.5.2.10	commentary		
ecNumber	3.5.2.17	commentary		
ecNumber	3.5.3.1	commentary	2 isoenzymes	
ecNumber	3.5.3.1	commentary	isozyme type II	
ecNumber	3.5.3.1	commentary	isozyme II	
ecNumber	3.5.3.1	commentary	patients with cystic fibrosis, before and after 14 days of antibiotic treatment for pulmonary exacerbation	
ecNumber	3.5.3.1	commentary	isoform arginase II	
ecNumber	3.5.3.1	commentary	outpatients with sickle cell disease	
ecNumber	3.5.3.1	commentary	isoforms arginase-I and arginase-II	
ecNumber	3.5.3.1	commentary	recombinat isoform arginase I	
ecNumber	3.5.3.1	commentary	control and physician-diagnosed asthma patients	
ecNumber	3.5.3.1	commentary	patients with histologically proven carcinoma of the gallbladder and 20 patients with cholecystitis	
ecNumber	3.5.3.1	commentary		
ecNumber	3.5.3.1	commentary	isoform arginase I	
ecNumber	3.5.3.1	commentary	control and physician-diagnosed asthma patients	
ecNumber	3.5.3.1	commentary	patients with liver cirrhosis or metastatic tumors	
ecNumber	3.5.3.1	commentary		
ecNumber	3.5.3.1	commentary	patients with liver cirrhosis or metastatic tumors	
ecNumber	3.5.3.1	commentary		
ecNumber	3.5.3.6	commentary		
ecNumber	3.5.3.8	commentary		
ecNumber	3.5.3.10	commentary		
ecNumber	3.5.3.11	commentary		
ecNumber	3.5.3.11	commentary		
ecNumber	3.5.3.15	commentary	enzyme isoform V	
ecNumber	3.5.3.15	commentary	rheumatoid arthritis patients	
ecNumber	3.5.3.15	commentary	peptidylarginine deiminase 2	
ecNumber	3.5.3.15	commentary	patients with Alzheimer's disease	
ecNumber	3.5.3.15	commentary	gene padi4, isozyme PADI4	
ecNumber	3.5.3.15	commentary	isozyme PAD4	
ecNumber	3.5.3.15	commentary		
ecNumber	3.5.3.15	commentary	PAD6; isozyme PAD6	
ecNumber	3.5.3.15	commentary		
ecNumber	3.5.3.15	commentary	peptidylarginine deiminase 1	
ecNumber	3.5.3.15	commentary	PAD1	
ecNumber	3.5.3.15	commentary	PAD1; isozyme PAD1	
ecNumber	3.5.3.15	commentary	isozyme PAD1	
ecNumber	3.5.3.15	commentary		
ecNumber	3.5.3.15	commentary	peptidylarginine deiminase 3	
ecNumber	3.5.3.15	commentary	PAD3; isozyme PAD3	
ecNumber	3.5.3.15	commentary		
ecNumber	3.5.3.15	commentary	enzyme isoform PAD4	
ecNumber	3.5.3.15	commentary	recombinant	
ecNumber	3.5.3.15	commentary	PAD4	
ecNumber	3.5.3.15	commentary	isozyme PAD4	
ecNumber	3.5.3.15	commentary		
ecNumber	3.5.3.15	commentary	peptidylarginine deiminase 2, patients with rheumatoid arthitis and healthy controls; peptidylarginine deiminase 4, patients with rheumatoid arthitis and healthy controls	
ecNumber	3.5.3.15	commentary	PAD2	
ecNumber	3.5.3.15	commentary	PAD2; isozyme PAD2	
ecNumber	3.5.3.15	commentary		
ecNumber	3.5.3.18	commentary	transgenic mouse model with oxerexpressed human dimethylarginine dimethylaminohydrolase	
ecNumber	3.5.3.18	commentary	transfected to rats with recombinant adenoviruses	
ecNumber	3.5.3.18	commentary		
ecNumber	3.5.3.18	commentary	isoform DDAH-1	
ecNumber	3.5.3.18	commentary		
ecNumber	3.5.3.18	commentary	2 dimethylarginine dimethylaminohydrolases: DDAH I and II	
ecNumber	3.5.3.18	commentary		
ecNumber	3.5.4.1	commentary	recombinant enzyme	
ecNumber	3.5.4.1	commentary		
ecNumber	3.5.4.2	commentary		
ecNumber	3.5.4.3	commentary	human	
ecNumber	3.5.4.3	commentary		
ecNumber	3.5.4.3	commentary	human	
ecNumber	3.5.4.3	commentary		
ecNumber	3.5.4.4	commentary	CCRF-CEM; larger enzyme: El, smaller enzyme: Es; normal B-cells and T-cell lines MOLT-4; RPMI-8402	
ecNumber	3.5.4.4	commentary	CCRF-CEM; normal B-cells and T-cell lines MOLT-4; RPMI-8402; type 1, 2 and 2-1	
ecNumber	3.5.4.4	commentary	CCRF-CEM; normal B-cells and T-cell lines MOLT-4; RPMI-8402; type small, intermediate and large	
ecNumber	3.5.4.4	commentary	CCRF-CEM; normal B-cells and T-cell lines MOLT-4; RPMI-8402; type a and b	
ecNumber	3.5.4.4	commentary	CCRF-CEM; CCRF-HSB-2; normal B-cells and T-cell lines MOLT-4; RPMI-8402	
ecNumber	3.5.4.4	commentary	CCRF-CEM; expression in Escherichia coli; normal B-cells and T-cell lines MOLT-4; RPMI-8402	
ecNumber	3.5.4.4	commentary	CCRF-CEM; normal B-cells and T-cell lines MOLT-4; RPMI-8402	
ecNumber	3.5.4.4	commentary	small and large isozymes SADA and LADA	
ecNumber	3.5.4.4	commentary	isozymes ADA1 and ADA2	
ecNumber	3.5.4.4	commentary	healthy persons and tuberculous or non-infectious meningitis patients	
ecNumber	3.5.4.4	commentary	isoenzymes ADA1 and ADA2	
ecNumber	3.5.4.4	commentary	female, isozymes ADA1 and ADA2	
ecNumber	3.5.4.4	commentary	healthy and multiple sclerosis patients	
ecNumber	3.5.4.4	commentary	patients with various primary immunodeficiency (PID) syndromes	
ecNumber	3.5.4.4	commentary	patients with familial mediterranean fever	
ecNumber	3.5.4.4	commentary		
ecNumber	3.5.4.4	commentary		
ecNumber	3.5.4.4	commentary	isozyme ADA2	
ecNumber	3.5.4.4	commentary		
ecNumber	3.5.4.5	commentary	expression in mouse	
ecNumber	3.5.4.5	commentary	HeLa cells; human	
ecNumber	3.5.4.5	commentary	hematopoietic cell lines; human	
ecNumber	3.5.4.5	commentary	human	
ecNumber	3.5.4.5	commentary	glioblastoma multiforme (GBM) patients	
ecNumber	3.5.4.5	commentary		
ecNumber	3.5.4.6	commentary	4 isoenzymes	
ecNumber	3.5.4.6	commentary	AMPD1, AMPD2 and AMPD3	
ecNumber	3.5.4.6	commentary	C34T mutation of the AMPD1 gene is detected in a elite, male white endurance runner (28 years of age). World class status in endurance running can be reached despite partial deficiency in muscle AMPD	
ecNumber	3.5.4.6	commentary		
ecNumber	3.5.4.9	commentary	bifunctional domain of trifunctional methylenetetrahydrofolate dehydrogenase/methenyltetrahydrofolate cyclohydrolase/formyltetrahydrofolate synthetase	
ecNumber	3.5.4.9	commentary	human, bifunctional mitochondrial enzyme, trifunctional cytoplasmic enzyme	
ecNumber	3.5.4.9	commentary	bifunctional methenyltetrahydrofolate dehydrogenase/cyclohydrolase	
ecNumber	3.5.4.9	commentary	female	
ecNumber	3.5.4.9	commentary	; enzyme is unique in mammals	
ecNumber	3.5.4.9	commentary		
ecNumber	3.5.4.9	commentary		
ecNumber	3.5.4.B9	commentary		
ecNumber	3.5.4.B9	commentary		
ecNumber	3.5.4.10	commentary		
ecNumber	3.5.4.10	commentary	bifunctional enzyme 5-aminoimidazole-4-carboxamide ribonucleotide transformylase/inosine 5'-monophosphate cyclohydrolase	
ecNumber	3.5.4.10	commentary	bifunctional enzyme 5-amino-4-imidazolecarboxamide ribonucleotide transformylase/inosine 5'-monophosphate cyclohydrolase	
ecNumber	3.5.4.10	commentary	bifunctional aminoimidazole carboxamide ribonucleotide formyltransferase/inosine monophosphate cyclohydrolase	
ecNumber	3.5.4.10	commentary	gene ITGA2	
ecNumber	3.5.4.10	commentary	bifunctional enzyme aminoimidazole-4-carboxamide ribonucleotide transformylase/IMP cyclohydrolase	
ecNumber	3.5.4.10	commentary	bifunctional inosine monophosphate cyclohydrolase/AICAR transformylase. Female infant patient with lack in transformylase activity and about 40% residual enzymic activity, showing massive excretion of 5-amino-4-imidazolecarboxamide riboside, dysmorphic features, severe neurological defects, and congenital blindness	
ecNumber	3.5.4.10	commentary		
ecNumber	3.5.4.12	commentary	human; patients with acute nonlymphocytic leukemia	
ecNumber	3.5.4.12	commentary	human	
ecNumber	3.5.4.12	commentary		
ecNumber	3.5.4.15	commentary		
ecNumber	3.5.4.16	commentary	IMR-32 neuroblastoma cells	
ecNumber	3.5.4.16	commentary		
ecNumber	3.5.4.16	commentary		
ecNumber	3.5.4.34	commentary		
ecNumber	3.5.4.36	commentary		
ecNumber	3.5.4.37	commentary		
ecNumber	3.5.4.37	commentary		
ecNumber	3.5.4.37	commentary		
ecNumber	3.5.4.37	commentary	P55265-1, isoform ADAR1	
ecNumber	3.5.4.37	commentary		
ecNumber	3.5.4.38	commentary		
ecNumber	3.5.4.38	commentary		
ecNumber	3.5.5.1	commentary		
ecNumber	3.5.99.6	commentary		
ecNumber	3.5.99.6	commentary		
ecNumber	3.5.99.6	commentary	isozyme GNPDA1; isozyme GNPDA1	
ecNumber	3.5.99.6	commentary	isozyme GNPDA2; isozyme GNPDA2	
ecNumber	3.6.1.1	commentary		
ecNumber	3.6.1.1	commentary	gene PPA1, isozyme PPase1; gene PPA1, isozyme PPase1	
ecNumber	3.6.1.1	commentary		
ecNumber	3.6.1.1	commentary	gene PPA2, isozyme PPase2, mitochondrial precursor; gene PPA2, isozyme PPase2	
ecNumber	3.6.1.2	commentary		
ecNumber	3.6.1.3	commentary	gene CHD1L	
ecNumber	3.6.1.3	commentary		
ecNumber	3.6.1.5	commentary	hLALP70 and the splice variant hLALP70v	
ecNumber	3.6.1.5	commentary	recombinant enzyme	
ecNumber	3.6.1.5	commentary		
ecNumber	3.6.1.5	commentary		
ecNumber	3.6.1.5	commentary		
ecNumber	3.6.1.5	commentary		
ecNumber	3.6.1.5	commentary		
ecNumber	3.6.1.6	commentary		
ecNumber	3.6.1.7	commentary	human; two isoenzymatic forms: one prevalent in skeletal and cardiac muscle, the other in red blood cells	
ecNumber	3.6.1.7	commentary	human; two different isoenzymes: skeletal muscle and erythrocyte enzyme	
ecNumber	3.6.1.7	commentary	human; several mutants, wild-type, DELTA6 deletion mutant: lacking residues 1-6 at the N-terminus and mutated, R97Q and Y98Q, recombinant; two different isoenzymes: skeletal muscle and erythrocyte enzyme	
ecNumber	3.6.1.7	commentary	human; wild-type and Cys21 mutants: C21A and C21S	
ecNumber	3.6.1.7	commentary	human; recombinant and mutants, R23Q mutant	
ecNumber	3.6.1.7	commentary	C21S mutant; human	
ecNumber	3.6.1.7	commentary	human	
ecNumber	3.6.1.7	commentary		
ecNumber	3.6.1.9	commentary	NPP1; NPP2	
ecNumber	3.6.1.9	commentary		
ecNumber	3.6.1.9	commentary		
ecNumber	3.6.1.9	commentary	NPP3	
ecNumber	3.6.1.9	commentary		
ecNumber	3.6.1.9	commentary	NPP1	
ecNumber	3.6.1.11	commentary		
ecNumber	3.6.1.12	commentary		
ecNumber	3.6.1.12	commentary		
ecNumber	3.6.1.13	commentary	gene NUDT5	
ecNumber	3.6.1.13	commentary		
ecNumber	3.6.1.13	commentary	Nudix motif	
ecNumber	3.6.1.13	commentary		
ecNumber	3.6.1.13	commentary		
ecNumber	3.6.1.14	commentary		
ecNumber	3.6.1.15	commentary		
ecNumber	3.6.1.17	commentary		
ecNumber	3.6.1.17	commentary		
ecNumber	3.6.1.17	commentary		
ecNumber	3.6.1.17	commentary		
ecNumber	3.6.1.18	commentary		
ecNumber	3.6.1.22	commentary		
ecNumber	3.6.1.23	commentary	after infection with herpes simplex type 1 virus a distinct species of dUTPase is induced in HeLa S3 cells	
ecNumber	3.6.1.23	commentary	HSV-1-induced dUTPase and KB dUTPase	
ecNumber	3.6.1.23	commentary		
ecNumber	3.6.1.23	commentary	gene DUT; gene DUT	
ecNumber	3.6.1.23	commentary		
ecNumber	3.6.1.28	commentary		
ecNumber	3.6.1.28	commentary		
ecNumber	3.6.1.29	commentary	chinese cancer patients	
ecNumber	3.6.1.29	commentary	gene FHIT	
ecNumber	3.6.1.29	commentary		
ecNumber	3.6.1.29	commentary		
ecNumber	3.6.1.39	commentary		
ecNumber	3.6.1.42	commentary	normal and transforming PCPH proteins: PCPH, PCPH proto-oncogene and mt-PCPH, PCPH oncogene having guanosine diphosphatase activity	
ecNumber	3.6.1.42	commentary		
ecNumber	3.6.1.43	commentary		
ecNumber	3.6.1.45	commentary	gene UGPP	
ecNumber	3.6.1.52	commentary	recombinant enzyme	
ecNumber	3.6.1.52	commentary	isoenzyme hDIPP1, hDIPP2alpha and hDIPP2beta	
ecNumber	3.6.1.52	commentary		
ecNumber	3.6.1.52	commentary		
ecNumber	3.6.1.52	commentary		
ecNumber	3.6.1.52	commentary		
ecNumber	3.6.1.53	commentary		
ecNumber	3.6.1.55	commentary		
ecNumber	3.6.1.56	commentary		
ecNumber	3.6.1.56	commentary	sequence comparison with the Escherichia coli homolog, MutT, which hydrolyzes only 8-oxo-dGTP and 8-oxo-GTP but not oxidized forms of dATP or ATP	
ecNumber	3.6.1.56	commentary		
ecNumber	3.6.1.58	commentary		
ecNumber	3.6.1.58	commentary		
ecNumber	3.6.1.59	commentary		
ecNumber	3.6.1.60	commentary		
ecNumber	3.6.1.60	commentary		
ecNumber	3.6.1.60	commentary		
ecNumber	3.6.1.62	commentary		
ecNumber	3.6.1.62	commentary		
ecNumber	3.6.1.62	commentary		
ecNumber	3.6.1.64	commentary		
ecNumber	3.6.1.64	commentary	bifunctional U8 snoRNA-decapping enzyme and IDP phosphatase	
ecNumber	3.6.1.64	commentary		
ecNumber	3.6.3.1	commentary		
ecNumber	3.6.3.1	commentary	mRNA of ATP8B1; isozyme ATP8B1	
ecNumber	3.6.3.1	commentary		
ecNumber	3.6.3.1	commentary		
ecNumber	3.6.3.1	commentary		
ecNumber	3.6.3.1	commentary		
ecNumber	3.6.3.1	commentary		
ecNumber	3.6.3.1	commentary		
ecNumber	3.6.3.1	commentary		
ecNumber	3.6.3.1	commentary	gene atp8a2	
ecNumber	3.6.3.1	commentary		
ecNumber	3.6.3.1	commentary		
ecNumber	3.6.3.1	commentary		
ecNumber	3.6.3.2	commentary	gene gene MRS2L	
ecNumber	3.6.3.2	commentary		
ecNumber	3.6.3.4	commentary	isozymes ATP7A and ATP7B	
ecNumber	3.6.3.4	commentary	gene ATP7B	
ecNumber	3.6.3.4	commentary	gene ATP7A	
ecNumber	3.6.3.4	commentary	genes ATP7A and ATP7B	
ecNumber	3.6.3.4	commentary		
ecNumber	3.6.3.4	commentary	gene ATP7B	
ecNumber	3.6.3.4	commentary		
ecNumber	3.6.3.4	commentary	ATP7A	
ecNumber	3.6.3.4	commentary	ATP7A and ATP7B	
ecNumber	3.6.3.4	commentary	gene ATP7A	
ecNumber	3.6.3.4	commentary		
ecNumber	3.6.3.4	commentary		
ecNumber	3.6.3.B5	commentary		
ecNumber	3.6.3.B5	commentary		
ecNumber	3.6.3.6	commentary		
ecNumber	3.6.3.6	commentary		
ecNumber	3.6.3.B6	commentary		
ecNumber	3.6.3.7	commentary		
ecNumber	3.6.3.8	commentary	enzyme isoforms PMCA 1, PMCA 2, PMCA 4	
ecNumber	3.6.3.8	commentary	isoform 4b	
ecNumber	3.6.3.8	commentary	isozymes SPCA1 and SPCA2, genes ATP2C1 and ATP2C2	
ecNumber	3.6.3.8	commentary	isozyme 1	
ecNumber	3.6.3.8	commentary	genes ATP2C1 and ATP2C2, isoenzymes SPCA 1 and 2	
ecNumber	3.6.3.8	commentary	isozyme SERCA1	
ecNumber	3.6.3.8	commentary		
ecNumber	3.6.3.8	commentary	gene ATP2C2; gene ATP2C2	
ecNumber	3.6.3.8	commentary		
ecNumber	3.6.3.8	commentary	isozymes SPCA1a-SPCA1d; isozymes 1a-d	
ecNumber	3.6.3.8	commentary		
ecNumber	3.6.3.8	commentary		
ecNumber	3.6.3.9	commentary	9 different isoenzymes	
ecNumber	3.6.3.9	commentary	untrained volunteers	
ecNumber	3.6.3.9	commentary	patients with familial rapid-onset dystonia parkinsonism	
ecNumber	3.6.3.9	commentary	three Na,K-ATPase isozymes, alpha1beta1, alpha2beta1, and alpha3beta1	
ecNumber	3.6.3.9	commentary		
ecNumber	3.6.3.10	commentary		
ecNumber	3.6.3.10	commentary		
ecNumber	3.6.3.10	commentary		
ecNumber	3.6.3.14	commentary		
ecNumber	3.6.3.15	commentary		
ecNumber	3.6.3.16	commentary		
ecNumber	3.6.3.20	commentary		
ecNumber	3.6.3.21	commentary		
ecNumber	3.6.3.27	commentary		
ecNumber	3.6.3.27	commentary		
ecNumber	3.6.3.30	commentary		
ecNumber	3.6.3.43	commentary	ATPase activity associated with transporter associated with antigen processing, TAP	
ecNumber	3.6.3.43	commentary	isozyme 12A	
ecNumber	3.6.3.43	commentary		
ecNumber	3.6.3.43	commentary		
ecNumber	3.6.3.43	commentary		
ecNumber	3.6.3.43	commentary		
ecNumber	3.6.3.43	commentary		
ecNumber	3.6.3.43	commentary		
ecNumber	3.6.3.44	commentary	MRP3	
ecNumber	3.6.3.44	commentary	MRP5	
ecNumber	3.6.3.44	commentary	isoforms ABCB1 and ABCC1	
ecNumber	3.6.3.44	commentary	isoform MDR1/P-glycoprotein	
ecNumber	3.6.3.44	commentary	isoforms ABCG5 and ABCG8	
ecNumber	3.6.3.44	commentary	isoform MDR1	
ecNumber	3.6.3.44	commentary	isoform ABCB1	
ecNumber	3.6.3.44	commentary	gene ABCB1 encoding MDR1	
ecNumber	3.6.3.44	commentary	gene MDR1 encoding Pgp	
ecNumber	3.6.3.44	commentary	gene mdr1 encoding P-gp	
ecNumber	3.6.3.44	commentary	gene MDR1 encodes P-gp	
ecNumber	3.6.3.44	commentary	healthy male Korean volunteers	
ecNumber	3.6.3.44	commentary		
ecNumber	3.6.3.44	commentary	human multidrug resistance gene MDR1 encoding a membrane-bound transporter P-glycoprotein	
ecNumber	3.6.3.44	commentary		
ecNumber	3.6.3.47	commentary	ALDP; PMP70	
ecNumber	3.6.3.47	commentary	isoform ABCD2	
ecNumber	3.6.3.47	commentary		
ecNumber	3.6.3.47	commentary	isoform ABCD1	
ecNumber	3.6.3.49	commentary	patients with hypertriglyceridemia	
ecNumber	3.6.3.49	commentary	isoform CFTR	
ecNumber	3.6.3.49	commentary	Jewish and Arab population in Israel	
ecNumber	3.6.3.49	commentary		
ecNumber	3.6.3.49	commentary	isoform CFTR	
ecNumber	3.6.3.49	commentary		
ecNumber	3.6.3.51	commentary		
ecNumber	3.6.3.51	commentary	the mitochondrial heat shock protein 70, mtHsp70 machinery components are highly conserved among eukaryotes, including humans	
ecNumber	3.6.3.51	commentary		
ecNumber	3.6.3.54	commentary		
ecNumber	3.6.3.54	commentary	ATP7B	
ecNumber	3.6.3.54	commentary		
ecNumber	3.6.3.54	commentary	ATP7A	
ecNumber	3.6.4.1	commentary	non-muscle myosin IIb, recombinant protein expressed in baculovirus expression system	
ecNumber	3.6.4.1	commentary	non-failing, idiopathic and ischemic cardiomyopathic individuals	
ecNumber	3.6.4.1	commentary		
ecNumber	3.6.4.B1	commentary		
ecNumber	3.6.4.B1	commentary	patients with idiopathic inflammatory myopathies	
ecNumber	3.6.4.B1	commentary	isoforms KIF5A, KIF5B, KIF5C	
ecNumber	3.6.4.2	commentary		
ecNumber	3.6.4.3	commentary	human; human cell lines MSU1.1 and HeLa	
ecNumber	3.6.4.3	commentary	human	
ecNumber	3.6.4.3	commentary	recombinant enzyme expressed by baculoviral system	
ecNumber	3.6.4.3	commentary		
ecNumber	3.6.4.3	commentary	human; human cell lines MSU1.1 and HeLa	
ecNumber	3.6.4.3	commentary		
ecNumber	3.6.4.4	commentary	human	
ecNumber	3.6.4.4	commentary	NRK, HeLa and M1 cells	
ecNumber	3.6.4.4	commentary	; isoform Eg5/KSP	
ecNumber	3.6.4.4	commentary	recombinantly expressed in Spodoptera frugiperda	
ecNumber	3.6.4.4	commentary	isoform Rg5	
ecNumber	3.6.4.4	commentary	isoform KSP	
ecNumber	3.6.4.4	commentary	isoform Eg5	
ecNumber	3.6.4.4	commentary	a 391 amino acid long version of human ubiquitous kinesin KIF5B	
ecNumber	3.6.4.4	commentary		
ecNumber	3.6.4.4	commentary	kinesin-1 heavy chain	
ecNumber	3.6.4.4	commentary		
ecNumber	3.6.4.4	commentary		
ecNumber	3.6.4.4	commentary	gene KIF11	
ecNumber	3.6.4.4	commentary		
ecNumber	3.6.4.4	commentary		
ecNumber	3.6.4.4	commentary		
ecNumber	3.6.4.4	commentary		
ecNumber	3.6.4.5	commentary	human, HeLa cells	
ecNumber	3.6.4.5	commentary		
ecNumber	3.6.4.6	commentary	human	
ecNumber	3.6.4.6	commentary	HeLa cells; human embryonic kidney HEK293 cells; human epidermoid carcinoma A-431 cells	
ecNumber	3.6.4.6	commentary		
ecNumber	3.6.4.7	commentary	human	
ecNumber	3.6.4.7	commentary		
ecNumber	3.6.4.7	commentary	PEX1; gene PEX1	
ecNumber	3.6.4.7	commentary	PEX6; gene PEX6	
ecNumber	3.6.4.8	commentary	human, hepatoblastoma HepG2 cells	
ecNumber	3.6.4.8	commentary		
ecNumber	3.6.4.9	commentary	human Hep-2 cells	
ecNumber	3.6.4.9	commentary		
ecNumber	3.6.4.10	commentary	human	
ecNumber	3.6.4.10	commentary	isoform Hsp90	
ecNumber	3.6.4.10	commentary		
ecNumber	3.6.4.10	commentary		
ecNumber	3.6.4.11	commentary	human	
ecNumber	3.6.4.11	commentary	isoform BRG1	
ecNumber	3.6.4.11	commentary	isoforms Brg1 and Brm	
ecNumber	3.6.4.11	commentary	generalized mammalian	
ecNumber	3.6.4.11	commentary		
ecNumber	3.6.4.11	commentary		
ecNumber	3.6.4.11	commentary		
ecNumber	3.6.4.11	commentary	isoform BFG1	
ecNumber	3.6.4.11	commentary		
ecNumber	3.6.4.11	commentary		
ecNumber	3.6.4.12	commentary		
ecNumber	3.6.4.12	commentary		
ecNumber	3.6.4.12	commentary		
ecNumber	3.6.4.12	commentary		
ecNumber	3.6.4.12	commentary		
ecNumber	3.6.4.12	commentary		
ecNumber	3.6.4.12	commentary	gene ChlR1 or DDX11	
ecNumber	3.6.4.12	commentary		
ecNumber	3.6.4.12	commentary		
ecNumber	3.6.4.12	commentary		
ecNumber	3.6.4.13	commentary		
ecNumber	3.6.4.13	commentary		
ecNumber	3.6.4.13	commentary		
ecNumber	3.6.4.13	commentary		
ecNumber	3.6.4.13	commentary		
ecNumber	3.6.4.13	commentary		
ecNumber	3.6.4.13	commentary		
ecNumber	3.6.4.13	commentary		
ecNumber	3.6.4.13	commentary		
ecNumber	3.6.4.13	commentary		
ecNumber	3.6.4.13	commentary		
ecNumber	3.6.4.13	commentary	gene ChlR1 or DDX11	
ecNumber	3.6.4.13	commentary		
ecNumber	3.6.4.13	commentary		
ecNumber	3.6.4.13	commentary		
ecNumber	3.6.4.13	commentary		
ecNumber	3.6.5.1	commentary	transducin GTPase activity	
ecNumber	3.6.5.1	commentary		
ecNumber	3.6.5.1	commentary		
ecNumber	3.6.5.2	commentary	two closely related isoforms, Rap1A and Rap1B encoded by genes rap1a and rap1b	
ecNumber	3.6.5.2	commentary	two Sar1 isoforms Sar1a and Sar1b	
ecNumber	3.6.5.2	commentary		
ecNumber	3.6.5.2	commentary	H-Ras	
ecNumber	3.6.5.2	commentary	K-Ras	
ecNumber	3.6.5.2	commentary		
ecNumber	3.6.5.2	commentary	isozyme Rac2	
ecNumber	3.6.5.2	commentary		
ecNumber	3.6.5.2	commentary		
ecNumber	3.6.5.2	commentary	isozyme Rac3	
ecNumber	3.6.5.2	commentary		
ecNumber	3.6.5.2	commentary		
ecNumber	3.6.5.2	commentary		
ecNumber	3.6.5.2	commentary	RhoA	
ecNumber	3.6.5.2	commentary		
ecNumber	3.6.5.2	commentary		
ecNumber	3.6.5.2	commentary		
ecNumber	3.6.5.2	commentary	isozyme Rac1	
ecNumber	3.6.5.2	commentary		
ecNumber	3.6.5.2	commentary		
ecNumber	3.6.5.2	commentary		
ecNumber	3.6.5.2	commentary	two isoforms of RASL11A transcript with different sizes of 1.6 and 1.2 kb	
ecNumber	3.6.5.2	commentary		
ecNumber	3.6.5.2	commentary		
ecNumber	3.6.5.2	commentary		
ecNumber	3.6.5.2	commentary		
ecNumber	3.6.5.2	commentary		
ecNumber	3.6.5.2	commentary		
ecNumber	3.6.5.2	commentary		
ecNumber	3.6.5.3	commentary		
ecNumber	3.6.5.4	commentary		
ecNumber	3.6.5.5	commentary	recombinant dynamin1	
ecNumber	3.6.5.5	commentary	neuron-specific isoform: dynamin-1	
ecNumber	3.6.5.5	commentary	recombinantly expressed in insect cells	
ecNumber	3.6.5.5	commentary		
ecNumber	3.6.5.5	commentary	three dynamin isoforms, dynamin1-dynamin3, and multiple splice variants for each of the three dynamins	
ecNumber	3.6.5.5	commentary		
ecNumber	3.6.5.5	commentary		
ecNumber	3.6.5.5	commentary		
ecNumber	3.6.5.5	commentary		
ecNumber	3.6.5.5	commentary		
ecNumber	3.6.5.5	commentary		
ecNumber	3.6.5.6	commentary		
ecNumber	3.6.99.B1	commentary	healthy persons and patients with sickle cell disease	
ecNumber	3.6.99.B1	commentary		
ecNumber	3.6.99.B1	commentary	PLSCR1	
ecNumber	3.6.99.B1	commentary	PLSCR4	
ecNumber	3.6.99.B1	commentary	PLSCR3	
ecNumber	3.6.99.B1	commentary	PLSCR2	
ecNumber	3.7.1.2	commentary		
ecNumber	3.7.1.3	commentary		
ecNumber	3.7.1.3	commentary		
ecNumber	3.7.1.4	commentary		
ecNumber	3.7.1.4	commentary		
ecNumber	3.7.1.5	commentary	isoform 2	
ecNumber	3.9.1.3	commentary		
ecNumber	3.9.1.3	commentary		
ecNumber	3.10.1.1	commentary	an adult Sanfilippo type A patient with homozygous mutation R206P in the sulfamidase gene shows a mild clinical phenotype characterized essentially by a moderate nonevolving metal retardation, polymorphism R456H is also found	
ecNumber	3.10.1.1	commentary	gene SGSH	
ecNumber	3.10.1.1	commentary		
ecNumber	3.10.1.1	commentary		
ecNumber	4.1.1.3	commentary		
ecNumber	4.1.1.6	commentary		
ecNumber	4.1.1.6	commentary	human gastric cancer cell lines SGC7901	
ecNumber	4.1.1.9	commentary	male, normal and with malonic aciduria	
ecNumber	4.1.1.9	commentary		
ecNumber	4.1.1.9	commentary	gene MLYCD	
ecNumber	4.1.1.9	commentary		
ecNumber	4.1.1.15	commentary	patients with diabetes and thyroid autoimmune diseases	
ecNumber	4.1.1.15	commentary	isoform GAD67, patients diagnosed with major unipolar depression	
ecNumber	4.1.1.15	commentary	recombinant isoforms GAD65 and GAD67	
ecNumber	4.1.1.15	commentary	recombinant isoform GAD67	
ecNumber	4.1.1.15	commentary	isoform GAD65 and GAD67	
ecNumber	4.1.1.15	commentary	coexpression with murine IL-4 in tobacco	
ecNumber	4.1.1.15	commentary	isoform GAD65, comparison with goldfish isoform GAD65	
ecNumber	4.1.1.15	commentary	isoform GAD65	
ecNumber	4.1.1.15	commentary	type 1 diabetes mellitus patients	
ecNumber	4.1.1.15	commentary	alcohol dependent and non-alcohol dependent individuals of Irish origin, male and female	
ecNumber	4.1.1.15	commentary	two isozymes Gad65 and GAd67, male and female Graves' disease patients	
ecNumber	4.1.1.15	commentary	isozymes GAD65 and GAD67	
ecNumber	4.1.1.15	commentary	smaller isoform of glutamate decarboxylase, GAD65	
ecNumber	4.1.1.15	commentary	gene GAD1 encodes the isozyme GAD67	
ecNumber	4.1.1.15	commentary	gene GAD65	
ecNumber	4.1.1.15	commentary		
ecNumber	4.1.1.15	commentary	GAD65	
ecNumber	4.1.1.15	commentary	GAD67	
ecNumber	4.1.1.15	commentary		
ecNumber	4.1.1.17	commentary	patients suffering from Helicobacter pylori-infected gastritis	
ecNumber	4.1.1.17	commentary	patients with colorectal adenoma and adenocarcinoma	
ecNumber	4.1.1.17	commentary	patients with chronic superficial gastritis, chronic atrophic gastritis with and without intestinal metaplasia, gastric dysplasia, and gastric cancer	
ecNumber	4.1.1.17	commentary	gene odc	
ecNumber	4.1.1.17	commentary		
ecNumber	4.1.1.17	commentary		
ecNumber	4.1.1.19	commentary		
ecNumber	4.1.1.19	commentary		
ecNumber	4.1.1.22	commentary		
ecNumber	4.1.1.22	commentary		
ecNumber	4.1.1.23	commentary	bifunctional UMP synthase contains activities of EC 2.4.2.10 and EC 4.1.1.23	
ecNumber	4.1.1.23	commentary		
ecNumber	4.1.1.23	commentary		
ecNumber	4.1.1.28	commentary	human	
ecNumber	4.1.1.28	commentary	heterozygous for mutation G102S, mutation decreases the binding affinity for the substrate, clinical phenotype caused by aromatic L-amino acid decarboxylase deficiency	
ecNumber	4.1.1.28	commentary	Macaca mulatta with parkinsonian syndrome, infused with different doses of adeno-associated virus type 2 including human AADC gene	
ecNumber	4.1.1.28	commentary		
ecNumber	4.1.1.28	commentary	human	
ecNumber	4.1.1.28	commentary		
ecNumber	4.1.1.29	commentary		
ecNumber	4.1.1.29	commentary	patients suffering from autoimmune polyendocrine syndrome type 1	
ecNumber	4.1.1.32	commentary	nondiabetic nonmenopausal women, aged 19 to 54 years	
ecNumber	4.1.1.32	commentary		
ecNumber	4.1.1.32	commentary		
ecNumber	4.1.1.32	commentary	women, aged 45.7 +/- 4.4 years and have body mass index of 30.3 +/- 1.4 kg m-2	
ecNumber	4.1.1.33	commentary		
ecNumber	4.1.1.33	commentary		
ecNumber	4.1.1.36	commentary	human	
ecNumber	4.1.1.36	commentary		
ecNumber	4.1.1.37	commentary	human, italian porphyria cutanea tarda patients	
ecNumber	4.1.1.37	commentary	human	
ecNumber	4.1.1.37	commentary	Danish patients with familial porphyria cutanea tarda	
ecNumber	4.1.1.37	commentary		
ecNumber	4.1.1.37	commentary	human	
ecNumber	4.1.1.37	commentary		
ecNumber	4.1.1.45	commentary	human	
ecNumber	4.1.1.45	commentary		
ecNumber	4.1.1.45	commentary	human	
ecNumber	4.1.1.45	commentary		
ecNumber	4.1.1.50	commentary	recombinant protein, expression in Escherichia coli	
ecNumber	4.1.1.50	commentary	enzyme alpha subunit	
ecNumber	4.1.1.50	commentary		
ecNumber	4.1.1.50	commentary		
ecNumber	4.1.1.50	commentary	proenzyme	
ecNumber	4.1.1.53	commentary	human	
ecNumber	4.1.1.65	commentary		
ecNumber	4.1.1.71	commentary		
ecNumber	4.1.1.72	commentary	simultaneous expression of human alpha-subunit and bovine beta-subunit of enzyme in Escherichia coli	
ecNumber	4.1.1.72	commentary		
ecNumber	4.1.1.84	commentary		
ecNumber	4.1.1.84	commentary	UVB-induced	
ecNumber	4.1.1.84	commentary		
ecNumber	4.1.1.90	commentary		
ecNumber	4.1.1.90	commentary		
ecNumber	4.1.1.90	commentary		
ecNumber	4.1.1.94	commentary		
ecNumber	4.1.2.4	commentary		
ecNumber	4.1.2.13	commentary	patients with fructose intolerance	
ecNumber	4.1.2.13	commentary		
ecNumber	4.1.2.13	commentary		
ecNumber	4.1.2.13	commentary		
ecNumber	4.1.2.26	commentary		
ecNumber	4.1.2.27	commentary	expression in HEK293 cell	
ecNumber	4.1.2.27	commentary	expression in HEK293 or A459 cells	
ecNumber	4.1.2.27	commentary	breast cancer patient	
ecNumber	4.1.2.27	commentary		
ecNumber	4.1.2.27	commentary		
ecNumber	4.1.3.3	commentary		
ecNumber	4.1.3.3	commentary		
ecNumber	4.1.3.4	commentary	human, mitochondrial and peroxisomal enzyme	
ecNumber	4.1.3.4	commentary	recombinant enzyme	
ecNumber	4.1.3.4	commentary	normal and patients with Zellweger syndrome	
ecNumber	4.1.3.4	commentary	Spanish patients with the Mediterranean nonsense mutation G109T. The mutation can produce aberrant splicing with three mRNA variants: one of the expected size, the second with deletion of exon 2, and the third with deletion of exons 2 and 3	
ecNumber	4.1.3.4	commentary	E37X is a common HMGCL mutation in Portuguese patients with 3-hydroxy-3-methylglutaric CoA lyase deficiency	
ecNumber	4.1.3.4	commentary		
ecNumber	4.1.3.4	commentary	mitochondrial precursor	
ecNumber	4.1.3.4	commentary		
ecNumber	4.1.3.6	commentary		
ecNumber	4.1.3.6	commentary		
ecNumber	4.1.3.16	commentary		
ecNumber	4.1.99.1	commentary		
ecNumber	4.1.99.3	commentary		
ecNumber	4.1.99.13	commentary		
ecNumber	4.1.99.22	commentary		
ecNumber	4.1.99.22	commentary		
ecNumber	4.2.1.1	commentary	American Negroes	
ecNumber	4.2.1.1	commentary	wild-type carbonic anhydrase I and active-site mutants V62N, H67N, H200T, double-mutant V62N,H67N, and triple-mutant V62H,H67N,H200T. Wild-type carbonic anhydrase II and active site mutant enzymes N62V, N67H and T200H	
ecNumber	4.2.1.1	commentary	carbonic anhydrase I, II and III; carbonic anhydrase IV	
ecNumber	4.2.1.1	commentary	carbonic anhydrase II; carbonic anhydrase IV	
ecNumber	4.2.1.1	commentary	carbonic anhydrase II	
ecNumber	4.2.1.1	commentary	carbonic anhydrase III	
ecNumber	4.2.1.1	commentary	carbonic anhydrase IV	
ecNumber	4.2.1.1	commentary	human	
ecNumber	4.2.1.1	commentary	recombinant	
ecNumber	4.2.1.1	commentary	isozyme CAIX	
ecNumber	4.2.1.1	commentary	isozymes hCA I, hCA II, hCA IX, and hCA XII	
ecNumber	4.2.1.1	commentary	isozymes, hCA I, hCA II, hCA IX, and hCA XII	
ecNumber	4.2.1.1	commentary	isozymes I, II, IX and XII	
ecNumber	4.2.1.1	commentary	isozymes hCA I, II, III, VII and XIII	
ecNumber	4.2.1.1	commentary	isozymes carbonic anhydrase I and II	
ecNumber	4.2.1.1	commentary		
ecNumber	4.2.1.1	commentary		
ecNumber	4.2.1.1	commentary	recombinant	
ecNumber	4.2.1.1	commentary		
ecNumber	4.2.1.1	commentary		
ecNumber	4.2.1.1	commentary		
ecNumber	4.2.1.1	commentary		
ecNumber	4.2.1.1	commentary	no expression of carbonic anhydrase XV	
ecNumber	4.2.1.1	commentary		
ecNumber	4.2.1.1	commentary		
ecNumber	4.2.1.1	commentary		
ecNumber	4.2.1.1	commentary		
ecNumber	4.2.1.1	commentary		
ecNumber	4.2.1.1	commentary	recombinant	
ecNumber	4.2.1.1	commentary	isozyme CA IX	
ecNumber	4.2.1.1	commentary		
ecNumber	4.2.1.1	commentary	carbonic anhydrase 14 precursor; recombinant	
ecNumber	4.2.1.1	commentary		
ecNumber	4.2.1.1	commentary		
ecNumber	4.2.1.2	commentary	homozygous carriers of the mutation Q376P suffer from severe encephalopthy and die at a young age	
ecNumber	4.2.1.2	commentary		
ecNumber	4.2.1.2	commentary		
ecNumber	4.2.1.3	commentary		
ecNumber	4.2.1.3	commentary	bifunctional iron regulatory protein and cytosolic acontiatse	
ecNumber	4.2.1.3	commentary	IRP1	
ecNumber	4.2.1.3	commentary		
ecNumber	4.2.1.3	commentary		
ecNumber	4.2.1.11	commentary	2 forms: homdimeric form and heterodimeric form	
ecNumber	4.2.1.11	commentary	recombinant alpha-enolase	
ecNumber	4.2.1.11	commentary	three genes, ENO1, ENO2 and ENO3 encoding for three isoforms of the enzyme, alpha-enolase, gamma-enolase, and beta-enolase, respectively	
ecNumber	4.2.1.11	commentary		
ecNumber	4.2.1.11	commentary		
ecNumber	4.2.1.11	commentary		
ecNumber	4.2.1.17	commentary		
ecNumber	4.2.1.17	commentary	the classification is ambiguous because the stereochemistry is not exactly determined	
ecNumber	4.2.1.18	commentary		
ecNumber	4.2.1.18	commentary	patients with methylglutaconyl-CoA hydratase deficiency with diverse clinical syndromes	
ecNumber	4.2.1.18	commentary	patients with 3-methylglutaconic aciduria type I	
ecNumber	4.2.1.18	commentary	gene AUH	
ecNumber	4.2.1.18	commentary		
ecNumber	4.2.1.22	commentary	patients with homocystinuria	
ecNumber	4.2.1.22	commentary	Down's syndrome patients	
ecNumber	4.2.1.22	commentary	recombinant	
ecNumber	4.2.1.22	commentary	gene mutations in Venezuelan patients: G85R, T191M, D234N, D444N and Q243X. The mutations present in each country differ from each other depending on the demographic profile	
ecNumber	4.2.1.22	commentary	a cobalt-substituted variant of hCBS, i.e. Co hCBS, in which CoPPIX replaces FePPIX, i.e. heme	
ecNumber	4.2.1.22	commentary		
ecNumber	4.2.1.22	commentary		
ecNumber	4.2.1.24	commentary	workers occupationally exposed to lead	
ecNumber	4.2.1.24	commentary		
ecNumber	4.2.1.24	commentary		
ecNumber	4.2.1.47	commentary	human	
ecNumber	4.2.1.47	commentary		
ecNumber	4.2.1.47	commentary	human	
ecNumber	4.2.1.47	commentary		
ecNumber	4.2.1.48	commentary		
ecNumber	4.2.1.49	commentary		
ecNumber	4.2.1.75	commentary		
ecNumber	4.2.1.75	commentary		
ecNumber	4.2.1.84	commentary		
ecNumber	4.2.1.92	commentary		
ecNumber	4.2.1.96	commentary	wild type and mutant enzymes E57A, H61A, H62A, H79A, Y69F, and D60A and double-mutant H61A,H62A expressed in Escherichia coli	
ecNumber	4.2.1.96	commentary	wild type and mutant enzymes Cys81Ser and Cys81Arg	
ecNumber	4.2.1.96	commentary		
ecNumber	4.2.1.96	commentary		
ecNumber	4.2.1.107	commentary		
ecNumber	4.2.1.109	commentary	gene mtnB	
ecNumber	4.2.1.109	commentary		
ecNumber	4.2.1.119	commentary		
ecNumber	4.2.1.119	commentary	2-enoyl-CoA hydratase 2 is the middle part of the mammalian peroxisomal multifunctional enzyme type 2 (MFE-2)	
ecNumber	4.2.1.130	commentary		
ecNumber	4.2.1.134	commentary		
ecNumber	4.2.1.152	commentary		
ecNumber	4.2.2.1	commentary	recombinant	
ecNumber	4.2.2.1	commentary	recombinant hyaluronidase enzyme (rHuPH20)	
ecNumber	4.2.2.1	commentary	several different isozymes	
ecNumber	4.2.2.1	commentary		
ecNumber	4.2.2.1	commentary		
ecNumber	4.2.2.3	commentary		
ecNumber	4.2.2.5	commentary		
ecNumber	4.2.2.7	commentary		
ecNumber	4.2.2.8	commentary		
ecNumber	4.2.2.19	commentary		
ecNumber	4.2.3.12	commentary		
ecNumber	4.2.3.12	commentary	cloned in Escherichia coli	
ecNumber	4.2.3.12	commentary		
ecNumber	4.2.3.134	commentary		
ecNumber	4.2.99.B1	commentary		
ecNumber	4.2.99.B1	commentary		
ecNumber	4.2.99.B1	commentary	the 8-kDa-domain of pol lambda, residues 240-325 show high amino acid similarity (30%) with that of pol beta, catalyzing the same reaction, residues 1-87, UniProt-ID: P06746	
ecNumber	4.2.99.18	commentary	endonuclease A	
ecNumber	4.2.99.18	commentary	expressed in fibroblasts of Mus musculus	
ecNumber	4.2.99.18	commentary		
ecNumber	4.2.99.18	commentary		
ecNumber	4.2.99.18	commentary	recombinant	
ecNumber	4.2.99.18	commentary	human sequence	
ecNumber	4.2.99.18	commentary		
ecNumber	4.2.99.18	commentary		
ecNumber	4.3.1.3	commentary	patients with histidinemia. Identification of four missense mutations within the histidase gene: R322P, P259L, R206T and R208L	
ecNumber	4.3.1.3	commentary		
ecNumber	4.3.1.4	commentary		
ecNumber	4.3.1.4	commentary		
ecNumber	4.3.1.7	commentary		
ecNumber	4.3.1.17	commentary	bifunctional enzyme, racemization of serine and elimination of L-serine and L-serine-O-sulfate to form pyruvate	
ecNumber	4.3.1.17	commentary		
ecNumber	4.3.1.17	commentary		
ecNumber	4.3.1.17	commentary		
ecNumber	4.3.2.1	commentary	mutations in ASL result in the clinical condition argininosuccinic aciduria, an autosomal recessive disorder	
ecNumber	4.3.2.1	commentary	ASL deficiency results in the autosomal, recessive disorder argininosuccinic aciduria	
ecNumber	4.3.2.1	commentary	mutations in ASL result the clinical condition argininosuccinate aciuria	
ecNumber	4.3.2.1	commentary		
ecNumber	4.3.2.1	commentary		
ecNumber	4.3.2.2	commentary	normal and mutant enzyme S413P	
ecNumber	4.3.2.2	commentary	4 normal cell lines: 894, 1707, 1502 and 1454, 2 cell lines from patients with infantile autism: 1751, 1753	
ecNumber	4.3.2.2	commentary	Polish patients with adenylosuccinate lyase deficiency	
ecNumber	4.3.2.2	commentary		
ecNumber	4.3.2.2	commentary	gene ADSL	
ecNumber	4.3.2.2	commentary		
ecNumber	4.3.2.5	commentary	EC 1.14.17.3 (PHM) and EC 4.3.2.5 (PAL) are part of a bifunctional protein	
ecNumber	4.3.2.5	commentary		
ecNumber	4.3.2.5	commentary		
ecNumber	4.3.2.7	commentary		
ecNumber	4.3.2.8	commentary		
ecNumber	4.3.2.9	commentary	recombinant	
ecNumber	4.3.2.9	commentary	patients with gastrointestinal fistula during and after enteral feeding	
ecNumber	4.3.2.9	commentary		
ecNumber	4.3.2.9	commentary		
ecNumber	4.3.2.9	commentary		
ecNumber	4.4.1.1	commentary	Northern Chinese Han population	
ecNumber	4.4.1.1	commentary		
ecNumber	4.4.1.1	commentary	two isoforms	
ecNumber	4.4.1.1	commentary		
ecNumber	4.4.1.B1	commentary		
ecNumber	4.4.1.5	commentary	3 isoenzymes	
ecNumber	4.4.1.5	commentary	two isoforms of glyoxalase I showing different electrophoretic properties result from a change in one amino acid residue at psotion 11 (Ala/Gln)	
ecNumber	4.4.1.5	commentary	expressed in bovine aortic endothelial cells	
ecNumber	4.4.1.5	commentary	caucasians	
ecNumber	4.4.1.5	commentary	isoform glyoxalase I	
ecNumber	4.4.1.5	commentary		
ecNumber	4.4.1.5	commentary		
ecNumber	4.4.1.11	commentary		
ecNumber	4.4.1.13	commentary	enzymic activity of branched-chain aminotransferases	
ecNumber	4.4.1.13	commentary	recombinant enzyme expressed in LLC-PK1 cells	
ecNumber	4.4.1.13	commentary		
ecNumber	4.4.1.13	commentary		
ecNumber	4.4.1.16	commentary		
ecNumber	4.4.1.16	commentary		
ecNumber	4.4.1.17	commentary	female patients with microphthalmia with linear skin defects syndrome, i.e. MLS or MIDAS	
ecNumber	4.4.1.17	commentary	possibly associated with microphtalmia with linear skin defects syndrome	
ecNumber	4.4.1.17	commentary		
ecNumber	4.4.1.20	commentary	patients with abdominal aortic aneurysm	
ecNumber	4.4.1.20	commentary		
ecNumber	4.4.1.20	commentary		
ecNumber	4.6.1.1	commentary	isoenzyme AC9	
ecNumber	4.6.1.1	commentary	isoenzyme AC5; isoenzyme AC9	
ecNumber	4.6.1.1	commentary	gene ADCY6	
ecNumber	4.6.1.1	commentary	isozyme AC10, gene ADCY10	
ecNumber	4.6.1.1	commentary	isozyme AC6	
ecNumber	4.6.1.1	commentary		
ecNumber	4.6.1.1	commentary	isoenzyme AC	
ecNumber	4.6.1.1	commentary	isozyme ACVI	
ecNumber	4.6.1.1	commentary	isozyme AC6	
ecNumber	4.6.1.1	commentary	isoenzyme AC3	
ecNumber	4.6.1.1	commentary	isozyme AC3; isozyme AC3	
ecNumber	4.6.1.1	commentary	isoenzyme AC4	
ecNumber	4.6.1.1	commentary	isoenzyme AC8	
ecNumber	4.6.1.1	commentary	isoenzyme AC7	
ecNumber	4.6.1.1	commentary		
ecNumber	4.6.1.1	commentary	gene Adcy7 encoding isozyme AC7	
ecNumber	4.6.1.1	commentary		
ecNumber	4.6.1.1	commentary	isoenzyme AC2	
ecNumber	4.6.1.1	commentary	isoenzyme AC1	
ecNumber	4.6.1.1	commentary	isoenzyme AC	
ecNumber	4.6.1.1	commentary		
ecNumber	4.6.1.2	commentary	isozymes GC-D, GC-E, and GC-G	
ecNumber	4.6.1.2	commentary	hypertensive and normotensive Japanese	
ecNumber	4.6.1.2	commentary	male	
ecNumber	4.6.1.2	commentary		
ecNumber	4.6.1.2	commentary		
ecNumber	4.6.1.2	commentary	isozyme GC-A; isozyme GC-A	
ecNumber	4.6.1.2	commentary	GC-B; isozyme GC-B	
ecNumber	4.6.1.2	commentary	isozyme GC-C	
ecNumber	4.6.1.2	commentary		
ecNumber	4.6.1.2	commentary	isozyme GC-F; isozyme GC-F	
ecNumber	4.6.1.2	commentary		
ecNumber	4.6.1.2	commentary		
ecNumber	4.6.1.15	commentary		
ecNumber	4.6.1.15	commentary		
ecNumber	4.6.1.16	commentary		
ecNumber	4.6.1.17	commentary		
ecNumber	4.99.1.1	commentary		
ecNumber	4.99.1.1	commentary		
ecNumber	5.1.1.10	commentary	bifunctional enzyme, racemization of serine and elimination of L-serine and L-serine-O-sulfate to form pyruvate	
ecNumber	5.1.1.18	commentary	bifunctional enzyme, racemization of serine and elimination of L-serine and L-serine-O-sulfate to form pyruvate	
ecNumber	5.1.1.18	commentary	different SRR genetic variants	
ecNumber	5.1.1.18	commentary		
ecNumber	5.1.1.18	commentary		
ecNumber	5.1.3.1	commentary		
ecNumber	5.1.3.1	commentary	malformed and severely mentally retarded girl with a de novo interstitial deletion 46,XX.del(2)(q32.lq34)	
ecNumber	5.1.3.1	commentary		
ecNumber	5.1.3.B1	commentary		
ecNumber	5.1.3.2	commentary	CHO-K1	
ecNumber	5.1.3.2	commentary		
ecNumber	5.1.3.2	commentary		
ecNumber	5.1.3.3	commentary		
ecNumber	5.1.3.3	commentary		
ecNumber	5.1.3.7	commentary		
ecNumber	5.1.3.8	commentary		
ecNumber	5.1.3.14	commentary	mutations in patients with hereditary inclusion body myopathy: G135V/R246W (GNE/GNE domain mutation), UDP-N-acetylglucosamine 2-epimerase activity is 38% of wild-type, N-acetylmannosamine kinase activity is 72% of wild-type. V216A/A631V (GNE/MNK domain mutation), UDP-N-acetylglucosamine 2-epimerase activity is 48% of wild-type, N-acetylmannosamine kinase activity is 63% of wild-type. M712T/M712T (MNK/MNK domain mutation), UDP-N-acetylglucosamine 2-epimerase activity is 83% of wild-type, N-acetylmannosamine kinase activity is 55% of wild-type	
ecNumber	5.1.3.14	commentary	bifunctional UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase, splice variant hGNE2	
ecNumber	5.1.3.14	commentary	bifunctional UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase	
ecNumber	5.1.3.14	commentary	three different isozymes, hGNE1, hGNE2, and hGNE3, from the two splice variants including exon A1, The N-terminus of hGNE2 is prolonged by 31 additional amino acids. The lack of exon 2 in the cDNA encoding for hGNE3 leads to loss of the first 55 amino acids of hGNE1	
ecNumber	5.1.3.14	commentary		
ecNumber	5.1.3.14	commentary		
ecNumber	5.1.3.14	commentary	isoform 2; isoform 3	
ecNumber	5.1.3.14	commentary	gene GNE	
ecNumber	5.1.3.17	commentary	patients with breast cancer	
ecNumber	5.1.3.17	commentary		
ecNumber	5.1.3.17	commentary		
ecNumber	5.1.3.19	commentary		
ecNumber	5.1.3.19	commentary		
ecNumber	5.1.3.19	commentary		
ecNumber	5.1.3.29	commentary		
ecNumber	5.1.99.1	commentary		
ecNumber	5.1.99.1	commentary		
ecNumber	5.1.99.2	commentary		
ecNumber	5.1.99.4	commentary	isoenzyme IIA	
ecNumber	5.1.99.4	commentary	patients with gastric intestinal-type adenocarcinoma and its precursors	
ecNumber	5.1.99.4	commentary	patients with early Barrett's adenocarcinoma treated with surgery	
ecNumber	5.1.99.4	commentary	patients with noninvasive bladder cancer	
ecNumber	5.1.99.4	commentary		
ecNumber	5.1.99.4	commentary	isoenzyme IIAs	
ecNumber	5.1.99.4	commentary	isoenzyme IIB	
ecNumber	5.1.99.4	commentary	isoenzyme IA; isoenzyme IB	
ecNumber	5.1.99.4	commentary		
ecNumber	5.1.99.6	commentary	gene Aibp	
ecNumber	5.2.1.2	commentary		
ecNumber	5.2.1.2	commentary		
ecNumber	5.2.1.8	commentary	wild-type and mutant enzymes W121A, H54Q, R55A, F60A, Q111A, F133A, and H126Q	
ecNumber	5.2.1.8	commentary	recombinant protein, expressed in Escherichia coli	
ecNumber	5.2.1.8	commentary	cyclophilin B, is critical for the efficient replication of the hepatitis C virus genome	
ecNumber	5.2.1.8	commentary	isoform Pin1, recombinant enzyme	
ecNumber	5.2.1.8	commentary	isoform FKBP	
ecNumber	5.2.1.8	commentary	isoform PPIL1	
ecNumber	5.2.1.8	commentary	isoform cyclophilin Cyp-18	
ecNumber	5.2.1.8	commentary	isoform cyclophorin A	
ecNumber	5.2.1.8	commentary	isoform FKBP12, recombinant protein	
ecNumber	5.2.1.8	commentary	isoform FKBP12	
ecNumber	5.2.1.8	commentary	isoform cyclophilin A	
ecNumber	5.2.1.8	commentary	isoform CypA is necessary for the prolactin-induced activation of Janus-activated kinase 2 and the progression of human breast cancer	
ecNumber	5.2.1.8	commentary	isoform cyclophilin B	
ecNumber	5.2.1.8	commentary	isoform Pin1	
ecNumber	5.2.1.8	commentary		
ecNumber	5.2.1.8	commentary		
ecNumber	5.2.1.8	commentary		
ecNumber	5.2.1.8	commentary		
ecNumber	5.2.1.8	commentary		
ecNumber	5.2.1.8	commentary	cyclophilin A	
ecNumber	5.2.1.8	commentary		
ecNumber	5.2.1.8	commentary	isoform FKBP12	
ecNumber	5.2.1.8	commentary		
ecNumber	5.2.1.8	commentary		
ecNumber	5.2.1.8	commentary	isoform Pin1	
ecNumber	5.2.1.8	commentary		
ecNumber	5.2.1.8	commentary	isoform FKBP38	
ecNumber	5.2.1.8	commentary		
ecNumber	5.2.1.8	commentary	peptidylprolyl isomerase containing WD40 repeat	
ecNumber	5.2.1.8	commentary	; isoform cyclophilin J	
ecNumber	5.2.1.8	commentary	gene FKBP14 encodes enzyme FKBP22	
ecNumber	5.2.1.8	commentary		
ecNumber	5.2.1.8	commentary	isoform PPIL1	
ecNumber	5.3.1.1	commentary	multiple forms of triosephosphate isomerase are the consequence of minor post-synthetic alteration(s) of form A, three major forms: A, B, C	
ecNumber	5.3.1.1	commentary	adult, recombinant enzyme	
ecNumber	5.3.1.1	commentary		
ecNumber	5.3.1.1	commentary		
ecNumber	5.3.1.6	commentary		
ecNumber	5.3.1.8	commentary		
ecNumber	5.3.1.9	commentary	4 isoforms: 1, 2 ,3 and 4	
ecNumber	5.3.1.9	commentary	native enzyme and mutant enzymes Thr5 to Ile, Thr224 to Met, Gln343 to Arg, and Asp539 to Asn	
ecNumber	5.3.1.9	commentary	patients with rheumatid arthritis	
ecNumber	5.3.1.9	commentary	patient suffering chronic nonspherocytic hemolytic anemia	
ecNumber	5.3.1.9	commentary	patients with inflammatory arthritic diseases	
ecNumber	5.3.1.9	commentary	phosphoglucose isomerase/autocrine motility factor	
ecNumber	5.3.1.9	commentary	autocrine motility factor/glucose-6-phosphate isomerase	
ecNumber	5.3.1.9	commentary	isozymes PGI1-PGI3	
ecNumber	5.3.1.9	commentary		
ecNumber	5.3.1.9	commentary		
ecNumber	5.3.1.21	commentary		
ecNumber	5.3.1.23	commentary		
ecNumber	5.3.1.23	commentary		
ecNumber	5.3.2.1	commentary		
ecNumber	5.3.2.1	commentary		
ecNumber	5.3.3.1	commentary	enzyme complex of 3beta-hydroxy-5-ene-steroid dehydrogenase and Steroid DELTA-isomerase	
ecNumber	5.3.3.1	commentary		
ecNumber	5.3.3.1	commentary	type I 3beta-hydroxysteroid dehydrogenase/isomerase	
ecNumber	5.3.3.1	commentary	bifunctional 3beta-hydroxysteroid dehydrogenase/isomerase, isoforms type 1 and 2	
ecNumber	5.3.3.1	commentary	bifunctional 3beta-hydroxysteroid dehydrogenase/DELTA5-DELTA4-isomerase, isoform 3betaHSD1; bifunctional 3beta-hydroxysteroid dehydrogenase/DELTA5-DELTA4-isomerase, isoform 3betaHSD2	
ecNumber	5.3.3.1	commentary	isozyme type 1; isozyme type 1	
ecNumber	5.3.3.1	commentary	isozyme type 2; isozyme type 2	
ecNumber	5.3.3.1	commentary		
ecNumber	5.3.3.2	commentary		
ecNumber	5.3.3.2	commentary	isoform IDI2	
ecNumber	5.3.3.2	commentary	type I enzyme	
ecNumber	5.3.3.2	commentary		
ecNumber	5.3.3.2	commentary	isoform 1 and isoform 2	
ecNumber	5.3.3.5	commentary		
ecNumber	5.3.3.5	commentary		
ecNumber	5.3.3.8	commentary	monofunctional enzyme	
ecNumber	5.3.3.8	commentary	at least 2 isoforms in liver: 1. monofunctional mitochondrial enzyme, 2. peroxisomal enzyme forming a part of a multifunctional enzyme	
ecNumber	5.3.3.8	commentary		
ecNumber	5.3.3.8	commentary		
ecNumber	5.3.3.9	commentary	weak activity	
ecNumber	5.3.3.9	commentary		
ecNumber	5.3.3.12	commentary	different isoforms of enzyme	
ecNumber	5.3.3.12	commentary		
ecNumber	5.3.3.12	commentary		
ecNumber	5.3.4.1	commentary	protein disulfide isomerase is identical to the beta-subunit of prolyl-4-hydroxylase; thyroid hormone binding protein is apparently identical to protein disulfide isomerase	
ecNumber	5.3.4.1	commentary	protein disulfide isomerase is identical to the beta-subunit of prolyl-4-hydroxylase	
ecNumber	5.3.4.1	commentary	recombinant enzyme obtained from Escherichia coli strain BL21	
ecNumber	5.3.4.1	commentary	isoform pancreas-specific protein disulfide isomerase homolog, PDIp	
ecNumber	5.3.4.1	commentary	isoform procollagen-proline, 2-oxoglutarate-4-dioxygenase beta subunit	
ecNumber	5.3.4.1	commentary	isoform ERdj5; isoform PDI	
ecNumber	5.3.4.1	commentary	isoform PDI	
ecNumber	5.3.4.1	commentary		
ecNumber	5.3.4.1	commentary	PDIA1	
ecNumber	5.3.4.1	commentary		
ecNumber	5.3.4.1	commentary	ERp72 or PDIA4, respecitvely	
ecNumber	5.3.4.1	commentary		
ecNumber	5.3.4.1	commentary	ERp57	
ecNumber	5.3.4.1	commentary		
ecNumber	5.3.4.1	commentary	PDIA2 precursor	
ecNumber	5.3.4.1	commentary		
ecNumber	5.3.4.1	commentary		
ecNumber	5.3.4.1	commentary	ERp27	
ecNumber	5.3.99.2	commentary	recombinant enzyme	
ecNumber	5.3.99.2	commentary	patients with osteoarthritis	
ecNumber	5.3.99.2	commentary	patients with stable coronary artery disease who underwent diagnostic coronary angiography	
ecNumber	5.3.99.2	commentary	lipocalin-type prostaglandin-D synthase	
ecNumber	5.3.99.2	commentary	patients with acute inflammatory demyelinating polyneuropathy	
ecNumber	5.3.99.2	commentary	patients with HIV infection	
ecNumber	5.3.99.2	commentary	lipocalin-type prostaglandin D synthase. Isoform is identical to beta-trace, a major protein in human cerebrospinal fluid, and acts as both a PGD2-producing enzyme and as an extracellular transporter for lipophilic ligands	
ecNumber	5.3.99.2	commentary	isoform liocalin-type prostaglandin D-synthase	
ecNumber	5.3.99.2	commentary		
ecNumber	5.3.99.2	commentary		
ecNumber	5.3.99.2	commentary		
ecNumber	5.3.99.3	commentary	mPGES expression is induced by interleukin-1beta	
ecNumber	5.3.99.3	commentary	inducible isozyme mPGES-1	
ecNumber	5.3.99.3	commentary	women undergoing treatment for infertility, isozymes mPGES-2, mPGES-1, and cPGES	
ecNumber	5.3.99.3	commentary	isoform mPGES-2	
ecNumber	5.3.99.3	commentary	isoforms mPGES-1, mPGES-2 and cPGES	
ecNumber	5.3.99.3	commentary	isoform mPGES-1	
ecNumber	5.3.99.3	commentary	isoforms mPGES-1 and cPGES	
ecNumber	5.3.99.3	commentary		
ecNumber	5.3.99.3	commentary	microsomal isozyme mPGES-1	
ecNumber	5.3.99.3	commentary		
ecNumber	5.3.99.3	commentary	isozyme microsomal PGE2 synthase-1	
ecNumber	5.3.99.3	commentary	isoform mPGES-2	
ecNumber	5.3.99.4	commentary	recombinant protein	
ecNumber	5.3.99.4	commentary		
ecNumber	5.3.99.4	commentary	recombinant enzyme	
ecNumber	5.3.99.4	commentary		
ecNumber	5.3.99.5	commentary	resonance raman spectrum of recombinant TXAS	
ecNumber	5.3.99.5	commentary	recombinant enzyme	
ecNumber	5.3.99.5	commentary	patients with colorectal carcinoma	
ecNumber	5.3.99.5	commentary	unrelated families of Tunasian and Pakistani origin with Ghosal hematodiaphyseal dysplasia syndrome (GHDD, i.e. Ghosal syndrome), a rare autosomal recessive disorder characterized by increased bone densitiy	
ecNumber	5.3.99.5	commentary		
ecNumber	5.4.2.2	commentary	human	
ecNumber	5.4.2.2	commentary	Li+-treated bipolar patients	
ecNumber	5.4.2.3	commentary		
ecNumber	5.4.2.4	commentary		
ecNumber	5.4.2.4	commentary		
ecNumber	5.4.2.8	commentary	human liver enzyme and recombinant PMM1 from individuals with carbohydrate-deficient glycoprotein syndrome type I	
ecNumber	5.4.2.8	commentary		
ecNumber	5.4.2.8	commentary	isoform alpha-PMM2	
ecNumber	5.4.2.8	commentary		
ecNumber	5.4.2.8	commentary	isoform alpha-PMM1	
ecNumber	5.4.2.8	commentary		
ecNumber	5.4.2.11	commentary	B-type phosphoglycerate mutase	
ecNumber	5.4.2.11	commentary	patient with hereditary sperocytosis and 50% deficiency of enzyme activity in red blood cells	
ecNumber	5.4.2.11	commentary	BB isoenzyme deficiency in a patient with non-spherocytic anemia	
ecNumber	5.4.2.11	commentary		
ecNumber	5.4.2.11	commentary		
ecNumber	5.4.3.7	commentary		
ecNumber	5.4.4.7	commentary		
ecNumber	5.4.99.1	commentary		
ecNumber	5.4.99.2	commentary	expressed in Saccharomyces cerevisiae	
ecNumber	5.4.99.2	commentary		
ecNumber	5.4.99.2	commentary		
ecNumber	5.4.99.7	commentary	recombinant enzyme	
ecNumber	5.4.99.7	commentary		
ecNumber	5.4.99.7	commentary		
ecNumber	5.4.99.B22	commentary		
ecNumber	5.5.1.4	commentary	gene ISYNA1	
ecNumber	5.5.1.4	commentary		
ecNumber	5.5.1.4	commentary		
ecNumber	5.99.1.2	commentary	gene Top1	
ecNumber	5.99.1.2	commentary		
ecNumber	5.99.1.2	commentary		
ecNumber	5.99.1.2	commentary		
ecNumber	5.99.1.3	commentary	2 isoenzymes: IIalpha and IIbeta	
ecNumber	5.99.1.3	commentary	topoisomerase IIalpha	
ecNumber	5.99.1.3	commentary	DNA topoisomerase IIbeta	
ecNumber	5.99.1.3	commentary	isozyme alpha	
ecNumber	5.99.1.3	commentary	isozyme IIalpha	
ecNumber	5.99.1.3	commentary	two isozymes IIalpha and IIbeta	
ecNumber	5.99.1.3	commentary	isozymes IIalpha and IIbeta	
ecNumber	5.99.1.3	commentary	isoforms TopoIIalpha and TopoIIbeta	
ecNumber	5.99.1.3	commentary	recombinant enzyme	
ecNumber	5.99.1.3	commentary	isoforms II alpha and II beta	
ecNumber	5.99.1.3	commentary	isoform IIA	
ecNumber	5.99.1.3	commentary	topoisomerase II, commercial product	
ecNumber	5.99.1.3	commentary	recombinant topoisomerase II	
ecNumber	5.99.1.3	commentary	isoform topoisomerase IIalpha	
ecNumber	5.99.1.3	commentary	isoform IIalpha, enzyme is activated in response to genotoxic stress, and enzyme expression is increased following DNA damage	
ecNumber	5.99.1.3	commentary	isoform IIalpha, commercial product	
ecNumber	5.99.1.3	commentary	isoforms IIalpha and IIbeta	
ecNumber	5.99.1.3	commentary	isoform IIalpha	
ecNumber	5.99.1.3	commentary	gene TOP2A	
ecNumber	5.99.1.3	commentary	isozyme IIbeta	
ecNumber	5.99.1.3	commentary	isozymes alpha and beta	
ecNumber	5.99.1.3	commentary	isozymes topo IIalpha and beta	
ecNumber	5.99.1.3	commentary		
ecNumber	5.99.1.3	commentary	isoform IIalpha	
ecNumber	5.99.1.3	commentary		
ecNumber	5.99.1.3	commentary	topoisomerase IIalpha	
ecNumber	5.99.1.3	commentary	isoform IIbeta	
ecNumber	6.1.1.1	commentary	the enzyme's C-terminal domain is a endothelial monocyte activating polypeptide II-like, i.e. an EMAP II-like, protein with cytokine activity	
ecNumber	6.1.1.1	commentary	gene TyrS	
ecNumber	6.1.1.1	commentary		
ecNumber	6.1.1.1	commentary		
ecNumber	6.1.1.1	commentary		
ecNumber	6.1.1.2	commentary	2 enzyme isoforms by alternative splicing in vivo, i.e. full-length and mini enzyme	
ecNumber	6.1.1.2	commentary		
ecNumber	6.1.1.2	commentary	recombinant purified native and selenomethionyl-enzyme	
ecNumber	6.1.1.2	commentary	gene trpS	
ecNumber	6.1.1.2	commentary		
ecNumber	6.1.1.2	commentary	mitochondrial specific isozyme containing a mitochondrial localization signal sequence	
ecNumber	6.1.1.3	commentary		
ecNumber	6.1.1.3	commentary		
ecNumber	6.1.1.4	commentary	gene LARS1	
ecNumber	6.1.1.4	commentary		
ecNumber	6.1.1.4	commentary	class I enzyme	
ecNumber	6.1.1.4	commentary		
ecNumber	6.1.1.5	commentary		
ecNumber	6.1.1.6	commentary	overexpressed and purified His-tagged enzyme from Escherichia coli	
ecNumber	6.1.1.6	commentary	His-tagged recombinant wild-type purified from Escherichia coli strain DE3, N-terminally truncated recombinant enzyme, comprising amino acid residues 66-597, purified from enzyme-deficient variant Escherichia coli strain DE3	
ecNumber	6.1.1.6	commentary		
ecNumber	6.1.1.6	commentary	1 gene encodes a cytoplasmic isozyme, the second encodes both a cytoplasmic and mitochondrial isozyme, which are differenciated by alternative splicing; 1 gene encodes a cytoplasmic isozyme, the second encodes both a cytoplasmic and mitochondrial isozyme, which are differentiated by alternative splicing	
ecNumber	6.1.1.6	commentary		
ecNumber	6.1.1.6	commentary	sequence alignment of class II LysRS from Homo sapiens, Drosophila melanogaster, Saccharomyces cerevisiae, and Escherichia coli shown	
ecNumber	6.1.1.7	commentary	expression in Pichia sp.	
ecNumber	6.1.1.7	commentary		
ecNumber	6.1.1.9	commentary		
ecNumber	6.1.1.9	commentary	gene VARS2	
ecNumber	6.1.1.9	commentary	cytoplasmic valRS; gene VARS	
ecNumber	6.1.1.10	commentary		
ecNumber	6.1.1.10	commentary	class I enzyme	
ecNumber	6.1.1.10	commentary		
ecNumber	6.1.1.11	commentary	class II enzyme	
ecNumber	6.1.1.11	commentary		
ecNumber	6.1.1.11	commentary		
ecNumber	6.1.1.11	commentary		
ecNumber	6.1.1.12	commentary	expression COS cells	
ecNumber	6.1.1.12	commentary	wild-type and N-terminal 32-residue truncated form (hDRS delta 32) expressed in Escherichia coli	
ecNumber	6.1.1.12	commentary	gene DARS2	
ecNumber	6.1.1.12	commentary	gene DARS2; male, DARS2 gene	
ecNumber	6.1.1.12	commentary		
ecNumber	6.1.1.12	commentary		
ecNumber	6.1.1.12	commentary	gene DARS2	
ecNumber	6.1.1.12	commentary		
ecNumber	6.1.1.14	commentary	gene GARS	
ecNumber	6.1.1.14	commentary		
ecNumber	6.1.1.14	commentary	gene GARS	
ecNumber	6.1.1.14	commentary		
ecNumber	6.1.1.15	commentary	isoform glutamyl-prolyl-tRNA synthetase	
ecNumber	6.1.1.15	commentary		
ecNumber	6.1.1.15	commentary		
ecNumber	6.1.1.16	commentary	gene cysS	
ecNumber	6.1.1.16	commentary		
ecNumber	6.1.1.17	commentary		
ecNumber	6.1.1.18	commentary	enzyme forms a macromolecular protein complex	
ecNumber	6.1.1.18	commentary	purified recombinant His-tagged enzyme expressed in Escherichia coli	
ecNumber	6.1.1.18	commentary		
ecNumber	6.1.1.19	commentary		
ecNumber	6.1.1.20	commentary		
ecNumber	6.1.1.20	commentary	mitochondrial isozyme, class II enzyme	
ecNumber	6.1.1.20	commentary		
ecNumber	6.1.1.20	commentary	class II enzyme	
ecNumber	6.1.1.20	commentary	beta chain	
ecNumber	6.1.1.20	commentary	class II enzyme	
ecNumber	6.1.1.20	commentary	alpha chain	
ecNumber	6.1.1.21	commentary	expression in Cis 1 cells	
ecNumber	6.1.1.21	commentary	His-tagged recombinant deletion mutant lacking the N-terminal 60 amino acid resdiues and His-tagged recombinant N-terminal part comprising residues 1-48	
ecNumber	6.1.1.21	commentary	expression in T24 cell, HeLa cell and L6 cell	
ecNumber	6.1.1.21	commentary	Jo-1-positive patients with myositis	
ecNumber	6.1.1.21	commentary		
ecNumber	6.1.1.21	commentary		
ecNumber	6.1.1.21	commentary	histidyl-tRNA synthetase-like enzyme	
ecNumber	6.1.1.21	commentary		
ecNumber	6.1.1.22	commentary		
ecNumber	6.1.1.22	commentary	phylogenetic analysis, evolutionary development of the enzyme	
ecNumber	6.1.1.22	commentary		
ecNumber	6.1.1.23	commentary	gene DARS2	
ecNumber	6.2.1.1	commentary	patients with hepatocellular carcinoma	
ecNumber	6.2.1.1	commentary		
ecNumber	6.2.1.1	commentary	acetyl-coenzyme A synthetase 2-like, mitochondrial. Precursor	
ecNumber	6.2.1.2	commentary		
ecNumber	6.2.1.3	commentary	heat inactivation does not distinguish between arachidonoyl-CoA synthetase, EC 6.2.1.15, and palmitoyl-CoA synthetase	
ecNumber	6.2.1.3	commentary	palmitoyl-CoA synthetase and arachidonoyl-CoA synthetase, EC 6.2.1.5, are not separate enzymes	
ecNumber	6.2.1.3	commentary	isozyme ACSL5	
ecNumber	6.2.1.3	commentary	isozyme ACSL6	
ecNumber	6.2.1.3	commentary	isozymes ACSL1, ACSL3, and ACSL5	
ecNumber	6.2.1.3	commentary		
ecNumber	6.2.1.3	commentary		
ecNumber	6.2.1.3	commentary		
ecNumber	6.2.1.3	commentary		
ecNumber	6.2.1.3	commentary		
ecNumber	6.2.1.3	commentary		
ecNumber	6.2.1.3	commentary		
ecNumber	6.2.1.4	commentary	gene SUCLG1 encodes the alpha-subunit and SUCLG2 encodes the catalytic beta-subunit	
ecNumber	6.2.1.4	commentary	gene SUCLA2	
ecNumber	6.2.1.4	commentary		
ecNumber	6.2.1.4	commentary	alpha-subunit	
ecNumber	6.2.1.4	commentary	beta-subunit	
ecNumber	6.2.1.5	commentary	gene SUCLA1 encodes the alpha-subunit and gene SUCLA2 encodes the catalytic beta-subunit	
ecNumber	6.2.1.5	commentary	gene SUCLG2	
ecNumber	6.2.1.5	commentary		
ecNumber	6.2.1.5	commentary	alpha-subunit	
ecNumber	6.2.1.5	commentary	beta-subunit	
ecNumber	6.2.1.7	commentary		
ecNumber	6.2.1.15	commentary	palmitoyl-CoA (or unspecific) synthetase activity, EC 6.2.1.3, and arachidonoyl-CoA synthetase activity, are catalyzed by the same enzyme	
ecNumber	6.2.1.15	commentary	arachidonoyl-CoA synthetase is a protein distinct from non-specific long chain acyl-CoA synthetase	
ecNumber	6.2.1.15	commentary		
ecNumber	6.2.1.15	commentary	ACSL4 variant 1	
ecNumber	6.2.1.16	commentary		
ecNumber	6.2.1.16	commentary	89% homology with AACS from rat	
ecNumber	6.2.1.24	commentary		
ecNumber	6.2.1.45	commentary		
ecNumber	6.2.1.45	commentary	eight human E1s	
ecNumber	6.2.1.45	commentary		
ecNumber	6.2.1.45	commentary		
ecNumber	6.2.1.45	commentary		
ecNumber	6.2.1.45	commentary	isoform Uba3	
ecNumber	6.2.1.45	commentary	; isoform UBA5	
ecNumber	6.2.1.45	commentary		
ecNumber	6.3.1.1	commentary	lymphoblastic leukemia patients	
ecNumber	6.3.1.1	commentary		
ecNumber	6.3.1.2	commentary	male Sprague Dawley rats	
ecNumber	6.3.1.2	commentary		
ecNumber	6.3.1.2	commentary		
ecNumber	6.3.1.2	commentary	french population	
ecNumber	6.3.1.4	commentary	lymphoblastic leukemia patients	
ecNumber	6.3.1.4	commentary		
ecNumber	6.3.1.4	commentary	patients with acute lymphoblastic leukemia	
ecNumber	6.3.2.2	commentary	enzyme consists of a catalytic GCLC and a modulatory GCLM subunit encoded by 2 separate gcl genes	
ecNumber	6.3.2.2	commentary	2 subunits encoded by 2 genes	
ecNumber	6.3.2.2	commentary	gene gclC and gclM encoding the two subunits of the enzyme	
ecNumber	6.3.2.2	commentary	Japanese individuals and patients with methamphetamine dependence and induced psychosis, genes gclC and gclM encoding the catalytic and the modifier subunit of the enzyme	
ecNumber	6.3.2.2	commentary	healthy individuals and chronic obstructive pulmonary disease patients, genes gclC and gclM encoding the two subunits of the enzyme	
ecNumber	6.3.2.2	commentary	genes gclC and gclM encoding the two subunits of the enzyme	
ecNumber	6.3.2.2	commentary	activity of the gamma-glutamylcysteine synthetase promoter decreases after indomethacin treatment; leukemia cell. Cells show increased expression of gamma-glutamylcysteine synthetase. Expression decreases by indomethacin treatment	
ecNumber	6.3.2.2	commentary	patients with non-alcoholic steatohepatitis	
ecNumber	6.3.2.2	commentary		
ecNumber	6.3.2.2	commentary	heavy, catalytic subunit	
ecNumber	6.3.2.2	commentary		
ecNumber	6.3.2.2	commentary	light, regulatory subunit	
ecNumber	6.3.2.3	commentary	wild-type and mutant enzymes: Cys294Ala, Cys409Ala, Cys422Ala and Cys294/Cys409/Cys422 to Ala294/Ala409/Ala422	
ecNumber	6.3.2.3	commentary		
ecNumber	6.3.2.3	commentary		
ecNumber	6.3.2.5	commentary		
ecNumber	6.3.2.6	commentary		
ecNumber	6.3.2.6	commentary	gene purCE	
ecNumber	6.3.2.11	commentary		
ecNumber	6.3.2.11	commentary		
ecNumber	6.3.2.17	commentary	human, children	
ecNumber	6.3.2.17	commentary	human	
ecNumber	6.3.2.17	commentary	recombinant	
ecNumber	6.3.2.17	commentary	patients with colorectal cancer	
ecNumber	6.3.2.17	commentary		
ecNumber	6.3.2.25	commentary		
ecNumber	6.3.2.25	commentary		
ecNumber	6.3.2.51	commentary		
ecNumber	6.3.2.51	commentary		
ecNumber	6.3.3.1	commentary		
ecNumber	6.3.3.1	commentary	trifunctional enzyme with AIR synthetase activity, phosphoribosylglycinamide synthetase activity, and phosphoribosylglycinamide transformylase activity	
ecNumber	6.3.3.2	commentary		
ecNumber	6.3.3.2	commentary		
ecNumber	6.3.4.2	commentary	CTP synthetase type II	
ecNumber	6.3.4.2	commentary	genes CTPS1 and CTPS2	
ecNumber	6.3.4.2	commentary		
ecNumber	6.3.4.2	commentary	CTP synthetase type I	
ecNumber	6.3.4.2	commentary	CTP synthetase type II	
ecNumber	6.3.4.2	commentary		
ecNumber	6.3.4.2	commentary	CTP synthase 2	
ecNumber	6.3.4.3	commentary	trifunctional enzyme with 10-formyltetrahydrofolate synthetase, EC 6.3.4.3, 5,10-methenyltetrahydrofolate cyclohydrolase, EC 3.5.4.9, and 5,10-methylenetetrahydrofolate dehydrogenase activity, EC 1.5.1.5	
ecNumber	6.3.4.3	commentary	mutation in MTHFD can act as a risk factor in human neural tube defects, however, it is unlikely that this gene plays a major role in the etiology of neural tube defects	
ecNumber	6.3.4.3	commentary		
ecNumber	6.3.4.3	commentary		
ecNumber	6.3.4.3	commentary		
ecNumber	6.3.4.3	commentary	trifunctional enzyme	
ecNumber	6.3.4.4	commentary	human	
ecNumber	6.3.4.4	commentary		
ecNumber	6.3.4.4	commentary		
ecNumber	6.3.4.5	commentary	adult-type citrullinemia with neuro-psychiatric symptoms of late onset, 24-28 years old, caused by ASS abnormalities	
ecNumber	6.3.4.5	commentary	citrullinemia is an autosomal recessive disease caused by a deficiency of argininosuccinate synthetase; wild-type and mutant enzyme; wild-type and mutant enzymes	
ecNumber	6.3.4.5	commentary	patients with Alzheimer disease and nondemented, age-matched controls	
ecNumber	6.3.4.5	commentary		
ecNumber	6.3.4.5	commentary	ASS1	
ecNumber	6.3.4.5	commentary		
ecNumber	6.3.4.10	commentary	; holocarboxylase synthetase catalyzes the biotinylation of the four biotin-dependent carboxylases found in human, mitochondrial propionyl-CoA carboxylase, pyruvate carboxylase, beta-methylcrotonyl-CoA carboxylase, and cytosolic acetyl-CoA carboxylase	
ecNumber	6.3.4.10	commentary	three isozymes that differ at the N-terminus	
ecNumber	6.3.4.10	commentary	two isozymes that differ at the amino terminus by 57 amino acids	
ecNumber	6.3.4.10	commentary		
ecNumber	6.3.4.13	commentary	trifunctional enzyme with phosphoribosylamine-glycine ligase activity, glycinamide ribonucleotide transformylase activity, and aminoimidazole ribonucleotide synthetase activity	
ecNumber	6.3.4.13	commentary		
ecNumber	6.3.4.14	commentary	contains isozymes ACC1 and ACC2	
ecNumber	6.3.4.14	commentary	component of pyruvate carboxylase	
ecNumber	6.3.4.14	commentary		
ecNumber	6.3.4.15	commentary	holocarboxylase synthetase catalyzes the biotinylation of the four biotin-dependent carboxylases found in human, mitochondrial propionyl-CoA carboxylase, pyruvate carboxylase, beta-methylcrotonyl-CoA carboxylase, and cytosolic acetyl-CoA carboxylase	
ecNumber	6.3.4.15	commentary	three isozymes that differ at the N-terminus	
ecNumber	6.3.4.15	commentary		
ecNumber	6.3.4.16	commentary	gene CPSI	
ecNumber	6.3.4.16	commentary		
ecNumber	6.3.4.16	commentary	gene CPSI	
ecNumber	6.3.4.16	commentary	African American children	
ecNumber	6.3.4.16	commentary	isoform CPS1	
ecNumber	6.3.4.16	commentary		
ecNumber	6.3.4.17	commentary		
ecNumber	6.3.4.21	commentary		
ecNumber	6.3.4.21	commentary		
ecNumber	6.3.5.1	commentary		
ecNumber	6.3.5.1	commentary	recombinant enzyme	
ecNumber	6.3.5.1	commentary		
ecNumber	6.3.5.2	commentary		
ecNumber	6.3.5.2	commentary	with diagnosed metastatic neuroblastoma	
ecNumber	6.3.5.2	commentary		
ecNumber	6.3.5.3	commentary		
ecNumber	6.3.5.4	commentary		
ecNumber	6.3.5.4	commentary	patients with acute lymphoblastic leukemia	
ecNumber	6.3.5.4	commentary		
ecNumber	6.3.5.5	commentary		
ecNumber	6.3.5.6	commentary		
ecNumber	6.3.5.7	commentary	subunit C	
ecNumber	6.3.5.7	commentary	subunit B	
ecNumber	6.3.5.7	commentary	subunit A	
ecNumber	6.4.1.1	commentary	lung cancer patients	
ecNumber	6.4.1.1	commentary		
ecNumber	6.4.1.1	commentary		
ecNumber	6.4.1.2	commentary	two isozymes Acc1 and Acc2	
ecNumber	6.4.1.2	commentary	isozymes ACC1 and ACC2	
ecNumber	6.4.1.2	commentary		
ecNumber	6.4.1.2	commentary	2 isoforms ACC1 and ACC2	
ecNumber	6.4.1.2	commentary	female and male individuals	
ecNumber	6.4.1.2	commentary	isozyme ACC2; gene ACACA, encoding isozyme ACC1 or ACC-alpha, and gene ACACB, encoding isozyme ACC2 or ACC-beta	
ecNumber	6.4.1.2	commentary		
ecNumber	6.4.1.2	commentary	isozyme ACC1; gene ACACA, encoding isozyme ACC1 or ACC-alpha, and gene ACACB, encoding isozyme ACC2 or ACC-beta	
ecNumber	6.4.1.2	commentary		
ecNumber	6.4.1.3	commentary	cDNA encoding for the alpha subunit	
ecNumber	6.4.1.3	commentary		
ecNumber	6.4.1.3	commentary	cDNA encoding for the beta subunit	
ecNumber	6.4.1.4	commentary	human, healthy caucasian adults	
ecNumber	6.4.1.4	commentary	pregnant women	
ecNumber	6.4.1.4	commentary	patient with 3-methylcrotonyl-CoA carboxylase deficiency	
ecNumber	6.4.1.4	commentary	family with 3-methylcrotonyl-CoA carboxylase deficiency	
ecNumber	6.4.1.4	commentary		
ecNumber	6.5.1.1	commentary	DNA ligase IV	
ecNumber	6.5.1.1	commentary	DNA ligase III and IV	
ecNumber	6.5.1.1	commentary	DNA ligase I	
ecNumber	6.5.1.1	commentary	2-3fold increase in DNA ligase I protein levels after 1 day exposure of MiaPaCa cells to 0.000015-0.00024 mM 2',2'-difluoro-2'-deoxycytidine	
ecNumber	6.5.1.1	commentary	3fold increase in DNA ligase I protein levels after exposure of MiaPa cells to 1-beta-arabinosylcytosine, DNA ligase I is also induced by aphidicolin	
ecNumber	6.5.1.1	commentary		
ecNumber	6.5.1.1	commentary		
ecNumber	6.5.1.1	commentary		
ecNumber	6.5.1.1	commentary		
ecNumber	6.5.1.3	commentary		
ecNumber	6.5.1.4	commentary	human	
ecNumber	6.5.1.4	commentary		
ecNumber	6.5.1.4	commentary		
ecNumber	6.5.1.8	commentary		
